<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia - Richter, B - 2018 | Cochrane Library</title> <meta content="Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia - Richter, B - 2018 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012661.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia - Richter, B - 2018 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012661.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012661.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia" name="citation_title"/> <meta content="Bernd Richter" name="citation_author"/> <meta content="Institute of General Practice, Medical Faculty of the Heinrich‐Heine‐University Düsseldorf" name="citation_author_institution"/> <meta content="richterb@uni-duesseldorf.de" name="citation_author_email"/> <meta content="Bianca Hemmingsen" name="citation_author"/> <meta content="Institute of General Practice, Medical Faculty of the Heinrich‐Heine‐University Düsseldorf" name="citation_author_institution"/> <meta content="Maria‐Inti Metzendorf" name="citation_author"/> <meta content="Institute of General Practice, Medical Faculty of the Heinrich‐Heine‐University Düsseldorf" name="citation_author_institution"/> <meta content="Yemisi Takwoingi" name="citation_author"/> <meta content="University of Birmingham" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="10" name="citation_issue"/> <meta content="10.1002/14651858.CD012661.pub2" name="citation_doi"/> <meta content="2018" name="citation_date"/> <meta content="2018/10/29" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012661.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012661.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012661.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Blood Glucose [analysis]; Diabetes Mellitus, Type 2 [epidemiology, *etiology]; Disease Progression; Hyperglycemia [blood, *complications]; Incidence; Prediabetic State [blood]; Prognosis; Prospective Studies" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012661.pub2&amp;doi=10.1002/14651858.CD012661.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012661.pub2&amp;doi=10.1002/14651858.CD012661.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012661.pub2&amp;doi=10.1002/14651858.CD012661.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012661.pub2&amp;doi=10.1002/14651858.CD012661.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012661.pub2&amp;doi=10.1002/14651858.CD012661.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012661.pub2&amp;doi=10.1002/14651858.CD012661.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012661.pub2&amp;doi=10.1002/14651858.CD012661.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012661.pub2&amp;doi=10.1002/14651858.CD012661.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012661.pub2&amp;doi=10.1002/14651858.CD012661.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012661.pub2&amp;doi=10.1002/14651858.CD012661.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012661.pub2&amp;doi=10.1002/14651858.CD012661.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012661.pub2&amp;doi=10.1002/14651858.CD012661.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012661.pub2&amp;doi=10.1002/14651858.CD012661.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012661.pub2&amp;doi=10.1002/14651858.CD012661.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012661.pub2&amp;doi=10.1002/14651858.CD012661.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012661.pub2&amp;doi=10.1002/14651858.CD012661.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012661.pub2&amp;doi=10.1002/14651858.CD012661.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012661.pub2&amp;doi=10.1002/14651858.CD012661.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012661.pub2&amp;doi=10.1002/14651858.CD012661.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012661.pub2&amp;doi=10.1002/14651858.CD012661.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012661.pub2&amp;doi=10.1002/14651858.CD012661.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012661.pub2&amp;doi=10.1002/14651858.CD012661.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012661.pub2&amp;doi=10.1002/14651858.CD012661.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="Xsb6SJyC";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012661\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012661\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012661\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012661\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ms","fr","de","fa","pt"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012661.pub2",title:"Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia",firstPublishedDate:"Oct 29, 2018 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Metabolic and Endocrine Disorders Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Xsb6SJyC&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012661.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012661.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012661.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012661.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012661.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012661.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012661.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012661.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012661.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012661.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>16759 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012661.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012661.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012661.pub2/full#CD012661-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012661.pub2/full#CD012661-sec-0130"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012661.pub2/full#CD012661-sec-0036"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012661.pub2/full#CD012661-sec-0037"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012661.pub2/full#CD012661-sec-0038"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012661.pub2/full#CD012661-sec-0039"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012661.pub2/full#CD012661-sec-0062"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012661.pub2/full#CD012661-sec-0124"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012661.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012661.pub2/appendices#CD012661-sec-0135"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012661.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012661.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/table_n/CD012661StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/table_n/CD012661StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012661.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012661.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012661.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012661.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012661.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012661.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Prognosis</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012661.pub2/information#CD012661-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Bernd Richter</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012661.pub2/information#CD012661-cr-0003">Bianca Hemmingsen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012661.pub2/information#CD012661-cr-0004">Maria‐Inti Metzendorf</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012661.pub2/information#CD012661-cr-0005">Yemisi Takwoingi</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/information/en#CD012661-sec-0155">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 29 October 2018 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012661.pub2">https://doi.org/10.1002/14651858.CD012661.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012661-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012661-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD012661-abs-0008">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD012661-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012661-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012661-abs-0002">Français</a> </li> <li class="section-language"> <a class="" href="full/pt#CD012661-abs-0012">Português</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012661-abs-0001" lang="en"> <section id="CD012661-sec-0001"> <h3 class="title" id="CD012661-sec-0001">Background</h3> <p>Intermediate hyperglycaemia (IH) is characterised by one or more measurements of elevated blood glucose concentrations, such as impaired fasting glucose (IFG), impaired glucose tolerance (IGT) and elevated glycosylated haemoglobin A1c (HbA1c). These levels are higher than normal but below the diagnostic threshold for type 2 diabetes mellitus (T2DM). The reduced threshold of 5.6 mmol/L (100 mg/dL) fasting plasma glucose (FPG) for defining IFG, introduced by the American Diabetes Association (ADA) in 2003, substantially increased the prevalence of IFG. Likewise, the lowering of the HbA1c threshold from 6.0% to 5.7% by the ADA in 2010 could potentially have significant medical, public health and socioeconomic impacts. </p> </section> <section id="CD012661-sec-0002"> <h3 class="title" id="CD012661-sec-0002">Objectives</h3> <p>To assess the overall prognosis of people with IH for developing T2DM, regression from IH to normoglycaemia and the difference in T2DM incidence in people with IH versus people with normoglycaemia. </p> </section> <section id="CD012661-sec-0003"> <h3 class="title" id="CD012661-sec-0003">Search methods</h3> <p>We searched MEDLINE, Embase, ClincialTrials.gov and the International Clinical Trials Registry Platform (ICTRP) Search Portal up to December 2016 and updated the MEDLINE search in February 2018. We used several complementary search methods in addition to a Boolean search based on analytical text mining. </p> </section> <section id="CD012661-sec-0004"> <h3 class="title" id="CD012661-sec-0004">Selection criteria</h3> <p>We included prospective cohort studies investigating the development of T2DM in people with IH. We used standard definitions of IH as described by the ADA or World Health Organization (WHO). We excluded intervention trials and studies on cohorts with additional comorbidities at baseline, studies with missing data on the transition from IH to T2DM, and studies where T2DM incidence was evaluated by documents or self‐report only. </p> </section> <section id="CD012661-sec-0005"> <h3 class="title" id="CD012661-sec-0005">Data collection and analysis</h3> <p>One review author extracted study characteristics, and a second author checked the extracted data. We used a tailored version of the Quality In Prognosis Studies (QUIPS) tool for assessing risk of bias. We pooled incidence and incidence rate ratios (IRR) using a random‐effects model to account for between‐study heterogeneity. To meta‐analyse incidence data, we used a method for pooling proportions. For hazard ratios (HR) and odds ratios (OR) of IH versus normoglycaemia, reported with 95% confidence intervals (CI), we obtained standard errors from these CIs and performed random‐effects meta‐analyses using the generic inverse‐variance method. We used multivariable HRs and the model with the greatest number of covariates. We evaluated the certainty of the evidence with an adapted version of the GRADE framework. </p> </section> <section id="CD012661-sec-0006"> <h3 class="title" id="CD012661-sec-0006">Main results</h3> <p>We included 103 prospective cohort studies. The studies mainly defined IH by IFG<sub>5.6</sub> (FPG mmol/L 5.6 to 6.9 mmol/L or 100 mg/dL to 125 mg/dL), IFG<sub>6.1</sub> (FPG 6.1 mmol/L to 6.9 mmol/L or 110 mg/dL to 125 mg/dL), IGT (plasma glucose 7.8 mmol/L to 11.1 mmol/L or 140 mg/dL to 199 mg/dL two hours after a 75 g glucose load on the oral glucose tolerance test, combined IFG and IGT (IFG/IGT), and elevated HbA1c (HbA1c<sub>5.7</sub>: HbA1c 5.7% to 6.4% or 39 mmol/mol to 46 mmol/mol; HbA1c<sub>6.0</sub>: HbA1c 6.0% to 6.4% or 42 mmol/mol to 46 mmol/mol). The follow‐up period ranged from 1 to 24 years. Ninety‐three studies evaluated the overall prognosis of people with IH measured by cumulative T2DM incidence, and 52 studies evaluated glycaemic status as a prognostic factor for T2DM by comparing a cohort with IH to a cohort with normoglycaemia. Participants were of Australian, European or North American origin in 41 studies; Latin American in 7; Asian or Middle Eastern in 50; and Islanders or American Indians in 5. Six studies included children and/or adolescents. </p> <p>Cumulative incidence of T2DM associated with IFG<sub>5.6</sub>, IFG<sub>6.1</sub>, IGT and the combination of IFG/IGT increased with length of follow‐up. Cumulative incidence was highest with IFG/IGT, followed by IGT, IFG<sub>6.1</sub> and IFG<sub>5.6</sub>. Limited data showed a higher T2DM incidence associated with HbA1c<sub>6.0</sub> compared to HbA1c<sub>5.7</sub>. We rated the evidence for overall prognosis as of moderate certainty because of imprecision (wide CIs in most studies). In the 47 studies reporting restitution of normoglycaemia, regression ranged from 33% to 59% within one to five years follow‐up, and from 17% to 42% for 6 to 11 years of follow‐up (moderate‐certainty evidence). </p> <p>Studies evaluating the prognostic effect of IH versus normoglycaemia reported different effect measures (HRs, IRRs and ORs). Overall, the effect measures all indicated an elevated risk of T2DM at 1 to 24 years of follow‐up. Taking into account the long‐term follow‐up of cohort studies, estimation of HRs for time‐dependent events like T2DM incidence appeared most reliable. The pooled HR and the number of studies and participants for different IH definitions as compared to normoglycaemia were: IFG<sub>5.6</sub>: HR 4.32 (95% CI 2.61 to 7.12), 8 studies, 9017 participants; IFG<sub>6.1</sub>: HR 5.47 (95% CI 3.50 to 8.54), 9 studies, 2818 participants; IGT: HR 3.61 (95% CI 2.31 to 5.64), 5 studies, 4010 participants; IFG and IGT: HR 6.90 (95% CI 4.15 to 11.45), 5 studies, 1038 participants; HbA1c<sub>5.7</sub>: HR 5.55 (95% CI 2.77 to 11.12), 4 studies, 5223 participants; HbA1c<sub>6.0</sub>: HR 10.10 (95% CI 3.59 to 28.43), 6 studies, 4532 participants. In subgroup analyses, there was no clear pattern of differences between geographic regions. We downgraded the evidence for the prognostic effect of IH versus normoglycaemia to low‐certainty evidence due to study limitations because many studies did not adequately adjust for confounders. Imprecision and inconsistency required further downgrading due to wide 95% CIs and wide 95% prediction intervals (sometimes ranging from negative to positive prognostic factor to outcome associations), respectively. </p> <p>This evidence is up to date as of 26 February 2018.</p> </section> <section id="CD012661-sec-0007"> <h3 class="title" id="CD012661-sec-0007">Authors' conclusions</h3> <p>Overall prognosis of people with IH worsened over time. T2DM cumulative incidence generally increased over the course of follow‐up but varied with IH definition. Regression from IH to normoglycaemia decreased over time but was observed even after 11 years of follow‐up. The risk of developing T2DM when comparing IH with normoglycaemia at baseline varied by IH definition. Taking into consideration the uncertainty of the available evidence, as well as the fluctuating stages of normoglycaemia, IH and T2DM, which may transition from one stage to another in both directions even after years of follow‐up, practitioners should be careful about the potential implications of any active intervention for people 'diagnosed' with IH. </p> </section> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012661-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012661-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD012661-abs-0009">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD012661-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012661-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012661-abs-0006">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012661-abs-0005">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pt#CD012661-abs-0013">Português</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012661-abs-0004" lang="en"> <h3>Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia ('prediabetes') </h3> <p><b>Review question</b> </p> <p>We wanted to find out whether raised blood sugar ('prediabetes') increases the risk of developing type 2 diabetes and how many of these people return to having normal blood sugar levels (normoglycaemia). We also investigated the difference in type 2 diabetes development in people with prediabetes compared to people with normoglycaemia. </p> <p><b>Background</b> </p> <p>Type 2 diabetes is often diagnosed by blood sugar measurements like fasting blood glucose or glucose measurements after an oral glucose tolerance test (drinking 75 g of glucose on an empty stomach) or by measuring glycosylated haemoglobin A1c (HbA1c), a long‐term marker of blood glucose levels. Type 2 diabetes can have bad effects on health in the long term (diabetic complications), like severe eye or kidney disease or diabetic feet, eventually resulting in foot ulcers. </p> <p>Raised blood glucose levels (hyperglycaemia), which are above normal ranges but below the limit of diagnosing type 2 diabetes, indicate prediabetes, or intermediate hyperglycaemia. The way prediabetes is defined has important effects on public health because some physicians treat people with prediabetes with medications that can be harmful. For example, reducing the threshold for defining impaired fasting glucose (after an overnight fast) from 6.1 mmol/L or 110 mg/dL to 5.6 mmol/L or 100 mg/dL, as done by the American Diabetes Association (ADA), dramatically increased the number of people diagnosed with prediabetes worldwide. </p> <p><b>Study characteristics</b> </p> <p>We searched for observational studies (studies where no intervention takes place but people are observed over prolonged periods of time) that investigated how many people with prediabetes at the beginning of the study developed type 2 diabetes. We also evaluated studies comparing people with prediabetes to people with normoglycaemia. Prediabetes was defined by different blood glucose measurements. </p> <p>We found 103 studies, monitoring people over 1 to 24 years. More than 250,000 participants began the studies. In 41 studies the participants were of Australian, European or North American origin, in 7 studies participants were primarily of Latin American origin and in 50 studies participants were of Asian or Middle Eastern origin. Three studies had American Indians as participants, and one study each invited people from Mauritius and Nauru. Six studies included children, adolescents or both as participants. </p> <p>This evidence is up to date as of 26 February 2018.</p> <p><b>Key results</b> </p> <p>Generally, the development of new type 2 diabetes (diabetes incidence) in people with prediabetes increased over time. However, many participants also reverted from prediabetes back to normal blood glucose levels. Compared to people with normoglycaemia, those with prediabetes (any definition) showed an increased risk of developing type 2 diabetes, but results showed wide differences and depended on how prediabetes was measured. There were no clear differences with regard to several regions in the world or different populations. Because people with prediabetes may develop diabetes but may also change back to normoglycaemia almost any time, doctors should be careful about treating prediabetes because we are not sure whether this will result in more benefit than harm, especially when done on a global scale affecting many people worldwide. </p> <p><b>Certainty of the evidence</b> </p> <p>The certainty of the evidence for overall prognosis was moderate because results varied widely. The certainty of evidence for studies comparing prediabetic with normoglycaemic people was low because the results were not precise and varied widely. In our included observational studies the researchers often did not investigate well enough whether factors like physical inactivity, age or increased body weight also influenced the development of type 2 diabetes, thus making the relationship between prediabetes and the development of type 2 diabetes less clear. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012661-sec-0130" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012661-sec-0130"></div> <section id="CD012661-sec-0131"> <h3 class="title" id="CD012661-sec-0131">Implications for practice</h3> <p>Our systematic review on the development of type 2 diabetes mellitus (T2DM) in people with intermediate hyperglycaemia (IH) or 'prediabetes' identified several uncertainties: glycaemic status can be measured in various ways, with IH usually defined by impaired fasting glucose (IFG) with cut‐off levels of 5.6 mmol/L or 6.1 mmol/L, by impaired glucose tolerance (IGT) or by elevated HbA1c levels with thresholds of 5.7% or 6.0%. These definitions imply specific settings and demands on resources. It is likely that the accuracy of information provided by the tests will need to be balanced against the time, effort and cost required to capture them. IFG measurement is cumbersome because of the need for overnight fasting. HbA1c measurement is resource intensive and must be standardised, taking into account potential interference factors like anaemia, haemoglobinopathy or renal insufficiency. IGT measurement is cumbersome and also resource intensive. Overall, the certainty of the evidence was low for IH versus normoglycaemia, mainly because many of the prospective cohort studies did not adequately investigate other factors or covariates which could have confounded or modified the prognostic effect of glycaemic status on T2DM incidence. Moreover, results varied widely, making it difficult to specify the best definition for IH. The certainty of the evidence for the overall prognosis of people with IH as well as regression from IH to normoglycaemia was moderate because of imprecise results for most intermediate hyperglycaemia definitions. With increasing years of follow‐up, T2DM incidence increased, but regression from IH to normoglycaemia was also high. There was no clear pattern of geographical differences; again, studies showed wide variation depending on the definition of IH, mode of measurement and length of follow‐up. Due to the fluctuating stages of normoglycaemia, IH and T2DM, which might show transition from one stage to another in both directions and even after years of follow‐up, practitioners should be careful about the potential implications of any active intervention for people 'diagnosed' with IH. </p> </section> <section id="CD012661-sec-0132"> <h3 class="title" id="CD012661-sec-0132">Implications for research</h3> <p>Future prospective cohort studies should address the consequences of IH to minimise secondary analyses of cohort studies where investigators synthetically form a subgroup of people with prediabetes, as such analyses are suboptimal. There is an urgent need for data from Eastern Europe and Africa to enable assessment of the prognostic value of IH in these regions, and for prospective cohort studies designed to examine the relationship between IH and normoglycaemia, T2DM incidence and the development of diabetic complications. The studies should adjust for confounding using important, well‐defined factors such as age, sex, 'ethnicity', anthropometric measures and physical activity. Also, studies should be adequately powered and analysed using suitable statistical techniques such as time‐dependent regression methods. There is a need for a database of cohort studies with details on all analysed prognostic factor to outcome associations because many cohort studies start with general questions like the influence of various risk factors on cardiovascular disease, and specific factors may only be identified by investigating the full text. The nature of these investigations means that search strategies basing their retrieval on titles and abstracts only will not be sufficient to identify these studies. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012661-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012661-sec-0036"></div> <div class="table" id="CD012661-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Summary of findings: overall prognosis of people with intermediate hyperglycaemia for developing T2DM</span></div> <tbody> <tr class="table-header separated"> <td align="" class="table-header" colspan="9" rowspan="1" valign="top"> <p><b>Outcome: development of T2DM<br/> Prognosis of people with intermediate hyperglycaemia</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Follow‐up<br/> (years)</b> </p> </td> <td align="center" class="table-header" colspan="6" rowspan="1" valign="top"> <p><b>Cumulative T2DM incidence % (95% CI) <br/> [no of studies; no of participants with intermediate hyperglycaemia]</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Regression from intermediate hyperglycaemia to normoglycaemia % (95% CI) <br/> [no of studies; no of participants with intermediate hyperglycaemia]</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Overall certainty of the evidence (GRADE)<sup>a</sup> </b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>IFG<sub>5.6</sub> </b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>IFG<sub>6.1</sub> </b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>IGT</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>IFG + IGT</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>HbA1c<sub>5.7</sub> </b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>HbA1c<sub>6.0</sub> </b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>1</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>13 (5–23)</b> </p> <p>[3; 671]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>29 (23–36)</b> </p> <p>[1; 207]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>59 (54–64)</b> </p> <p>[2; 375]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="14" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>b</sup> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>2</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2 (1–2)</b> </p> <p>[1; 1335]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>11 (8–14)</b> </p> <p>[2; 549]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>16 (9–26)</b> </p> <p>[9; 1998]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>46 (36–55)</b> </p> <p>[9; 2852]</p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>3</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>17 (6–32)</b> </p> <p>[3; 1091]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>9 (2–20)</b> </p> <p>[3; 927]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>22 (18–27)</b> </p> <p>[3; 417]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>34 (28–41)</b> </p> <p>[1; 209]—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>7 (5–10)</b> </p> <p>[1; 370]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>41 (24–69)</b> </p> <p>[7; 1356]</p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>4</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>17 (13–22)</b> </p> <p>[3; 800]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>30 (17–44)</b> </p> <p>[2; 1567]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>22 (12–34)</b> </p> <p>[5; 1042]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>14 (7–23)</b> </p> <p>[3; 5352]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>44 (40–48)</b> </p> <p>[2; 627]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>33 (26–40)</b> </p> <p>[3; 807]</p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>5</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>18 (10–27)</b> </p> <p>[7; 3530]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>26 (19–33)</b> </p> <p>[11; 3837]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>39 (25–53)</b> </p> <p>[12; 3444]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>50 (37–63)</b> </p> <p>[5; 478]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>25 (18–32)</b> </p> <p>[4; 3524]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>38 (26–51)</b> </p> <p>[3; 1462]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>34 (27–42)</b> </p> <p>[9; 2603]</p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>6</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>22 (15–31)</b> </p> <p>[4; 738]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>37 (31–43)</b> </p> <p>[5; 279]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>29 (25–34)</b> </p> <p>[7; 775]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>58 (48–67)</b> </p> <p>[4; 106]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>17 (14–20)</b> </p> <p>[1; 675]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>23 (3–53)</b> </p> <p>[5; 1328]</p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>7</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>18 (8–30)</b> </p> <p>[5; 980]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>15 (0–45)</b> </p> <p>[4; 434]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>19 (13–26)</b> </p> <p>[5; 835]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>32 (20–45)</b> </p> <p>[4; 753]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>21 (16–27)</b> </p> <p>[1; 207]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>41 (37–45)</b> </p> <p>[4; 679]</p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>8</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>34 (27–40)</b> </p> <p>[2; 1887]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>48 (31–66)</b> </p> <p>[1;29]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>43 (37–49)</b> </p> <p>[4; 1021]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>52 (47–57)</b> </p> <p>[1; 356]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>39 (33–44)</b> </p> <p>[2; 328]</p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>9</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>38 (10–70)</b> </p> <p>[3; 1356]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>53 (45–60)</b> </p> <p>[1; 163]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>84 (74–91)</b> </p> <p>[1; 69]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>17 (14–22)</b> </p> <p>[1; 299]</p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>10</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>23 (14–33)</b> </p> <p>[6; 1542]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>29 (17–43)</b> </p> <p>[6; 537]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>26 (17–37)</b> </p> <p>[6; 443]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>30 (17–44)</b> </p> <p>[2; 49]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>31 (29–33)</b> </p> <p>[2; 2854]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>42 (22–63)</b> </p> <p>[7; 894]</p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>11</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>38 (33–43)</b> </p> <p>[1; 402]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>46 (43–49)</b> </p> <p>[1; 1253]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>28 (17–39)</b> </p> <p>[2; 736]</p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>12</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>31 (19–34)</b> </p> <p>[3; 433]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>31 (28–33)</b> </p> <p>[1; 1382]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>41 (38–43)</b> </p> <p>[2; 1552]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>70 (63–76)</b> </p> <p>[2; 207]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>15</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>29 (19–40)</b> </p> <p>[1; 70]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>20</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>60 (5–68)</b> </p> <p>[1; 114]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign="top"> <p><b>CI</b> : confidence interval; <b>HbA1c<sub>5.7</sub> </b> : glycosylated haemoglobin A1c, 5.7% threshold; <b>HbA1c<sub>6.0</sub> </b> : glycosylated haemoglobin A1c, 6.0% threshold; <b>IFG<sub>5.6</sub> </b> : impaired fasting glucose, 5.6 mmol/L threshold; <b>IFG<sub>6.1</sub> </b> : impaired fasting glucose, 6.1 mmol/L threshold; <b>IGT</b> : impaired glucose tolerance; <b>T2DM</b>: type 2 diabetes mellitus. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/> <b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p><sup>a</sup>With phase 2 explanatory studies aiming to confirm independent associations between the prognostic factor and the outcome, GRADE starts with 'high quality' (<a href="./references#CD012661-bbs2-0339" title="HuguetA , HaydenJA , StinsonJ , McGrathPJ , ChambersCT , TougasME , et al. Judging the quality of evidence in reviews of prognostic factor research: adapting the GRADE framework. Systematic Reviews2013;2:71. ">Huguet 2013</a>). We assumed the GRADE factor publication bias was inherent with this type of research (phase 2 design), so we did not use it as a potential downgrading factor<br/> <sup>b</sup>Downgraded by one level because of imprecision (wide CIs for most intermediate hyperglycaemia definitions and the association with T2DM incidence and regression from intermediate hyperglycaemia) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012661-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings: risk of intermediate hyperglycaemia (IFG5.6 mmol/L definition) versus normoglycaemia for developing T2DM</span></div> <tbody> <tr class="table-header separated"> <td align="" class="table-header" colspan="5" rowspan="1" valign="top"> <p><b>Outcome: development of T2DM<br/> Prognostic factor: intermediate hyperglycaemia versus normoglycaemia as measured by IFG<sub>5.6</sub> </b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>No of studies</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>No of participants with intermediate hyperglycaemia</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Geographic region/special population</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Estimated effect (95% CI)<br/> [95% prediction interval]</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Overall certainty of the evidence (GRADE)<sup>a</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 4</p> <p>IRR: 6</p> <p>OR: 10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 2385</p> <p>IRR: 15,661</p> <p>OR: 6359</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asia/Middle East</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR: 5.07 (3.41–4.86)</b> [1.07–24.02] </p> <p><b>IRR: 5.23 (3.77–7.25)</b> [1.72–15.89] </p> <p><b>OR: 2.94 (1.77–4.86)</b> [0.43–19.93] </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 3</p> <p>IRR: 3</p> <p>OR: 9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 5685</p> <p>IRR: 6322</p> <p>OR: 1949</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Australia/Europe/North America</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR: 4.15 (1.24–13.9)</b> [N/M] </p> <p><b>IRR: 4.96 (3.25–7.57)</b> [0.32–77.24] </p> <p><b>OR: 6.47 (3.81–11.00)</b> [0.99–42.32] </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 0</p> <p>IRR: 0</p> <p>OR: 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 0</p> <p>IRR: 0</p> <p>OR: 65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Latin America</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR: NA</b> </p> <p><b>IRR</b> : <b>NA</b> </p> <p><b>OR: 4.28 (3.21–5.71)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 1</p> <p>IRR: 1</p> <p>OR: 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 947</p> <p>IRR: 2374</p> <p>OR: 947</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>American Indians/Islands</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR: 2.38 (1.85–3.06)</b> </p> <p><b>IRR: 2.74 (1.88–3.99)</b> </p> <p><b>OR: 3.12 (2.31–4.21)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 8</p> <p>IRR: 10</p> <p>OR: 21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 9017</p> <p>IRR: 24,357</p> <p>OR: 9320</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR: 4.32 (2.61–7.12)</b> [0.75–25.0] </p> <p><b>IRR: 4.81 (3.67–6.30)</b> [1.95–11.83] </p> <p><b>OR: 4.15 (2.75–6.28)</b> [0.53–32.4] </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>CI</b> : confidence interval; <b>HR</b> : hazard ratio;<b>IFG<sub>5.6</sub> </b> : impaired fasting glucose 5.6 mmol/L threshold; <b>IRR</b> : incidence rate ratio; <b>NA</b> : not applicable; <b>N/M</b> : fewer than 3 studies or calculation of the 95% prediction interval did not provide a meaningful estimate; <b>OR</b> : odds ratio; <b>T2DM</b>: type 2 diabetes mellitus. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/> <b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>a</sup>With phase 2 explanatory studies aiming to confirm independent associations between the prognostic factor and the outcome, GRADE starts with 'high quality' (<a href="./references#CD012661-bbs2-0339" title="HuguetA , HaydenJA , StinsonJ , McGrathPJ , ChambersCT , TougasME , et al. Judging the quality of evidence in reviews of prognostic factor research: adapting the GRADE framework. Systematic Reviews2013;2:71. ">Huguet 2013</a>). We assumed the GRADE factor publication bias was inherent with this type of research (phase 2 design), so we did not use it as a potential downgrading factor<br/> <sup>b</sup>Downgraded by one level because of study limitations (many studies did not adequately adjust for confounders, if at all) and by one level because of imprecision (CIs were wide) and inconsistency (wide 95% prediction intervals sometimes ranging from negative to positive prognostic factor to outcome associations) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012661-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Summary of findings: risk of intermediate hyperglycaemia (IFG6.1 mmol/L definition) versus normoglycaemia for developing T2DM</span></div> <tbody> <tr class="table-header separated"> <td align="" class="table-header" colspan="5" rowspan="1" valign="top"> <p><b>Outcome: development of T2DM<br/> Prognostic factor: intermediate hyperglycaemia as measured by IFG<sub>6.1</sub> </b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>No of studies</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>No of participants with intermediate hyperglycaemia</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Geographic region/special population</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Estimated effect (95% CI)<br/> [95% prediction interval]</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Overall certainty of<br/> the evidence (GRADE)<sup>a</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 5</p> <p>IRR: 2</p> <p>OR: 7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 1054</p> <p>IRR: 1677</p> <p>OR: 3317</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asia/Middle East</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR: 10.55 (3.61–30.81)</b> [N/M] </p> <p><b>IRR: 3.62 (1.67–7.83)</b> [N/M] </p> <p><b>OR: 5.18 (2.32–11.53)</b> [0.29–91.37] </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 4</p> <p>IRR: 4</p> <p>OR: 7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 1736</p> <p>IRR: 3438</p> <p>OR: 1240</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Australia/Europe/North America</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR: 3.30 (2.32–4.67)</b> [0.84–12.99] </p> <p><b>IRR: 8.55 (6.37–11.48)</b> [4.37–16.73] </p> <p><b>OR: 8.69 (4.95–15.24)</b> [1.20–62.69] </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 0</p> <p>IRR: 0</p> <p>OR: 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 0</p> <p>IRR: 0</p> <p>OR: 17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Latin America</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR: NA</b> </p> <p><b>IRR: NA</b> </p> <p><b>OR: 3.73 (2.18–6.38)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 0</p> <p>IRR: 0</p> <p>OR: 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 0</p> <p>IRR: 0</p> <p>OR: 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>American Indians/Islands</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR: NA</b> </p> <p><b>IRR: NA</b> </p> <p><b>OR: NA</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 9</p> <p>IRR: 6</p> <p>OR: 15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 2818</p> <p>IRR: 5115</p> <p>OR: 4574</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR: 5.47 (3.50–8.54)</b> [1.09–27.56] </p> <p><b>IRR: 6.82 (4.53–10.25)</b> [2.03–22.87] </p> <p><b>OR: 6.60 (4.18–10.43)</b> [0.93–46.82] </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>CI</b> : confidence interval; <b>HR</b> : hazard ratio;<b>IFG<sub>6.1</sub> </b> : impaired fasting glucose 6.1 mmol/L threshold; <b>IRR</b> : incidence rate ratio; <b>NA</b> : not applicable; <b>N/M</b> : fewer than 3 studies or calculation of the 95% prediction interval did not provide a meaningful estimate; <b>OR</b> : odds ratio; <b>T2DM</b>: type 2 diabetes mellitus. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/> <b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>a</sup>With phase 2 explanatory studies aiming to confirm independent associations between the prognostic factor and the outcome, GRADE starts with 'high quality' (<a href="./references#CD012661-bbs2-0339" title="HuguetA , HaydenJA , StinsonJ , McGrathPJ , ChambersCT , TougasME , et al. Judging the quality of evidence in reviews of prognostic factor research: adapting the GRADE framework. Systematic Reviews2013;2:71. ">Huguet 2013</a>). We assumed the GRADE factor publication bias was inherent with this type of research (phase 2 design), so we did not use it as a potential downgrading factor<br/> <sup>b</sup>Downgraded by one level because of study limitations (many studies did not adequately adjust for confounders, if at all) and by one level because of imprecision (CIs were wide) and inconsistency (wide 95% prediction intervals sometimes ranging from negative to positive prognostic factor to outcome associations) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012661-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Summary of findings: risk of intermediate hyperglycaemia (IGT definition) versus normoglycaemia for developing T2DM</span></div> <tbody> <tr class="table-header separated"> <td align="" class="table-header" colspan="5" rowspan="1" valign="top"> <p><b>Outcome: development of T2DM<br/> Prognostic factor: intermediate hyperglycaemia as measured by IGT</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>No of studies</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>No of participants with intermediate hyperglycaemia</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Geographic region/special population</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Estimated effect (95% CI)<br/> [95% prediction interval]</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Overall certainty of the evidence (GRADE)<sup>a</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 3</p> <p>IRR: 5</p> <p>OR: 6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 1780</p> <p>IRR: 14,809</p> <p>OR: 1226</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asia/Middle East</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR: 4.48 (2.81–7.15)</b> [N/M] </p> <p><b>IRR: 3.93 (3.03–5.10)</b> [1.71–9.02] </p> <p><b>OR: 3.74 (2.83–4.94)</b> [1.70–8.21] </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 2</p> <p>IRR: 5</p> <p>OR: 11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 2230</p> <p>IRR: 2572</p> <p>OR: 1481</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Australia/Europe/North America</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR: 2.53 (1.52–4.19)</b> [N/M] </p> <p><b>IRR: 5.93 (4.11–8.57)</b> [2.38–14.81] </p> <p><b>OR: 5.20 (3.62–7.45)</b> [1.50–18.09] </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 0</p> <p>IRR: 0</p> <p>OR: 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 0</p> <p>IRR: 0</p> <p>OR: 381</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Latin America</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR: NA</b> </p> <p><b>IRR: NA</b> </p> <p><b>OR: 4.94 (3.15–7.76)</b> [N/M] </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IRR: 2<br/> OR: 1<br/> HR: 0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IRR: 1087<br/> OR: 51<br/> HR: 0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>American Indians/Islands</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IRR: 4.46 (3.12–6.38)</b> [N/M] </p> <p><b>OR: 3.60 (1.40–9.26)</b> </p> <p><b>HR: NA</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 5</p> <p>IRR: 12</p> <p>OR: 20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 4010</p> <p>IRR: 18,468</p> <p>OR: 3139</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR: 3.61 (2.31–5.64)</b> [0.69–18.97] </p> <p><b>IRR: 4.48 (3.59–5.44)</b> [2.60–7.70] </p> <p><b>OR: 4.61 (3.76–5.64)</b> [2.10–10.13] </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>CI</b> : confidence interval; <b>HR</b> : hazard ratio;<b>IGT</b> : impaired glucose tolerance; <b>IRR</b> : incidence rate ratio; <b>NA</b> : not applicable; <b>N/M</b> : fewer than 3 studies or calculation of the 95% prediction interval did not provide a meaningful estimate; <b>T2DM</b>: type 2 diabetes mellitus. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/> <b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>a</sup>With phase 2 explanatory studies aiming to confirm independent associations between the prognostic factor and the outcome, GRADE starts with 'high quality' (<a href="./references#CD012661-bbs2-0339" title="HuguetA , HaydenJA , StinsonJ , McGrathPJ , ChambersCT , TougasME , et al. Judging the quality of evidence in reviews of prognostic factor research: adapting the GRADE framework. Systematic Reviews2013;2:71. ">Huguet 2013</a>). We assumed the GRADE factor publication bias was inherent with this type of research (phase 2 design), so we did not use it as a potential downgrading factor<br/> <sup>b</sup>Downgraded by one level because of study limitations (many studies did not adequately adjust for confounders, if at all) and by one level because of imprecision (CIs were wide) and inconsistency (wide 95% prediction intervals sometimes ranging from negative to positive prognostic factor to outcome associations) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012661-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Summary of findings: risk of intermediate hyperglycaemia (combined IFG and IGT definition) versus normoglycaemia for developing T2DM</span></div> <tbody> <tr class="table-header separated"> <td align="" class="table-header" colspan="5" rowspan="1" valign="top"> <p><b>Outcome: development of T2DM<br/> Prognostic factor: intermediate hyperglycaemia as measured by combined IFG and IGT</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>No of studies</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>No of participants with intermediate hyperglycaemia</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Geographic region/special population</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Estimated effect (95% CI)<br/> [95% prediction interval]</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Overall certainty of the evidence (GRADE)<sup>a</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 3</p> <p>IRR: 4</p> <p>OR: 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 461</p> <p>IRR: 3166</p> <p>OR: 498</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asia/Middle East</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR: 10.20 (5.45–19.09)</b> [N/M] </p> <p><b>IRR: 11.20 (5.59–22.43)</b> [N/M] </p> <p><b>OR: 6.99 (3.09–15.83)</b> [N/M] </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 1</p> <p>IRR: 4</p> <p>OR: 6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 221</p> <p>IRR: 699</p> <p>OR: 154</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Australia/Europe/North America</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR: 3.80 (2.30–6.28)</b> [N/M] </p> <p><b>IRR: 13.92 (9.99–19.40)</b> [6.71–28.85] </p> <p><b>OR: 20.95 (12.40–35.40)</b> [4.93–89.05] </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 0</p> <p>IRR: 0</p> <p>OR: 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 0</p> <p>IRR: 0</p> <p>OR: 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Latin America</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR: NA</b> </p> <p><b>IRR: NA</b> </p> <p><b>OR: NA</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 1</p> <p>IRR: 1<br/> OR: 0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 356</p> <p>IRR: 605<br/> OR: 0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>American Indians/Islands</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR: 4.06 (3.05–5.40)</b> </p> <p><b>IRR: 5.18 (3.42–7.83)</b> <br/> <b>OR: NA</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 5</p> <p>IRR: 9</p> <p>OR: 9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 1038</p> <p>IRR: 4470</p> <p>OR: 652</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR: 6.90 (4.15–11.45)</b> [1.06–44.95] </p> <p><b>IRR: 10.94 (7.22–16.58)</b> [2.58–46.46] </p> <p><b>OR: 13.14 (7.41–23.30)</b> [1.84–93.66] </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>CI</b> : confidence interval; HR: hazard ratio;<b>IFG</b> : impaired fasting glucose; <b>IGT</b> : impaired glucose tolerance; <b>IRR</b> : incidence rate ratio; <b>NA</b> : not applicable; <b>N/M</b> : fewer than 3 studies or calculation of the 95% prediction interval did not provide a meaningful estimate; <b>OR</b> : odds ratio; <b>T2DM</b>: type 2 diabetes mellitus. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/> <b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>a</sup>With phase 2 explanatory studies aiming to confirm independent associations between the prognostic factor and the outcome, GRADE starts with 'high quality' (<a href="./references#CD012661-bbs2-0339" title="HuguetA , HaydenJA , StinsonJ , McGrathPJ , ChambersCT , TougasME , et al. Judging the quality of evidence in reviews of prognostic factor research: adapting the GRADE framework. Systematic Reviews2013;2:71. ">Huguet 2013</a>). We assumed the GRADE factor publication bias was inherent with this type of research (phase 2 design), so we did not use it as a potential downgrading factor<br/> <sup>b</sup>Downgraded by one level because of study limitations (many studies did not adequately adjust for confounders, if at all) and by one level because of imprecision (CIs were wide) and inconsistency (wide 95% prediction intervals) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012661-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Summary of findings: risk of intermediate hyperglycaemia (HbA1c5.7 definition) versus normoglycaemia for developing T2DM</span></div> <tbody> <tr class="table-header separated"> <td align="" class="table-header" colspan="5" rowspan="1" valign="top"> <p><b>Outcome: development of T2DM<br/> Prognostic factor: intermediate hyperglycaemia as measured by HbA1c<sub>5.7</sub> </b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>No of studies</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>No of participants with intermediate hyperglycaemia</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Geographic region/special population</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Estimated effect (95% CI)<br/> [95% prediction interval]</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Overall certainty of the evidence (GRADE)<sup>a</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 3</p> <p>IRR: 1</p> <p>OR: 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 3196</p> <p>IRR: 1965</p> <p>OR: 675</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asia/Middle East</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR: 7.21 (5.14–10.11)</b> [0.81–64.52] </p> <p><b>IRR: 6.62 (4.18–10.49)</b> [N/M] </p> <p><b>OR: 4.54 (2.65–7.78)</b> [N/M] </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 1</p> <p>IRR: 0</p> <p>OR: 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 2027</p> <p>IRR: 0</p> <p>OR: 231</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Australia/Europe/North America</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR: 2.71 (2.48–2.96)</b> [N/M] </p> <p><b>IRR: NA</b> </p> <p><b>OR: 4.38 (1.36–14.15)</b> [N/M] </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 0</p> <p>IRR: 0</p> <p>OR: 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 0</p> <p>IRR: 0</p> <p>OR: 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Latin America</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR: NA</b> </p> <p><b>IRR: NA</b> </p> <p><b>OR: NA</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 0</p> <p>IRR: 0</p> <p>OR: 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 0</p> <p>IRR: 0</p> <p>OR: 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>American Indians/Islands</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR: NA</b> </p> <p><b>IRR: NA</b> </p> <p><b>OR: NA</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 4</p> <p>IRR: 1</p> <p>OR: 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 5223</p> <p>IRR: 1965</p> <p>OR: 906</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR: 5.55 (2.77–11.12)</b> [0.23–141.18] </p> <p><b>IRR: 6.62 (4.18–10.49)</b> [N/M] </p> <p><b>OR: 4.43 (2.20–8.88)</b> [N/M] </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>CI</b> : confidence interval; <b>HbA1c<sub>5.7</sub> </b> : glycosylated haemoglobin A1c 5.7% threshold; <b>HR</b> : hazard ratio;<b>IRR</b> : incidence rate ratio; <b>NA</b> : not applicable; <b>N/M</b> : fewer than 3 studies or calculation of the 95% prediction interval did not provide a meaningful estimate; <b>OR</b> : odds ratio; <b>T2DM</b>: type 2 diabetes mellitus. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/> <b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>a</sup>With phase 2 explanatory studies aiming to confirm independent associations between the prognostic factor and the outcome, GRADE starts with 'high quality' (<a href="./references#CD012661-bbs2-0339" title="HuguetA , HaydenJA , StinsonJ , McGrathPJ , ChambersCT , TougasME , et al. Judging the quality of evidence in reviews of prognostic factor research: adapting the GRADE framework. Systematic Reviews2013;2:71. ">Huguet 2013</a>). We assumed the GRADE factor publication bias was inherent with this type of research (phase 2 design), so we did not use it as a potential downgrading factor<br/> <sup>b</sup>Downgraded by one level because of study limitations (many studies did not adequately adjust for confounders, if at all) and by one level because of imprecision (CIs were wide) and inconsistency (95% prediction intervals sometimes ranging from negative to positive prognostic factor to outcome associations) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012661-tbl-0007"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Summary of findings: risk of intermediate hyperglycaemia (HbA1c6.0 definition) versus normoglycaemia for developing T2DM</span></div> <tbody> <tr class="table-header separated"> <td align="" class="table-header" colspan="5" rowspan="1" valign="top"> <p><b>Outcome: development of T2DM<br/> Prognostic factor: intermediate hyperglycaemia as measured by HbA1c<sub>6.0</sub> </b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>No of studies</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>No of participants with intermediate hyperglycaemia</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Geographic region/special population</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Estimated effect (95% CI)<br/> [95% prediction interval]</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Overall certainty of the evidence (GRADE)<sup>a</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 2</p> <p>IRR: 0</p> <p>OR: 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 1040</p> <p>IRR: 0</p> <p>OR: 370</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Australia/Europe/North America</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR: 5.09 (1.69–15.37)</b> [N/M] </p> <p><b>IRR: NA</b> </p> <p><b>OR: 15.60 (6.90–35.27)</b> [N/M] </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 4</p> <p>IRR: 0</p> <p>OR: 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 3492</p> <p>IRR: 0</p> <p>OR: 1103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asia/Middle East</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR: 13.12 (4.10–41.96)</b> [N/M] </p> <p><b>IRR:</b> NA </p> <p><b>OR: 23.20 (18.70–28.78)</b> [N/M] </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 0</p> <p>IRR: 0</p> <p>OR: 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 0</p> <p>IRR: 0</p> <p>OR: 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Latin America</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR: NA</b> </p> <p><b>IRR: NA</b> </p> <p><b>OR: NA</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IRR: 0<br/> OR: 1<br/> HR: 0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IRR: 0<br/> OR: 121 </p> <p>HR: 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>American Indians/Islands</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IRR: NA</b> </p> <p><b>OR: 5.89 (4.23–8.20)</b> [N/M] </p> <p><b>HR: NA</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 6</p> <p>IRR: 0</p> <p>OR: 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 4532</p> <p>IRR: 0</p> <p>OR: 1594</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR: 10.10 (3.59–28.43)</b> [N/M] </p> <p><b>IRR: NA</b> </p> <p><b>OR: 12.79 [4.56–35.85]</b> [N/M] </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>CI</b> : confidence interval; <b>HbA1c<sub>6.0</sub> </b> : glycosylated haemoglobin A1c 6.0% threshold; <b>HR</b> : hazard ratio;<b>IRR</b> : incidence rate ratio; <b>NA</b> : not applicable; <b>N/M</b> : fewer than 3 studies or calculation of the 95% prediction interval did not provide a meaningful estimate; <b>OR</b> : odds ratio; <b>T2DM</b>: type 2 diabetes mellitus. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/> <b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>a</sup>With phase 2 explanatory studies aiming to confirm independent associations between the prognostic factor and the outcome, GRADE starts with 'high quality' (<a href="./references#CD012661-bbs2-0339" title="HuguetA , HaydenJA , StinsonJ , McGrathPJ , ChambersCT , TougasME , et al. Judging the quality of evidence in reviews of prognostic factor research: adapting the GRADE framework. Systematic Reviews2013;2:71. ">Huguet 2013</a>). We assumed the GRADE factor publication bias was inherent with this type of research (phase 2 design), so we did not use it as a potential downgrading factor<br/> <sup>b</sup>Downgraded by one level because of study limitations (many studies did not adequately adjust for confounders, if at all) and by one level because of imprecision (most CIs were wide) </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012661-sec-0037" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD012661-sec-0037"></div> <p>For a glossary of terms please see <a href="./appendices#CD012661-sec-0136">Appendix 1</a>. </p> <p>'Prediabetes', 'borderline diabetes', 'prediabetic stage', 'high risk of diabetes', 'dysglycaemia' or 'intermediate hyperglycaemia' (IH) are terms used to characterise various measurements of elevated blood glucose concentrations, such as impaired fasting glucose (IFG), impaired glucose tolerance (IGT), elevated glycosylated haemoglobin A1c (HbA1c) or combinations of these conditions (<a href="./references#CD012661-bbs2-0377" title="World Health Organization/ International Diabetes Federation. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: report of a WHO/IDF consultation. WHO, 2006. Available from www.who.int/diabetes/publications/Definition%20and%20diagnosis%20of%20diabetes_new.pdf Vol. (assessed 3 March 2018). ">WHO/IDF 2006</a>). Elevated blood glucose levels that indicate hyperglycaemia are too high to be considered normal, but they are below the diagnostic threshold for type 2 diabetes mellitus (T2DM). Therefore, due to the continuous glycaemic spectrum from normal to the diabetic stage, a sound evidence base is needed to define glycaemic thresholds for people at high risk of T2DM, especially because dysglycaemia is commonly an asymptomatic condition, so naturally it often remains undiagnosed (<a href="./references#CD012661-bbs2-0308" title="Centers for Disease Control and Prevention. 2014 National Diabetes Statistics Report. www.cdc.gov/diabetes/pdfs/data/2014‐report‐estimates‐of‐diabetes‐and‐its‐burden‐in‐the‐united‐states.pdf (accessed 3 March 2018). ">CDC 2015</a>). The various terms used to describe stages of hyperglycaemia may cause people to have marked emotional reactions. For example, the term prediabetes may imply (at least for non‐experts) that diabetes is unavoidable, whereas (high) risk of diabetes gives people the impression that they can possibly avoid the disease altogether. In addition to the disputable construct of intermediate health states termed 'predisease' (<a href="./references#CD012661-bbs2-0374" title="VieraAJ . Predisease: when does it make sense?. Epidemiologic Reviews2011;33:122‐34. ">Viera 2011</a>), many people may associate the label 'prediabetes' with dire consequences. Alternatively, any diagnosis of prediabetes may be an opportunity to reassess, for example, eating habits and physical activity levels, thus enabling affected individuals to actively change their health‐related behaviours. </p> <p>Several institutional bodies like the American Diabetes Association (ADA) and the World Health Organization (WHO) have established commonly used criteria to define people who are at a high risk of developing T2DM. </p> <p> <ul id="CD012661-list-0001"> <li> <p>In 1979, the National Diabetes Data Group (NDDG) described glucose intolerance as an intermediate metabolic state between normoglycaemia and diabetes (<a href="./references#CD012661-bbs2-0358" title="National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes1979;28(12):1039‐57. [PUBMED: 510803] ">NDDG 1979</a>). NDDG defined this IGT as an elevated plasma glucose concentration (7.8 mmol/L to 11.1 mmol/L or 140 mg/dL to 199 mg/dL) two hours after a 75 g glucose load on the oral glucose tolerance test (OGTT). </p> </li> <li> <p>In 1997, the Expert Committe on the Diagnosis and Classification of Diabetes Mellitus and later the WHO defined two intermediate states of glucose regulation existing between regular glucose homeostasis and diabetes: IGT was diagnosed two hours after a 75 g OGTT by a plasma glucose level of 7.8 mmol/L to 11.1 mmol/L (140 mg/dL to 199 mg/dL) or by the concept of IFG (<a href="./references#CD012661-bbs2-0298" title="The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care1997;20(7):1183‐97. ">ADA 1997</a>; <a href="./references#CD012661-bbs2-0376" title="World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications: Report of a WHO consultation. Part 1. Diagnosis and Classification of Diabetes Mellitus. WHO, 1999. ">WHO 1999</a>). The initial definition of IFG was a fasting plasma glucose (FPG) level of 6.1 mmol/L to 6.9 mmol/L (110 mg/dL to 125 mg/dL). In 2003, the ADA reduced the lower threshold to 5.6 mmol/L (100 mg/dL) (<a href="./references#CD012661-bbs2-0299" title="Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care2003;26(Suppl 1):S5‐20. ">ADA 2003</a>). However, the WHO did not endorse this lower cut‐off point for IFG (<a href="./references#CD012661-bbs2-0377" title="World Health Organization/ International Diabetes Federation. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: report of a WHO/IDF consultation. WHO, 2006. Available from www.who.int/diabetes/publications/Definition%20and%20diagnosis%20of%20diabetes_new.pdf Vol. (assessed 3 March 2018). ">WHO/IDF 2006</a>). </p> </li> <li> <p>More recently, an elevated HbA1c has been introduced to identify people at high risk of developing T2DM. In 2009, the International Expert Committee (IEC) proposed HbA1c measurements of 6.0% to 6.4% (42 mmol/mol to 46 mmol/mol) to identify people at a high risk of T2DM (<a href="./references#CD012661-bbs2-0341" title="International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care2009;32(7):1327‐34. [PUBMED: 19502545] ">IEC 2009</a>). In 2010, the ADA re‐defined this HbA1c level as 5.7% to 6.4% (39 mmol/mol to 46 mmol/mol) (<a href="./references#CD012661-bbs2-0300" title="American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care2010;33(Suppl 1):S62‐9. [PUBMED: 20042775] ">ADA 2010</a>), a decision not endorsed by WHO, IEC or other organisations. </p> </li> </ul> </p> <p>The various glycaemic tests do not identify the same people at risk, as there is an imperfect overlap among the glycaemic modalities available to define IH (<a href="./references#CD012661-bbs2-0310" title="ChengC , KushnerH , FalknerBE . The utility of fasting glucose for detection of prediabetes. Metabolism: Clinical and Experimental2006;55(4):434‐8. [PUBMED: 16546472] ">Cheng 2006</a>; <a href="./references#CD012661-bbs2-0324" title="GosmanovAR , WanJ . Low positive predictive value of hemoglobin A1c for diagnosis of prediabetes in clinical practice. American Journal of the Medical Sciences2014;348(3):191‐4. [PUBMED: 24556928] ">Gosmanov 2014</a>; <a href="./references#CD012661-bbs2-0354" title="MorrisDH , KhuntiK , AchanaF , SrinivasanB , GrayLJ , DaviesMJ , et al. Progression rates from HbA1c 6.0‐6.4% and other prediabetes definitions to type 2 diabetes: a meta‐analysis. Diabetologia2013;56(7):1489‐93. [PUBMED: 23584433] ">Morris 2013</a>; <a href="./references#CD012661-bbs2-0369" title="SelvinE , SteffesMW , BallantyneCM , HoogeveenRC , CoreshJ , BrancatiFL . Racial differences in glycemic markers: a cross‐sectional analysis of community‐based data. Annals of Internal Medicine2011;154(5):303‐9. [PUBMED: 21357907] ">Selvin 2011</a>). Unlike IFG and IGT, HbA1c reflects longer‐term glycaemic control, that is, how a person's blood glucose concentrations have been during the preceding two to three months (<a href="./references#CD012661-bbs2-0343" title="InzucchiSE . Clinical practice. Diagnosis of diabetes. New England Journal of Medicine2012;367(6):542‐50. [PUBMED: 22873534] ">Inzucchi 2012</a>). Compared with IFG and IGT measurements, HbA1c assessments have less intrapersonal variability when repeated. However, haemoglobin variants, genetic haemoglobinopathies, thalassemias and iron deficiency anaemia substantially influence HbA1c measurements (<a href="./references#CD012661-bbs2-0355" title="MostafaSA , KhuntiK , SrinivasanBT , WebbD , DaviesMJ . Detecting type 2 diabetes and impaired glucose regulation using glycated hemoglobin in different populations. Diabetes Management2011;1:77‐97. ">Mostafa 2011</a>). The FPG thresholds of defining IFG and the question whether HbA1c is an adequate tool to diagnose IH are still a subject of debate (<a href="./references#CD012661-bbs2-0306" title="BuysschaertM , BergmanM . Definition of prediabetes. Medical Clinics of North America2011;95:289‐97, vii. ">Buysschaert 2011</a>; <a href="./references#CD012661-bbs2-0307" title="BuysschaertM , MedinaJL , BuysschaertB , BergmanM . Definitions (and current controversies) of diabetes and prediabetes. Current Diabetes Reviews2016;12:8‐13. ">Buysschaert 2016</a>). In studies investigating the risk of IH as measured by HbA1c, the association is probably underestimated if time‐dependent effects are not taken into account (<a href="./references#CD012661-bbs2-0350" title="LindM , OdenA , FahlenM , EliassonB . The true value of HbA1c as a predictor of diabetic complications: simulations of HbA1c variables. PLOS ONE2009;4:e4412. ">Lind 2009</a>). On the other hand, some investigators question whether HbA1c as such is the right outcome measure for studies of diabetes (<a href="./references#CD012661-bbs2-0351" title="LipskaKJ , KrumholzHM . Is hemoglobin A1c the right outcome for studies of diabetes?. JAMA2017;317:1017‐8. ">Lipska 2017</a>). </p> <p>Also, IFG and IGT differ in their age and sex distribution, and both increase with advancing age (<a href="./references#CD012661-bbs2-0357" title="NathanDM , DavidsonMB , DeFronzoRA , HeineRJ , HenryRR , PratleyR , et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care2007;30:753‐9. ">Nathan 2007</a>), as glucose tolerance deteriorates with age (<a href="./references#CD012661-bbs2-0322" title="GaleEA . Can NICE prevent diabetes?. Heart2013;99:824‐6. ">Gale 2013</a>). 'Ethnicity' and geography are additional important features: the prevalence of elevated HbA1c in black people is twice as high as in non‐Hispanic white people, but the opposite is true for IGT (<a href="./references#CD012661-bbs2-0369" title="SelvinE , SteffesMW , BallantyneCM , HoogeveenRC , CoreshJ , BrancatiFL . Racial differences in glycemic markers: a cross‐sectional analysis of community‐based data. Annals of Internal Medicine2011;154(5):303‐9. [PUBMED: 21357907] ">Selvin 2011</a>; <a href="./references#CD012661-bbs2-0388" title="ZiemerDC , KolmP , WeintraubWS , VaccarinoV , RheeMK , TwomblyJG , et al. Glucose‐independent, black‐white differences in hemoglobin A1c levels: a cross‐sectional analysis of 2 studies. Annals of Internal Medicine2010;152:770‐7. ">Ziemer 2010</a>). The number of people with IH identified in South Asian compared with European cohorts and the associated cardiovascular disease (CVD) risk depend on how prediabetes is diagnosed (<a href="./references#CD012661-bbs2-0317" title="EastwoodSV , TillinT , MayetJ , ShibataDK , WrightA , HeasmanJ , et al. Ethnic differences in cross‐sectional associations between impaired glucose regulation, identified by oral glucose tolerance test or HbA1c values, and cardiovascular disease in a cohort of European and South Asian origin. Diabetic Medicine2016;33:340‐7. ">Eastwood 2016</a>). </p> <p>The increase in T2DM results from an interaction between genetic and environmental factors, reflecting behavioural changes over time such as decreased physical activity levels and increased body weight (<a href="./references#CD012661-bbs2-0315" title="DeFronzoRA , Abdul‐GhaniMA . Preservation of beta‐cell function: the key to diabetes prevention. Journal of Clinical Endocrinology and Metabolism2011;96:2354‐66. ">DeFronzo 2011</a>; <a href="./references#CD012661-bbs2-0357" title="NathanDM , DavidsonMB , DeFronzoRA , HeineRJ , HenryRR , PratleyR , et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care2007;30:753‐9. ">Nathan 2007</a>). Both IFG and IGT are insulin‐resistant states, and insulin resistance is thought to be the core defect in T2DM: people with (isolated) IFG predominantly have β‐cell dysfunction with impaired insulin secretion (<a href="./references#CD012661-bbs2-0314" title="DeFronzoRA , FerranniniE , SimonsonDC . Fasting hyperglycemia in non‐insulin‐dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake. Metabolism: Clinical and Experimental1989;38(4):387‐95. [PUBMED: 2657323] ">DeFronzo 1989</a>), plus moderate hepatic insulin resistance, but near‐normal muscle insulin sensitivity. The consequence is excessive fasting hepatic glucose production followed by elevated FPG. During an OGTT the early insulin response (0 to 30/60 min) is impaired, resulting in an excessive early rise in postload glucose (PG). The late insulin response (60 min to 120 min) appears intact and the two‐hour PG returns to its approximately starting FPG level (<a href="./references#CD012661-bbs2-0315" title="DeFronzoRA , Abdul‐GhaniMA . Preservation of beta‐cell function: the key to diabetes prevention. Journal of Clinical Endocrinology and Metabolism2011;96:2354‐66. ">DeFronzo 2011</a>; <a href="./references#CD012661-bbs2-0357" title="NathanDM , DavidsonMB , DeFronzoRA , HeineRJ , HenryRR , PratleyR , et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care2007;30:753‐9. ">Nathan 2007</a>). People with (isolated) IGT have normal to slightly reduced hepatic insulin sensitivity and moderate to severe muscle insulin resistance (<a href="./references#CD012661-bbs2-0297" title="Abdul‐GhaniMA , JenkinsonCP , RichardsonDK , TripathyD , DeFronzoRA . Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans administration genetic epidemiology study. Diabetes2006;55(5):1430‐5. [PUBMED: 16644701] ">Abdul‐Ghani 2006</a>; <a href="./references#CD012661-bbs2-0345" title="JensenCC , CnopM , HullRL , FujimotoWY , KahnSE . Beta‐cell function is a major contributor to oral glucose tolerance in high‐risk relatives of four ethnic groups in the U.S. Diabetes2002;51(7):2170‐8. [PUBMED: 12086947] ">Jensen 2002</a>). During an OGTT both the early and the late insulin response are impaired. Hyperglycaemia is progressive and prolonged after the glucose load, and the two‐hour PG remains above its starting FPG level (<a href="./references#CD012661-bbs2-0315" title="DeFronzoRA , Abdul‐GhaniMA . Preservation of beta‐cell function: the key to diabetes prevention. Journal of Clinical Endocrinology and Metabolism2011;96:2354‐66. ">DeFronzo 2011</a>; <a href="./references#CD012661-bbs2-0357" title="NathanDM , DavidsonMB , DeFronzoRA , HeineRJ , HenryRR , PratleyR , et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care2007;30:753‐9. ">Nathan 2007</a>). </p> <p>There are some known risk indicators for the development of T2DM, including a positive family history, gestational diabetes mellitus, obesity, 'ethnicity' (e.g. the risk of diabetes is thought to be higher among Asians, Hispanics, and 'black' people), polycystic ovarian syndrome, impaired insulin secretion and insulin resistance, abnormal coagulation factors and endothelial dysfunction. However, the evidence base for the weight of a single risk indicator and the interplay of various factors is still under investigation. Type 2 diabetes mellitus is a rather complex metabolic state and could be described as an asymptomatic risk factor for a future disease (<a href="./references#CD012661-bbs2-0384" title='YudkinJS . "Prediabetes": Are there problems with this label? Yes, the label creates further problems!. Diabetes Care2016;39:1468‐71. '>Yudkin 2016</a>), and hence prediabetes a risk factor for another risk factor (<a href="./references#CD012661-bbs2-0357" title="NathanDM , DavidsonMB , DeFronzoRA , HeineRJ , HenryRR , PratleyR , et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care2007;30:753‐9. ">Nathan 2007</a>). </p> <p>Diabetes is a category, whereas IFG and IGT reflect a continuous variable with more or less arbitrarily chosen cut‐off points (<a href="./references#CD012661-bbs2-0382" title="YudkinJS , AlbertiKG , McLartyDG , SwaiAB . Impaired glucose tolerance. BMJ1990;301:397‐402. ">Yudkin 1990</a>; <a href="./references#CD012661-bbs2-0383" title="YudkinJS , MontoriVM . The epidemic of pre‐diabetes: the medicine and the politics. BMJ2014;349:g4485. ">Yudkin 2014</a>). The reduced lower threshold of 5.6 mmol/L (100 mg/dL) to define IFG by the ADA in 2003 substantially increased the prevalence of IFG with potentially significant public health and socioeconomic implications (<a href="./references#CD012661-bbs2-0311" title="DavidsonMB , LandsmanPB , AlexanderCM . Lowering the criterion for impaired fasting glucose will not provide clinical benefit. Diabetes Care2003;26:3329‐30. ">Davidson 2003</a>; <a href="./references#CD012661-bbs2-0383" title="YudkinJS , MontoriVM . The epidemic of pre‐diabetes: the medicine and the politics. BMJ2014;349:g4485. ">Yudkin 2014</a>; <a href="./references#CD012661-bbs2-0384" title='YudkinJS . "Prediabetes": Are there problems with this label? Yes, the label creates further problems!. Diabetes Care2016;39:1468‐71. '>Yudkin 2016</a>). Some authors have argued that substantial benefits might ensue even if it were only possible to delay the onset of diabetes by detecting and treating prediabetes (<a href="./references#CD012661-bbs2-0309" title='CefaluWT . "Prediabetes": Are there problems with this label? No, we need heightened awareness of this condition!. Diabetes Care2016;39:1472‐7. '>Cefalu 2016</a>). Interestingly, some people with IH will not develop T2DM, and some people will return or 'regress' to normoglycaemia. In the Diabetes Prevention Program (DPP), the hazard ratio of developing T2DM was 0.44 (95% confidence interval 0.37 to 0.55) in people having at least one normal OGTT during the DPP compared with people who never regressed to normoglycaemia during the DPP (<a href="./references#CD012661-bbs2-0361" title="PerreaultL , PanQ , MatherKJ , WatsonKE , HammanRF , KahnSE , et al. Effect of regression from prediabetes to normal glucose regulation on long‐term reduction in diabetes risk: results from the diabetes prevention program outcomes study. Lancet2012;379:2243‐51. ">Perreault 2012</a>; <a href="./references#CD012661-bbs2-0362" title="PerreaultL , TemprosaM , MatherKJ , HortonE , KitabchiA , LarkinM , et al. Regression from prediabetes to normal glucose regulation is associated with reduction in cardiovascular risk: results from the diabetes prevention program outcomes study. Diabetes Care2014;37:2622‐31. ">Perreault 2014</a>). The ADA associated regression with remission and defined it as a partial or complete diabetes remission of glycaemic measurements for at least one year without pharmacological or surgical interventions (<a href="./references#CD012661-bbs2-0305" title="BuseJB , CaprioS , CefaluWT , CerielloA , DelPratoS , InzucchiSE , et al. How do we define cure of diabetes?. Diabetes Care2009;32:2133‐5. ">Buse 2009</a>). This could have significant impact on "the therapeutic strategy from diabetes prevention and lifelong glucose‐lowering treatment to induction of regression and monitoring for relapse" (<a href="./references#CD012661-bbs2-0381" title="YakubovichN , GersteinHC . Is regression to normoglycaemia clinically important?. Lancet2012;379:2216‐8. ">Yakubovich 2012</a>). </p> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012661-sec-0038" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012661-sec-0038"></div> <p><b>Objective 1</b>: to assess the overall prognosis of people with IH for the development of T2DM and to assess how many people with IH revert back to normoglycaemia (regression). </p> <p>With regard to objective 1 we established the following 'Population, Intervention, Outcome, Timing, Setting' (PICOTS) table (adapted according to the PICOTS system presented in <a href="./references#CD012661-bbs2-0313" title="DebrayTP , DamenJA , SnellKI , EnsorJ , HooftL , ReitsmaJB , et al. A guide to systematic review and meta‐analysis of prediction model performance. BMJ2017;356:i6460. ">Debray 2017</a>). </p> <p> <div class="table" id="CD012661-tblf-0001"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Item</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Definition</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P</b>opulation </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People with intermediate hyperglycaemia (defined by IFG, IGT or elevated HbA1c)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>I</b>ntervention </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>C</b>omparator </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>O</b>utcome </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Development of type 2 diabetes</p> <p>Regression to normoglycaemia</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>T</b>iming </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At least 1 year follow‐up</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>S</b>etting </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatients</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>IFG</b> : impaired fasting glucose; <b>IGT</b> : impaired glucose tolerance; <b>HbA1c</b>: glycosylated haemoglobin A1c </p> </td> </tr> </tbody> </table> </div> </p> <p><b>Objective 2</b>: to assess the difference in T2DM incidence in people with IH versus people with normoglycaemia. </p> <p>With regard to objective 2 we established the following PICOTS table (adapted according to the PICOTS system presented in <a href="./references#CD012661-bbs2-0313" title="DebrayTP , DamenJA , SnellKI , EnsorJ , HooftL , ReitsmaJB , et al. A guide to systematic review and meta‐analysis of prediction model performance. BMJ2017;356:i6460. ">Debray 2017</a>). </p> <p> <div class="table" id="CD012661-tblf-0002"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Item</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Definition</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P</b>opulation </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People with intermediate hyperglycaemia (defined by IFG, IGT or elevated HbA1c)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>I</b>ntervention </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intermediate hyperglycaemia as a prognostic factor</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>C</b>omparator </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Normoglycaemia</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>O</b>utcome </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Development of type 2 diabetes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>T</b>iming </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At least one year follow‐up</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>S</b>etting </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatients</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>IFG</b> : impaired fasting glucose; <b>IGT</b> : impaired glucose tolerance; <b>HbA1c</b>: glycosylated haemoglobin A1c </p> </td> </tr> </tbody> </table> </div> </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012661-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012661-sec-0039"></div> <section id="CD012661-sec-0040"> <h3 class="title" id="CD012661-sec-0040">Criteria for considering studies for this review</h3> <section id="CD012661-sec-0041"> <h4 class="title">Study design</h4> <p>Prospective cohort studies investigating either the overall prognosis of people with IH for developing T2DM or IH versus normoglycaemia as a prognostic factor for developing T2DM (<a href="./references#CD012661-bbs2-0301" title="AltmanD G . Systematic reviews of evaluations of prognostic variables. BMJ2001;323:224‐8. ">Altman 2001</a>). </p> </section> <section id="CD012661-sec-0042"> <h4 class="title">Inclusion criteria</h4> <section id="CD012661-sec-0043"> <h5 class="title">Types of participants</h5> <p>To study the overall prognosis of people with IH and regression from IH to normoglycaemia, we included cohort studies in people with IH at baseline, defined by impaired fasting glucose (IFG), impaired glucose tolerance (IGT), elevated glycosylated haemoglobin A1c (HbA1c) or any combination of these. IH had to be established by standard cut‐off values for IFG, IGT or elevated HbA1c, as defined by ADA or WHO (<a href="./references#CD012661-bbs2-0298" title="The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care1997;20(7):1183‐97. ">ADA 1997</a>; <a href="./references#CD012661-bbs2-0299" title="Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care2003;26(Suppl 1):S5‐20. ">ADA 2003</a>; <a href="./references#CD012661-bbs2-0300" title="American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care2010;33(Suppl 1):S62‐9. [PUBMED: 20042775] ">ADA 2010</a>; <a href="./references#CD012661-bbs2-0340" title="International Conference on Harmonisation Expert Working Group. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice //1997 CFR &amp; ICH Guidelines. PA 19063‐2043USA: Barnett International/PAREXEL, 1997. ">ICH 1997</a>; <a href="./references#CD012661-bbs2-0341" title="International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care2009;32(7):1327‐34. [PUBMED: 19502545] ">IEC 2009</a>; <a href="./references#CD012661-bbs2-0375" title="AlbertiKM , ZimmetPZ . Definition, diagnosis and classification of diabetes mellitus and its complications. Part I: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabetic Medicine1998;15(7):539‐53. ">WHO 1998</a>; <a href="./references#CD012661-bbs2-0377" title="World Health Organization/ International Diabetes Federation. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: report of a WHO/IDF consultation. WHO, 2006. Available from www.who.int/diabetes/publications/Definition%20and%20diagnosis%20of%20diabetes_new.pdf Vol. (assessed 3 March 2018). ">WHO/IDF 2006</a>). </p> <p>To study whether IH compared to normoglycaemia is a prognostic factor for developing T2DM, we included cohort studies in people with IH and normoglycaemia at baseline. </p> </section> <section id="CD012661-sec-0044"> <h5 class="title">Definition of IH</h5> <p>We defined IH according to ADA and WHO descriptions.</p> <p> <ul id="CD012661-list-0002"> <li> <p>IFG<sub>5.6</sub> threshold, usually defined as a fasting plasma glucose level between 5.6 mmol/L and 6.9 mmol/L at baseline. </p> </li> <li> <p>IFG<sub>6.1</sub> threshold, usually defined as a fasting plasma glucose level between 6.1 mmol/L and 6.9 mmol/L at baseline. </p> </li> <li> <p>IGT, usually defined as a plasma glucose level between 7.8 mmol/L and 11.1 mmol/L two hours after a 75 g OGTT at baseline. </p> </li> <li> <p>Isolated IFG was defined as IFG<sub>5.6</sub> or IFG<sub>6.1</sub> only (without IGT), and isolated IGT was defined as IGT only (without IFG<sub>5.6</sub> or IFG<sub>6.1</sub>). </p> </li> <li> <p>HbA1c<sub>5.7</sub> threshold, usually defined as HbA1c measurement between 5.7% and 6.4% at baseline. </p> </li> <li> <p>HbA1c<sub>6.0</sub> threshold, usually defined as HbA1c measurement between 6.0% and 6.4% at baseline. </p> </li> </ul> </p> </section> <section id="CD012661-sec-0045"> <h5 class="title">Types of outcome measures</h5> <p>Our outcome of primary interest was the diagnosis of newly developed T2DM (T2DM incidence). T2DM incidence should have been diagnosed by blood glucose measurements such as fasting plasma glucose (FPG), two‐hour postload glucose (PG) or HbA1c. Diagnosis could have been combined with self‐reported diabetes, physician‐diagnosed diabetes or use of antihyperglycaemic medications such as oral hypoglycaemic drugs, insulin or both. </p> </section> </section> <section id="CD012661-sec-0046"> <h4 class="title">Exclusion criteria</h4> <p> <ul id="CD012661-list-0003"> <li> <p>Intervention trials and study designs other than prospective cohort studies.</p> </li> <li> <p>People with comorbidities at baseline (e.g. people with coronary heart disease and IGT). </p> </li> <li> <p>Missing data on transition from IH to T2DM.</p> </li> <li> <p>Follow‐up period after baseline assessment not specified (not possible to associate T2DM incidence with length of follow‐up). </p> </li> <li> <p>T2DM incidence evaluated by documents (e.g. hospital records, retrospective use of registers) or self‐report only. </p> </li> </ul> </p> </section> <section id="CD012661-sec-0047"> <h4 class="title">Search methods for identification of studies</h4> <p>The fundamental challenge of this review question was to define the population of interest, that is, people with IH. We expected a great number of terms describing this population, such as people with prediabetes, mentions of IFG, IGT or HbA1c somewhere in the title or abstract of relevant publications, and terms like risk factors, predictors, prevalence, incidence and several other concepts which cannot be foreseen when developing a Boolean search strategy in a conceptual way. </p> <p>One option to address this problem would have been to design a highly sensitive search strategy, which would have resulted in a yield of more than 15,000 references, which was unfeasible for fast human screening but could be addressed in the future with robust automated classification algorithms. Instead, we designed a more specific Boolean search approach based on text analysis and augmented by the following complementary search methods. </p> <p> <ol id="CD012661-list-0004"> <li> <p>Identification of systematic reviews addressing our review question.</p> </li> <li> <p>Careful checking of reference lists and Discussion sections of relevant studies.</p> </li> <li> <p>A non‐human skill dependent search method based on PubMed's 'similar articles' algorithm.</p> </li> </ol> </p> <section id="CD012661-sec-0048"> <h5 class="title">Boolean search</h5> <p>We developed the search strategy using analytical text mining of 44 relevant publications (range of publication years 2008 to 2015, from 31 journals) already known to review author BR. We used the tools PubReMiner, TerMine and AntConc and applied the prognosis filters by the Hedges Team (<a href="./references#CD012661-bbs2-0378" title="WilczynskiNL , HaynesRB . Developing optimal search strategies for detecting clinically sound prognostic studies in MEDLINE: an analytic survey. BMC Medicine2004;2(1):23. ">Wilczynski 2004</a>; <a href="./references#CD012661-bbs2-0379" title="WilczynskiNL , HaynesRB . Optimal search strategies for detecting clinically sound prognostic studies in EMBASE: an analytic survey. Journal of the American Medical Informatics Association2005;12(4):481‐5. ">Wilczynski 2005</a>). </p> <p>We searched the following sources from database inception to the specified date.</p> <p> <ul id="CD012661-list-0005"> <li> <p>MEDLINE Ovid Epub Ahead of Print, In‐Process &amp; Other Non‐Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) (1946 to 15 December 2016 and then updated to 26 February 2018). </p> </li> <li> <p>Embase Ovid (1974 to 2016 Week 50, last searched 15 December 2016).</p> </li> <li> <p><a href="http://clinicaltrials.gov/" target="_blank">ClinicalTrials.gov</a> (searched 15 December 2016). </p> </li> <li> <p>WHO International Clinical Trials Registry Platform (ICTRP) Search Portal (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch</a>; searched 15 December 2016). </p> </li> </ul> </p> <p>Before publication, we updated the MEDLINE search as reflected above. We restricted the update to MEDLINE because 98% of the publications of included studies identified up to the point of updating (on 26 February 2018) were indexed in MEDLINE. </p> <p>The search strategy consisted of two tiers.</p> <p> <ol id="CD012661-list-0006"> <li> <p>Prediabetes as predictor for cardiovascular disease (CVD), mortality, stroke, cancer, micro‐ and macrovascular complications. </p> </li> <li> <p>Prediabetes as predictor for diabetes incidence.</p> </li> </ol> </p> <p>We combined both strategies with the conjunction 'OR' because it was likely that search results for prediabetes as a predictor for complications also contained data on diabetes incidence. For details of all search strategies see <a href="./appendices#CD012661-sec-0137">Appendix 2</a>. </p> </section> <section id="CD012661-sec-0049"> <h5 class="title">Study extraction of relevant systematic reviews</h5> <p>In addition, we extracted relevant publications from 16 identified systematic reviews (<a href="./references#CD012661-bbs2-0318" title="Echouffo‐TcheuguiJB , NarayanKM , WeismanD , GoldenSH , JaarBG . Association between prediabetes and risk of chronic kidney disease: a systematic review and meta‐analysis. Diabetic Medicine2016;33(12):1615‐24. ">Echouffo‐Tcheugui 2016</a>; <a href="./references#CD012661-bbs2-0319" title="ErqouS , LeeCT , SuffolettoM , Echouffo‐TcheuguiJB , deBoerRA , vanMelleJP , et al. Association between glycated haemoglobin and the risk of congestive heart failure in diabetes mellitus: systematic review and meta‐analysis. European Journal of Heart Failure2013;15(2):185‐93. ">Erqou 2013</a>; <a href="./references#CD012661-bbs2-0320" title="FordES , ZhaoG , LiC . Pre‐diabetes and the risk for cardiovascular disease: a systematic review of the evidence. Journal of the American College of Cardiology2010;55(13):1310‐7. ">Ford 2010</a>; <a href="./references#CD012661-bbs2-0335" title="HopeC , RobertshawA , CheungKL , IdrisI , EnglishE . Relationship between HbA1c and cancer in people with or without diabetes: a systematic review. Diabetic Medicine2016;33(8):1013‐25. ">Hope 2016</a>; <a href="./references#CD012661-bbs2-0337" title="HuangY , CaiX , ChenP , MaiW , TangH , HuangY , et al. Associations of prediabetes with all‐cause and cardiovascular mortality: a meta‐analysis. Annals of Medicine2014;46(8):684‐92. ">Huang 2014b</a>; <a href="./references#CD012661-bbs2-0336" title="HuangY , CaiX , QiuM , ChenP , TangH , HuY , et al. Prediabetes and the risk of cancer: a meta‐analysis. Diabetologia2014;57(11):2261‐9. ">Huang 2014a</a>; <a href="./references#CD012661-bbs2-0338" title="HuangY , CaiX , MaiW , LiM , HuY . Association between prediabetes and risk of cardiovascular disease and all cause mortality: systematic review and meta‐analysis. BMJ2016;355:i5953. ">Huang 2016</a>; <a href="./references#CD012661-bbs2-0347" title="LeeM , SaverJL , HongKS , SongS , ChangKH , OvbiageleB . Effect of pre‐diabetes on future risk of stroke: meta‐analysis. BMJ2012;344:e3564. ">Lee 2012</a>; <a href="./references#CD012661-bbs2-0354" title="MorrisDH , KhuntiK , AchanaF , SrinivasanB , GrayLJ , DaviesMJ , et al. Progression rates from HbA1c 6.0‐6.4% and other prediabetes definitions to type 2 diabetes: a meta‐analysis. Diabetologia2013;56(7):1489‐93. [PUBMED: 23584433] ">Morris 2013</a>; <a href="./references#CD012661-bbs2-0366" title="Santos‐OliveiraR , PurdyC , daSilvaMP , dos Anjos Carneiro‐LeaoAM , MachadoM , EinarsonTR . Haemoglobin A1c levels and subsequent cardiovascular disease in persons without diabetes: a meta‐analysis of prospective cohorts. Diabetologia2011;54(6):1327‐34. ">Santos‐Oliveira 2011</a>; <a href="./references#CD012661-bbs2-0367" title="SarwarN , AspelundT , EiriksdottirG , GobinR , SeshasaiSR , ForouhiNG , et al. Markers of dysglycaemia and risk of coronary heart disease in people without diabetes: Reykjavik prospective study and systematic review. PLOS Medicine2010;7(5):e1000278. ">Sarwar 2010</a>; <a href="./references#CD012661-bbs2-0368" title="SchottkerB , RathmannW , HerderC , ThorandB , WilsgaardT , NjolstadI , et al. HbA1c levels in non‐diabetic older adults ‐ No J‐shaped associations with primary cardiovascular events, cardiovascular and all‐cause mortality after adjustment for confounders in a meta‐analysis of individual participant data from six cohort studies. BMC Medicine2016;14:26. ">Schottker 2016</a>; <a href="./references#CD012661-bbs2-0373" title="TwitoO , FrankelM , NabriskiD . Impact of glucose level on morbidity and mortality in elderly with diabetes and pre‐diabetes. World Journal of Diabetes2015;6(2):345‐51. ">Twito 2015</a>; <a href="./references#CD012661-bbs2-0380" title="XuT , LiuW , CaiX , DingJ , TangH , HuangY , et al. Risk of coronary heart disease in different criterion of impaired fasting glucose: a meta‐analysis. Medicine2015;94(40):e1740. ">Xu 2015</a>; <a href="./references#CD012661-bbs2-0386" title="ZhangY , HuG , YuanZ , ChenL . Glycosylated hemoglobin in relationship to cardiovascular outcomes and death in patients with type 2 diabetes: a systematic review and meta‐analysis. PLOS ONE2012;7(8):e42551. ">Zhang 2012a</a>; <a href="./references#CD012661-bbs2-0387" title="ZhongGC , YeMX , ChengJH , ZhaoY , GongJP . HbA1c and risks of all‐cause and cause‐specific death in subjects without known diabetes: a dose‐response meta‐analysis of prospective cohort studies. Scientific Reports2016;6:24071. ">Zhong 2016</a>). </p> </section> <section id="CD012661-sec-0050"> <h5 class="title">Reference checking of included studies</h5> <p>We extracted relevant publications after handsearching the full texts of included studies (Methods section, Discussion section, reference lists). </p> </section> <section id="CD012661-sec-0051"> <h5 class="title">'Similar articles'‐based search method</h5> <p>On 15 March 2018 we ran PubMed's 'similar articles' algorithm with the 224 publications of included studies identified by our search methods so far ('seed publications' in <a href="./appendices#CD012661-sec-0137">Appendix 2</a>). When using the 'similar articles' algorithm, search results in PubMed are retrieved and ranked according to pre‐calculated similarities of the seed publications. We downloaded the first 500 results (of 24,124), deduplicated them against the already identified seed publications and screened the resulting set. </p> </section> </section> <section id="CD012661-sec-0052"> <h4 class="title">Selection of studies</h4> <p>Two review authors (BR and BH) independently scanned the title, abstract, or both, of every record retrieved in the literature searches to determine which studies to assess further. We investigated the full text of all potentially relevant articles, resolving discrepancies through consensus or by recourse to a third review author (MIM). We prepared a flow diagram of the number of studies identified and excluded at each stage in accordance with the PRISMA flow diagram of study selection (<a href="./references#CD012661-bbs2-0348" title="LiberatiA , AltmanDG , TetzlaffJ , MulrowC , GøtzschePC , IoannidisJPA , et al. The PRISMA statement for reporting systematic and meta‐analyses of studies that evaluate interventions: explanation and elaboration. PLOS Medicine2009;6(7):1‐28. [DOI: 10.1371/journal.pmed.1000100] ">Liberati 2009</a>). </p> </section> <section id="CD012661-sec-0053"> <h4 class="title">Data extraction and management</h4> <p>For studies that fulfilled our inclusion criteria, one review author (BR) extracted key study characteristics, inclusion and exclusion criteria of study participants, stated aim of the study, definitions of prognosis, prognostic factor and outcome (normoglycaemia, intermediate glycaemia and T2DM incidence), baseline characteristics of study participants and data on transition from IH (as defined by IFG, IGT, elevated HbA1c or combinations thereof) to T2DM. Another author (MIM) checked these data extractions, and we resolved any disagreements by discussion or, if required, by consultation with a third review author (BH). We used parts of the checklist for critical appraisal and data extraction for systematic <b>r</b> eviews of prediction <b>m</b> odelling <b>s</b>tudies (CHARMS), which helps to evaluate prediction modelling studies (<a href="./references#CD012661-bbs2-0353" title="MoonsKG , deGrootJA , BouwmeesterW , VergouweY , MallettS , AltmanDG , et al. Critical appraisal and data extraction for systematic reviews of prediction modelling studies: the CHARMS checklist. PLOS Medicine2014;11(10):e1001744. ">Moons 2014</a>), and we established our own context‐specific data extraction sheets after piloting data extraction for 15 studies. </p> </section> <section id="CD012661-sec-0054"> <h4 class="title">Dealing with companion publications</h4> <p>In the event of companion publications or multiple reports of a prospective cohort study (e.g. because of different time points investigated) we focused on the analysis of the publication describing the longest follow‐up from baseline and extracted data from shorter follow‐ups in case some measures were not reported in the publication on the longest follow‐up (e.g. the most recent paper might have described the association between elevated HbA1c and T2DM incidence, but an older publication might have described the association between IGT and T2DM incidence). Companion publications or multiple reports of a primary study were listed as secondary references under the primary reference of the included, ongoing or excluded study. </p> </section> <section id="CD012661-sec-0055"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>One review author (BR) assessed the risk of bias of each included study and another review author (MIM) checked the accuracy of this assessment. We resolved any disagreements by consensus, or by consultation with a third review author (BH). We used a tailored version of the Quality In Prognosis Studies (QUIPS) tool for assessing risk of bias in studies of the prognostic factor IH versus normoglycaemia (<a href="./references#CD012661-bbs2-0316" title="DretzkeJ , EnsorJ , BaylissS , HodgkinsonJ , LordkipanidzeM , RileyRD , et al. Methodological issues and recommendations for systematic reviews of prognostic studies: an example from cardiovascular disease. Systematic Reviews2014;3:140. ">Dretzke 2014</a>; <a href="./references#CD012661-bbs2-0327" title="HaydenJA , van derWindtDA , CartwrightJL , CoteP , BombardierC . Assessing bias in studies of prognostic factors. Annals of Internal Medicine2013;158(4):280‐6. ">Hayden 2013</a>; see <a href="./appendices#CD012661-sec-0138">Appendix 3</a>). Our tool consisted of six risk of bias domains: study participation, study attrition, glycaemic status measurement, outcome measurement, study confounding; and statistical analysis and reporting. The study participation domain consisted of five items: description of the source population or population of interest, description of the baseline study sample, adequate description of the sampling frame and recruitment, adequate description of the period and place of recruitment, and adequate description of inclusion and exclusion criteria. The study attrition domain consisted of four items: description of attempts to collect information on participants who dropped out, reasons for loss to follow‐up provided, adequate description of participants lost to follow‐up, and no important differences between participants who completed the study and those who did not. The glycaemic status measurement domain consisted of four items: provision of clear definition or description of the glycaemic status, adequately valid and reliable method of measuring glycaemic status, reporting of continuous variables or use of appropriate cut points, and use of same method and setting of measurement of glycaemic status in all study participants. The outcome measurement domain consisted of three items: provision of clear definition of the outcome, use of adequately valid and reliable method of outcome measurement, and use of same method and setting of outcome measurement in all study participants. The study confounding domain consisted of the seven items: measurement of all important confounders, provision of clear definitions of the important confounders measured, adequately valid and reliable measurement of all important confounders, use of same method and setting of confounding measurement in all study participants, appropriate imputation methods used for missing confounders (if applicable), important potential confounders accounted for in the study design, and important potential confounders accounted for in the analysis. The statistical analysis and reporting domain consisted of two items: sufficient presentation of data to assess the adequacy of the analytic strategy, and adequate statistical model for the design of the study. There is no recommended tool for assessing risk of bias in studies of overall prognosis. Therefore, we applied the tailored QUIPS tool to these studies as well but without the domains for study confounding and statistical analysis and reporting because these were not suitable to basic calculations of cumulative incidence. We planned to investigate the influence of low risk of bias (low risk of bias in all domains) versus unclear/high risk of bias (unclear or high risk of bias in at least one of these domains). </p> </section> <section id="CD012661-sec-0056"> <h4 class="title">Measures of T2DM incidence and unit of analyses issues</h4> <p>If more than one group from the same cohort study was eligible for inclusion in the same meta‐analysis, we included the groups only if separate information was available (e.g. data on T2DM incidence for female and male participants). If more than one time point of T2DM was available for a study (e.g. cumulative incidence data) we included data in the appropriate meta‐analysis for each time point separately and did not pool data across different follow‐up periods. </p> </section> <section id="CD012661-sec-0057"> <h4 class="title">Data synthesis</h4> <p>Our primary aim for overall prognosis in people with IH was to provide a transparent overview of the whole data matrix describing a wide variety of possible associations between various isolated and combined definitions of IH and incident T2DM in dissimilar populations covering diverse time periods. We also evaluated whether IH compared to normoglycaemia is a prognostic factor for developing T2DM. </p> <p>First, we grouped studies on IH definitions, i.e. isolated IFG 5.6 mmol/L to 6.9 mmol/L (<b>IFG<sub>5.6</sub> threshold</b> ), isolated IFG 6.1 mmol/L to 6.9 mmol/L (<b>IFG<sub>6.1</sub> threshold</b> ), isolated <b>IGT</b> (glucose concentration 7.8 mmol/L to 11.1 mmol/L two hours after a 75 g glucose load on the OGTT), <b>IFG and IGT</b> combined, HbA1c 6.0% to 6.4% (<b>HbA1c<sub>6.0</sub> threshold</b> ), and HbA1c 5.7% to 6.4% (<b>HbA1c<sub>5.7</sub> threshold</b>). Then we evaluated subgroups of different geographic locations/'ethnicities' for each IH definition. </p> <p>We expected the following outcome measures.</p> <p> <ul id="CD012661-list-0007"> <li> <p>Cases (cumulative incidence at follow‐up; e.g. 20 new diabetes cases out of 400 people with IFG at baseline (5%)) and cumulative incidence rates (cases per 1000 person‐years) for overall prognosis of people with IH. </p> </li> <li> <p>Odds ratios (ORs), incidence rate ratios (IRRs), and hazard ratios (HRs) for IH versus normoglycaemia as a prognostic factor for developing T2DM. </p> </li> </ul> </p> <p>We pooled incidence and incidence rate ratios (IRR) using a random‐effects model to account for between‐study heterogeneity. For meta‐analysis of incidence data, we used a method for pooling proportions which uses the Freeman‐Tukey Double Arcsine Transformation to stabilise the variances (<a href="./references#CD012661-bbs2-0321" title="FreemanMF , TukeyJW . Transformations related to the angular and the square root. Annals of Mathematical Statistics1950;21:607‐11. ">Freeman 1950</a>). The meta‐analysis was performed using the Stata software user written programme metaprop (<a href="./references#CD012661-bbs2-0371" title="StataCorp LP. Stata. Version 14. College Station (TX): StataCorp LP, 2015. ">Stata 2015</a>). For the confidence intervals (CI) for individual studies shown on the forest plots for incidence, we used the Wilson approach (<a href="./references#CD012661-bbs2-0359" title="NewcombeRG . Two‐sided confidence intervals for the single proportion: comparison of seven methods. Statistics in Medicine1998;17:857‐72. ">Newcombe 1998</a>). For meta‐analysis of IRRs, we first computed the log IRRs and their approximate standard errors and then used an inverse variance weighted random‐effects model to pool the log IRRs (<a href="./references#CD012661-bbs2-0326" title="HasselbladVV , McCroryDCD . Meta‐analytic tools for medical decision making: a practical guide. Medical Decision Making1994;15(1):81‐96. ">Hasselblad 1994</a>; <a href="./references#CD012661-bbs2-0334" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Section 9.4.8: Meta‐analysis of counts and rates. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011b</a>). We exponentiated the pooled log IRR to obtain the pooled IRR. The meta‐analysis of log IRRs was performed using the Stata user written programme metan. </p> <p>If publications reported HRs with associated 95% CIs, we obtained standard errors from these CIs as described in chapter 7.7.7.3 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012661-bbs2-0333" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011a</a>), and we performed meta‐analysis using the generic inverse‐variance method (<a href="./references#CD012661-bbs2-0363" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). When possible, we reported both adjusted and unadjusted HRs, but we primarily used adjusted HRs from multivariable models of studies incorporating similar covariates (<a href="./references#CD012661-bbs2-0316" title="DretzkeJ , EnsorJ , BaylissS , HodgkinsonJ , LordkipanidzeM , RileyRD , et al. Methodological issues and recommendations for systematic reviews of prognostic studies: an example from cardiovascular disease. Systematic Reviews2014;3:140. ">Dretzke 2014</a>). </p> </section> <section id="CD012661-sec-0058"> <h4 class="title">Assessment of heterogeneity</h4> <p>We expected substantial clinical heterogeneity between studies because of geographical/'ethnic' and methodological diversity. We did not intend to address statistical heterogeneity (inconsistency) using the I<sup>2</sup> statistic because this statistic does not indicate how much the effect size varies, which is what people want to know when asking about the implications of heterogeneity (<a href="./references#CD012661-bbs2-0303" title="BorensteinM , HigginsJP , HedgesLV , RothsteinHR . Basics of meta‐analysis: I2 is not an absolute measure of heterogeneity. Research Synthesis Methods2017;8(1):5‐18. ">Borenstein 2017a</a>). Also, the I<sup>2</sup> statistic is problematic in the context of prognosis studies because individual studies often have large sample sizes resulting in narrow CIs, which can result in high I<sup>2</sup> values even if inconsistency between studies is moderate (<a href="./references#CD012661-bbs2-0344" title="IorioA , SpencerFA , FalavignaM , AlbaC , LangE , BurnandB , et al. Use of GRADE for assessment of evidence about prognosis: rating confidence in estimates of event rates in broad categories of patients. BMJ2015;350:h870. ">Iorio 2015</a>). Instead, when there were at least three studies, we reported the range of the effects of the random‐effects meta‐analyses using prediction intervals (<a href="./references#CD012661-bbs2-0304" title="BorensteinM . Prediction intervals. www.meta‐analysis.com/prediction (accessed 3 March 2018). ">Borenstein 2017b</a>; <a href="./references#CD012661-bbs2-0332" title="HigginsJP , ThompsonSG , SpiegelhalterDJ . A re‐evaluation of random‐effects meta‐analysis. Journal of the Royal Statistical Society: Series A (Statistics in Society)2009;172:137‐59. ">Higgins 2009</a>; <a href="./references#CD012661-bbs2-0342" title="IntHoutJ , IoannidisJP , RoversMM , GoemanJJ . Plea for routinely presenting prediction intervals in meta‐analysis. BMJ Open2016;6:e010247. ">IntHout 2016</a>; <a href="./references#CD012661-bbs2-0364" title="RileyRD , HigginsJP , DeeksJJ . Interpretation of random effects meta‐analyses. BMJ2011;342:d549. ">Riley 2011</a>; <a href="./references#CD012661-bbs2-0365" title="RileyRD , EliaEG , MalinG , HemmingK , PriceMP . Multivariate meta‐analysis of prognostic factor studies with multiple cut‐points and/or methods of measurement. Statistics in Medicine2015;34:2481‐96. ">Riley 2015</a>). In a random‐effects meta‐analysis, the prediction interval reflects the whole distribution of effects across study populations, including the effect expected in a future study (<a href="./references#CD012661-bbs2-0342" title="IntHoutJ , IoannidisJP , RoversMM , GoemanJJ . Plea for routinely presenting prediction intervals in meta‐analysis. BMJ Open2016;6:e010247. ">IntHout 2016</a>; <a href="./references#CD012661-bbs2-0365" title="RileyRD , EliaEG , MalinG , HemmingK , PriceMP . Multivariate meta‐analysis of prognostic factor studies with multiple cut‐points and/or methods of measurement. Statistics in Medicine2015;34:2481‐96. ">Riley 2015</a>). </p> </section> <section id="CD012661-sec-0059"> <h4 class="title">Certainty of the evidence</h4> <p>We created a 'Summary of findings' table using Review Manager 5 (<a href="./references#CD012661-bbs2-0363" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). We used an adapted version of the GRADE framework for prognostic factor research for describing the influence of IFG, IGT, elevated HbA1c and both IFG and IGT on the development of T2DM (<a href="./references#CD012661-bbs2-0339" title="HuguetA , HaydenJA , StinsonJ , McGrathPJ , ChambersCT , TougasME , et al. Judging the quality of evidence in reviews of prognostic factor research: adapting the GRADE framework. Systematic Reviews2013;2:71. ">Huguet 2013</a>). We justified all decisions to downgrade the certainty of evidence using footnotes, and we made comments to aid the reader's understanding of this Cochrane Review where necessary. </p> </section> <section id="CD012661-sec-0060"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to perform sensitivity analyses to explore the influence of the following factors (when applicable) on effect sizes by excluding: </p> <p> <ul id="CD012661-list-0008"> <li> <p>studies at high or unclear risk of bias;</p> </li> <li> <p>very long or large studies to establish the extent to which they dominate the results.</p> </li> </ul> </p> </section> <section id="CD012661-sec-0061"> <h4 class="title">Subgroup analysis</h4> <p>Because we stratified the analyses by IH definition and geographical locations/'ethnicity', which we thought were the main sources of heterogeneity, we did not plan to perform subgroup analyses. However, if at least 10 studies specifying diabetes incidence data were included, we would have investigated age and sex by testing for interactions between subgroups. </p> <p>If T2DM incidence data were available for children and adolescents, we reported the results separately. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012661-sec-0062" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012661-sec-0062"></div> <section id="CD012661-sec-0063"> <h3 class="title" id="CD012661-sec-0063">Description of studies</h3> <section id="CD012661-sec-0064"> <h4 class="title">Results of the search</h4> <p>We identified a total of 8354 records through database searching and an additional 259 records from 16 systematic reviews. After excluding duplicates and non‐relevant records based on title and abstract screening, we assessed 450 full‐text records. Of these we excluded 213 full‐text articles; the remaining 237 articles were reports of 110 studies. Of the 110 studies, 4 were potentially relevant ongoing trials (<a href="./references#CD012661-bbs2-0293" title="NCT00786890 . A survey to evaluate the cardiovascular risk status of subjects with pre‐diabetes in Hong Kong (JADE‐HK2). clinicaltrials.gov/show/NCT00786890 (accessed 1 November 2017). ">NCT00786890</a>; <a href="./references#CD012661-bbs2-0294" title="NCT02838693 . Assessing progression to type‐2 diabetes (APT‐2D): a prospective cohort study expanded from BRITE‐SPOT (bio‐bank and registry for stratIfication and targeted interventions in the spectrum of type 2 diabetes) (APT‐2D). clinicaltrials.gov/show/NCT02838693 (accessed 1 November 2017). ">NCT02838693</a>; <a href="./references#CD012661-bbs2-0295" title="NCT02958579 . A population based study on metabolic syndrome complications, and mortality (MetSCoM). clinicaltrials.gov/show/NCT02958579 (accessed 1 November 2017). ">NCT02958579</a>; <a href="./references#CD012661-bbs2-0296" title="VilanovaMB , FalgueraM , MarsalJR , RubinatE , AlcubierreN , CastelblancoE , et al. Prevalence, clinical features and risk assessment of pre‐diabetes in Spain: the prospective Mollerussa cohort study. BMJ Open2017;7(6):e015158. ">Vilanova 2017</a>), and 3 are awaiting classification (<a href="./references#CD012661-bbs2-0290" title="LiG , WangJ , ChenC . [Model of development of diabetes mellitus in adult Chinese]. Zhonghua Yi Xue Za Zhi [National Medical Journal of China]2001;81(15):914‐7. ">Li 2001</a>; <a href="./references#CD012661-bbs2-0291" title="MisnikovaIV , DrevalAV , BarsukovIA , DzebisashviliTG . Risk of diabetes and cardiovascular events in persons with early glucose metabolism impairments. Diabetologia2011;54(Suppl 1):S119. ">Misnikova 2011</a>; <a href="./references#CD012661-bbs2-0292" title="NCT00816608 . The effect of maximum body weight in lifetime on the development of type 2 diabetes (MAXWEL) [Study of MAXimum Weight in Lifetime on glucose homeostasis (MAXWEL)]. clinicaltrials.gov/show/NCT00816608 (first received 1 January 2009). ">NCT00816608</a>). Therefore, we included 103 studies. We added 86 new publications after handsearching the full texts of included studies, but these were all secondary publications of the included studies. </p> <p>The complementary 'similar articles' algorithm search using our set of known publications yielded 263 publications for screening after deduplication. This resulted in 24 new publications after excluding irrelevant articles based on title and abstract screening. We did not identify new studies but found 13 secondary publications of studies we had already included. </p> <p>Altogether, we included 103 prospective cohort studies (329 publications) in the review. After the initial search in four databases (in December 2016), we observed that 98% of all included publications were indexed in Ovid MEDLINE. Therefore, we decided to restrict the pre‐publication update search in February 2018 to Ovid MEDLINE. </p> <p>For full details of search results see <a href="#CD012661-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD012661-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD012661-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> </section> <section id="CD012661-sec-0065"> <h4 class="title">Included studies</h4> <p>For a detailed description of the characteristics of the included studies, see <a href="./references#CD012661-sec-0161" title="">Characteristics of included studies</a>; <a href="./appendices#CD012661-sec-0139">Appendix 4</a>; <a href="./appendices#CD012661-sec-0140">Appendix 5</a>; <a href="./appendices#CD012661-sec-0141">Appendix 6</a>; <a href="./appendices#CD012661-sec-0142">Appendix 7</a>; <a href="./appendices#CD012661-sec-0143">Appendix 8</a>; <a href="./appendices#CD012661-sec-0144">Appendix 9</a>; <a href="./appendices#CD012661-sec-0145">Appendix 10</a>; <a href="./appendices#CD012661-sec-0146">Appendix 11</a>; <a href="./appendices#CD012661-sec-0147">Appendix 12</a>; <a href="./appendices#CD012661-sec-0148">Appendix 13</a>; <a href="./appendices#CD012661-sec-0149">Appendix 14</a>; <a href="./appendices#CD012661-sec-0150">Appendix 15</a>; <a href="./appendices#CD012661-sec-0151">Appendix 16</a>; and <a href="./appendices#CD012661-sec-0152">Appendix 17</a>. The following is a succinct overview. </p> <section id="CD012661-sec-0066"> <h5 class="title">Source of data</h5> <p>The 103 studies took place in the following regions of the world.</p> <p> <ul id="CD012661-list-0009"> <li> <p>Australia: 3 studies.</p> </li> <li> <p>Latin America: 7 studies (Chile, 1 study; Columbia, 1 study; Mexico, 5 studies (2 studies with primarily Mexican Americans took place in the USA (<a href="./references#CD012661-bbs2-0024" title="GarciaL , LeeA , Al HazzouriAZ , NeuhausJM , MoyceS , AielloA , et al. Influence of neighbourhood socioeconomic position on the transition to type II diabetes in older Mexican Americans: the Sacramento area longitudinal study on aging. BMJ Open2016;6(8):e010905. [PUBMED: 27515749] ">Garcia 2016</a>; <a href="./references#CD012661-bbs2-0057" title="Abdul‐GhaniMA , WilliamsK , DeFronzoR , SternM . Risk of progression to type 2 diabetes based on relationship between postload plasma glucose and fasting plasma glucose. Diabetes Care2006;29(7):1613‐8. HaffnerSM , BowsherRR , MykkänenL , HazudaHP , MitchellBD , ValdezRA , et al. Proinsulin and specific insulin concentration in high‐ and low‐risk populations for NIDDM. Diabetes1994;43(12):1490‐3. HaffnerSM , MiettinenH , GaskillSP , SternMP . Decreased insulin secretion and increased insulin resistance are independently related to the 7‐year risk of NIDDM in Mexican‐Americans. Diabetes1995;44(12):1386‐91. [PUBMED: 7589843] HaffnerSM , MiettinenH , SternM P . The homeostasis model in the San Antonio heart study. Diabetes Care1997;20(7):1087‐92. HaffnerSM , MiettinenH , SternMP . Are risk factors for conversion to NIDDM similar in high and low risk populations?. Diabetologia1997;40(1):62‐6. [PUBMED: 9028719] HaffnerSM , SternMP , MitchellBD , HazudaHP , PattersonJK . Incidence of type II diabetes in Mexican Americans predicted by fasting insulin and glucose levels, obesity, and body‐fat distribution. Diabetes1990;39(3):283‐8. [PUBMED: 2407581] HazudaHP , HaffnerSM , SternMP , EiflerCW . Effects of acculturation and socioeconomic status on obesity and diabetes in Mexican Americans. The San Antonio heart study. American Journal of Epidemiology1988;128(6):1289‐301. LorenzoC , OkoloiseM , WilliamsK , SternMP , HaffnerS M . The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study. Diabetes Care2003;26(11):3153‐9. [PUBMED: 14578254] MitchellBD , SternMP , HaffnerSM , HazudaHP , PattersonJK . Risk factors for cardiovascular mortality in Mexican Americans and non‐Hispanic whites. San Antonio heart study. American Journal of Epidemiology1990;131(3):423‐33. SternMP , MoralesPA , ValdezRA , MonterrosaA , HaffnerSM , MitchellBD , et al. Predicting diabetes. Moving beyond impaired glucose tolerance. Diabetes1993;42(5):706‐14. [PUBMED: 8482427] SternMP , RosenthalM , HaffnerSM , HazudaHP , FrancoLJ . Sex difference in the effects of sociocultural status on diabetes and cardiovascular risk factors in Mexican Americans. The San Antonio heart study. American Journal of Epidemiology1984;120(6):834‐51. [PUBMED: 6507426] ">Lorenzo 2003</a>)). </p> </li> <li> <p>North America: 12 studies (USA ,12 studies, with 4 studies in particular populations: Pima Indians/Native Americans, 3 studies (<a href="./references#CD012661-bbs2-0093" title="VijayakumarP , NelsonR G , HansonR L , KnowlerW C , SinhaM . HbA1c and the prediction of type 2 diabetes in children and adults. Diabetes Care2017;40(1):16‐21. [PUBMED: 27810987] ">Vijayakumar 2017</a>; <a href="./references#CD012661-bbs2-0096" title="HowardBV , LeeET , CowanLD , DevereuxRB , GallowayJM , GoOT , et al. Rising tide of cardiovascular disease in American Indians. The strong heart study. Circulation1999;99(18):2389‐95. LeeET , HowardBV , GoO , SavagePJ , FabsitzRR , RobbinsDC , et al. Prevalence of undiagnosed diabetes in three American Indian populations. A comparison of the 1997 American Diabetes Association diagnostic criteria and the 1985 World Health Organization diagnostic criteria: the strong heart study. Diabetes Care2000;23(2):181‐6. LeeET , HowardBV , SavagePJ , CowanLD , FabsitzRR , OopikAJ , et al. Diabetes and impaired glucose tolerance in three American Indian populations aged 45‐74 years. The strong heart study. Diabetes Care1995;18(5):599‐610. LeeET , WeltyTK , CowanLD , WangW , RhoadesDA , DevereuxR , et al. Incidence of diabetes in American Indians of three geographic areas: the strong heart study. Diabetes Care2002;25(1):49‐54. [PUBMED: 11772900] LeeET , WeltyTK , FabsitzR , CowanLD , LeNA , OopikAJ , et al. The strong heart study. A study of cardiovascular disease in American Indians: design and methods. American Journal of Epidemiology1990;132(6):1141‐55. [PUBMED: 2260546] LuW , ResnickHE , JainAK , Adams‐CampbellLL , JablonskiKA , GottliebAM , et al. Effects of isolated post‐challenge hyperglycemia on mortality in American Indians: the strong heart study. Annals of Epidemiology2003;13(3):182‐8. WangH , SharaN M , CalhounD , UmansJG , LeeET , HowardBV . Incidence rates and predictors of diabetes in those with prediabetes: the strong heart study. Diabetes/metabolism Research and Reviews2010;26(5):378‐85. [PUBMED: 20578203] WangW , LeeET , FabsitzR , WeltyTK , HowardBV . Using HbA(1c) to improve efficacy of the American Diabetes Association fasting plasma glucose criterion in screening for new type 2 diabetes in American Indians: the strong heart study. Diabetes Care2002;25(8):1365‐70. WangW , LeeET , HowardBV , FabsitzRR , DevereuxRB , WeltyTK . Fasting plasma glucose and hemoglobin A1c in identifying and predicting diabetes: the strong heart study. Diabetes Care2011;34(2):363‐8. [PUBMED: 21270194] deSimoneG , DevereuxRB , ChinaliM , BestLG , LeeET , GallowayJM , et al. Prognostic impact of metabolic syndrome by different definitions in a population with high prevalence of obesity and diabetes: the strong heart study. Diabetes Care2007;30(7):1851‐6. ">Wang 2011</a>; <a href="./references#CD012661-bbs2-0100" title="WheelockKM , SinhaM , KnowlerWC , NelsonRG , FufaaGD , HansonRL . Metabolic risk factors and type 2 diabetes incidence in American Indian children. Journal of Clinical Endocrinology &amp; Metabolism2016;101(4):1437‐44. [PUBMED: 26913636] ">Wheelock 2016</a>); and Japanese Americans, 1 study (<a href="./references#CD012661-bbs2-0062" title="BergstromRW , Newell‐MorrisLL , LeonettiDL , ShumanWP , WahlPW , FujimotoWY . Association of elevated fasting C‐peptide level and increased intra‐abdominal fat distribution with development of NIDDM in Japanese‐American men. Diabetes1990;39(1):104‐11. FujimotoWY , BergstromRW , BoykoEJ , KinyounJL , LeonettiDL , Newell‐MorrisLL , et al. Diabetes and diabetes risk factors in second‐ and third‐generation Japanese Americans in Seattle, Washington. Diabetes Research and Clinical Practice1994;24(Suppl):S43‐52. [PUBMED: 7859632] FujimotoWY , BergstromRW , Newell‐MorrisL , LeonettiD L . Nature and nurture in the etiology of type 2 diabetes mellitus in Japanese Americans. Diabetes/metabolism Reviews1989;5(7):607‐25. [PUBMED: 2689122] KahnSE , LeonettiDL , PrigeonRL , BoykoEJ , BergstomRW , FujimotoWY . Proinsulin levels predict the development of non‐insulin‐dependent diabetes mellitus (NIDDM) in Japanese‐American men. Diabetic Medicine1996;13(9 Suppl 6):S63‐6. [PUBMED: 8894485] KahnSE , LeonettiDL , PrigeonRL , BoykoEJ , BergstromRW , FujimotoWY . Proinsulin as a marker for the development of NIDDM in Japanese‐American men. Diabetes1995;44(2):173‐9. McNeelyMJ , BoykoEJ , LeonettiDL , KahnSE , FujimotoWY . Comparison of a clinical model, the oral glucose tolerance test, and fasting glucose for prediction of type 2 diabetes risk in Japanese Americans. Diabetes Care2003;26(3):758‐63. [PUBMED: 12610034] RodriguezBL , AbbottRD , FujimotoW , WaitzfelderB , ChenR , MasakiK , et al. The American Diabetes Association and World Health Organization classifications for diabetes ‐ their impact on diabetes prevalence and total and cardiovascular disease mortality in elderly Japanese‐American men. Diabetes Care2002;25(6):951‐5. [PUBMED: 12032097] ">McNeely 2003</a>)). </p> </li> <li> <p>Africa: 1 study (performed in South Africa but with a population consisting of South African Indians (<a href="./references#CD012661-bbs2-0065" title="MotalaAA , OmarMA . Evaluation of WHO and NDDG criteria for impaired glucose tolerance. Diabetes Research and Clinical Practice1994;23(2):103‐9. [PUBMED: 8070301] MotalaAA , OmarMA . Evidence for impaired pancreatic beta cell function in South African Indians with impaired glucose tolerance. Diabetic Medicine1994;11(5):437‐44. MotalaAA , OmarMA , GouwsE . High risk of progression to NIDDM in South‐African Indians with impaired glucose tolerance. Diabetes1993;42(4):556‐63. [PUBMED: 8454106] MotalaAA , OmarMA , GouwsE . Transient impaired glucose tolerance in South African Indians does not carry a risk for progression to NIDDM. Diabetes Care1997;20(7):1101‐7. [PUBMED: 9203444] MotalaAA , PirieFJ , GouwsE , AmodA , OmarMA . High incidence of type 2 diabetes mellitus in South African Indians: a 10‐year follow‐up study. Diabetic Medicine2003;20(1):23‐30. [PUBMED: 12519316] OmarMA , SeedatMA , DyerRB , MotalaAA , KnightLT , BeckerPJ . South African Indians show a high prevalence of NIDDM and bimodality in plasma glucose distribution patterns. Diabetes Care1994;17(1):70‐3. ">Motala 2003</a>)). </p> </li> <li> <p>Middle East: 7 studies (Iran, 5 studies; Israel, 1 study; Jordan, 1 study).</p> </li> <li> <p>Asia: 42 studies (China, 11 studies; India, 5 studies; Japan, 8 studies; Korea, 11 studies; Singapore, 2 studies; Taiwan, 2 studies; Thailand, 3 studies). </p> </li> <li> <p>Islands: 2 studies (Mauritius, 1 study; Micronesia (Nauru), 1 study).</p> </li> <li> <p>Europe: 29 studies (Denmark, 1 study; Finland, 5 studies; France, 3 studies; Germany, 3 studies; Greece, 1 study; Italy, 3 studies; Malta, 1 study; Spain, 3 studies; Sweden, 3 studies; Netherlands, 4 studies; UK, 2 studies). One study in the Netherlands included a mixed population of South‐Asian Surinamese participants, African Surinamese participants and "Ethnic Dutch" participants (<a href="./references#CD012661-bbs2-0001" title="AdmiraalWM , HollemanF , SnijderMB , PetersRJ , BrewsterLM , HoekstraJB , et al. Ethnic disparities in the association of impaired fasting glucose with the 10‐year cumulative incidence of type 2 diabetes. Diabetes Research and Clinical Practice2014;103(1):127‐32. [PUBMED: 24355200] AgyemangC , vanValkengoedI , van denBornB J , StronksK . Prevalence and determinants of prehypertension among African Surinamese, Hindustani Surinamese, and White Dutch in Amsterdam, the Netherlands: the SUNSET study. European Journal of Cardiovascular Prevention and Rehabilitation2007;14(6):775‐81. BindrabanNR , vanValkengoedIG , MairuhuG , HollemanF , HoekstraJB , MichelsBP , et al. Prevalence of diabetes mellitus and the performance of a risk score among Hindustani Surinamese, African Surinamese and ethnic Dutch: a cross‐sectional population‐based study. BMC Public Health2008;8:271. [PUBMED: 18673544] DekkerLH , NicolaouM , van derADl , BusschersWB , BrewsterLM , SnijderMB , et al. Sex differences in the association between serum ferritin and fasting glucose in type 2 diabetes among South Asian Surinamese, African Surinamese, and ethnic Dutch: the population‐based SUNSET study. Diabetes Care2013;36(4):965‐71. ">Admiraal 2014</a>). </p> </li> </ul> </p> <p>Fifty‐eight studies contributed most of the data (<a href="./appendices#CD012661-sec-0139">Appendix 4</a>). </p> </section> <section id="CD012661-sec-0067"> <h5 class="title">Measurements of overall prognosis of people with IH and of the prognostic factor IH versus normoglycaemia </h5> <p>Of the 103 included studies, 17 evaluated the overall prognosis of people with IH for the development of type 2 diabetes mellitus without a normoglycaemic comparison group. Of these studies, six recruited participants with IFG at baseline (<a href="./references#CD012661-bbs2-0006" title="Baena‐DiezJM , Bermudez‐ChillidaN , MundetX , delVal‐GarciaJL , MunozMA , SchroderH . Impaired fasting glucose and risk of diabetes mellitus at 10 years. Cohort study. Medicina Clinica2011;136(9):382‐5. [PUBMED: 21300382] ">Baena‐Diez 2011</a>; <a href="./references#CD012661-bbs2-0025" title="BalkauB , LangeC , FezeuL , TichetJ , deLauzon‐GuillainB , CzernichowS , et al. Predicting diabetes: clinical, biological, and genetic approaches: data from the epidemiological study on the insulin resistance syndrome (DESIR). Diabetes Care2008;31(10):2056‐61. [PUBMED: 18689695] DroumaguetC , BalkauB , SimonD , CacesE , TichetJ , CharlesMA , et al. Use of HbA1c in predicting progression to diabetes in French men and women: data from an epidemiological study on the insulin resistance syndrome (DESIR). Diabetes Care2006;29(7):1619‐25. [PUBMED: 16801588] GautierA , RousselR , DucluzeauPH , LangeC , VolS , BalkauB , et al. Increases in waist circumference and weight as predictors of type 2 diabetes in individuals with impaired fasting glucose: influence of baseline BMI. Data from the DESIR study. Diabetes Care2010;33(8):1850‐2. [PUBMED: 20484131] SoulimaneS , SimonD , ShawJ , WitteD , ZimmetP , VolS , et al. HbA1c, fasting plasma glucose and the prediction of diabetes: Inter99, AusDiab and D.E.S.I.R. Diabetes Research and Clinical Practice2012;96(3):392‐9. [PUBMED: 21741107] SoulimaneS , SimonD , ShawJE , ZimmetPZ , VolS , VistisenD , et al. Comparing incident diabetes as defined by fasting plasma glucose or by HbA(1c). The AusDiab, Inter99 and DESIR studies. Diabetic Medicine2011;28(11):1311‐8. [PUBMED: 21824186] ">Gautier 2010</a>; <a href="./references#CD012661-bbs2-0046" title="LecomteP , VolS , CacèsE , BornC , ChabrolleC , LasfarguesG , et al. Five‐year predictive factors of type 2 diabetes in men with impaired fasting glucose. Diabetes &amp; Metabolism2007;33(2):140‐7. [PUBMED: 17320447] ">Lecomte 2007</a>; <a href="./references#CD012661-bbs2-0048" title="LeivaE , MujicaV , OrregoR , WehingerS , SotoA , IcazaG , et al. Subjects with impaired fasting glucose: evolution in a period of 6 years. Journal of Diabetes Research2014;2014:710370. [DOI: 10.1155/2014/710370; PUBMED: 25215305] PalomoGI , IcazaNG , MujicaEV , NunezFL , LeivaME , VasquezRM , et al. Prevalence of cardiovascular risk factors in adult from Talca, Chile [Prevalencia de factores de riesgo cardiovascular clásicos en población adulta de Talca, Chile, 2005]. Revista Medica de Chile2007;135(7):904‐12. [PUBMED: 17914548] ">Leiva 2014</a>; <a href="./references#CD012661-bbs2-0049" title="DawberTR , KannelWB , LyellLP . An approach to longitudinal studies in a community: the Framingham study. Annals of the New York Academy of Sciences1963;107:539‐56. [PUBMED: 14025561] HrubyA , MaJ , RogersG , MeigsJB , JacquesPF . Associations of dairy intake with incident prediabetes or diabetes in middle‐aged adults vary by both dairy type and glycemic status. Journal of Nutrition2017;147(9):1764‐75. [PUBMED: 28768835] LeongA , DayaN , PornealaB , DevlinJJ , ShiffmanD , McPhaulMJ , et al. Prediction of type 2 diabetes by hemoglobin A1c in two community‐based cohorts. Diabetes Care2018;41(1):60‐8. [PUBMED: 29074816] LevitzkyYS , PencinaMJ , D'AgostinoRB , MeigsJB , MurabitoJM , VasanRS , et al. Impact of impaired fasting glucose on cardiovascular disease: the Framingham heart study. Journal of the American College of Cardiology2008;51(3):264‐70. [PUBMED: 18206734] WilsonPW , AndersonKM , KannelWB . Epidemiology of diabetes mellitus in the elderly. The Framingham study. American Journal of Medicine1986;80(5A):3‐9. [PUBMED: 3706388] WilsonPW , MeigsJB , SullivanL , FoxCS , NathanDM , D'AgostinoRBSr . Prediction of incident diabetes mellitus in middle‐aged adults: the Framingham offspring study. Archives of Internal Medicine2007;167(10):1068‐74. [PUBMED: 17533210] ">Levitzky 2008</a>; <a href="./references#CD012661-bbs2-0083" title="SharifiF , JaberiY , MirzamohammadiF , MirzamohammadiH , MousavinasabN . Determinants of developing diabetes mellitus and vascular complications in patients with impaired fasting glucose. Indian Journal of Endocrinology and Metabolism2013;17(5):899‐905. [PUBMED: 24083174] ">Sharifi 2013</a>), six recruited participants with IGT at baseline (<a href="./references#CD012661-bbs2-0040" title="KleberM , LassN , PapckeS , WabitschM , ReinehrT . One‐year follow‐up of untreated obese white children and adolescents with impaired glucose tolerance: high conversion rate to normal glucose tolerance. Diabetic Medicine2010;27(5):516‐21. [PUBMED: 20536946] ">Kleber 2010</a>; <a href="./references#CD012661-bbs2-0041" title="KleberM , deSousaG , PapckeS , WabitschM , ReinehrT . Impaired glucose tolerance in obese white children and adolescents: three to five year follow‐up in untreated patients. Experimental and Clinical Endocrinology &amp; Diabetes2011;119(3):172‐6. [PUBMED: 20827664] ">Kleber 2011</a>; <a href="./references#CD012661-bbs2-0042" title="KoGT , ChanJC , LauE , WooJ , CockramCS . Fasting plasma glucose as a screening test for diabetes and its relationship with cardiovascular risk factors in Hong Kong Chinese. Diabetes Care1997;20(2):170‐2. KoGT , LiJK , CheungAY , YeungVT , ChowCC , TsangLW , et al. Two‐hour post‐glucose loading plasma glucose is the main determinant for the progression from impaired glucose tolerance to diabetes in Hong Kong Chinese. Diabetes Care1999;22(12):2096‐7. [PUBMED: 10587859] ">Ko 1999</a>; <a href="./references#CD012661-bbs2-0061" title="BaxterJ , HammanRF , LopezTK , MarshallJA , HoagS , SwensonCJ . Excess incidence of known non‐insulin‐dependent diabetes mellitus (NIDDM) in Hispanics compared with non‐Hispanic whites in the San Luis Valley, Colorado. Ethnicity &amp; Disease1993;3(1):11‐21. BoykoEJ , KeaneEM , MarshallJA , HammanRF . Higher insulin and C‐peptide concentrations in Hispanic population at high risk for NIDDM. San Luis Valley diabetes study. Diabetes1991;40(4):509‐15. HammanRF , MarshallJA , BaxterJ , KahnLB , MayerEJ , OrleansM , et al. Methods and prevalence of non‐insulin‐dependent diabetes mellitus in a bi‐ethnic Colorado population. The San Luis Valley diabetes study. American Journal of Epidemiology1989;129(2):295‐311. [PUBMED: 2912042] MarshallJA , HoagS , ShetterlyS , HammanRF . Dietary fat predicts conversion from impaired glucose tolerance to NIDDM: the San Luis Valley diabetes study. Diabetes Care1994;17(1):50‐6. [PUBMED: 8112189] NelsonTL , BessesenDH , MarshallJA . Relationship of abdominal obesity measured by DXA and waist circumference with insulin sensitivity in Hispanic and non‐Hispanic white individuals: the San Luis Valley diabetes study. Diabetes/metabolism Research and Reviews2008;24(1):33‐40. ">Marshall 1994</a>; <a href="./references#CD012661-bbs2-0074" title="QiaoQ , Keinanen‐KiukaanniemiS , RajalaU , UusimakiA , KivelaSL . Risk for diabetes and persistent impaired glucose tolerance among middle‐aged Finns. Diabetes Research &amp; Clinical Practice1996;33(3):191‐8. [PUBMED: 8922541] RajalaU , Keinanen‐KiukaanniemiS , UusimakiA , ReijulaK , KivelaSL . Prevalence of diabetes mellitus and impaired glucose tolerance in a middle‐aged Finnish population. Scandinavian Journal of Primary Health Care1995;13(3):222‐8. [PUBMED: 7481176] RajalaU , QiaoQ , LaaksoM , Keinänen‐KiukaanniemiS . Antihypertensive drugs as predictors of type 2 diabetes among subjects with impaired glucose tolerance. Diabetes Research and Clinical Practice2000;50(3):231‐9. [PUBMED: 11106838] ">Rajala 2000</a>; <a href="./references#CD012661-bbs2-0075" title="RamachandranA , SnehalathaC , NaikRA , MohanV , ShobanaR , ViswanathanM . Significance of impaired glucose tolerance in an Asian Indian population: a follow‐up study. Diabetes Research and Clinical Practice1986;2(3):173‐8. [PUBMED: 3527626] ">Ramachandran 1986</a>), two recruited a mixed IFG/IGT cohort (<a href="./references#CD012661-bbs2-0076" title="RasmussenSS , GlumerC , SandbaekA , LauritzenT , Borch‐JohnsenK . Determinants of progression from impaired fasting glucose and impaired glucose tolerance to diabetes in a high‐risk screened population: 3 year follow‐up in the ADDITION study, Denmark. Diabetologia2008;51(2):249‐57. [PUBMED: 18060659] RasmussenSS , GlumerC , SandbaekA , LauritzenT , Borch‐JohnsenK . Progression from impaired fasting glucose and impaired glucose tolerance to diabetes in a high‐risk screening programme in general practice: the ADDITION study, Denmark. Diabetologia2007;50(2):293‐7. [PUBMED: 17143605] ">Rasmussen 2008</a>; <a href="./references#CD012661-bbs2-0090" title="ToshihiroM , SaitoK , TakikawaS , TakebeN , OnodaT , SatohJ . Psychosocial factors are independent risk factors for the development of type 2 diabetes in Japanese workers with impaired fasting glucose and/or impaired glucose tolerance. Diabetic Medicine2008;25(10):1211‐7. [PUBMED: 19046200] ">Toshihiro 2008</a>), and three recruited participants with various definitions of IH (<a href="./references#CD012661-bbs2-0038" title="KimYA , KuEJ , KhangAR , HongES , KimKM , MoonJH , et al. Role of various indices derived from an oral glucose tolerance test in the prediction of conversion from prediabetes to type 2 diabetes. Diabetes Research and Clinical Practice2014;106(2):351‐9. [PUBMED: 25245975] ">Kim 2014</a>; <a href="./references#CD012661-bbs2-0047" title="LeeJH , LimJT , KimHG , OhMK , LeeWJ . Effect of coffee consumption on the progression of type 2 diabetes mellitus among prediabetic individuals. Korean Journal of Family Medicine2016;37(1):7‐13. [PUBMED: 26885316] ">Lee 2016</a>; <a href="./references#CD012661-bbs2-0087" title="QiuM , ShenW , SongX , JuL , TongW , WangH , et al. Effects of prediabetes mellitus alone or plus hypertension on subsequent occurrence of cardiovascular disease and diabetes mellitus: longitudinal study. Hypertension2015;65(3):525‐30. [PUBMED: 25624343] SongX , QiuM , ZhangX , WangH , TongW , JuL , et al. Gender‐related affecting factors of prediabetes on its 10‐year outcome. BMJ Open Diabetes Research &amp; Care2016;4(1):e000169. [PUBMED: 27239315] TianJY , ChengQ , SongXM , LiG , JiangGX , GuYY , et al. Birth weight and risk of type 2 diabetes, abdominal obesity and hypertension among Chinese adults. European Journal of Endocrinology/European Federation of Endocrine Societies2006;155(4):601‐7. [PUBMED: 16990660] ">Song 2016a</a>). In addition, 76 studies with a normoglycaemic comparison group contributed data to evaluate the overall prognosis of people with IH by means of cumulative incidence. Therefore, analysis of overall prognosis is based on 93 studies. </p> <p>Fifty‐two studies assessed the prognostic effect of IH versus normoglycaemia for the development of type 2 diabetes mellitus and provided outcome measures as ratios (hazard ratio (HR), incidence rate ratio (IRR) and/or odds ratio (OR)). Forty‐seven studies explicitly defined normoglycaemia, often by a combination of FPG thresholds and two hour post‐load glucose thresholds (<a href="./references#CD012661-bbs2-0004" title="AnjanaRM , Shanthi RaniCS , DeepaM , PradeepaR , SudhaV , Divya NairH , et al. Incidence of diabetes and prediabetes and predictors of progression among Asian Indians: 10‐year follow‐up of the Chennai urban rural epidemiology study (CURES). Diabetes Care2015;38(8):1441‐8. [PUBMED: 25906786] DeepaM , PradeepaR , RemaM , MohanA , DeepaR , ShanthiraniS , et al. The Chennai urban rural epidemiology study (CURES) ‐ study design and methodology (urban component) (CURES‐I). Journal of the Association of Physicians of India2003;51:863‐70. [PUBMED: 14710970] MohanD , RajD , ShanthiraniCS , DattaM , UnwinNC , KapurA , et al. Awareness and knowledge of diabetes in Chennai ‐ the Chennai urban rural epidemiology study [CURES‐9]. Journal of the Association of Physicians of India2005;53:283‐7. MohanV , DeepaM , FarooqS , DattaM , DeepaR . Prevalence, awareness and control of hypertension in Chennai ‐ the Chennai urban rural epidemiology study (CURES‐52). Journal of the Association of Physicians of India2007;55:326‐32. MohanV , DeepaR , PradeepaR , VimaleswaranKS , MohanA , VelmuruganK , et al. Association of low adiponectin levels with the metabolic syndrome ‐ the Chennai urban rural epidemiology study (CURES‐4). Metabolism2005;54(4):476‐81. MohanV , SandeepS , DeepaM , GokulakrishnanK , DattaM , DeepaR . A diabetes risk score helps identify metabolic syndrome and cardiovascular risk in Indians ‐ the Chennai urban rural epidemiology study (CURES‐38). Diabetes, Obesity &amp; Metabolism2007;9(3):337‐43. RadhikaG , SathyaRM , SudhaV , GanesanA , MohanV . Dietary salt intake and hypertension in an urban south Indian population ‐ [CURES ‐ 53]. Journal of the Association of Physicians of India2007;55:405‐11. ">Anjana 2015</a>; <a href="./references#CD012661-bbs2-0006" title="Baena‐DiezJM , Bermudez‐ChillidaN , MundetX , delVal‐GarciaJL , MunozMA , SchroderH . Impaired fasting glucose and risk of diabetes mellitus at 10 years. Cohort study. Medicina Clinica2011;136(9):382‐5. [PUBMED: 21300382] ">Baena‐Diez 2011</a>; <a href="./references#CD012661-bbs2-0008" title="BergmanM , ChetritA , RothJ , JagannathanR , SevickM , DanknerR . One‐hour post‐load plasma glucose level during the OGTT predicts dysglycemia: observations from the 24year follow‐up of the Israel study of glucose intolerance, obesity and hypertension. Diabetes Research and Clinical Practice2016;120:221‐8. [PUBMED: 27596059] DanknerR , Abdul‐GhaniMA , GerberY , ChetritA , WainsteinJ , RazI . Predicting the 20‐year diabetes incidence rate. Diabetes/metabolism Research and Reviews2007;23(7):551‐8. [PUBMED: 17315136] ModanM , HalkinH , KarasikA , LuskyA . Effectiveness of glycosylated hemoglobin, fasting plasma glucose, and a single post load plasma glucose level in population screening for glucose intolerance. American Journal of Epidemiology1984;119(3):431‐44. [PUBMED: 6702817] ModanM , KarasikA , HalkinH , FuchsZ , LuskyA , ShitritA , et al. Effect of past and concurrent body mass index on prevalence of glucose intolerance and type 2 (non‐insulin‐dependent) diabetes and on insulin response. Diabetologia1986;29(2):82‐9. [PUBMED: 3516770] ">Bergman 2016</a>; <a href="./references#CD012661-bbs2-0013" title="ChenKT , ChenCJ , GreggEW , ImperatoreG , NarayanKMV . Impaired fasting glucose and risk of diabetes in Taiwan: follow‐up over 3 years. Diabetes Research and Clinical Practice2003;60(3):177‐82. [PUBMED: 12757990] ChenKT , ChenCJ , GreggEW , WilliamsonDF , NarayanKM . High prevalence of impaired fasting glucose and type 2 diabetes mellitus in Penghu Islets, Taiwan: evidence of a rapidly emerging epidemic?. Diabetes Research and Clinical Practice1999;44(1):59‐69. [PUBMED: 10414941] ">Chen 2003</a>; <a href="./references#CD012661-bbs2-0014" title="ChenG , LinL , ChenL , LiL , HuangH , WangW , et al. Comparison of insulin resistance and beta‐cell dysfunction between the young and the elderly in normal glucose tolerance and prediabetes population: a prospective study. Hormone and Metabolic Research2017;49(2):135‐41. [DOI: 10.1055/s‐0042‐111325; PUBMED: 27459384] ">Chen 2017</a>; <a href="./references#CD012661-bbs2-0015" title="Coronado‐MalagonM , Gomez‐VargasJI , Espinoza‐PeraltaD , Arce‐SalinasA . Progression toward type‐2 diabetes mellitus among Mexican pre‐diabetics. Assessment of a cohort. Gaceta Medica De Mexico2009;145(4):269‐72. [PUBMED: 20073428] ">Coronado‐Malagon 2009</a>; <a href="./references#CD012661-bbs2-0018" title="DenBiggelaarLJ , SepSJ , EussenSJ , MariA , FerranniniE , vanGreevenbroekMM , et al. Discriminatory ability of simple OGTT‐based beta cell function indices for prediction of prediabetes and type 2 diabetes: the CODAM study. Diabetologia2016;60(3):432‐41. [PUBMED: 27933333] KruijshoopM , FeskensEJ , BlaakEE , deBruinTW . Validation of capillary glucose measurements to detect glucose intolerance or type 2 diabetes mellitus in the general population. Clinica Chimica Acta2004;341(1‐2):33‐40. [PUBMED: 14967156] ">Den Biggelaar 2016</a>; <a href="./references#CD012661-bbs2-0019" title="Aghaei MeybodiHR , AziziF . Changes in body weight and fat distribution; risk factors for abnormal glucose homeostasis? Tehran lipid and glucose study. Iranian Journal of Diabetes and Lipid Disorders2009;8(1):1‐12. BozorgmaneshM , HadaeghF , AziziF . A simple clinical model predicted diabetes progression among prediabetic individuals. Diabetes Research and Clinical Practice2012;97(2):e34‐6. [PUBMED: 22647753] DerakhshanA , Bagherzadeh‐KhiabaniF , ArshiB , RamezankhaniA , AziziF , HadaeghF . Different combinations of glucose tolerance and blood pressure status and incident diabetes, hypertension, and chronic kidney disease. Journal of the American Heart Association2016;5(8):pii: e003917. [DOI: 10.1161/JAHA.116.003917; PUBMED: 27543801] DerakhshanA , SardariniaM , KhaliliD , MomenanAA , AziziF , HadaeghF . Sex specific incidence rates of type 2 diabetes and its risk factors over 9 years of follow‐up: Tehran lipid and glucose study. PLOS ONE2014;9(7):e102563. [PUBMED: 25029368] DerakhshanA , TohidiM , ArshiB , KhaliliD , AziziF , HadaeghF . Relationship of hyperinsulinaemia, insulin resistance and beta‐cell dysfunction with incident diabetes and pre‐diabetes: the Tehran lipid and glucose study. Diabetic Medicine2015;32(1):24‐32. [PUBMED: 25131451] HadaeghF , BozorgmaneshMR , GhasemiA , HaratiH , SaadatN , AziziF . High prevalence of undiagnosed diabetes and abnormal glucose tolerance in the Iranian urban population: Tehran lipid and glucose study. BMC Public Health2008;8:176. HadaeghF , DerakhshanA , ZafariN , KhaliliD , MirboloukM , SaadatN , et al. Pre‐diabetes tsunami: incidence rates and risk factors of pre‐diabetes and its different phenotypes over 9 years of follow‐up. Diabetic Medicine2017;34(1):69‐78. [PUBMED: 26606421] HadaeghF , GhasemiAr , PadyabM , TohidiM , AziziF . The metabolic syndrome and incident diabetes: assessment of alternative definitions of the metabolic syndrome in an Iranian urban population. Diabetes Research and Clinical Practice2008;80(2):328‐34. [PUBMED: 18282630] HaratiH , HadaeghF , SaadatN , AziziF . Population‐based incidence of type 2 diabetes and its associated risk factors: results from a six‐year cohort study in Iran. BMC Public Health2009;9:186. [DOI: 10.1186/1471‐2458‐9‐186; PUBMED: 19531260] HaratiH , HadaeghF , TohidiM , AziziF . Impaired fasting glucose cutoff value of 5.6 mmol/l combined with other cardiovascular risk markers is a better predictor for incident type 2 diabetes than the 6.1 mmol/l value: Tehran lipid and glucose study. Diabetes Research and Clinical Practice2009;85(1):90‐5. [PUBMED: 19414206] ">Derakhshan 2016</a>; <a href="./references#CD012661-bbs2-0020" title='DowseGK , ZimmetPZ , CollinsVR . Insulin levels and the natural history of glucose intolerance in Nauruans. Diabetes1996;45(10):1367‐72. DowseGK , ZimmetPZ , CollinsVR . Insulin levels and the natural history of glucose intolerance in Nauruans. Diabetes1996;45(10):1367‐72. [PUBMED: 8826973] DowseGK , ZimmetPZ , FinchCF , CollinsVR . Decline in incidence of epidemic glucose intolerance in Nauruans: implications for the "thrifty genotype". American Journal of Epidemiology1991;133(11):1093‐104. [PUBMED: 2035513] KingH , ZimmetP , RaperLR , BalkauB . The natural history of impaired glucose tolerance in the Micronesian population of Nauru: a six‐year follow‐up study. Diabetologia1984;26(1):39‐43. [PUBMED: 6706044] SicreeRA , ZimmetPZ , KingHOM , CoventryJS . Plasma‐insulin response among Nauruans ‐ prediction of deterioration in glucose‐tolerance over 6‐yr. Diabetes1987;36(2):179‐86. [PUBMED: 3542644] '>Dowse 1991</a>; <a href="./references#CD012661-bbs2-0023" title="ForouhiNG , LuanJ , HenningsS , WarehamNJ . Incidence of type 2 diabetes in England and its association with baseline impaired fasting glucose: the Ely study 1990‐2000. Diabetic Medicine2007;24(2):200‐7. [PUBMED: 17257284] SimmonsRK , RahmanM , JakesRW , YuyunMF , NiggebruggeAR , HenningsSH , et al. Effect of population screening for type 2 diabetes on mortality: long‐term follow‐up of the Ely cohort. Diabetologia2011;54:312‐9. [PUBMED: 20978739] WarehamNJ , ByrneCD , WilliamsR , DayNE , HalesCN . Fasting proinsulin concentrations predict the development of type 2 diabetes. Diabetes Care1999;22(2):262‐70. [PUBMED: 10333943] WilliamsDR , WarehamNJ , BrownDC , ByrneCD , ClarkPM , CoxBD , et al. Undiagnosed glucose intolerance in the community: the Isle of Ely diabetes project. Diabetic Medicine1995;12:30‐5. [PUBMED: 7712700] ">Forouhi 2007</a>; <a href="./references#CD012661-bbs2-0027" title="Guerrero‐RomerF , Rodriguez‐MoranM , Gonzalez‐OrtizM , Martinez‐AbundisE . Insulin action and secretion in healthy Hispanic‐Mexican first‐degree relatives of subjects with type 2 diabetes. Journal of Endocrinological Investigation2001;24:580‐6. [PUBMED: 11686540] Guerrero‐RomeroF , Rodriguez‐MoranM . Assessing progression to impaired glucose tolerance and type 2 diabetes mellitus. European Journal of Clinical Investigation2006;36(11):796‐802. [PUBMED: 17032347] Rodriguez‐MoranM , Guerrero‐RomeroF . Hyperinsulinemia and abdominal obesity are more prevalent in non‐diabetic subjects with family history of type 2 diabetes. Archives of Medical Research2000;31:399‐403. [PUBMED: 11068083] ">Guerrero‐Romero 2006</a>; <a href="./references#CD012661-bbs2-0030" title="HeianzaY , AraseY , FujiharaK , HsiehSD , SaitoK , TsujiH , et al. Longitudinal trajectories of HbA1c and fasting plasma glucose levels during the development of type 2 diabetes: the Toranomon hospital health management center study 7 (TOPICS 7). Diabetes Care2012;35(5):1050‐2. [PUBMED: 22456865] HeianzaY , AraseY , FujiharaK , TsujiH , SaitoK , HsiehSD , et al. High normal HbA(1c) levels were associated with impaired insulin secretion without escalating insulin resistance in Japanese individuals: the Toranomon hospital health management center study 8 (TOPICS 8). Diabetic Medicine2012;29(10):1285‐90. HeianzaY , AraseY , FujiharaK , TsujiH , SaitoK , HsiehSD , et al. Screening for pre‐diabetes to predict future diabetes using various cut‐off points for HbA(1c) and impaired fasting glucose: the Toranomon hospital health management center study 4 (TOPICS 4). Diabetic Medicine2012;29(9):e279‐85. [PUBMED: 22510023] HeianzaY , AraseY , HsiehSD , SaitoK , TsujiH , KodamaS , et al. Development of a new scoring system for predicting the 5 year incidence of type 2 diabetes in Japan: the Toranomon hospital health management center study 6 (TOPICS 6). Diabetologia2012;55(12):3213‐23. [PUBMED: 22955996] HeianzaY , HaraS , AraseY , SaitoK , FujiwaraK , TsujiH , et al. HbA1c 5.7‐6.4% and impaired fasting plasma glucose for diagnosis of prediabetes and risk of progression to diabetes in Japan (TOPICS 3): a longitudinal cohort study. Lancet2011;378(9786):147‐55. [MEDLINE: 21705064] HeianzaY , HaraS , AraseY , SaitoK , TotsukaK , TsujiH , et al. Low serum potassium levels and risk of type 2 diabetes: the Toranomon hospital health management center study 1 (TOPICS 1). Diabetologia2011;54(4):762‐6. [PUBMED: 21212932] ">Heianza 2012</a>; <a href="./references#CD012661-bbs2-0032" title="AminiM , JanghorbaniM . Comparison of metabolic syndrome with glucose measurement for prediction of type 2 diabetes: the Isfahan diabetes prevention study. Diabetes &amp; Metabolic Syndrome: Clinical Research &amp; Reviews2009;3(2):84‐9. HaghighatdoostF , AminiM , FeiziA , IrajB . Are body mass index and waist circumference significant predictors of diabetes and prediabetes risk: results from a population based cohort study. World Journal of Diabetes2017;8(7):365‐73. [PUBMED: 28751960] JanghorbaniM , AminiM . Normal fasting plasma glucose and risk of prediabetes and type 2 diabetes: the Isfahan diabetes prevention study. Review of Diabetic Studies2011;8(4):490‐8. [PUBMED: 22580730] JanghorbaniM , AminiM . Progression from optimal blood glucose and pre‐diabetes to type 2 diabetes in a high risk population with or without hypertension in Isfahan, Iran. Diabetes Research and Clinical Practice2015;108(3):414‐22. [PUBMED: 25814432] ">Janghorbani 2015</a>; <a href="./references#CD012661-bbs2-0033" title="JaruratanasirikulS , ThammaratchuchaiS , PuwanantM , Mo‐SuwanL , SriplungH . Progression from impaired glucose tolerance to type 2 diabetes in obese children and adolescents: a 3‐6‐year cohort study in southern Thailand. Journal of Pediatric Endocrinology &amp; Metabolism2016;29(11):1267‐75. [PUBMED: 27740930] ">Jaruratanasirikul 2016</a>; <a href="./references#CD012661-bbs2-0036" title="KimDJ , ChoNH , NohJH , KimHJ , ChoiYH , JungJH , et al. Fasting plasma glucose cutoff value for the prediction of future diabetes development: a study of middle‐aged Koreans in a health promotion center. Journal of Korean Medical Science2005;20(4):562‐5. [PUBMED: 16100444] KimDJ , ChoNH , NohJH , LeeMS , LeeMK , KimKW . Lack of excess maternal transmission of type 2 diabetes in a Korean population. Diabetes Research and Clinical Practice2004;65(2):117‐24. [PUBMED: 15223223] ">Kim 2005</a>; <a href="./references#CD012661-bbs2-0042" title="KoGT , ChanJC , LauE , WooJ , CockramCS . Fasting plasma glucose as a screening test for diabetes and its relationship with cardiovascular risk factors in Hong Kong Chinese. Diabetes Care1997;20(2):170‐2. KoGT , LiJK , CheungAY , YeungVT , ChowCC , TsangLW , et al. Two‐hour post‐glucose loading plasma glucose is the main determinant for the progression from impaired glucose tolerance to diabetes in Hong Kong Chinese. Diabetes Care1999;22(12):2096‐7. [PUBMED: 10587859] ">Ko 1999</a>; <a href="./references#CD012661-bbs2-0043" title="KoGT , ChanJC , CockramCS . Change of glycaemic status in Chinese subjects with impaired fasting glycaemia. Diabetic Medicine2001;18(9):745‐8. [PUBMED: 11606173] ">Ko 2001</a>; <a href="./references#CD012661-bbs2-0044" title="LarssonH , AhrenB , LindgardeF , BerglundG . Fasting blood glucose in determining the prevalence of diabetes in a large, homogeneous population of Caucasian middle‐aged women. Journal of Internal Medicine1995;237(6):537‐41. [PUBMED: 7782724] LarssonH , BerglundG , LindgardeF , AhrenB . Comparison of ADA and WHO criteria for diagnosis of diabetes and glucose intolerance. Diabetologia1998;41(9):1124‐5. [PUBMED: 9754834] LarssonH , LindgärdeF , BerglundG , AhrénB . Prediction of diabetes using ADA or WHO criteria in post‐menopausal women: a 10‐year follow‐up study. Diabetologia2000;43(10):1224‐8. [PUBMED: 11079739] ">Larsson 2000</a>; <a href="./references#CD012661-bbs2-0046" title="LecomteP , VolS , CacèsE , BornC , ChabrolleC , LasfarguesG , et al. Five‐year predictive factors of type 2 diabetes in men with impaired fasting glucose. Diabetes &amp; Metabolism2007;33(2):140‐7. [PUBMED: 17320447] ">Lecomte 2007</a>; <a href="./references#CD012661-bbs2-0048" title="LeivaE , MujicaV , OrregoR , WehingerS , SotoA , IcazaG , et al. Subjects with impaired fasting glucose: evolution in a period of 6 years. Journal of Diabetes Research2014;2014:710370. [DOI: 10.1155/2014/710370; PUBMED: 25215305] PalomoGI , IcazaNG , MujicaEV , NunezFL , LeivaME , VasquezRM , et al. Prevalence of cardiovascular risk factors in adult from Talca, Chile [Prevalencia de factores de riesgo cardiovascular clásicos en población adulta de Talca, Chile, 2005]. Revista Medica de Chile2007;135(7):904‐12. [PUBMED: 17914548] ">Leiva 2014</a>; <a href="./references#CD012661-bbs2-0050" title="ChouPS , LiCL , WuGS , TsaiST . Progression to type 2 diabetes among high‐risk groups in Kin‐Chen, Kinmen ‐ exploring the natural history of type 2 diabetes. Diabetes Care1998;21(7):1183‐7. [PUBMED: 9653617] LiCL , TsaiST , ChouP . Comparison of the results between two diagnostic criteria by ADA and WHO among subjects with FPG 5.6‐7.8 mmol/l in Kin‐Hu and Kin‐Chen, Kinmen, 1991‐94. Diabetes Research and Clinical Practice1999;45(1):51‐9. LiCL , TsaiST , ChouP . Persistent impaired glucose tolerance, insulin resistance, and beta‐cell dysfunction were independent predictors of type 2 diabetes. Journal of Clinical Epidemiology2005;58(7):728‐32. LiCL , TsaiST , ChouP . Relative role of insulin resistance and beta‐cell dysfunction in the progression to type 2 diabetes ‐ the Kinmen study. Diabetes Research and Clinical Practice2003;59(3):225‐32. [PUBMED: 12590020] TsaiST , LiCL , ChenCH , ChouP . Community‐based epidemiological study of glucose tolerance in Kin‐Chen, Kinmen: support for a new intermediate classification. Journal of Clinical Epidemiology2000;53(5):505‐10. [PUBMED: 10812323] ">Li 2003</a>; <a href="./references#CD012661-bbs2-0051" title="BrahimajA , LigthartS , GhanbariM , IkramMA , HofmanA , FrancoOH , et al. Novel inflammatory markers for incident pre‐diabetes and type 2 diabetes: the Rotterdam Study. European Journal of Epidemiology2017;32(3):217‐26. [PUBMED: 28258520] HofmanA , Darwish MuradS , vanDuijnCM , FrancoOH , GoedegebureA , IkramMA , et al. The Rotterdam study: 2014 objectives and design update. European Journal of Epidemiology2013;28(11):889‐926. LigthartS , vanHerptTT , LeeningMJ , KavousiM , HofmanA , StrickerBH , et al. Lifetime risk of developing impaired glucose metabolism and eventual progression from prediabetes to type 2 diabetes: a prospective cohort study. Lancet Diabetes &amp; Endocrinology2016;4(1):44‐51. [PUBMED: 26575606] van derSchaftN , BrahimajA , WenKX , FrancoOH , DehghanA . The association between serum uric acid and the incidence of prediabetes and type 2 diabetes mellitus: the Rotterdam study. PLOS ONE2017;12(6):e0179482. [PUBMED: 28632742] ">Ligthart 2016</a>; <a href="./references#CD012661-bbs2-0052" title="LipskaKJ , InzucchiSE , VanNessPH , GillTM , StrotmeyerES , KosterA , et al. Elevated HbA1c and fasting plasma glucose in predicting diabetes incidence among older adults: are two better than one?. Diabetes Care2013;36(12):3923‐9. [PUBMED: 24135387] StrotmeyerES , deRekeneireN , SchwartzAV , FaulknerKA , ResnickHE , GoodpasterBH , et al. The relationship of reduced peripheral nerve function and diabetes with physical performance in older white and black adults: the health, aging, and body composition (Health ABC) study. Diabetes Care2008;31(9):1767‐72. [PUBMED: 18535192] ">Lipska 2013</a>; <a href="./references#CD012661-bbs2-0054" title="LiuJ , WuYY , HuangXM , YangM , ZhaBB , WangF , et al. Ageing and type 2 diabetes in an elderly Chinese population: the role of insulin resistance and beta cell dysfunction. European Review for Medical and Pharmacological Sciences2014;18(12):1790‐7. [PUBMED: 24992623] ">Liu 2014</a>; <a href="./references#CD012661-bbs2-0056" title="HeJ , NealB , GuD , SuriyawongpaisalP , XinX , ReynoldsR , et al. International collaborative study of cardiovascular disease in Asia: design, rationale, and preliminary results. Ethnicity &amp; Disease2004;14(2):260‐8. LiuFC , YangXL , LiJX , CaoJ , ChenJC , LiY , et al. Association of fasting glucose levels with incident atherosclerotic cardiovascular disease: an 8‐year follow‐up study in a Chinese population. Journal of Diabetes2017;9(1):14‐23. [PUBMED: 26840038] ">Liu 2017</a>; <a href="./references#CD012661-bbs2-0058" title="GroopL , ForsblomC , LehtovirtaM , TuomiT , KarankoS , NissenM , et al. Metabolic consequences of a family history of NIDDM (the Botnia study): evidence for sex‐specific parental effects. Diabetes1996;45(11):1585‐93. [PUBMED: 8866565] LyssenkoV , AlmgrenP , AnevskiD , PerfektR , LahtiK , NissenM , et al. Predictors of and longitudinal changes in insulin sensitivity and secretion preceding onset of type 2 diabetes. Diabetes2005;54(1):166‐74. [PUBMED: 15616025] TripathyD , CarlssonM , AlmgrenP , IsomaaB , TaskinenMR , TuomiT , et al. Insulin secretion and insulin sensitivity in relation to glucose tolerance: lessons from the Botnia Study. Diabetes2000;49(6):975‐80. ">Lyssenko 2005</a>; <a href="./references#CD012661-bbs2-0059" title="Al SalmiI , HoyWE , Kondalsamy‐ChennakesavanS , WangZ , GobeGC , BarrEL , et al. Disorders of glucose regulation in adults and birth weight: results from the Australian diabetes, obesity and lifestyle (AUSDIAB) study. Diabetes Care2008;31(1):159‐64. DunstanDW , ZimmetPZ , WelbornTA , CameronAJ , ShawJ , deCourtenM , et al. The Australian diabetes, obesity and lifestyle study (AusDiab) ‐ methods and response rates. Diabetes Research and Clinical Practice2002;57:119‐29. [PUBMED: 12062857] DunstanDW , ZimmetPZ , WelbornTA , DeCourtenMP , CameronAJ , SicreeRA , et al. The rising prevalence of diabetes and impaired glucose tolerance: the Australian diabetes, obesity and lifestyle study. Diabetes Care2002;25:829‐34. [PUBMED: 11978676] MaglianoDJ , BarrELM , ZimmetPZ , CameronAJ , DunstanDW , ColagiuriS , et al. Glucose indices, health behaviors, and incidence of diabetes in Australia: the Australian diabetes, obesity and lifestyle study. Diabetes Care2008;31(2):267‐72. [PUBMED: 17989310] SicreeRA , ZimmetPZ , DunstanDW , CameronAJ , WelbornTA , ShawJE . Differences in height explain gender differences in the response to the oral glucose tolerance test‐ the AusDiab study. Diabetic Medicine2008;25(3):296‐302. SoulimaneS , SimonD , ShawJE , ZimmetPZ , VolS , VistisenD , et al. Comparing incident diabetes as defined by fasting plasma glucose or by HbA(1c). The AusDiab, Inter99 and DESIR studies. Diabetic Medicine2011;28(11):1311‐8. [PUBMED: 21824186] WilliamsED , MaglianoDJ , TappRJ , OldenburgBF , ShawJE . Psychosocial stress predicts abnormal glucose metabolism: the Australian diabetes, obesity and lifestyle (AusDiab) study. Annals of Behavioral Medicine2013;46(1):62‐72. [PUBMED: 23389687] ">Magliano 2008</a>; <a href="./references#CD012661-bbs2-0060" title="FoongAW , SawSM , LooJL , ShenS , LoonSC , RosmanM , et al. Rationale and methodology for a population‐based study of eye diseases in Malay people: the Singapore Malay eye study (SiMES). Ophthalmic Epidemiology2007;14(1):25‐35. ManRE , CharumathiS , GanAT , FenwickEK , TeyCS , ChuaJ , et al. Cumulative incidence and risk factors of prediabetes and type 2 diabetes in a Singaporean Malay cohort. Diabetes Research and Clinical Practice2017;127:163‐71. [PUBMED: 28371687] ">Man 2017</a>; <a href="./references#CD012661-bbs2-0063" title="BlakeDR , MeigsJB , MullerDC , NajjarSS , AndresR , NathanDM . Impaired glucose tolerance, but not impaired fasting glucose, is associated with increased levels of coronary heart disease risk factors: results from the Baltimore longitudinal study on aging. Diabetes2004;53(8):2095‐100. MeigsJB , MullerDC , NathanDM , BlakeDR , AndresR . The natural history of progression from normal glucose tolerance to type 2 diabetes in the Baltimore longitudinal study of aging. Diabetes2003;52(6):1475‐84. [PUBMED: 12765960] RodriguezA , MullerDC , EngelhardtM , AndresR . Contribution of impaired glucose tolerance in subjects with the metabolic syndrome: Baltimore longitudinal study of aging. Metabolism2005;54(4):542‐7. ShockNW , GreulichRC , ArembergD , CostaPT , LakattaEG , TobinJD . Normal human aging: the Baltimore longitudinal study of aging. Washington, DC: U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health, National Institute on Aging, Gerontology Research Center, Baltimore City Hospitals; 1984. Report No.: NIH‐84‐2450. SorkinJD , MullerDC , FlegJL , AndresR . The relation of fasting and 2‐h postchallenge plasma glucose concentrations to mortality: data from the Baltimore longitudinal study of aging with a critical review of the literature. Diabetes Care2005;28(11):2626‐32. ">Meigs 2003</a>; <a href="./references#CD012661-bbs2-0065" title="MotalaAA , OmarMA . Evaluation of WHO and NDDG criteria for impaired glucose tolerance. Diabetes Research and Clinical Practice1994;23(2):103‐9. [PUBMED: 8070301] MotalaAA , OmarMA . Evidence for impaired pancreatic beta cell function in South African Indians with impaired glucose tolerance. Diabetic Medicine1994;11(5):437‐44. MotalaAA , OmarMA , GouwsE . High risk of progression to NIDDM in South‐African Indians with impaired glucose tolerance. Diabetes1993;42(4):556‐63. [PUBMED: 8454106] MotalaAA , OmarMA , GouwsE . Transient impaired glucose tolerance in South African Indians does not carry a risk for progression to NIDDM. Diabetes Care1997;20(7):1101‐7. [PUBMED: 9203444] MotalaAA , PirieFJ , GouwsE , AmodA , OmarMA . High incidence of type 2 diabetes mellitus in South African Indians: a 10‐year follow‐up study. Diabetic Medicine2003;20(1):23‐30. [PUBMED: 12519316] OmarMA , SeedatMA , DyerRB , MotalaAA , KnightLT , BeckerPJ . South African Indians show a high prevalence of NIDDM and bimodality in plasma glucose distribution patterns. Diabetes Care1994;17(1):70‐3. ">Motala 2003</a>; <a href="./references#CD012661-bbs2-0066" title="Anonymous . Prevalence of chronic diseases in older Italians: comparing self‐reported and clinical diagnoses. The Italian longitudinal study on aging working group. International Journal of Epidemiology1997;26(5):995‐1002. [PUBMED: 9363520] MaggiS , ZucchettoM , GrigolettoF , BaldereschiM , CandeliseL , ScarpiniE , et al. The Italian longitudinal study on aging (ILSA): design and methods. Aging1994;6(6):464‐73. [PUBMED: 7748921] MottaM , BennatiE , CardilloE , FerlitoL , MalaguarneraM . The value of glycosylated hemoglobin (HbA1c) as a predictive risk factor in the diagnosis of diabetes mellitus (DM) in the elderly. Archives of Gerontology and Geriatrics2010;50(1):60‐4. MottaM , BennatiE , CardilloE , FerlitoL , PassamonteM , VacanteM , et al. A combination of glycosylated hemoglobin, impaired fasting glucose and waist circumference is effective in screening for individuals at risk for future type 2 diabetes. Archives of Gerontology and Geriatrics2010;50(1):105‐9. [PUBMED: 19414203] ">Motta 2010</a>; <a href="./references#CD012661-bbs2-0067" title="MykkänenL , KuusistoJ , PyoralaK , LaaksoM . Cardiovascular‐disease risk‐factors as predictors of type‐2 (non‐insulin‐dependent) diabetes‐mellitus in elderly subjects. Diabetologia1993;36(6):553‐9. [PUBMED: 8335178] MykkänenL , LaaksoM , PenttilaI , PyoralaK . Asymptomatic hyperglycemia and cardiovascular risk factors in the elderly. Atherosclerosis1991;88:153‐61. [PUBMED: 1892482] MykkänenL , LaaksoM , UusitupaM , PyoralaK . Prevalence of diabetes and impaired glucose tolerance in elderly subjects and their association with obesity and family history of diabetes. Diabetes Care1990;13:1099‐105. [PUBMED: 2261821] WangJ , RuotsalainenS , MoilanenL , LepistoP , LaaksoM , KuusistoJ . The metabolic syndrome predicts cardiovascular mortality: a 13‐year follow‐up study in elderly non‐diabetic Finns. European Heart Journal2007;28(7):857‐64. ">Mykkänen 1993</a>; <a href="./references#CD012661-bbs2-0069" title="NakanishiN , TakatorigeT , FukudaH , ShiraiK , LiW , OkamotoM , et al. Components of the metabolic syndrome as predictors of cardiovascular disease and type 2 diabetes in middle‐aged Japanese men. Diabetes Research and Clinical Practice2004;64(1):59‐70. [PUBMED: 15036828] ">Nakanishi 2004</a>; <a href="./references#CD012661-bbs2-0072" title="NorbergM , WallS , BomanK , WeinehallL . The Västerbotten intervention programme: background, design and implications. Global Health Action2010;3(1):4643. [PUBMED: 20339479] PetersonM , PingelR , LagaliN , DahlinLB , RolandssonO . Association between HbA1c and peripheral neuropathy in a 10‐year follow‐up study of people with normal glucose tolerance, impaired glucose tolerance and type 2 diabetes. Diabetic Medicine2017;34(12):1756‐64. [PUBMED: 28929513] PourhamidiK , DahlinLB , BomanK , RolandssonO . Heat shock protein 27 is associated with better nerve function and fewer signs of neuropathy. Diabetologia2011;54(12):3143‐9. [PUBMED: 21909836] ">Peterson 2017</a>; <a href="./references#CD012661-bbs2-0073" title="FengB , LiX , HuangYW . A survey of diabetes mellitus and its risk factors among permanent inhabitants in Shanghai Pudong new economic area. Chinese Journal of Diabetes2004;12:187‐90. QianQ , LiX , HuangX , FuM , MengZ , ChenM , et al. Glucose metabolism among residents in Shanghai: natural outcome of a 5‐year follow‐up study. Journal of Endocrinological Investigation2012;35(5):453‐8. [PUBMED: 21738002] ">Qian 2012</a>; <a href="./references#CD012661-bbs2-0074" title="QiaoQ , Keinanen‐KiukaanniemiS , RajalaU , UusimakiA , KivelaSL . Risk for diabetes and persistent impaired glucose tolerance among middle‐aged Finns. Diabetes Research &amp; Clinical Practice1996;33(3):191‐8. [PUBMED: 8922541] RajalaU , Keinanen‐KiukaanniemiS , UusimakiA , ReijulaK , KivelaSL . Prevalence of diabetes mellitus and impaired glucose tolerance in a middle‐aged Finnish population. Scandinavian Journal of Primary Health Care1995;13(3):222‐8. [PUBMED: 7481176] RajalaU , QiaoQ , LaaksoM , Keinänen‐KiukaanniemiS . Antihypertensive drugs as predictors of type 2 diabetes among subjects with impaired glucose tolerance. Diabetes Research and Clinical Practice2000;50(3):231‐9. [PUBMED: 11106838] ">Rajala 2000</a>; <a href="./references#CD012661-bbs2-0077" title="HerderC , KannenbergJM , Carstensen‐KirbergM , HuthC , MeisingerC , KoenigW , et al. Serum levels of interleukin‐22, cardiometabolic risk factors and incident type 2 diabetes: KORA F4/FF4 study. Cardiovascular Diabetology2017;16(1):17. [PUBMED: 28143481] KowallB , RathmannW , StrassburgerK , MeisingerC , HolleR , MielckA . Socioeconomic status is not associated with type 2 diabetes incidence in an elderly population in Germany: KORA S4/F4 cohort study. Journal of Epidemiology &amp; Community Health2011;65(7):606‐12. [PUBMED: 20693490] MeisingerC , DoringA , HeierM . Blood pressure and risk of type 2 diabetes mellitus in men and women from the general population: the monitoring trends and determinants on cardiovascular diseases/cooperative health research in the region of Augsburg cohort study. Journal of Hypertension2008;26(9):1809‐15. MeisingerC , DoringA , ThorandB , HeierM , LowelH . Body fat distribution and risk of type 2 diabetes in the general population: are there differences between men and women? The MONICA/KORA Augsburg cohort study. American Journal of Clinical Nutrition2006;84(3):483‐9. MeisingerC , ThorandB , SchneiderA , StieberJ , DoringA , LowelH . Sex differences in risk factors for incident type 2 diabetes mellitus: the MONICA Augsburg cohort study. Archives of Internal Medicine2002;162(1):82‐9. [PUBMED: 11784224] RathmannW , HaastertB , IcksA , LowelH , MeisingerC , HolleR , et al. High prevalence of undiagnosed diabetes mellitus in Southern Germany: target populations for efficient screening. The KORA survey 2000. Diabetologia2003;46(2):182‐9. [PUBMED: 12627316] RathmannW , MeisingerC . How prevalent is type 2 diabetes in Germany? Results from the MONICA/KORA studies [Wie häufig ist Typ‐2‐Diabetes in Deutschland?]. Diabetologe2010;6(3):170‐6. RathmannW , StrassburgerK , HeierM , HolleR , ThorandB , GianiG , et al. Incidence of type 2 diabetes in the elderly German population and the effect of clinical and lifestyle risk factors: KORA S4/F4 cohort study. Diabetic Medicine2009;26(12):1212‐9. [PUBMED: 20002472] ">Rathmann 2009</a>; <a href="./references#CD012661-bbs2-0078" title="HeineRJ , NijpelsG , MooyJM . New data on the rate of progression of impaired glucose tolerance to NIDDM and predicting factors. Diabetic Medicine1996;13(3 Suppl 2):S12‐4. MooyJM , GrootenhuisPA , deVriesH , ValkenburgHA , BouterLM , KostensePJ , et al. Prevalence and determinants of glucose intolerance in a Dutch Caucasian population. The Hoorn study. Diabetes Care1995;18:1270‐3. [PUBMED: 8612442] NijpelsG , Popp‐SnijdersC , KostenseP J , BouterLM , HeineRJ . Fasting proinsulin and 2‐h post‐load glucose levels predict the conversion to NIDDM in subjects with impaired glucose tolerance: the Hoorn study. Diabetologia1996;39(1):113‐8. [PUBMED: 8720611] NijpelsG , Popp‐SnijdersC , KostensePJ , BouterLM , HeineRJ . Cardiovascular risk factors prior to the development of non‐insulin‐dependent diabetes mellitus in persons with impaired glucose tolerance: the Hoorn Study. Journal of Clinical Epidemiology1997;50(9):1003‐9. RijkelijkhuizenJM , NijpelsG , HeineRJ , BouterLM , StehouwerCD , DekkerJM . High risk of cardiovascular mortality in individuals with impaired fasting glucose is explained by conversion to diabetes: the Hoorn study. Diabetes Care2007;30(2):332‐6. [PUBMED: 17259503] RuijgrokC , DekkerJM , BeulensJW , BrouwerIA , CoupeVMH , HeymansMW , et al. Size and shape of the associations of glucose, HbA1c, insulin and HOMA‐IR with incident type 2 diabetes: the Hoorn study. Diabetologia2018;61(1):93‐100. [PUBMED: 29018885] deVegtF , DekkerJM , JagerA , HienkensE , KostensePJ , StehouwerCD , et al. Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: the Hoorn study. JAMA2001;285(16):2109‐13. [PUBMED: 11311100] deVegtF , DekkerJM , StehouwerCD , NijpelsG , BouterLM , HeineRJ . Similar 9‐year mortality risks and reproducibility for the World Health Organization and American Diabetes Association glucose tolerance categories: the Hoorn study. Diabetes Care2000;23(1):40‐4. deVegtF , DekkerJM , StehouwerCD , NijpelsG , BouterLM , HeineRJ . The 1997 American Diabetes Association criteria versus the 1985 World Health Organization criteria for the diagnosis of abnormal glucose tolerance: poor agreement in the Hoorn study. Diabetes Care1998;21(10):1686‐90. ">Rijkelijkhuizen 2007</a>; <a href="./references#CD012661-bbs2-0080" title="SasakiA , SuzukiT , HoriuchiN . Development of diabetes in Japanese subjects with impaired glucose tolerance: a seven year follow‐up study. Diabetologia1982;22(3):154‐7. [PUBMED: 7075915] SasakiA , SuzukiT , HoriuchiN . Survival rate and causes of death in Japan. A 10‐year follow‐up study. Journal of Chronic Diseases1980;33:341‐6. ">Sasaki 1982</a>; <a href="./references#CD012661-bbs2-0088" title="SoriguerF , Rojo‐MartínezG , AlmarazMC , EstevaI , Ruiz de AdanaMS , MorcilloS , et al. Incidence of type 2 diabetes in southern Spain (Pizarra study). European Journal of Clinical Investigation2008;38(2):126‐33. [PUBMED: 18226046] Soriguer‐EscofetF , EstevaI , Rojo‐MartinezG , Ruiz de AdanaS , CatalaM , MereloMJ , et al. Prevalence of latent autoimmune diabetes of adults (LADA) in Southern Spain. Diabetes Research and Clinical Practice2002;56(3):213‐20. ">Soriguer 2008</a>; <a href="./references#CD012661-bbs2-0090" title="ToshihiroM , SaitoK , TakikawaS , TakebeN , OnodaT , SatohJ . Psychosocial factors are independent risk factors for the development of type 2 diabetes in Japanese workers with impaired fasting glucose and/or impaired glucose tolerance. Diabetic Medicine2008;25(10):1211‐7. [PUBMED: 19046200] ">Toshihiro 2008</a>; <a href="./references#CD012661-bbs2-0091" title="VaccaroO , RuffaG , ImperatoreG , IovinoV , RivelleseAA , RiccardiG . Risk of diabetes in the new diagnostic category of impaired fasting glucose: a prospective analysis. Diabetes Care1999;22(9):1490‐3. [PUBMED: 10480514] ">Vaccaro 1999</a>; <a href="./references#CD012661-bbs2-0092" title="ValdesS , BotasP , DelgadoE , AlvarezF , CadornigaFD . Population‐based incidence of type 2 diabetes in northern Spain: the Asturias study. Diabetes Care2007;30(9):2258‐63. [PUBMED: 17536076] ValdesS , BotasP , DelgadoE , AlvarezF , Diaz‐CadornigaF . HbA(1c) in the prediction of type 2 diabetes compared with fasting and 2‐h post‐challenge plasma glucose: the Asturias study (1998‐2005). Diabetes &amp; Metabolism2011;37(1):27‐32. [PUBMED: 20934897] ValdésS , BotasP , DelgadoE , ÁlvarezF , CadórnigaFD . Does the new American Diabetes Association definition for impaired fasting glucose improve its ability to predict type 2 diabetes mellitus in Spanish persons? The Asturias study. Metabolism2008;57(3):399‐403. [PUBMED: 18249214] ">Valdes 2008</a>; <a href="./references#CD012661-bbs2-0094" title="ViswanathanV , ClementinaM , NairBM , SatyavaniK . Risk of future diabetes is as high with abnormal intermediate post‐glucose response as with impaired glucose tolerance. Journal of the Association of Physicians of India2007;55:833‐7. [PUBMED: 18405128] ">Viswanathan 2007</a>; <a href="./references#CD012661-bbs2-0096" title="HowardBV , LeeET , CowanLD , DevereuxRB , GallowayJM , GoOT , et al. Rising tide of cardiovascular disease in American Indians. The strong heart study. Circulation1999;99(18):2389‐95. LeeET , HowardBV , GoO , SavagePJ , FabsitzRR , RobbinsDC , et al. Prevalence of undiagnosed diabetes in three American Indian populations. A comparison of the 1997 American Diabetes Association diagnostic criteria and the 1985 World Health Organization diagnostic criteria: the strong heart study. Diabetes Care2000;23(2):181‐6. LeeET , HowardBV , SavagePJ , CowanLD , FabsitzRR , OopikAJ , et al. Diabetes and impaired glucose tolerance in three American Indian populations aged 45‐74 years. The strong heart study. Diabetes Care1995;18(5):599‐610. LeeET , WeltyTK , CowanLD , WangW , RhoadesDA , DevereuxR , et al. Incidence of diabetes in American Indians of three geographic areas: the strong heart study. Diabetes Care2002;25(1):49‐54. [PUBMED: 11772900] LeeET , WeltyTK , FabsitzR , CowanLD , LeNA , OopikAJ , et al. The strong heart study. A study of cardiovascular disease in American Indians: design and methods. American Journal of Epidemiology1990;132(6):1141‐55. [PUBMED: 2260546] LuW , ResnickHE , JainAK , Adams‐CampbellLL , JablonskiKA , GottliebAM , et al. Effects of isolated post‐challenge hyperglycemia on mortality in American Indians: the strong heart study. Annals of Epidemiology2003;13(3):182‐8. WangH , SharaN M , CalhounD , UmansJG , LeeET , HowardBV . Incidence rates and predictors of diabetes in those with prediabetes: the strong heart study. Diabetes/metabolism Research and Reviews2010;26(5):378‐85. [PUBMED: 20578203] WangW , LeeET , FabsitzR , WeltyTK , HowardBV . Using HbA(1c) to improve efficacy of the American Diabetes Association fasting plasma glucose criterion in screening for new type 2 diabetes in American Indians: the strong heart study. Diabetes Care2002;25(8):1365‐70. WangW , LeeET , HowardBV , FabsitzRR , DevereuxRB , WeltyTK . Fasting plasma glucose and hemoglobin A1c in identifying and predicting diabetes: the strong heart study. Diabetes Care2011;34(2):363‐8. [PUBMED: 21270194] deSimoneG , DevereuxRB , ChinaliM , BestLG , LeeET , GallowayJM , et al. Prognostic impact of metabolic syndrome by different definitions in a population with high prevalence of obesity and diabetes: the strong heart study. Diabetes Care2007;30(7):1851‐6. ">Wang 2011</a>; <a href="./references#CD012661-bbs2-0098" title="JanusED . Epidemiology of cardiovascular risk factors in Hong Kong. Clinical and Experimental Pharmacology &amp; Physiology1997;24(12):987‐8. [PUBMED: 9406673] JanusED , WattNM , LamKS , CockramCS , SiuST , LiuLJ , et al. The prevalence of diabetes, association with cardiovascular risk factors and implications of diagnostic criteria (ADA 1997 and WHO 1998) in a 1996 community‐based population study in Hong Kong Chinese. Diabetic Medicine2000;17(10):741‐5. [PUBMED: 11110508] TanKC , WatNM , TamSC , JanusED , LamTH , LamKS . C‐reactive protein predicts the deterioration of glycemia in Chinese subjects with impaired glucose tolerance. Diabetes Care2003;26(8):2323‐8. WatNM , LamTH , JanusED , LamKS . Central obesity predicts the worsening of glycemia in southern Chinese. International Journal of Obesity and Related Metabolic Disorders2001;25(12):1789‐93. [PUBMED: 11781759] ">Wat 2001</a>; <a href="./references#CD012661-bbs2-0099" title="WeissR , DziuraJ , BurgertTS , TamborlaneWV , TaksaliSE , YeckelCW , et al. Obesity and the metabolic syndrome in children and adolescents. New England Journal of Medicine2004;350(23):2362‐74. [PUBMED: 15175438] WeissR , TaksaliSE , TamborlaneWV , BurgertTS , SavoyeM , CaprioS . Predictors of changes in glucose tolerance status in obese youth. Diabetes Care2005;28(4):902‐9. [PUBMED: 15793193] ">Weiss 2005</a>; <a href="./references#CD012661-bbs2-0102" title="BildDE , BluemkeDA , BurkeGL , DetranoR , Diez RouxAV , FolsomAR , et al. Multi‐ethnic study of atherosclerosis: objectives and design. American Journal of Epidemiology2002;156(9):871‐81. [PUBMED: 12397006] YeboahJ , BertoniA G , HerringtonDM , PostWS , BurkeGL . Impaired fasting glucose and the risk of incident diabetes mellitus and cardiovascular events in an adult population: MESA (multi‐ethnic study of atherosclerosis). Journal of the American College of Cardiology2011;58(2):140‐6. [PUBMED: 21718910] ">Yeboah 2011</a>). In the remaining studies, it was evident that normoglycaemia reflected the population with neither IH nor T2DM at baseline. </p> <p>IH was commonly defined by the IFG<sub>5.6</sub> threshold (FPG level 5.6 mmol/L to 6.9 mmol/L or 100 mg/dL to 125 mg/dL), IFG<sub>6.1</sub>threshold (FPG level 6.1 mmol/L to 6.9 mmol/L or 110 mg/dL to 125 mg/dL), IGT (plasma glucose concentration 7.8 mmol/L to 11.1 mmol/L or 140 mg/dL to 199 mg/dL two hours after a 75 g glucose load on the OGTT), or combinations of these criteria (<a href="./appendices#CD012661-sec-0140">Appendix 5</a>; <a href="./appendices#CD012661-sec-0141">Appendix 6</a>). Sixty‐six studies used an OGTT at baseline as part of the strategy to assess glycaemic status, and 46 studies used OGTT at baseline and follow‐up (<a href="./appendices#CD012661-sec-0140">Appendix 5</a>). </p> <p>Twelve studies defined IH by applying the HbA1c<sub>5.7</sub> threshold (HbA1c 5.7% to 6.4% or 39 mmol/mol to 46 mmol/mol) (<a href="./references#CD012661-bbs2-0005" title="BaeJC , RheeEJ , LeeWY , ParkSE , ParkCY , OhKW , et al. Combined effect of nonalcoholic fatty liver disease and impaired fasting glucose on the development of type 2 diabetes: a 4‐year retrospective longitudinal study. Diabetes Care2011;34(3):727‐9. [PUBMED: 21278140] BaeJC , RheeEJ , LeeWY , ParkSE , ParkCY , OhKW , et al. Optimal range of HbA1c for the prediction of future diabetes: a 4‐year longitudinal study. Diabetes Research and Clinical Practice2011;93(2):255‐9. [PUBMED: 21676480] ">Bae 2011</a>; <a href="./references#CD012661-bbs2-0010" title="CederbergH , SaukkonenT , LaaksoM , JokelainenJ , HarkonenP , TimonenM , et al. Postchallenge glucose, A1C, and fasting glucose as predictors of type 2 diabetes and cardiovascular disease: a 10‐year prospective cohort study. Diabetes Care2010;33(9):2077‐83. [PUBMED: 20573752] RajalaU , LaaksoM , PaivansaloM , PelkonenO , SuramoI , Keinanen‐KiukaanniemiS . Low insulin sensitivity measured by both quantitative insulin sensitivity check index and homeostasis model assessment method as a risk factor of increased intima‐media thickness of the carotid artery. Journal of Clinical Endocrinology and Metabolism2002;87(11):5092‐7. [PUBMED: 12414877] ">Cederberg 2010</a>; <a href="./references#CD012661-bbs2-0028" title="ChoiSH , KimTH , LimS , ParkKS , JangHC , ChoNH . Hemoglobin A1c as a diagnostic tool for diabetes screening and new‐onset diabetes prediction: a 6‐year community‐based prospective study. Diabetes Care2011;34(4):944‐9. [PUBMED: 21335372] HanSJ , KimHJ , KimDJ , LeeKW , ChoNH . Incidence and predictors of type 2 diabetes among Koreans: a 12‐year follow up of the Korean genome and epidemiology study. Diabetes Research and Clinical Practice2017;123:173‐80. [PUBMED: 28043048] JungDH , ByunYS , KwonYJ , KimGS . Microalbuminuria as a simple predictor of incident diabetes over 8 years in the Korean genome and epidemiology study (KoGES). Scientific Reports2017;7(1):15445. [PUBMED: 29133894] JungJY , OhCM , RyooJH , ChoiJM , ChoiYJ , HamW T , et al. The influence of prehypertension, hypertension, and glycated hemoglobin on the development of type 2 diabetes mellitus in prediabetes: the Korean genome and epidemiology study (KoGES). Endocrine2018;59(3):593‐601. [PUBMED: 29380232] Keun ParkS , RyooJH , OhCM , ChoiJM , ChoiYJ , Ok LeeK , et al. The risk of type 2 diabetes mellitus according to 2‐hour plasma glucose level: the Korean genome and epidemiology study (KoGES). Diabetes Research and Clinical Practice 2017 Aug 9 [Epub ahead of print]. [DOI: 10.1016/j.diabres.2017.08.002; PUBMED: 28951335] LimNK , ParkSH , ChoiSJ , LeeKS , ParkHY . A risk score for predicting the incidence of type 2 diabetes in a middle‐aged Korean cohort: the Korean genome and epidemiology study. Circulation Journal2012;76(8):1904‐10. [PUBMED: 22640983] ">Han 2017</a>; <a href="./references#CD012661-bbs2-0030" title="HeianzaY , AraseY , FujiharaK , HsiehSD , SaitoK , TsujiH , et al. Longitudinal trajectories of HbA1c and fasting plasma glucose levels during the development of type 2 diabetes: the Toranomon hospital health management center study 7 (TOPICS 7). Diabetes Care2012;35(5):1050‐2. [PUBMED: 22456865] HeianzaY , AraseY , FujiharaK , TsujiH , SaitoK , HsiehSD , et al. High normal HbA(1c) levels were associated with impaired insulin secretion without escalating insulin resistance in Japanese individuals: the Toranomon hospital health management center study 8 (TOPICS 8). Diabetic Medicine2012;29(10):1285‐90. HeianzaY , AraseY , FujiharaK , TsujiH , SaitoK , HsiehSD , et al. Screening for pre‐diabetes to predict future diabetes using various cut‐off points for HbA(1c) and impaired fasting glucose: the Toranomon hospital health management center study 4 (TOPICS 4). Diabetic Medicine2012;29(9):e279‐85. [PUBMED: 22510023] HeianzaY , AraseY , HsiehSD , SaitoK , TsujiH , KodamaS , et al. Development of a new scoring system for predicting the 5 year incidence of type 2 diabetes in Japan: the Toranomon hospital health management center study 6 (TOPICS 6). Diabetologia2012;55(12):3213‐23. [PUBMED: 22955996] HeianzaY , HaraS , AraseY , SaitoK , FujiwaraK , TsujiH , et al. HbA1c 5.7‐6.4% and impaired fasting plasma glucose for diagnosis of prediabetes and risk of progression to diabetes in Japan (TOPICS 3): a longitudinal cohort study. Lancet2011;378(9786):147‐55. [MEDLINE: 21705064] HeianzaY , HaraS , AraseY , SaitoK , TotsukaK , TsujiH , et al. Low serum potassium levels and risk of type 2 diabetes: the Toranomon hospital health management center study 1 (TOPICS 1). Diabetologia2011;54(4):762‐6. [PUBMED: 21212932] ">Heianza 2012</a>; <a href="./references#CD012661-bbs2-0038" title="KimYA , KuEJ , KhangAR , HongES , KimKM , MoonJH , et al. Role of various indices derived from an oral glucose tolerance test in the prediction of conversion from prediabetes to type 2 diabetes. Diabetes Research and Clinical Practice2014;106(2):351‐9. [PUBMED: 25245975] ">Kim 2014</a>; <a href="./references#CD012661-bbs2-0039" title="KimCH , KimHK , KimEH , BaeSJ , ChoeJ , ParkJY . Risk of progression to diabetes from prediabetes defined by HbA1c or fasting plasma glucose criteria in Koreans. Diabetes Research and Clinical Practice2016;118:105‐11. [PUBMED: 27368062] ">Kim 2016a</a>; <a href="./references#CD012661-bbs2-0047" title="LeeJH , LimJT , KimHG , OhMK , LeeWJ . Effect of coffee consumption on the progression of type 2 diabetes mellitus among prediabetic individuals. Korean Journal of Family Medicine2016;37(1):7‐13. [PUBMED: 26885316] ">Lee 2016</a>; <a href="./references#CD012661-bbs2-0052" title="LipskaKJ , InzucchiSE , VanNessPH , GillTM , StrotmeyerES , KosterA , et al. Elevated HbA1c and fasting plasma glucose in predicting diabetes incidence among older adults: are two better than one?. Diabetes Care2013;36(12):3923‐9. [PUBMED: 24135387] StrotmeyerES , deRekeneireN , SchwartzAV , FaulknerKA , ResnickHE , GoodpasterBH , et al. The relationship of reduced peripheral nerve function and diabetes with physical performance in older white and black adults: the health, aging, and body composition (Health ABC) study. Diabetes Care2008;31(9):1767‐72. [PUBMED: 18535192] ">Lipska 2013</a>; <a href="./references#CD012661-bbs2-0060" title="FoongAW , SawSM , LooJL , ShenS , LoonSC , RosmanM , et al. Rationale and methodology for a population‐based study of eye diseases in Malay people: the Singapore Malay eye study (SiMES). Ophthalmic Epidemiology2007;14(1):25‐35. ManRE , CharumathiS , GanAT , FenwickEK , TeyCS , ChuaJ , et al. Cumulative incidence and risk factors of prediabetes and type 2 diabetes in a Singaporean Malay cohort. Diabetes Research and Clinical Practice2017;127:163‐71. [PUBMED: 28371687] ">Man 2017</a>; <a href="./references#CD012661-bbs2-0068" title="NakagamiT , TanakaY , OyaJ , KuritaM , IsagoC , HasegawaY , et al. Associations of HbA1c and fasting plasma glucose with incident diabetes: implications for pre‐diabetes thresholds in a Japanese population. Primary Care Diabetes2016;10(6):407‐14. [PUBMED: 27515716] ">Nakagami 2016</a>; <a href="./references#CD012661-bbs2-0093" title="VijayakumarP , NelsonR G , HansonR L , KnowlerW C , SinhaM . HbA1c and the prediction of type 2 diabetes in children and adults. Diabetes Care2017;40(1):16‐21. [PUBMED: 27810987] ">Vijayakumar 2017</a>; <a href="./references#CD012661-bbs2-0097" title="LeongA , DayaN , PornealaB , DevlinJJ , ShiffmanD , McPhaulMJ , et al. Prediction of type 2 diabetes by hemoglobin A1c in two community‐based cohorts. Diabetes Care2018;41(1):60‐8. [PUBMED: 29074816] SchmidtMI , DuncanBB , BangH , PankowJS , BallantyneCM , GoldenSH , et al. Identifying individuals at high risk for diabetes ‐ the atherosclerosis risk in communities study. Diabetes Care2005;28(8):2013‐8. [PUBMED: 16043747] SelvinE , RawlingsAM , GramsM , KleinR , SharrettAR , SteffesM , et al. Fructosamine and glycated albumin for risk stratification and prediction of incident diabetes and microvascular complications: a prospective cohort analysis of the atherosclerosis risk in communities (ARIC) study. Lancet Diabetes &amp; Endocrinology2014;2(4):279‐88. [PUBMED: 24703046] SelvinE , SteffesM W , GreggE , BrancatiF L , CoreshJ . Performance of A1C for the classification and prediction of diabetes. Diabetes Care2011;34(1):84‐9. [PUBMED: 20855549] SelvinE , SteffesMW , ZhuH , MatsushitaK , WagenknechtL , PankowJ , et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. New England Journal of Medicine2010;362(9):800‐11. [PUBMED: 20200384] WarrenB , PankowJ S , MatsushitaK , PunjabiNM , DayaNR , GramsM , et al. Comparative prognostic performance of definitions of prediabetes: a prospective cohort analysis of the atherosclerosis risk in communities (ARIC) study. Lancet Diabetes &amp; Endocrinology2017;5(1):34‐42. [PUBMED: 27863979] WheltonSP , McEvoyJW , LazoM , CoreshJ , BallantyneCM , SelvinE . High‐sensitivity cardiac troponin T (hs‐cTnT) as a predictor of incident diabetes in the atherosclerosis risk in communities study. Diabetes Care2017;40(2):261‐9. [PUBMED: 28108537] ">Warren 2017</a>), and 10 studies used the HbA1c<sub>6.0</sub> threshold (HbA1c 6.0% to 6.4% or 42 mmol/mol to 46 mmol/mol) (<a href="./references#CD012661-bbs2-0005" title="BaeJC , RheeEJ , LeeWY , ParkSE , ParkCY , OhKW , et al. Combined effect of nonalcoholic fatty liver disease and impaired fasting glucose on the development of type 2 diabetes: a 4‐year retrospective longitudinal study. Diabetes Care2011;34(3):727‐9. [PUBMED: 21278140] BaeJC , RheeEJ , LeeWY , ParkSE , ParkCY , OhKW , et al. Optimal range of HbA1c for the prediction of future diabetes: a 4‐year longitudinal study. Diabetes Research and Clinical Practice2011;93(2):255‐9. [PUBMED: 21676480] ">Bae 2011</a>; <a href="./references#CD012661-bbs2-0009" title="BonoraE , KiechlS , MayrA , ZoppiniG , TargherG , BonadonnaRC , et al. High‐normal HbA1c is a strong predictor of type 2 diabetes in the general population. Diabetes Care2011;34(4):1038‐40. [PUBMED: 21307378] BonoraE , KiechlS , WilleitJ , OberhollenzerF , EggerG , MeigsJB , et al. Insulin resistance as estimated by homeostasis model assessment predicts incident symptomatic cardiovascular disease in Caucasian subjects from the general population: the Bruneck study. Diabetes Care2007;30(2):318‐24. BonoraE , KiechlS , WilleitJ , OberhollenzerF , EggerG , MeigsJB , et al. Population‐based incidence rates and risk factors for type 2 diabetes in white individuals: the Bruneck study. Diabetes2004;53(7):1782‐9. [PUBMED: 15220202] ">Bonora 2011</a>; <a href="./references#CD012661-bbs2-0011" title="ChamnanP , SimmonsRK , ForouhiNG , LubenRN , KhawKT , WarehamNJ , et al. Incidence of type 2 diabetes using proposed HbA1c diagnostic criteria in the European prospective investigation of Cancer‐Norfolk cohort: implications for preventive strategies. Diabetes Care2011;34(4):950‐6. [PUBMED: 20622160] DayN , OakesS , LubenR , KhawKT , BinghamS , WelchA , et al. EPIC‐Norfolk: study design and characteristics of the cohort. European prospective investigation of cancer. British Journal of Cancer1999;80(Suppl 1):95‐103. [PUBMED: 10466767] KhawKT , WarehamN , LubenR , BinghamS , OakesS , WelchA , et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European prospective investigation of cancer and nutrition (EPIC‐Norfolk). BMJ2001;322(7277):15‐8. [PUBMED: 11141143] ">Chamnan 2011</a>; <a href="./references#CD012661-bbs2-0028" title="ChoiSH , KimTH , LimS , ParkKS , JangHC , ChoNH . Hemoglobin A1c as a diagnostic tool for diabetes screening and new‐onset diabetes prediction: a 6‐year community‐based prospective study. Diabetes Care2011;34(4):944‐9. [PUBMED: 21335372] HanSJ , KimHJ , KimDJ , LeeKW , ChoNH . Incidence and predictors of type 2 diabetes among Koreans: a 12‐year follow up of the Korean genome and epidemiology study. Diabetes Research and Clinical Practice2017;123:173‐80. [PUBMED: 28043048] JungDH , ByunYS , KwonYJ , KimGS . Microalbuminuria as a simple predictor of incident diabetes over 8 years in the Korean genome and epidemiology study (KoGES). Scientific Reports2017;7(1):15445. [PUBMED: 29133894] JungJY , OhCM , RyooJH , ChoiJM , ChoiYJ , HamW T , et al. The influence of prehypertension, hypertension, and glycated hemoglobin on the development of type 2 diabetes mellitus in prediabetes: the Korean genome and epidemiology study (KoGES). Endocrine2018;59(3):593‐601. [PUBMED: 29380232] Keun ParkS , RyooJH , OhCM , ChoiJM , ChoiYJ , Ok LeeK , et al. The risk of type 2 diabetes mellitus according to 2‐hour plasma glucose level: the Korean genome and epidemiology study (KoGES). Diabetes Research and Clinical Practice 2017 Aug 9 [Epub ahead of print]. [DOI: 10.1016/j.diabres.2017.08.002; PUBMED: 28951335] LimNK , ParkSH , ChoiSJ , LeeKS , ParkHY . A risk score for predicting the incidence of type 2 diabetes in a middle‐aged Korean cohort: the Korean genome and epidemiology study. Circulation Journal2012;76(8):1904‐10. [PUBMED: 22640983] ">Han 2017</a>; <a href="./references#CD012661-bbs2-0030" title="HeianzaY , AraseY , FujiharaK , HsiehSD , SaitoK , TsujiH , et al. Longitudinal trajectories of HbA1c and fasting plasma glucose levels during the development of type 2 diabetes: the Toranomon hospital health management center study 7 (TOPICS 7). Diabetes Care2012;35(5):1050‐2. [PUBMED: 22456865] HeianzaY , AraseY , FujiharaK , TsujiH , SaitoK , HsiehSD , et al. High normal HbA(1c) levels were associated with impaired insulin secretion without escalating insulin resistance in Japanese individuals: the Toranomon hospital health management center study 8 (TOPICS 8). Diabetic Medicine2012;29(10):1285‐90. HeianzaY , AraseY , FujiharaK , TsujiH , SaitoK , HsiehSD , et al. Screening for pre‐diabetes to predict future diabetes using various cut‐off points for HbA(1c) and impaired fasting glucose: the Toranomon hospital health management center study 4 (TOPICS 4). Diabetic Medicine2012;29(9):e279‐85. [PUBMED: 22510023] HeianzaY , AraseY , HsiehSD , SaitoK , TsujiH , KodamaS , et al. Development of a new scoring system for predicting the 5 year incidence of type 2 diabetes in Japan: the Toranomon hospital health management center study 6 (TOPICS 6). Diabetologia2012;55(12):3213‐23. [PUBMED: 22955996] HeianzaY , HaraS , AraseY , SaitoK , FujiwaraK , TsujiH , et al. HbA1c 5.7‐6.4% and impaired fasting plasma glucose for diagnosis of prediabetes and risk of progression to diabetes in Japan (TOPICS 3): a longitudinal cohort study. Lancet2011;378(9786):147‐55. [MEDLINE: 21705064] HeianzaY , HaraS , AraseY , SaitoK , TotsukaK , TsujiH , et al. Low serum potassium levels and risk of type 2 diabetes: the Toranomon hospital health management center study 1 (TOPICS 1). Diabetologia2011;54(4):762‐6. [PUBMED: 21212932] ">Heianza 2012</a>; <a href="./references#CD012661-bbs2-0039" title="KimCH , KimHK , KimEH , BaeSJ , ChoeJ , ParkJY . Risk of progression to diabetes from prediabetes defined by HbA1c or fasting plasma glucose criteria in Koreans. Diabetes Research and Clinical Practice2016;118:105‐11. [PUBMED: 27368062] ">Kim 2016a</a>; <a href="./references#CD012661-bbs2-0068" title="NakagamiT , TanakaY , OyaJ , KuritaM , IsagoC , HasegawaY , et al. Associations of HbA1c and fasting plasma glucose with incident diabetes: implications for pre‐diabetes thresholds in a Japanese population. Primary Care Diabetes2016;10(6):407‐14. [PUBMED: 27515716] ">Nakagami 2016</a>; <a href="./references#CD012661-bbs2-0081" title="SatoKK , HayashiT , HaritaN , YonedaT , NakamuraY , EndoG , et al. Combined measurement of fasting plasma glucose and A1C is effective for the prediction of type 2 diabetes: the Kansai healthcare study. Diabetes Care2009;32(4):644‐6. [PUBMED: 19131461] SatoKK , HayashiT , KambeH , NakamuraY , HaritaN , EndoG , et al. Walking to work is an independent predictor of incidence of type 2 diabetes in Japanese men: the Kansai healthcare study. Diabetes Care2007;30(9):2296‐8. [PUBMED: 17536075] SatoKK , HayashiT , NakamuraY , HaritaN , YonedaT , EndoG , et al. Liver enzymes compared with alcohol consumption in predicting the risk of type 2 diabetes: the Kansai healthcare study. Diabetes Care2008;31:1230‐6. [PUBMED: 18316395] ">Sato 2009</a>; <a href="./references#CD012661-bbs2-0096" title="HowardBV , LeeET , CowanLD , DevereuxRB , GallowayJM , GoOT , et al. Rising tide of cardiovascular disease in American Indians. The strong heart study. Circulation1999;99(18):2389‐95. LeeET , HowardBV , GoO , SavagePJ , FabsitzRR , RobbinsDC , et al. Prevalence of undiagnosed diabetes in three American Indian populations. A comparison of the 1997 American Diabetes Association diagnostic criteria and the 1985 World Health Organization diagnostic criteria: the strong heart study. Diabetes Care2000;23(2):181‐6. LeeET , HowardBV , SavagePJ , CowanLD , FabsitzRR , OopikAJ , et al. Diabetes and impaired glucose tolerance in three American Indian populations aged 45‐74 years. The strong heart study. Diabetes Care1995;18(5):599‐610. LeeET , WeltyTK , CowanLD , WangW , RhoadesDA , DevereuxR , et al. Incidence of diabetes in American Indians of three geographic areas: the strong heart study. Diabetes Care2002;25(1):49‐54. [PUBMED: 11772900] LeeET , WeltyTK , FabsitzR , CowanLD , LeNA , OopikAJ , et al. The strong heart study. A study of cardiovascular disease in American Indians: design and methods. American Journal of Epidemiology1990;132(6):1141‐55. [PUBMED: 2260546] LuW , ResnickHE , JainAK , Adams‐CampbellLL , JablonskiKA , GottliebAM , et al. Effects of isolated post‐challenge hyperglycemia on mortality in American Indians: the strong heart study. Annals of Epidemiology2003;13(3):182‐8. WangH , SharaN M , CalhounD , UmansJG , LeeET , HowardBV . Incidence rates and predictors of diabetes in those with prediabetes: the strong heart study. Diabetes/metabolism Research and Reviews2010;26(5):378‐85. [PUBMED: 20578203] WangW , LeeET , FabsitzR , WeltyTK , HowardBV . Using HbA(1c) to improve efficacy of the American Diabetes Association fasting plasma glucose criterion in screening for new type 2 diabetes in American Indians: the strong heart study. Diabetes Care2002;25(8):1365‐70. WangW , LeeET , HowardBV , FabsitzRR , DevereuxRB , WeltyTK . Fasting plasma glucose and hemoglobin A1c in identifying and predicting diabetes: the strong heart study. Diabetes Care2011;34(2):363‐8. [PUBMED: 21270194] deSimoneG , DevereuxRB , ChinaliM , BestLG , LeeET , GallowayJM , et al. Prognostic impact of metabolic syndrome by different definitions in a population with high prevalence of obesity and diabetes: the strong heart study. Diabetes Care2007;30(7):1851‐6. ">Wang 2011</a>; <a href="./references#CD012661-bbs2-0097" title="LeongA , DayaN , PornealaB , DevlinJJ , ShiffmanD , McPhaulMJ , et al. Prediction of type 2 diabetes by hemoglobin A1c in two community‐based cohorts. Diabetes Care2018;41(1):60‐8. [PUBMED: 29074816] SchmidtMI , DuncanBB , BangH , PankowJS , BallantyneCM , GoldenSH , et al. Identifying individuals at high risk for diabetes ‐ the atherosclerosis risk in communities study. Diabetes Care2005;28(8):2013‐8. [PUBMED: 16043747] SelvinE , RawlingsAM , GramsM , KleinR , SharrettAR , SteffesM , et al. Fructosamine and glycated albumin for risk stratification and prediction of incident diabetes and microvascular complications: a prospective cohort analysis of the atherosclerosis risk in communities (ARIC) study. Lancet Diabetes &amp; Endocrinology2014;2(4):279‐88. [PUBMED: 24703046] SelvinE , SteffesM W , GreggE , BrancatiF L , CoreshJ . Performance of A1C for the classification and prediction of diabetes. Diabetes Care2011;34(1):84‐9. [PUBMED: 20855549] SelvinE , SteffesMW , ZhuH , MatsushitaK , WagenknechtL , PankowJ , et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. New England Journal of Medicine2010;362(9):800‐11. [PUBMED: 20200384] WarrenB , PankowJ S , MatsushitaK , PunjabiNM , DayaNR , GramsM , et al. Comparative prognostic performance of definitions of prediabetes: a prospective cohort analysis of the atherosclerosis risk in communities (ARIC) study. Lancet Diabetes &amp; Endocrinology2017;5(1):34‐42. [PUBMED: 27863979] WheltonSP , McEvoyJW , LazoM , CoreshJ , BallantyneCM , SelvinE . High‐sensitivity cardiac troponin T (hs‐cTnT) as a predictor of incident diabetes in the atherosclerosis risk in communities study. Diabetes Care2017;40(2):261‐9. [PUBMED: 28108537] ">Warren 2017</a>). </p> </section> <section id="CD012661-sec-0068"> <h5 class="title">Overview of study populations</h5> <p>Sixty‐nine studies (67%) started recruitment after 1990 (see <a href="./references#CD012661-sec-0161" title="">Characteristics of included studies</a>), and overall follow‐up ranged from 1 year in <a href="./references#CD012661-bbs2-0007" title="BaiPV , KrishnaswamiCV , ChellamariappanM . Prevalence and incidence of type‐2 diabetes and impaired glucose tolerance in a selected Indian urban population. Journal of the Association of Physicians of India1999;47(11):1060‐4. [PUBMED: 10862313] ">Bai 1999,</a><a href="./references#CD012661-bbs2-0015" title="Coronado‐MalagonM , Gomez‐VargasJI , Espinoza‐PeraltaD , Arce‐SalinasA . Progression toward type‐2 diabetes mellitus among Mexican pre‐diabetics. Assessment of a cohort. Gaceta Medica De Mexico2009;145(4):269‐72. [PUBMED: 20073428] ">Coronado‐Malagon 2009</a> and <a href="./references#CD012661-bbs2-0040" title="KleberM , LassN , PapckeS , WabitschM , ReinehrT . One‐year follow‐up of untreated obese white children and adolescents with impaired glucose tolerance: high conversion rate to normal glucose tolerance. Diabetic Medicine2010;27(5):516‐21. [PUBMED: 20536946] ">Kleber 2010</a> to 24 years in <a href="./references#CD012661-bbs2-0008" title="BergmanM , ChetritA , RothJ , JagannathanR , SevickM , DanknerR . One‐hour post‐load plasma glucose level during the OGTT predicts dysglycemia: observations from the 24year follow‐up of the Israel study of glucose intolerance, obesity and hypertension. Diabetes Research and Clinical Practice2016;120:221‐8. [PUBMED: 27596059] DanknerR , Abdul‐GhaniMA , GerberY , ChetritA , WainsteinJ , RazI . Predicting the 20‐year diabetes incidence rate. Diabetes/metabolism Research and Reviews2007;23(7):551‐8. [PUBMED: 17315136] ModanM , HalkinH , KarasikA , LuskyA . Effectiveness of glycosylated hemoglobin, fasting plasma glucose, and a single post load plasma glucose level in population screening for glucose intolerance. American Journal of Epidemiology1984;119(3):431‐44. [PUBMED: 6702817] ModanM , KarasikA , HalkinH , FuchsZ , LuskyA , ShitritA , et al. Effect of past and concurrent body mass index on prevalence of glucose intolerance and type 2 (non‐insulin‐dependent) diabetes and on insulin response. Diabetologia1986;29(2):82‐9. [PUBMED: 3516770] ">Bergman 2016</a> (see <a href="./references#CD012661-sec-0161" title="">Characteristics of included studies</a>; <a href="./appendices#CD012661-sec-0142">Appendix 7</a>). </p> <p>Depending on the phase of the study, the number of participants differed. The first phase of every study often constituted a large epidemiological investigation of, for example, the importance of various risk factors for cardiovascular health; in total, more than 250,000 participants began the studies (<a href="./appendices#CD012661-sec-0143">Appendix 8</a>). The number of participants with IH depended on how the studies defined this condition at baseline and the way they measured the development of T2DM. </p> <p>The overall prognosis of participants with IH at baseline and across all follow‐up times (1 to 20 years) was based on the following data (<a href="#CD012661-tbl-0008">Table 1</a>). </p> <div class="table" id="CD012661-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Overview: overall prognosis of people with intermediate hyperglycaemia and regression from intermediate hyperglycaemia to normoglycaemia</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Follow‐up time (years)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>% (95% CI) cumulative T2DM incidence <br/> [no of studies; no of participants with IH]</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="16" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>% (95% CI) regression from IH to normoglycaemia<br/> [no of studies; no of participants with IH]</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IFG<sub>5.6</sub> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IFG<sub>6.1</sub> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IGT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IFG + IGT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HbA1c<sub>5.7</sub> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HbA1c<sub>6.0</sub> </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>13 (5–23)</b> </p> <p>[3; 671]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>29 (23–36)</b> </p> <p>[1; 207]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>59 (54–64)</b> </p> <p>[2; 375]</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2 (1–2)</b> </p> <p>[1; 1335]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>11 (8–14)</b> </p> <p>[2; 549]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>16 (9–26)</b> </p> <p>[9; 1998]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>46 (36–55)</b> </p> <p>[9; 2852]</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>17 (6–32)</b> </p> <p>[3; 1091]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>9 (2–20)</b> </p> <p>[3; 927]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>22 (18–27)</b> </p> <p>[3; 417]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>34 (28–41)</b> </p> <p>[1; 209]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>7 (5–10)</b> </p> <p>[1; 370]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>41 (24–59)</b> </p> <p>[7; 1356]</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>17 (13–22)</b> </p> <p>[3; 800]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>30 (17–44)</b> </p> <p>[2; 1567]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>22 (12–34)</b> </p> <p>[5; 1042]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>14 (7–23)</b> </p> <p>[3; 5352]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>44 (40–48)</b> </p> <p>[2; 627]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>33 (26–40)</b> </p> <p>[3; 807]</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>5</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>18 (10–27)</b> </p> <p>[7; 3530]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>26 (19–33)</b> </p> <p>[11; 3837]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>39 (25–53)</b> </p> <p>[12; 3444]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>50 (37–63)</b> </p> <p>[5; 478]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>25 (18–32)</b> </p> <p>[4; 3524]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>38 (26–51)</b> </p> <p>[3; 1462]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>34 (27–42)</b> </p> <p>[9; 2603]</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>6</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>22 (15–31)</b> </p> <p>[4; 738]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>37 (31–43)</b> </p> <p>[5; 279]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>29 (25–34)</b> </p> <p>[7; 775]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>58 (48–67)</b> </p> <p>[4; 106]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>17 (14–20)</b> </p> <p>[1; 675]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>23 (3–53)</b> </p> <p>[5; 1328]</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>7</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>18 (8–30)</b> </p> <p>[5; 980]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>15 (0–45)</b> </p> <p>[4; 434]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>19 (13–26)</b> </p> <p>[5; 835]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>32 (20–45)</b> </p> <p>[4; 753]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>21 (16–27)</b> </p> <p>[1; 207]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>41 (37–45)</b> </p> <p>[4; 679]</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>8</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>34 (27–40)</b> </p> <p>[2; 1887]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>48 (31–66)</b> </p> <p>[1;29]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>43 (37–49)</b> </p> <p>[4; 1021]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>52 (47–57)</b> </p> <p>[1; 356]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>39 (33–44)</b> </p> <p>[2; 328]</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>9</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>38 (10–70)</b> </p> <p>[3; 1356]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>53 (45–60)</b> </p> <p>[1; 163]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>84 (74–91)</b> </p> <p>[1; 69]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>17 (14–22)</b> </p> <p>[1; 299]</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>10</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>23 (14–33)</b> </p> <p>[6; 1542]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>29 (17–43)</b> </p> <p>[6; 537]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>26 (17–37)</b> </p> <p>[6; 443]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>30 (17–44)</b> </p> <p>[2; 49]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>31 (29–33)</b> </p> <p>[2; 2854]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>42 (22–63)</b> </p> <p>[7; 894]</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>11</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>38 (33–43)</b> </p> <p>[1; 402]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>46 (43–49)</b> </p> <p>[1; 1253]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>28 (17–39)</b> </p> <p>[2; 736]</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>12</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>31 (19–34)</b> </p> <p>[3; 433]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>31 (28–33)</b> </p> <p>[1; 1382]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>41 (38–43)</b> </p> <p>[2; 1552]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>70 (63–76)</b> </p> <p>[2; 207]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>15</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>29 (19–40)</b> </p> <p>[1; 70]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>20</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>60 (5–68)</b> </p> <p>[1; 114]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>CI</b> : confidence interval; <b>HbA1c</b>: glycosylated haemoglobin A1c; HbA1c<sub>5.7/6.0</sub> (threshold 5.7% or 6.0%); <b>IFG<sub>5.6/6.1</sub> </b> : impaired fasting glucose (threshold 5.6 mmol/L or 6.1 mmol/L); <b>IGT</b> : impaired glucose tolerance; <b>IFG + IGT</b> : both IFG and IGT; <b>IH</b> : intermediate hyperglycaemia; <b>T2DM</b>: type 2 diabetes mellitus </p> </div> </div> <p> <ul id="CD012661-list-0010"> <li> <p>IFG<sub>5.6</sub>: 13,692 participants. </p> </li> <li> <p>IFG<sub>6.1</sub>: 9943 participants. </p> </li> <li> <p>IGT: 13,728 participants.</p> </li> <li> <p>Both IFG and IGT: 2434 participants.</p> </li> <li> <p>HbA1c<sub>5.7</sub>: 9758 participants. </p> </li> <li> <p>HbA1c<sub>6.0</sub>: 2529 participants. </p> </li> </ul> </p> <p>Follow‐up time across all measures of IH at baseline had the following number of participants per year of follow‐up (in parentheses, number of people with IH who regressed to normoglycaemia); see <a href="#CD012661-tbl-0008">Table 1</a>. </p> <p> <ul id="CD012661-list-0011"> <li> <p>1 year: 878 (375) participants.</p> </li> <li> <p>2 years: 3882 (2852) participants.</p> </li> <li> <p>3 years: 3014 (1356) participants.</p> </li> <li> <p>4 years: 9388 (807) participants.</p> </li> <li> <p>5 years: 16,275 (2603) participants.</p> </li> <li> <p>6 years: 2573 (1328) participants.</p> </li> <li> <p>7 years: 3209 (679) participants.</p> </li> <li> <p>8 years: 3293 (328) participants.</p> </li> <li> <p>9 years: 1588 (299) participants.</p> </li> <li> <p>10 years: 5425 (894) participants.</p> </li> <li> <p>11 years: 1655 (736) participants.</p> </li> <li> <p>12 years: 3574 (no data) participants.</p> </li> <li> <p>15 years: 70 (no data) participants.</p> </li> <li> <p>20 years: 114 (no data) participants.</p> </li> </ul> </p> <p>Data on the prognostic factor IH versus normoglycaemia for the development of T2DM were based on the following number of participants with IH at baseline (<a href="#CD012661-tbl-0009">Table 2</a>). Data were reported by ratio measures (HR, IRR, OR). </p> <div class="table" id="CD012661-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Overview: intermediate hyperglycaemia versus normoglycaemia as a prognostic factor for the development of type 2 diabetes</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Ratio (95% CI)<br/> 95% prediction interval<sup>a,b</sup> </b> </p> <p><b>[no of studies; no of participants with IH/no of participants with normoglycaemia]</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Hazard ratio</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Region</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IFG<sub>5.6</sub> cohort</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IFG<sub>6.1</sub> cohort</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IGT cohort</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IFG + IGT cohort</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HbA1c<sub>5.7</sub> cohort</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HbA1c<sub>6.0</sub> cohort</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HbA1c<sub>5.7</sub> + IFG<sub>5.6</sub> cohort</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asia/Middle East</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>5.07 (3.41‐7.53)</b> </p> <p>1.07–24.02</p> <p>[4; 2385/12,837]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>10.55 (3.61–30.81)</b> </p> <p>NA<sup>b</sup> </p> <p>[5; 1054/9756]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4.48 (2.81–7.15)</b> </p> <p>NA<sup>b</sup> </p> <p>[3; 1780/6695]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>10.20 (5.45–19.09)</b> </p> <p>NA<sup>b</sup> </p> <p>[3; 461/6695]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>7.21 (5.14–10.11)</b> </p> <p>0.81–64.52</p> <p>[3; 3196/13,609]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>13.12 (4.10–41.96)</b> </p> <p>NA<sup>b</sup> </p> <p>[4; 3492/19,242]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>32.50 (23.00–45.92)</b><sup>c</sup> </p> <p>NA<sup>a</sup> </p> <p>[1; 410/4149]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Australia/Europe/North America</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4.15 (1.24–13.87)</b> </p> <p>NA<sup>b</sup> </p> <p>[3; 5685/12,837]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3.30 (2.32–4.67)</b> </p> <p>0.84–12.99</p> <p>[4; 1736/8835]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2.53 (1.52–4.19)</b> </p> <p>NA<sup>a</sup> </p> <p>[2; 2230/5871]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3.80 (2.30–6.28)</b> </p> <p>NA<sup>a</sup> </p> <p>[1; 221/1429]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2.71 (2.48–2.96)</b> </p> <p>NA<sup>a</sup> </p> <p>[1: 2027/6215]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>5.09 (1.69–15.37)</b> </p> <p>NA<sup>a</sup> </p> <p>[2; 1040/6925]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Latin America</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2.06 (1.76–2.41)</b> </p> <p>NA<sup>b</sup><br/> [1; 28/66] </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>American Indians/Islands</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2.38 (1.85–3.06)</b> </p> <p>NA<sup>a</sup> </p> <p>[1; 947/595]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4.06 (3.05–5.40)</b> </p> <p>NA<sup>a</sup> </p> <p>[1; 356/595]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i><b>Overall</b> </i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4.32 (2.61–7.12)</b> </p> <p>0.75–25.01</p> <p>[8; 9017/25,850]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>5.47 (3.50–8.54)</b> </p> <p>1.09–27.56</p> <p>[9; 2818/18,591]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3.61 (2.31–5.64)</b> </p> <p>0.69–18.97</p> <p>[5; 4010/12,566]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>6.90 (4.15–11.45)</b> </p> <p>1.06–44.95</p> <p>[5; 1038/8719]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>5.55 (2.77–11.12)</b> </p> <p>0.23–141.18</p> <p>[4; 5223/19,824]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>10.10 (3.59–28.43)</b> </p> <p>NA<sup>b</sup> </p> <p>[6; 4532/26,167]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>32.50 (23.00–45.92)</b> </p> <p>NA<sup>a</sup> </p> <p>[1; 410/4149]</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Incidence rate ratio</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Region</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IFG<sub>5.6</sub> cohort</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IFG<sub>6.1</sub> cohort</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IGT cohort</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IFG + IGT cohort</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HbA1c<sub>5.7</sub> cohort</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HbA1c<sub>6.0</sub> cohort</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HbA1c<sub>5.7</sub> + IFG<sub>5.6</sub> cohort</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asia/Middle East</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>5.23 (3.77–7.25)</b> </p> <p>1.72–15.89</p> <p>[6; 15,661/145,597]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3.62 (1.67–7.83)</b> </p> <p>NA<sup>a</sup> </p> <p>[2; 1677/36,334]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3.93 (3.03–5.10)</b> </p> <p>1.71–9.02</p> <p>[5; 14,809/73,128]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>11.20 (5.59–22.43)</b> </p> <p>NA<sup>b</sup> </p> <p>[4; 3166/69,463]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>6.62 (4.18–10.49)</b> </p> <p>NA<sup>a</sup> </p> <p>[1; 1965/19961]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>40.72 (29.30–56.61)</b> </p> <p>NA<sup>a</sup> </p> <p>[1; 1641/19,961]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Australia/Europe/North America</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4.96 (3.25–7.57)</b> </p> <p>0.32–77.24</p> <p>[3; 6322/8062]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>8.55 (6.37–11.48)</b> </p> <p>4.37–16.73</p> <p>[4; 3438/20,246]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>5.93 (4.11–8.57)</b> </p> <p>2.38–14.81</p> <p>[5; 2572/22,329]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>13.92 (9.99–19.40)</b> </p> <p>6.71–28.85</p> <p>[4; 699/18,966]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Latin America</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>American Indians/Islands</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2.74 (1.88–3.99)</b> </p> <p>NA<sup>a</sup> </p> <p>[1; 2374/1613]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4.46 (3.12–6.38)</b> </p> <p>NA<sup>a</sup> </p> <p>[2; 1087/2952]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>5.18 (3.42–7.83)</b> </p> <p>NA<sup>a</sup> </p> <p>[1; 605/1613]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i><b>Overall</b> </i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4.81 (3.67–6.30)</b> </p> <p>1.95–11.83</p> <p>[10; 24,357/155,272]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>6.82 (4.53–10.25)</b> </p> <p>2.03–22.87</p> <p>[6; 5115/56,580]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4.48 (3.69–5.44)</b> </p> <p>2.60–7.70</p> <p>[12; 18,468/98,409]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>10.94 (7.22–16.58)</b> </p> <p>2.58–46.46</p> <p>[9; 4470/90,072]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>6.62 (4.18–10.5)</b> </p> <p>NA<sup>a</sup> </p> <p>[1; 1965/19961]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>40.72 (29.30–56.61)</b> </p> <p>NA<sup>a</sup> </p> <p>[1; 1641/19,961]</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Odds ratio</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IFG<sub>5.6</sub> cohort</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IFG<sub>6.1</sub> cohort</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IGT cohort</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IFG + IGT cohort</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HbA1c<sub>5.7</sub> cohort</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HbA1c<sub>6.0</sub> cohort</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HbA1c<sub>5.7</sub> + IFG<sub>5.6</sub> cohort</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asia/Middle East</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2.94 (1.77–4.86)</b> </p> <p>0.43–19.93</p> <p>[10; 6359/28,218]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>5.18 (2.32–11.53)</b> </p> <p>0.29–91.37</p> <p>[7; 3317/25,604]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3.74 (2.83–4.94)</b> </p> <p>1.70–8.21</p> <p>[6; 1226/7417]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>6.99 (3.09–15.83)</b> </p> <p>NA<sup>b</sup> </p> <p>[3; 498/3704]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4.54 (2.65–7.78)</b> </p> <p>NA<sup>a</sup> </p> <p>[1; 675/462]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>23.20 (18.70–28.78)</b> </p> <p>NA<sup>a</sup> </p> <p>[1; 1103/10,763]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>46.70 (33.60–64.91)</b> </p> <p>NA<sup>a</sup> </p> <p>[1; 1951/10,761]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Australia/Europe/North America</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>6.47 (3.81–11.00)</b> </p> <p>0.99–42.32</p> <p>[9; 1949/7920]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>8.69 (4.95–15.24)</b> </p> <p>1.20–62.69</p> <p>[7; 1240/5094]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>5.20 (3.62–7.45)</b> </p> <p>1.50–18.09</p> <p>[11; 1481/7684]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>20.95 (12.40–35.40)</b> </p> <p>4.93–89.05</p> <p>[6; 154/5300]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4.38 (1.36–14.15)</b> </p> <p>NA<sup>a</sup> </p> <p>[2; 231/2100]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>15.60 (6.90–35.27)</b> </p> <p>NA<sup>a</sup> </p> <p>[1; 370/5365]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>26.20 (16.30–41.11)</b> </p> <p>NA<sup>a</sup> </p> <p>[1; 169/1125]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Latin America</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4.28 (3.21–5.71)</b> </p> <p>NA<sup>a</sup> </p> <p>[1; 65/1594]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3.73 (2.18–6.38)</b> </p> <p>NA<sup>a</sup> </p> <p>[1; 17/1594]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4.94 (3.15–7.76)</b> </p> <p>NA<sup>a</sup> </p> <p>[2; 381/3097]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>American Indians/Islands</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3.12 (2.31–4.21)</b> </p> <p>NA<sup>a</sup> </p> <p>[1; 947/595]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3.60 (1.40–9.26)</b> </p> <p>NA<sup>a</sup> </p> <p>[1; 51/215]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>5.89 (4.23–8.20)</b> </p> <p>NA<sup>a</sup> </p> <p>[1; 121/595]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i><b>Overall</b> </i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4.15 (2.75–6.28)</b> </p> <p>0.54–32.00</p> <p>[21; 9320/38,327]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>6.60 (4.18–10.43)</b> </p> <p>0.93–46.82</p> <p>[15; 4574/32,292]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4.61 (3.76–5.64)</b> </p> <p>2.10–10.13</p> <p>[20; 3139/18,413]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>13.14 (7.41–23.30)</b> </p> <p>1.84–93.66</p> <p>[9; 652/9004]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4.43 (2.20–8.88)</b> </p> <p>NA<sup>b</sup> </p> <p>[3; 906/2562]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>12.8 [4.56–35.9]</b> </p> <p>NA<sup>b</sup> </p> <p>[3; 1594/16,723]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>35.91 (20.43–63.12)</b> </p> <p>NA<sup>a</sup> </p> <p>[2; 2120/11,886]</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>CI</b> : confidence interval; <b>HbA1c</b> : glycosylated haemoglobin A1c; <b>HbA1c<sub>5.7/6.0</sub> </b> (threshold 5.7% or 6.0%); <b>HbA1c<sub>5.7</sub> + IFG<sub>5.6</sub> </b>: both HbA1c<sub>5.7</sub> and IFG<sub>5.6</sub>; <b>IFG<sub>5.6/6.1</sub> </b> : impaired fasting glucose (threshold 5.6 mmol/L or 6.1 mmol/L); <b>IGT</b> : impaired glucose tolerance; <b>IFG + IGT</b> : both IFG and IGT; <b>IH</b> : intermediate hyperglycaemia; <b>NA</b> : not applicable; <b>T2DM</b> : type 2 diabetes mellitus; <b>NR</b>: not reported<br/> <sup>a</sup>With fewer than 3 studies a prediction interval could not be calculated<br/> <sup>b</sup>Calculation of the 95% prediction interval did not provide a meaningful estimate<br/> <sup>c</sup>Combination of HbA1c<sub>6.0</sub> plus IFG<sub>5.6</sub> at baseline showed a hazard ratio for T2DM development of 53.7 (95% CI 38.4–75.1) </p> </div> </div> <p> <ul id="CD012661-list-0012"> <li> <p>IFG<sub>5.6</sub>: 42,694 participants. </p> </li> <li> <p>IFG<sub>6.1</sub>: 12,507 participants. </p> </li> <li> <p>IGT: 25,617 participants.</p> </li> <li> <p>Both IFG and IGT: 6160 participants.</p> </li> <li> <p>HbA1c<sub>5.7</sub>: 8094 participants. </p> </li> <li> <p>HbA1c<sub>6.0</sub>: 6126 participants. </p> </li> <li> <p>Both HbA1c<sub>5.7</sub> and IFG<sub>5.6</sub>: 3761 participants. </p> </li> </ul> </p> <p>The mean age of adult participants at baseline ranged from 30 years to 77 years (<a href="./appendices#CD012661-sec-0144">Appendix 9</a>). In two studies all the participants were female (<a href="./references#CD012661-bbs2-0017" title="DeAbreuLLF , HollowayKL , MohebbiM , SajjadMA , KotowiczMA , PascoJA . All‐cause mortality risk in Australian women with impaired fasting glucose and diabetes. Journal of Diabetes Research2017;2017:2042980. [PUBMED: 28698884] PascoJA , NicholsonGC , KotowiczMA . Cohort profile: Geelong osteoporosis study. International Journal of Epidemiology2012;41(6):1565‐75. [PUBMED: 23283714] deAbreuL , HollowayKL , KotowiczMA , PascoJA . Dysglycaemia and other predictors for progression or regression from impaired fasting glucose to diabetes or normoglycaemia. Journal of Diabetes Research2015;2015:373762. [DOI: 10.1155/2015/373762; PUBMED: 26273669] ">De Abreu 2015</a>; <a href="./references#CD012661-bbs2-0044" title="LarssonH , AhrenB , LindgardeF , BerglundG . Fasting blood glucose in determining the prevalence of diabetes in a large, homogeneous population of Caucasian middle‐aged women. Journal of Internal Medicine1995;237(6):537‐41. [PUBMED: 7782724] LarssonH , BerglundG , LindgardeF , AhrenB . Comparison of ADA and WHO criteria for diagnosis of diabetes and glucose intolerance. Diabetologia1998;41(9):1124‐5. [PUBMED: 9754834] LarssonH , LindgärdeF , BerglundG , AhrénB . Prediction of diabetes using ADA or WHO criteria in post‐menopausal women: a 10‐year follow‐up study. Diabetologia2000;43(10):1224‐8. [PUBMED: 11079739] ">Larsson 2000</a>), and in eight studies all the participants were male (<a href="./references#CD012661-bbs2-0012" title="BalkauB , ForhanA , EschwegeE . Two hour plasma glucose is not unequivocally predictive for early death in men with impaired fasting glucose: more results from the Paris prospective study. Diabetologia2002;45(9):1224‐30. CharlesMA , EschwegeE , ThibultN , ClaudeJR , WarnetJM , RosselinGE , et al. The role of non‐esterified fatty acids in the deterioration of glucose tolerance in Caucasian subjects: results of the Paris prospective study. Diabetologia1997;40(9):1101‐6. [PUBMED: 9300248] CharlesMA , FontbonneA , ThibultN , WarnetJM , RosselinGE , EschwegeE . Risk factors for NIDDM in white population. Paris prospective study. Diabetes1991;40(7):796‐9. [PUBMED: 2060716] EschwegeE , CharlesMA , SimonD , ThibultN , BalkauB . From policemen to policies: what is the future for 2‐h glucose? The Kelly West lecture, 2000. Diabetes Care2001;24(11):1945‐50. EschwegeE , CharlesMA , SimonD , ThibultN , BalkauB . Reproducibility of the diagnosis of diabetes over a 30‐month follow‐up: the Paris prospective study. Diabetes Care2001;24(11):1941‐4. [PUBMED: 11679461] ">Charles 1997</a>; <a href="./references#CD012661-bbs2-0046" title="LecomteP , VolS , CacèsE , BornC , ChabrolleC , LasfarguesG , et al. Five‐year predictive factors of type 2 diabetes in men with impaired fasting glucose. Diabetes &amp; Metabolism2007;33(2):140‐7. [PUBMED: 17320447] ">Lecomte 2007</a>; <a href="./references#CD012661-bbs2-0069" title="NakanishiN , TakatorigeT , FukudaH , ShiraiK , LiW , OkamotoM , et al. Components of the metabolic syndrome as predictors of cardiovascular disease and type 2 diabetes in middle‐aged Japanese men. Diabetes Research and Clinical Practice2004;64(1):59‐70. [PUBMED: 15036828] ">Nakanishi 2004</a>; <a href="./references#CD012661-bbs2-0071" title="ParkYW , ChangY , SungKC , RyuS , SungE , KimWS . The sequential changes in the fasting plasma glucose levels within normoglycemic range predict type 2 diabetes in healthy, young men. Diabetes Research and Clinical Practice2006;73(3):329‐35. [PUBMED: 16600415] RyuS , ShinH , ChangY , SungKC , SongJ , LeeS J . Should the lower limit of impaired fasting glucose be reduced from 110 mg/dL in Korea?. Metabolism2006;55(4):489‐93. ">Park 2006</a>; <a href="./references#CD012661-bbs2-0081" title="SatoKK , HayashiT , HaritaN , YonedaT , NakamuraY , EndoG , et al. Combined measurement of fasting plasma glucose and A1C is effective for the prediction of type 2 diabetes: the Kansai healthcare study. Diabetes Care2009;32(4):644‐6. [PUBMED: 19131461] SatoKK , HayashiT , KambeH , NakamuraY , HaritaN , EndoG , et al. Walking to work is an independent predictor of incidence of type 2 diabetes in Japanese men: the Kansai healthcare study. Diabetes Care2007;30(9):2296‐8. [PUBMED: 17536075] SatoKK , HayashiT , NakamuraY , HaritaN , YonedaT , EndoG , et al. Liver enzymes compared with alcohol consumption in predicting the risk of type 2 diabetes: the Kansai healthcare study. Diabetes Care2008;31:1230‐6. [PUBMED: 18316395] ">Sato 2009</a>; <a href="./references#CD012661-bbs2-0089" title="KeysA , AravanisC , BlackburnHW , VanBuchemFS , BuzinaR , DjordjevicBD , et al. Epidemiological studies related to coronary heart disease: characteristics of men aged 40‐59 in seven countries. Acta Medica Scandinavica. Supplementum1966;460:1‐392. [MEDLINE: 5226858] NissinenA , KivelaSL , PekkanenJ , TuomilehtoJ , KostiainenE , PiippoH , et al. Levels of some biological risk indicators among elderly men in Finland. Age and Ageing1986;15(4):203‐11. [PUBMED: 3751746] StengårdJH , PekkanenJ , TuomilehtoJ , KivinenP , KaarsaloE , TamminenM , et al. Changes in glucose tolerance among elderly Finnish men during a five‐year follow‐up: the Finnish cohorts of the seven countries study. Diabete &amp; Metabolisme1992;19(1 Pt 2):121‐9. [PUBMED: 8314414] ">Stengard 1992</a>; <a href="./references#CD012661-bbs2-0090" title="ToshihiroM , SaitoK , TakikawaS , TakebeN , OnodaT , SatohJ . Psychosocial factors are independent risk factors for the development of type 2 diabetes in Japanese workers with impaired fasting glucose and/or impaired glucose tolerance. Diabetic Medicine2008;25(10):1211‐7. [PUBMED: 19046200] ">Toshihiro 2008</a>; <a href="./references#CD012661-bbs2-0103" title="BybergL , McKeiguePM , ZetheliusB , LithellHO . Birth weight and the insulin resistance syndrome: association of low birth weight with truncal obesity and raised plasminogen activator inhibitor‐1 but not with abdominal obesity or plasma lipid disturbances. Diabetologia2000;43(1):54‐60. [PUBMED: 10663216] HedstrandH . A study of middle‐aged men with particular reference to risk factors for cardiovascular disease. Upsala Journal of Medical Sciences1975;Suppl 19:1‐61. [PUBMED: 1216390] ZetheliusB , HalesCN , LithellHO , BerneC . Insulin resistance, impaired early insulin response, and insulin propeptides as predictors of the development of type 2 diabetes: a population‐based, 7‐year follow‐up study in 70‐year‐old men. Diabetes Care2004;27(6):1433‐8. [PUBMED: 15161800] ">Zethelius 2004</a>). The body mass index (BMI) of the participants at baseline ranged from 23.2 kg/m<sup>2</sup> to 39.1 kg/m<sup>2</sup>. A family history of diabetes was reported in 3% to 100% of the study participants. </p> <p>At baseline, 60 studies (58%) reported diastolic and systolic blood pressure; 43 studies (22%), smoking status; 66 studies (64%), FPG; 24 studies (23%), HbA1c; 44 studies (43%), two‐hour glucose measurements; 7 studies (7%), medications; 26 studies (25%), comorbidities; 20 studies (19%), hypertension; and 5 studies (5%), dyslipidaemia (<a href="./appendices#CD012661-sec-0145">Appendix 10</a>). </p> </section> <section id="CD012661-sec-0069"> <h5 class="title">Categorisation of studies</h5> <p>In order to address the complexity of our dataset with regard to factors potentially influencing the definition, detection and development of T2DM, such as genetics, environmental and social conditions, the way risk factors and T2DM incidence were measured, and access to health care (<a href="./references#CD012661-bbs2-0302" title="Avilés‐SantaML , HsuLL , ArredondoM , MenkeA , WernerE , ThyagarajanB , et al. Differences in hemoglobin A1c between Hispanics/Latinos and non‐Hispanic whites: an analysis of the Hispanic Community Health Study/Study of Latinos and the 2007‐2012 National Health and Nutrition Examination Survey. Diabetes Care2016;39(6):1010‐7. ">Avilés‐Santa 2016</a>; <a href="./references#CD012661-bbs2-0312" title="DeRekeneireN , RooksRN , SimonsickEM , ShorrRI , KullerLH , SchwartzAV , et al. Racial differences in glycemic control in a well‐functioning older diabetic population: Findings from the Health, Aging and Body Composition study. Diabetes Care2007;26:1986‐92. ">De Rekeneire 2007</a>; <a href="./references#CD012661-bbs2-0331" title="HermanWH , CohenRM . Racial and ethnic differences in the relationship between HbA1c and blood glucose: implications for the diagnosis of diabetes. Journal of Clinical Endocrinology &amp; Metabolism2012;97(4):1067‐72. ">Herman 2012</a>; <a href="./references#CD012661-bbs2-0349" title="LikhariT , GamaR . Ethnic differences in glycated haemoglobin between White subjects and those of South Asian origin with normal glucose tolerance. Journal of Clinical Pathology2010;63:278‐80. ">Likhari 2010</a>; <a href="./references#CD012661-bbs2-0352" title="MaruthurNM , KaoWH , ClarkJM , BrancatiFL , ChengCY , PankowJS , et al. Does genetic ancestry explain higher values of glycated hemoglobin in African Americans?. Diabetes2011;60(9):2434‐8. ">Maruthur 2011</a>; <a href="./references#CD012661-bbs2-0360" title="ParrinelloCM , SharrettAR , MaruthurNM , BergenstalRM , GramsME , CoreshJ , et al. Racial differences in and prognostic value of biomarkers of hyperglycemia. Diabetes Care2016;39:4589‐95. ">Parrinello 2016</a>) – with all of these features interacting to some degree – we choose to provide the reader with a broad overview mainly focusing on geographic regions in the following way. </p> <p>Groups consisted of participants from studies taking place in Australia, Europe or North America; people from Latin America; individuals from Asia or the Middle East; and American (Pima) Indians and Pacific/Indian Ocean islanders ('American Indians/Islands' group). The logic of grouping participants in the last cohort together resided in the fact that they shared some characteristics relevant to T2DM, including a considerable genetic background risk, historic isolation from outside communities with substantial influence from Western diets, or both (<a href="./references#CD012661-bbs2-0325" title="HansonRL , MullerYL , KobesS , GuoT , BianL , OssowskiV , et al. A genome‐wide association study in American Indians implicates DNER as a susceptibility locus for type 2 diabetes. Diabetes2014;63(1):369‐76. ">Hanson 2014</a>; <a href="./references#CD012661-bbs2-0346" title="JowettJB , DiegoVP , KoteaN , KowlessurS , ChitsonP , DyerTD , et al. Genetic influences on type 2 diabetes and metabolic syndrome related quantitative traits in Mauritius. Twin Research and Human Genetics2009;12(1):44‐52. ">Jowett 2009</a>; <a href="./references#CD012661-bbs2-0356" title="NairAK , BaierLJ . Complex genetics of type 2 diabetes and effect size: what have we learned from isolated populations?. Review of Diabetic Studies2015;12(3‐4):299‐319. ">Nair 2015</a>; <a href="./references#CD012661-bbs2-0370" title="SerjeantsonSW , OwerbachD , ZimmetP , NerupJ , ThomaK . Genetics of diabetes in Nauru: effects of foreign admixture, HLA antigens and the insulin‐gene‐linked polymorphism. Diabetologia1983;25(1):13‐7. ">Serjeantson 1983</a>). </p> <p>For 41 studies, we categorised the origin of participants as 'Australia/Europe/North America' (<a href="./references#CD012661-bbs2-0001" title="AdmiraalWM , HollemanF , SnijderMB , PetersRJ , BrewsterLM , HoekstraJB , et al. Ethnic disparities in the association of impaired fasting glucose with the 10‐year cumulative incidence of type 2 diabetes. Diabetes Research and Clinical Practice2014;103(1):127‐32. [PUBMED: 24355200] AgyemangC , vanValkengoedI , van denBornB J , StronksK . Prevalence and determinants of prehypertension among African Surinamese, Hindustani Surinamese, and White Dutch in Amsterdam, the Netherlands: the SUNSET study. European Journal of Cardiovascular Prevention and Rehabilitation2007;14(6):775‐81. BindrabanNR , vanValkengoedIG , MairuhuG , HollemanF , HoekstraJB , MichelsBP , et al. Prevalence of diabetes mellitus and the performance of a risk score among Hindustani Surinamese, African Surinamese and ethnic Dutch: a cross‐sectional population‐based study. BMC Public Health2008;8:271. [PUBMED: 18673544] DekkerLH , NicolaouM , van derADl , BusschersWB , BrewsterLM , SnijderMB , et al. Sex differences in the association between serum ferritin and fasting glucose in type 2 diabetes among South Asian Surinamese, African Surinamese, and ethnic Dutch: the population‐based SUNSET study. Diabetes Care2013;36(4):965‐71. ">Admiraal 2014</a>; <a href="./references#CD012661-bbs2-0006" title="Baena‐DiezJM , Bermudez‐ChillidaN , MundetX , delVal‐GarciaJL , MunozMA , SchroderH . Impaired fasting glucose and risk of diabetes mellitus at 10 years. Cohort study. Medicina Clinica2011;136(9):382‐5. [PUBMED: 21300382] ">Baena‐Diez 2011</a>; <a href="./references#CD012661-bbs2-0009" title="BonoraE , KiechlS , MayrA , ZoppiniG , TargherG , BonadonnaRC , et al. High‐normal HbA1c is a strong predictor of type 2 diabetes in the general population. Diabetes Care2011;34(4):1038‐40. [PUBMED: 21307378] BonoraE , KiechlS , WilleitJ , OberhollenzerF , EggerG , MeigsJB , et al. Insulin resistance as estimated by homeostasis model assessment predicts incident symptomatic cardiovascular disease in Caucasian subjects from the general population: the Bruneck study. Diabetes Care2007;30(2):318‐24. BonoraE , KiechlS , WilleitJ , OberhollenzerF , EggerG , MeigsJB , et al. Population‐based incidence rates and risk factors for type 2 diabetes in white individuals: the Bruneck study. Diabetes2004;53(7):1782‐9. [PUBMED: 15220202] ">Bonora 2011</a>; <a href="./references#CD012661-bbs2-0010" title="CederbergH , SaukkonenT , LaaksoM , JokelainenJ , HarkonenP , TimonenM , et al. Postchallenge glucose, A1C, and fasting glucose as predictors of type 2 diabetes and cardiovascular disease: a 10‐year prospective cohort study. Diabetes Care2010;33(9):2077‐83. [PUBMED: 20573752] RajalaU , LaaksoM , PaivansaloM , PelkonenO , SuramoI , Keinanen‐KiukaanniemiS . Low insulin sensitivity measured by both quantitative insulin sensitivity check index and homeostasis model assessment method as a risk factor of increased intima‐media thickness of the carotid artery. Journal of Clinical Endocrinology and Metabolism2002;87(11):5092‐7. [PUBMED: 12414877] ">Cederberg 2010</a>; <a href="./references#CD012661-bbs2-0011" title="ChamnanP , SimmonsRK , ForouhiNG , LubenRN , KhawKT , WarehamNJ , et al. Incidence of type 2 diabetes using proposed HbA1c diagnostic criteria in the European prospective investigation of Cancer‐Norfolk cohort: implications for preventive strategies. Diabetes Care2011;34(4):950‐6. [PUBMED: 20622160] DayN , OakesS , LubenR , KhawKT , BinghamS , WelchA , et al. EPIC‐Norfolk: study design and characteristics of the cohort. European prospective investigation of cancer. British Journal of Cancer1999;80(Suppl 1):95‐103. [PUBMED: 10466767] KhawKT , WarehamN , LubenR , BinghamS , OakesS , WelchA , et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European prospective investigation of cancer and nutrition (EPIC‐Norfolk). BMJ2001;322(7277):15‐8. [PUBMED: 11141143] ">Chamnan 2011</a>; <a href="./references#CD012661-bbs2-0012" title="BalkauB , ForhanA , EschwegeE . Two hour plasma glucose is not unequivocally predictive for early death in men with impaired fasting glucose: more results from the Paris prospective study. Diabetologia2002;45(9):1224‐30. CharlesMA , EschwegeE , ThibultN , ClaudeJR , WarnetJM , RosselinGE , et al. The role of non‐esterified fatty acids in the deterioration of glucose tolerance in Caucasian subjects: results of the Paris prospective study. Diabetologia1997;40(9):1101‐6. [PUBMED: 9300248] CharlesMA , FontbonneA , ThibultN , WarnetJM , RosselinGE , EschwegeE . Risk factors for NIDDM in white population. Paris prospective study. Diabetes1991;40(7):796‐9. [PUBMED: 2060716] EschwegeE , CharlesMA , SimonD , ThibultN , BalkauB . From policemen to policies: what is the future for 2‐h glucose? The Kelly West lecture, 2000. Diabetes Care2001;24(11):1945‐50. EschwegeE , CharlesMA , SimonD , ThibultN , BalkauB . Reproducibility of the diagnosis of diabetes over a 30‐month follow‐up: the Paris prospective study. Diabetes Care2001;24(11):1941‐4. [PUBMED: 11679461] ">Charles 1997</a>; <a href="./references#CD012661-bbs2-0016" title="CugatiS , WangJJ , RochtchinaE , MitchellP . Ten‐year incidence of diabetes in older Australians: the Blue Mountains eye study. Medical Journal of Australia2007;186(3):131‐5. [PUBMED: 17309402] MitchellP , SmithW , WangJJ , CummingRG , LeederSR , BurnettL . Diabetes in an older Australian population. Diabetes Research and Clinical Practice1998;41(3):177‐84. [PUBMED: 9829346] ">Cugati 2007</a>; <a href="./references#CD012661-bbs2-0017" title="DeAbreuLLF , HollowayKL , MohebbiM , SajjadMA , KotowiczMA , PascoJA . All‐cause mortality risk in Australian women with impaired fasting glucose and diabetes. Journal of Diabetes Research2017;2017:2042980. [PUBMED: 28698884] PascoJA , NicholsonGC , KotowiczMA . Cohort profile: Geelong osteoporosis study. International Journal of Epidemiology2012;41(6):1565‐75. [PUBMED: 23283714] deAbreuL , HollowayKL , KotowiczMA , PascoJA . Dysglycaemia and other predictors for progression or regression from impaired fasting glucose to diabetes or normoglycaemia. Journal of Diabetes Research2015;2015:373762. [DOI: 10.1155/2015/373762; PUBMED: 26273669] ">De Abreu 2015</a>; <a href="./references#CD012661-bbs2-0018" title="DenBiggelaarLJ , SepSJ , EussenSJ , MariA , FerranniniE , vanGreevenbroekMM , et al. Discriminatory ability of simple OGTT‐based beta cell function indices for prediction of prediabetes and type 2 diabetes: the CODAM study. Diabetologia2016;60(3):432‐41. [PUBMED: 27933333] KruijshoopM , FeskensEJ , BlaakEE , deBruinTW . Validation of capillary glucose measurements to detect glucose intolerance or type 2 diabetes mellitus in the general population. Clinica Chimica Acta2004;341(1‐2):33‐40. [PUBMED: 14967156] ">Den Biggelaar 2016</a>; <a href="./references#CD012661-bbs2-0022" title="FilippatosTD , PanagiotakosDB , GeorgousopoulouEN , PitarakiE , KouliGM , ChrysohoouC , et al. Mediterranean diet and 10‐year (2002‐2012) incidence of diabetes and cardiovascular disease in participants with prediabetes: the ATTICA study. Review of Diabetic Studies2016;13(4):226‐35. [PUBMED: 28278309] KoloverouE , PanagiotakosDB , GeorgousopoulouEN , GrekasA , ChristouA , ChatzigeorgiouM , et al. Dietary patterns and 10‐year (2002‐2012) incidence of type 2 diabetes: results from the ATTICA cohort study. Review of Diabetic Studies2016;13(4):246‐56. [PUBMED: 28394951] KoloverouE , PanagiotakosDB , PitsavosC , ChrysohoouC , GeorgousopoulouEN , GrekasA , et al. Adherence to Mediterranean diet and 10‐year incidence (2002‐2012) of diabetes: correlations with inflammatory and oxidative stress biomarkers in the ATTICA cohort study. Diabetes/Metabolism Research and Reviews2016;32(1):73‐81. [PUBMED: 26104243] PitsavosC , PanagiotakosDB , ChrysohoouC , StefanadisC . Epidemiology of cardiovascular risk factors in Greece: aims, design and baseline characteristics of the ATTICA study. BMC Public Health2003;3:32. [PUBMED: 14567760] ">Filippatos 2016</a>; <a href="./references#CD012661-bbs2-0023" title="ForouhiNG , LuanJ , HenningsS , WarehamNJ . Incidence of type 2 diabetes in England and its association with baseline impaired fasting glucose: the Ely study 1990‐2000. Diabetic Medicine2007;24(2):200‐7. [PUBMED: 17257284] SimmonsRK , RahmanM , JakesRW , YuyunMF , NiggebruggeAR , HenningsSH , et al. Effect of population screening for type 2 diabetes on mortality: long‐term follow‐up of the Ely cohort. Diabetologia2011;54:312‐9. [PUBMED: 20978739] WarehamNJ , ByrneCD , WilliamsR , DayNE , HalesCN . Fasting proinsulin concentrations predict the development of type 2 diabetes. Diabetes Care1999;22(2):262‐70. [PUBMED: 10333943] WilliamsDR , WarehamNJ , BrownDC , ByrneCD , ClarkPM , CoxBD , et al. Undiagnosed glucose intolerance in the community: the Isle of Ely diabetes project. Diabetic Medicine1995;12:30‐5. [PUBMED: 7712700] ">Forouhi 2007</a>; <a href="./references#CD012661-bbs2-0025" title="BalkauB , LangeC , FezeuL , TichetJ , deLauzon‐GuillainB , CzernichowS , et al. Predicting diabetes: clinical, biological, and genetic approaches: data from the epidemiological study on the insulin resistance syndrome (DESIR). Diabetes Care2008;31(10):2056‐61. [PUBMED: 18689695] DroumaguetC , BalkauB , SimonD , CacesE , TichetJ , CharlesMA , et al. Use of HbA1c in predicting progression to diabetes in French men and women: data from an epidemiological study on the insulin resistance syndrome (DESIR). Diabetes Care2006;29(7):1619‐25. [PUBMED: 16801588] GautierA , RousselR , DucluzeauPH , LangeC , VolS , BalkauB , et al. Increases in waist circumference and weight as predictors of type 2 diabetes in individuals with impaired fasting glucose: influence of baseline BMI. Data from the DESIR study. Diabetes Care2010;33(8):1850‐2. [PUBMED: 20484131] SoulimaneS , SimonD , ShawJ , WitteD , ZimmetP , VolS , et al. HbA1c, fasting plasma glucose and the prediction of diabetes: Inter99, AusDiab and D.E.S.I.R. Diabetes Research and Clinical Practice2012;96(3):392‐9. [PUBMED: 21741107] SoulimaneS , SimonD , ShawJE , ZimmetPZ , VolS , VistisenD , et al. Comparing incident diabetes as defined by fasting plasma glucose or by HbA(1c). The AusDiab, Inter99 and DESIR studies. Diabetic Medicine2011;28(11):1311‐8. [PUBMED: 21824186] ">Gautier 2010</a>; <a href="./references#CD012661-bbs2-0029" title="FestaA , D'AgostinoRJr , HanleyAJ , KarterAJ , SaadMF , HaffnerSM . Differences in insulin resistance in nondiabetic subjects with isolated impaired glucose tolerance or isolated impaired fasting glucose. Diabetes2004;53(6):1549‐55. FestaA , D'AgostinoRJr , RichSS , JennyNS , TracyRP , HaffnerSM . Promoter (4G/5G) plasminogen activator inhibitor‐1 genotype and plasminogen activator inhibitor‐1 levels in blacks, Hispanics, and non‐Hispanic whites: the insulin resistance atherosclerosis study. Circulation2003;107(19):2422‐7. HaffnerSM , D'AgostinoRJr , GoffD , HowardB , FestaA , SaadMF , et al. LDL size in African Americans, Hispanics, and non‐Hispanic whites : the insulin resistance atherosclerosis study. Arteriosclerosis, Thrombosis, and Vascular Biology1999;19(9):2234‐40. HaffnerSM , D'AgostinoR , SaadMF , RewersM , MykkanenL , SelbyJ , et al. Increased insulin resistance and insulin secretion in nondiabetic African‐Americans and Hispanics compared with non‐Hispanic whites. The insulin resistance atherosclerosis study. Diabetes1996;45(6):742‐8. [PUBMED: 8635647] HaffnerSM , HowardG , MayerE , BergmanRN , SavagePJ , RewersM , et al. Insulin sensitivity and acute insulin response in African‐Americans, non‐Hispanic whites, and Hispanics with NIDDM: the insulin resistance atherosclerosis study. Diabetes1997;46(1):63‐9. HanleyAJ , D'AgostinoRBJr , WagenknechtLE , SaadMF , SavagePJ , BergmanR , et al. Increased proinsulin levels and decreased acute insulin response independently predict the incidence of type 2 diabetes in the insulin resistance atherosclerosis study. Diabetes2002;51(4):1263‐70. [PUBMED: 11916954] HanleyAJ , KarterAJ , WilliamsK , FestaA , D'AgostinoRBJr , WagenknechtLE , et al. Prediction of type 2 diabetes mellitus with alternative definitions of the metabolic syndrome: the insulin resistance atherosclerosis study. Circulation2005;112(24):3713‐21. [PUBMED: 16344402] HowardBV , Mayer‐DavisEJ , GoffD , ZaccaroDJ , LawsA , RobbinsDC , et al. Relationships between insulin resistance and lipoproteins in nondiabetic African Americans, Hispanics, and non‐Hispanic whites: the insulin resistance atherosclerosis study. Metabolism1998;47(10):1174‐9. KarterAJ , Mayer‐DavisEJ , SelbyJV , D'AgostinoRBJr , HaffnerSM , SholinskyP , et al. Insulin sensitivity and abdominal obesity in African‐American, Hispanic, and non‐Hispanic white men and women. The insulin resistance and atherosclerosis study. Diabetes1996;45(11):1547‐55. Mayer‐DavisEJ , LevinS , BergmanRN , D'AgostinoRBJr , KarterAJ , SaadMF , et al. Insulin secretion, obesity, and potential behavioral influences: results from the insulin resistance atherosclerosis study (IRAS). Diabetes/metabolism Research and Reviews2001;17(2):137‐45. Sanchez‐LugoL , Mayer‐DavisEJ , HowardG , SelbyJV , AyadMF , RewersM , et al. Insulin sensitivity and intake of vitamins E and C in African American, Hispanic, and non‐Hispanic white men and women: the insulin resistance and atherosclerosis study (IRAS). American Journal of Clinical Nutrition1997;66(5):1224‐31. WagenknechtLE , MayerEJ , RewersM , HaffnerS , SelbyJ , BorokGM , et al. The insulin resistance atherosclerosis study (IRAS) objectives, design, and recruitment results. Annals of Epidemiology1995;5(6):464‐72. [PUBMED: 8680609] ">Hanley 2005</a>; <a href="./references#CD012661-bbs2-0040" title="KleberM , LassN , PapckeS , WabitschM , ReinehrT . One‐year follow‐up of untreated obese white children and adolescents with impaired glucose tolerance: high conversion rate to normal glucose tolerance. Diabetic Medicine2010;27(5):516‐21. [PUBMED: 20536946] ">Kleber 2010</a>; <a href="./references#CD012661-bbs2-0041" title="KleberM , deSousaG , PapckeS , WabitschM , ReinehrT . Impaired glucose tolerance in obese white children and adolescents: three to five year follow‐up in untreated patients. Experimental and Clinical Endocrinology &amp; Diabetes2011;119(3):172‐6. [PUBMED: 20827664] ">Kleber 2011</a>; <a href="./references#CD012661-bbs2-0044" title="LarssonH , AhrenB , LindgardeF , BerglundG . Fasting blood glucose in determining the prevalence of diabetes in a large, homogeneous population of Caucasian middle‐aged women. Journal of Internal Medicine1995;237(6):537‐41. [PUBMED: 7782724] LarssonH , BerglundG , LindgardeF , AhrenB . Comparison of ADA and WHO criteria for diagnosis of diabetes and glucose intolerance. Diabetologia1998;41(9):1124‐5. [PUBMED: 9754834] LarssonH , LindgärdeF , BerglundG , AhrénB . Prediction of diabetes using ADA or WHO criteria in post‐menopausal women: a 10‐year follow‐up study. Diabetologia2000;43(10):1224‐8. [PUBMED: 11079739] ">Larsson 2000</a>; <a href="./references#CD012661-bbs2-0046" title="LecomteP , VolS , CacèsE , BornC , ChabrolleC , LasfarguesG , et al. Five‐year predictive factors of type 2 diabetes in men with impaired fasting glucose. Diabetes &amp; Metabolism2007;33(2):140‐7. [PUBMED: 17320447] ">Lecomte 2007</a>; <a href="./references#CD012661-bbs2-0049" title="DawberTR , KannelWB , LyellLP . An approach to longitudinal studies in a community: the Framingham study. Annals of the New York Academy of Sciences1963;107:539‐56. [PUBMED: 14025561] HrubyA , MaJ , RogersG , MeigsJB , JacquesPF . Associations of dairy intake with incident prediabetes or diabetes in middle‐aged adults vary by both dairy type and glycemic status. Journal of Nutrition2017;147(9):1764‐75. [PUBMED: 28768835] LeongA , DayaN , PornealaB , DevlinJJ , ShiffmanD , McPhaulMJ , et al. Prediction of type 2 diabetes by hemoglobin A1c in two community‐based cohorts. Diabetes Care2018;41(1):60‐8. [PUBMED: 29074816] LevitzkyYS , PencinaMJ , D'AgostinoRB , MeigsJB , MurabitoJM , VasanRS , et al. Impact of impaired fasting glucose on cardiovascular disease: the Framingham heart study. Journal of the American College of Cardiology2008;51(3):264‐70. [PUBMED: 18206734] WilsonPW , AndersonKM , KannelWB . Epidemiology of diabetes mellitus in the elderly. The Framingham study. American Journal of Medicine1986;80(5A):3‐9. [PUBMED: 3706388] WilsonPW , MeigsJB , SullivanL , FoxCS , NathanDM , D'AgostinoRBSr . Prediction of incident diabetes mellitus in middle‐aged adults: the Framingham offspring study. Archives of Internal Medicine2007;167(10):1068‐74. [PUBMED: 17533210] ">Levitzky 2008</a>; <a href="./references#CD012661-bbs2-0051" title="BrahimajA , LigthartS , GhanbariM , IkramMA , HofmanA , FrancoOH , et al. Novel inflammatory markers for incident pre‐diabetes and type 2 diabetes: the Rotterdam Study. European Journal of Epidemiology2017;32(3):217‐26. [PUBMED: 28258520] HofmanA , Darwish MuradS , vanDuijnCM , FrancoOH , GoedegebureA , IkramMA , et al. The Rotterdam study: 2014 objectives and design update. European Journal of Epidemiology2013;28(11):889‐926. LigthartS , vanHerptTT , LeeningMJ , KavousiM , HofmanA , StrickerBH , et al. Lifetime risk of developing impaired glucose metabolism and eventual progression from prediabetes to type 2 diabetes: a prospective cohort study. Lancet Diabetes &amp; Endocrinology2016;4(1):44‐51. [PUBMED: 26575606] van derSchaftN , BrahimajA , WenKX , FrancoOH , DehghanA . The association between serum uric acid and the incidence of prediabetes and type 2 diabetes mellitus: the Rotterdam study. PLOS ONE2017;12(6):e0179482. [PUBMED: 28632742] ">Ligthart 2016</a>; <a href="./references#CD012661-bbs2-0052" title="LipskaKJ , InzucchiSE , VanNessPH , GillTM , StrotmeyerES , KosterA , et al. Elevated HbA1c and fasting plasma glucose in predicting diabetes incidence among older adults: are two better than one?. Diabetes Care2013;36(12):3923‐9. [PUBMED: 24135387] StrotmeyerES , deRekeneireN , SchwartzAV , FaulknerKA , ResnickHE , GoodpasterBH , et al. The relationship of reduced peripheral nerve function and diabetes with physical performance in older white and black adults: the health, aging, and body composition (Health ABC) study. Diabetes Care2008;31(9):1767‐72. [PUBMED: 18535192] ">Lipska 2013</a>; <a href="./references#CD012661-bbs2-0058" title="GroopL , ForsblomC , LehtovirtaM , TuomiT , KarankoS , NissenM , et al. Metabolic consequences of a family history of NIDDM (the Botnia study): evidence for sex‐specific parental effects. Diabetes1996;45(11):1585‐93. [PUBMED: 8866565] LyssenkoV , AlmgrenP , AnevskiD , PerfektR , LahtiK , NissenM , et al. Predictors of and longitudinal changes in insulin sensitivity and secretion preceding onset of type 2 diabetes. Diabetes2005;54(1):166‐74. [PUBMED: 15616025] TripathyD , CarlssonM , AlmgrenP , IsomaaB , TaskinenMR , TuomiT , et al. Insulin secretion and insulin sensitivity in relation to glucose tolerance: lessons from the Botnia Study. Diabetes2000;49(6):975‐80. ">Lyssenko 2005</a>; <a href="./references#CD012661-bbs2-0059" title="Al SalmiI , HoyWE , Kondalsamy‐ChennakesavanS , WangZ , GobeGC , BarrEL , et al. Disorders of glucose regulation in adults and birth weight: results from the Australian diabetes, obesity and lifestyle (AUSDIAB) study. Diabetes Care2008;31(1):159‐64. DunstanDW , ZimmetPZ , WelbornTA , CameronAJ , ShawJ , deCourtenM , et al. The Australian diabetes, obesity and lifestyle study (AusDiab) ‐ methods and response rates. Diabetes Research and Clinical Practice2002;57:119‐29. [PUBMED: 12062857] DunstanDW , ZimmetPZ , WelbornTA , DeCourtenMP , CameronAJ , SicreeRA , et al. The rising prevalence of diabetes and impaired glucose tolerance: the Australian diabetes, obesity and lifestyle study. Diabetes Care2002;25:829‐34. [PUBMED: 11978676] MaglianoDJ , BarrELM , ZimmetPZ , CameronAJ , DunstanDW , ColagiuriS , et al. Glucose indices, health behaviors, and incidence of diabetes in Australia: the Australian diabetes, obesity and lifestyle study. Diabetes Care2008;31(2):267‐72. [PUBMED: 17989310] SicreeRA , ZimmetPZ , DunstanDW , CameronAJ , WelbornTA , ShawJE . Differences in height explain gender differences in the response to the oral glucose tolerance test‐ the AusDiab study. Diabetic Medicine2008;25(3):296‐302. SoulimaneS , SimonD , ShawJE , ZimmetPZ , VolS , VistisenD , et al. Comparing incident diabetes as defined by fasting plasma glucose or by HbA(1c). The AusDiab, Inter99 and DESIR studies. Diabetic Medicine2011;28(11):1311‐8. [PUBMED: 21824186] WilliamsED , MaglianoDJ , TappRJ , OldenburgBF , ShawJE . Psychosocial stress predicts abnormal glucose metabolism: the Australian diabetes, obesity and lifestyle (AusDiab) study. Annals of Behavioral Medicine2013;46(1):62‐72. [PUBMED: 23389687] ">Magliano 2008</a>; <a href="./references#CD012661-bbs2-0061" title="BaxterJ , HammanRF , LopezTK , MarshallJA , HoagS , SwensonCJ . Excess incidence of known non‐insulin‐dependent diabetes mellitus (NIDDM) in Hispanics compared with non‐Hispanic whites in the San Luis Valley, Colorado. Ethnicity &amp; Disease1993;3(1):11‐21. BoykoEJ , KeaneEM , MarshallJA , HammanRF . Higher insulin and C‐peptide concentrations in Hispanic population at high risk for NIDDM. San Luis Valley diabetes study. Diabetes1991;40(4):509‐15. HammanRF , MarshallJA , BaxterJ , KahnLB , MayerEJ , OrleansM , et al. Methods and prevalence of non‐insulin‐dependent diabetes mellitus in a bi‐ethnic Colorado population. The San Luis Valley diabetes study. American Journal of Epidemiology1989;129(2):295‐311. [PUBMED: 2912042] MarshallJA , HoagS , ShetterlyS , HammanRF . Dietary fat predicts conversion from impaired glucose tolerance to NIDDM: the San Luis Valley diabetes study. Diabetes Care1994;17(1):50‐6. [PUBMED: 8112189] NelsonTL , BessesenDH , MarshallJA . Relationship of abdominal obesity measured by DXA and waist circumference with insulin sensitivity in Hispanic and non‐Hispanic white individuals: the San Luis Valley diabetes study. Diabetes/metabolism Research and Reviews2008;24(1):33‐40. ">Marshall 1994</a>; <a href="./references#CD012661-bbs2-0062" title="BergstromRW , Newell‐MorrisLL , LeonettiDL , ShumanWP , WahlPW , FujimotoWY . Association of elevated fasting C‐peptide level and increased intra‐abdominal fat distribution with development of NIDDM in Japanese‐American men. Diabetes1990;39(1):104‐11. FujimotoWY , BergstromRW , BoykoEJ , KinyounJL , LeonettiDL , Newell‐MorrisLL , et al. Diabetes and diabetes risk factors in second‐ and third‐generation Japanese Americans in Seattle, Washington. Diabetes Research and Clinical Practice1994;24(Suppl):S43‐52. [PUBMED: 7859632] FujimotoWY , BergstromRW , Newell‐MorrisL , LeonettiD L . Nature and nurture in the etiology of type 2 diabetes mellitus in Japanese Americans. Diabetes/metabolism Reviews1989;5(7):607‐25. [PUBMED: 2689122] KahnSE , LeonettiDL , PrigeonRL , BoykoEJ , BergstomRW , FujimotoWY . Proinsulin levels predict the development of non‐insulin‐dependent diabetes mellitus (NIDDM) in Japanese‐American men. Diabetic Medicine1996;13(9 Suppl 6):S63‐6. [PUBMED: 8894485] KahnSE , LeonettiDL , PrigeonRL , BoykoEJ , BergstromRW , FujimotoWY . Proinsulin as a marker for the development of NIDDM in Japanese‐American men. Diabetes1995;44(2):173‐9. McNeelyMJ , BoykoEJ , LeonettiDL , KahnSE , FujimotoWY . Comparison of a clinical model, the oral glucose tolerance test, and fasting glucose for prediction of type 2 diabetes risk in Japanese Americans. Diabetes Care2003;26(3):758‐63. [PUBMED: 12610034] RodriguezBL , AbbottRD , FujimotoW , WaitzfelderB , ChenR , MasakiK , et al. The American Diabetes Association and World Health Organization classifications for diabetes ‐ their impact on diabetes prevalence and total and cardiovascular disease mortality in elderly Japanese‐American men. Diabetes Care2002;25(6):951‐5. [PUBMED: 12032097] ">McNeely 2003</a>; <a href="./references#CD012661-bbs2-0063" title="BlakeDR , MeigsJB , MullerDC , NajjarSS , AndresR , NathanDM . Impaired glucose tolerance, but not impaired fasting glucose, is associated with increased levels of coronary heart disease risk factors: results from the Baltimore longitudinal study on aging. Diabetes2004;53(8):2095‐100. MeigsJB , MullerDC , NathanDM , BlakeDR , AndresR . The natural history of progression from normal glucose tolerance to type 2 diabetes in the Baltimore longitudinal study of aging. Diabetes2003;52(6):1475‐84. [PUBMED: 12765960] RodriguezA , MullerDC , EngelhardtM , AndresR . Contribution of impaired glucose tolerance in subjects with the metabolic syndrome: Baltimore longitudinal study of aging. Metabolism2005;54(4):542‐7. ShockNW , GreulichRC , ArembergD , CostaPT , LakattaEG , TobinJD . Normal human aging: the Baltimore longitudinal study of aging. Washington, DC: U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health, National Institute on Aging, Gerontology Research Center, Baltimore City Hospitals; 1984. Report No.: NIH‐84‐2450. SorkinJD , MullerDC , FlegJL , AndresR . The relation of fasting and 2‐h postchallenge plasma glucose concentrations to mortality: data from the Baltimore longitudinal study of aging with a critical review of the literature. Diabetes Care2005;28(11):2626‐32. ">Meigs 2003</a>; <a href="./references#CD012661-bbs2-0066" title="Anonymous . Prevalence of chronic diseases in older Italians: comparing self‐reported and clinical diagnoses. The Italian longitudinal study on aging working group. International Journal of Epidemiology1997;26(5):995‐1002. [PUBMED: 9363520] MaggiS , ZucchettoM , GrigolettoF , BaldereschiM , CandeliseL , ScarpiniE , et al. The Italian longitudinal study on aging (ILSA): design and methods. Aging1994;6(6):464‐73. [PUBMED: 7748921] MottaM , BennatiE , CardilloE , FerlitoL , MalaguarneraM . The value of glycosylated hemoglobin (HbA1c) as a predictive risk factor in the diagnosis of diabetes mellitus (DM) in the elderly. Archives of Gerontology and Geriatrics2010;50(1):60‐4. MottaM , BennatiE , CardilloE , FerlitoL , PassamonteM , VacanteM , et al. A combination of glycosylated hemoglobin, impaired fasting glucose and waist circumference is effective in screening for individuals at risk for future type 2 diabetes. Archives of Gerontology and Geriatrics2010;50(1):105‐9. [PUBMED: 19414203] ">Motta 2010</a>; <a href="./references#CD012661-bbs2-0067" title="MykkänenL , KuusistoJ , PyoralaK , LaaksoM . Cardiovascular‐disease risk‐factors as predictors of type‐2 (non‐insulin‐dependent) diabetes‐mellitus in elderly subjects. Diabetologia1993;36(6):553‐9. [PUBMED: 8335178] MykkänenL , LaaksoM , PenttilaI , PyoralaK . Asymptomatic hyperglycemia and cardiovascular risk factors in the elderly. Atherosclerosis1991;88:153‐61. [PUBMED: 1892482] MykkänenL , LaaksoM , UusitupaM , PyoralaK . Prevalence of diabetes and impaired glucose tolerance in elderly subjects and their association with obesity and family history of diabetes. Diabetes Care1990;13:1099‐105. [PUBMED: 2261821] WangJ , RuotsalainenS , MoilanenL , LepistoP , LaaksoM , KuusistoJ . The metabolic syndrome predicts cardiovascular mortality: a 13‐year follow‐up study in elderly non‐diabetic Finns. European Heart Journal2007;28(7):857‐64. ">Mykkänen 1993</a>; <a href="./references#CD012661-bbs2-0072" title="NorbergM , WallS , BomanK , WeinehallL . The Västerbotten intervention programme: background, design and implications. Global Health Action2010;3(1):4643. [PUBMED: 20339479] PetersonM , PingelR , LagaliN , DahlinLB , RolandssonO . Association between HbA1c and peripheral neuropathy in a 10‐year follow‐up study of people with normal glucose tolerance, impaired glucose tolerance and type 2 diabetes. Diabetic Medicine2017;34(12):1756‐64. [PUBMED: 28929513] PourhamidiK , DahlinLB , BomanK , RolandssonO . Heat shock protein 27 is associated with better nerve function and fewer signs of neuropathy. Diabetologia2011;54(12):3143‐9. [PUBMED: 21909836] ">Peterson 2017</a>; <a href="./references#CD012661-bbs2-0074" title="QiaoQ , Keinanen‐KiukaanniemiS , RajalaU , UusimakiA , KivelaSL . Risk for diabetes and persistent impaired glucose tolerance among middle‐aged Finns. Diabetes Research &amp; Clinical Practice1996;33(3):191‐8. [PUBMED: 8922541] RajalaU , Keinanen‐KiukaanniemiS , UusimakiA , ReijulaK , KivelaSL . Prevalence of diabetes mellitus and impaired glucose tolerance in a middle‐aged Finnish population. Scandinavian Journal of Primary Health Care1995;13(3):222‐8. [PUBMED: 7481176] RajalaU , QiaoQ , LaaksoM , Keinänen‐KiukaanniemiS . Antihypertensive drugs as predictors of type 2 diabetes among subjects with impaired glucose tolerance. Diabetes Research and Clinical Practice2000;50(3):231‐9. [PUBMED: 11106838] ">Rajala 2000</a>; <a href="./references#CD012661-bbs2-0076" title="RasmussenSS , GlumerC , SandbaekA , LauritzenT , Borch‐JohnsenK . Determinants of progression from impaired fasting glucose and impaired glucose tolerance to diabetes in a high‐risk screened population: 3 year follow‐up in the ADDITION study, Denmark. Diabetologia2008;51(2):249‐57. [PUBMED: 18060659] RasmussenSS , GlumerC , SandbaekA , LauritzenT , Borch‐JohnsenK . Progression from impaired fasting glucose and impaired glucose tolerance to diabetes in a high‐risk screening programme in general practice: the ADDITION study, Denmark. Diabetologia2007;50(2):293‐7. [PUBMED: 17143605] ">Rasmussen 2008</a>; <a href="./references#CD012661-bbs2-0077" title="HerderC , KannenbergJM , Carstensen‐KirbergM , HuthC , MeisingerC , KoenigW , et al. Serum levels of interleukin‐22, cardiometabolic risk factors and incident type 2 diabetes: KORA F4/FF4 study. Cardiovascular Diabetology2017;16(1):17. [PUBMED: 28143481] KowallB , RathmannW , StrassburgerK , MeisingerC , HolleR , MielckA . Socioeconomic status is not associated with type 2 diabetes incidence in an elderly population in Germany: KORA S4/F4 cohort study. Journal of Epidemiology &amp; Community Health2011;65(7):606‐12. [PUBMED: 20693490] MeisingerC , DoringA , HeierM . Blood pressure and risk of type 2 diabetes mellitus in men and women from the general population: the monitoring trends and determinants on cardiovascular diseases/cooperative health research in the region of Augsburg cohort study. Journal of Hypertension2008;26(9):1809‐15. MeisingerC , DoringA , ThorandB , HeierM , LowelH . Body fat distribution and risk of type 2 diabetes in the general population: are there differences between men and women? The MONICA/KORA Augsburg cohort study. American Journal of Clinical Nutrition2006;84(3):483‐9. MeisingerC , ThorandB , SchneiderA , StieberJ , DoringA , LowelH . Sex differences in risk factors for incident type 2 diabetes mellitus: the MONICA Augsburg cohort study. Archives of Internal Medicine2002;162(1):82‐9. [PUBMED: 11784224] RathmannW , HaastertB , IcksA , LowelH , MeisingerC , HolleR , et al. High prevalence of undiagnosed diabetes mellitus in Southern Germany: target populations for efficient screening. The KORA survey 2000. Diabetologia2003;46(2):182‐9. [PUBMED: 12627316] RathmannW , MeisingerC . How prevalent is type 2 diabetes in Germany? Results from the MONICA/KORA studies [Wie häufig ist Typ‐2‐Diabetes in Deutschland?]. Diabetologe2010;6(3):170‐6. RathmannW , StrassburgerK , HeierM , HolleR , ThorandB , GianiG , et al. Incidence of type 2 diabetes in the elderly German population and the effect of clinical and lifestyle risk factors: KORA S4/F4 cohort study. Diabetic Medicine2009;26(12):1212‐9. [PUBMED: 20002472] ">Rathmann 2009</a>; <a href="./references#CD012661-bbs2-0078" title="HeineRJ , NijpelsG , MooyJM . New data on the rate of progression of impaired glucose tolerance to NIDDM and predicting factors. Diabetic Medicine1996;13(3 Suppl 2):S12‐4. MooyJM , GrootenhuisPA , deVriesH , ValkenburgHA , BouterLM , KostensePJ , et al. Prevalence and determinants of glucose intolerance in a Dutch Caucasian population. The Hoorn study. Diabetes Care1995;18:1270‐3. [PUBMED: 8612442] NijpelsG , Popp‐SnijdersC , KostenseP J , BouterLM , HeineRJ . Fasting proinsulin and 2‐h post‐load glucose levels predict the conversion to NIDDM in subjects with impaired glucose tolerance: the Hoorn study. Diabetologia1996;39(1):113‐8. [PUBMED: 8720611] NijpelsG , Popp‐SnijdersC , KostensePJ , BouterLM , HeineRJ . Cardiovascular risk factors prior to the development of non‐insulin‐dependent diabetes mellitus in persons with impaired glucose tolerance: the Hoorn Study. Journal of Clinical Epidemiology1997;50(9):1003‐9. RijkelijkhuizenJM , NijpelsG , HeineRJ , BouterLM , StehouwerCD , DekkerJM . High risk of cardiovascular mortality in individuals with impaired fasting glucose is explained by conversion to diabetes: the Hoorn study. Diabetes Care2007;30(2):332‐6. [PUBMED: 17259503] RuijgrokC , DekkerJM , BeulensJW , BrouwerIA , CoupeVMH , HeymansMW , et al. Size and shape of the associations of glucose, HbA1c, insulin and HOMA‐IR with incident type 2 diabetes: the Hoorn study. Diabetologia2018;61(1):93‐100. [PUBMED: 29018885] deVegtF , DekkerJM , JagerA , HienkensE , KostensePJ , StehouwerCD , et al. Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: the Hoorn study. JAMA2001;285(16):2109‐13. [PUBMED: 11311100] deVegtF , DekkerJM , StehouwerCD , NijpelsG , BouterLM , HeineRJ . Similar 9‐year mortality risks and reproducibility for the World Health Organization and American Diabetes Association glucose tolerance categories: the Hoorn study. Diabetes Care2000;23(1):40‐4. deVegtF , DekkerJM , StehouwerCD , NijpelsG , BouterLM , HeineRJ . The 1997 American Diabetes Association criteria versus the 1985 World Health Organization criteria for the diagnosis of abnormal glucose tolerance: poor agreement in the Hoorn study. Diabetes Care1998;21(10):1686‐90. ">Rijkelijkhuizen 2007</a>; <a href="./references#CD012661-bbs2-0082" title="KatonaG , AganovicI , VuksanV , SkrabaloZ . National Diabetes Programme in Malta: Phase I and II Final Report. Valletta: WHO, 1983. SchranzAG . Abnormal glucose tolerance in the Maltese. A population‐based longitudinal study of the natural history of NIDDM and IGT in Malta. Diabetes Research and Clinical Practice1989;7(1):7‐16. [PUBMED: 2752891] ">Schranz 1989</a>; <a href="./references#CD012661-bbs2-0088" title="SoriguerF , Rojo‐MartínezG , AlmarazMC , EstevaI , Ruiz de AdanaMS , MorcilloS , et al. Incidence of type 2 diabetes in southern Spain (Pizarra study). European Journal of Clinical Investigation2008;38(2):126‐33. [PUBMED: 18226046] Soriguer‐EscofetF , EstevaI , Rojo‐MartinezG , Ruiz de AdanaS , CatalaM , MereloMJ , et al. Prevalence of latent autoimmune diabetes of adults (LADA) in Southern Spain. Diabetes Research and Clinical Practice2002;56(3):213‐20. ">Soriguer 2008</a>; <a href="./references#CD012661-bbs2-0089" title="KeysA , AravanisC , BlackburnHW , VanBuchemFS , BuzinaR , DjordjevicBD , et al. Epidemiological studies related to coronary heart disease: characteristics of men aged 40‐59 in seven countries. Acta Medica Scandinavica. Supplementum1966;460:1‐392. [MEDLINE: 5226858] NissinenA , KivelaSL , PekkanenJ , TuomilehtoJ , KostiainenE , PiippoH , et al. Levels of some biological risk indicators among elderly men in Finland. Age and Ageing1986;15(4):203‐11. [PUBMED: 3751746] StengårdJH , PekkanenJ , TuomilehtoJ , KivinenP , KaarsaloE , TamminenM , et al. Changes in glucose tolerance among elderly Finnish men during a five‐year follow‐up: the Finnish cohorts of the seven countries study. Diabete &amp; Metabolisme1992;19(1 Pt 2):121‐9. [PUBMED: 8314414] ">Stengard 1992</a>; <a href="./references#CD012661-bbs2-0091" title="VaccaroO , RuffaG , ImperatoreG , IovinoV , RivelleseAA , RiccardiG . Risk of diabetes in the new diagnostic category of impaired fasting glucose: a prospective analysis. Diabetes Care1999;22(9):1490‐3. [PUBMED: 10480514] ">Vaccaro 1999</a>; <a href="./references#CD012661-bbs2-0092" title="ValdesS , BotasP , DelgadoE , AlvarezF , CadornigaFD . Population‐based incidence of type 2 diabetes in northern Spain: the Asturias study. Diabetes Care2007;30(9):2258‐63. [PUBMED: 17536076] ValdesS , BotasP , DelgadoE , AlvarezF , Diaz‐CadornigaF . HbA(1c) in the prediction of type 2 diabetes compared with fasting and 2‐h post‐challenge plasma glucose: the Asturias study (1998‐2005). Diabetes &amp; Metabolism2011;37(1):27‐32. [PUBMED: 20934897] ValdésS , BotasP , DelgadoE , ÁlvarezF , CadórnigaFD . Does the new American Diabetes Association definition for impaired fasting glucose improve its ability to predict type 2 diabetes mellitus in Spanish persons? The Asturias study. Metabolism2008;57(3):399‐403. [PUBMED: 18249214] ">Valdes 2008</a>; <a href="./references#CD012661-bbs2-0097" title="LeongA , DayaN , PornealaB , DevlinJJ , ShiffmanD , McPhaulMJ , et al. Prediction of type 2 diabetes by hemoglobin A1c in two community‐based cohorts. Diabetes Care2018;41(1):60‐8. [PUBMED: 29074816] SchmidtMI , DuncanBB , BangH , PankowJS , BallantyneCM , GoldenSH , et al. Identifying individuals at high risk for diabetes ‐ the atherosclerosis risk in communities study. Diabetes Care2005;28(8):2013‐8. [PUBMED: 16043747] SelvinE , RawlingsAM , GramsM , KleinR , SharrettAR , SteffesM , et al. Fructosamine and glycated albumin for risk stratification and prediction of incident diabetes and microvascular complications: a prospective cohort analysis of the atherosclerosis risk in communities (ARIC) study. Lancet Diabetes &amp; Endocrinology2014;2(4):279‐88. [PUBMED: 24703046] SelvinE , SteffesM W , GreggE , BrancatiF L , CoreshJ . Performance of A1C for the classification and prediction of diabetes. Diabetes Care2011;34(1):84‐9. [PUBMED: 20855549] SelvinE , SteffesMW , ZhuH , MatsushitaK , WagenknechtL , PankowJ , et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. New England Journal of Medicine2010;362(9):800‐11. [PUBMED: 20200384] WarrenB , PankowJ S , MatsushitaK , PunjabiNM , DayaNR , GramsM , et al. Comparative prognostic performance of definitions of prediabetes: a prospective cohort analysis of the atherosclerosis risk in communities (ARIC) study. Lancet Diabetes &amp; Endocrinology2017;5(1):34‐42. [PUBMED: 27863979] WheltonSP , McEvoyJW , LazoM , CoreshJ , BallantyneCM , SelvinE . High‐sensitivity cardiac troponin T (hs‐cTnT) as a predictor of incident diabetes in the atherosclerosis risk in communities study. Diabetes Care2017;40(2):261‐9. [PUBMED: 28108537] ">Warren 2017</a>; <a href="./references#CD012661-bbs2-0099" title="WeissR , DziuraJ , BurgertTS , TamborlaneWV , TaksaliSE , YeckelCW , et al. Obesity and the metabolic syndrome in children and adolescents. New England Journal of Medicine2004;350(23):2362‐74. [PUBMED: 15175438] WeissR , TaksaliSE , TamborlaneWV , BurgertTS , SavoyeM , CaprioS . Predictors of changes in glucose tolerance status in obese youth. Diabetes Care2005;28(4):902‐9. [PUBMED: 15793193] ">Weiss 2005</a>; <a href="./references#CD012661-bbs2-0102" title="BildDE , BluemkeDA , BurkeGL , DetranoR , Diez RouxAV , FolsomAR , et al. Multi‐ethnic study of atherosclerosis: objectives and design. American Journal of Epidemiology2002;156(9):871‐81. [PUBMED: 12397006] YeboahJ , BertoniA G , HerringtonDM , PostWS , BurkeGL . Impaired fasting glucose and the risk of incident diabetes mellitus and cardiovascular events in an adult population: MESA (multi‐ethnic study of atherosclerosis). Journal of the American College of Cardiology2011;58(2):140‐6. [PUBMED: 21718910] ">Yeboah 2011</a>; <a href="./references#CD012661-bbs2-0103" title="BybergL , McKeiguePM , ZetheliusB , LithellHO . Birth weight and the insulin resistance syndrome: association of low birth weight with truncal obesity and raised plasminogen activator inhibitor‐1 but not with abdominal obesity or plasma lipid disturbances. Diabetologia2000;43(1):54‐60. [PUBMED: 10663216] HedstrandH . A study of middle‐aged men with particular reference to risk factors for cardiovascular disease. Upsala Journal of Medical Sciences1975;Suppl 19:1‐61. [PUBMED: 1216390] ZetheliusB , HalesCN , LithellHO , BerneC . Insulin resistance, impaired early insulin response, and insulin propeptides as predictors of the development of type 2 diabetes: a population‐based, 7‐year follow‐up study in 70‐year‐old men. Diabetes Care2004;27(6):1433‐8. [PUBMED: 15161800] ">Zethelius 2004</a>). </p> <p>For seven studies, we categorised the origin of participants as 'Latin America' (<a href="./references#CD012661-bbs2-0015" title="Coronado‐MalagonM , Gomez‐VargasJI , Espinoza‐PeraltaD , Arce‐SalinasA . Progression toward type‐2 diabetes mellitus among Mexican pre‐diabetics. Assessment of a cohort. Gaceta Medica De Mexico2009;145(4):269‐72. [PUBMED: 20073428] ">Coronado‐Malagon 2009</a>; <a href="./references#CD012661-bbs2-0021" title="FerranniniE , MassariM , NannipieriM , NataliA , Lopez RidauraR , Gonzales‐VillalpandoC . Plasma glucose levels as predictors of diabetes: the Mexico City diabetes study. Diabetologia2009;52(5):818‐24. [PUBMED: 19224196] FerranniniE , NannipieriM , WilliamsK , GonzalesC , HaffnerSM , SternMP . Mode of onset of type 2 diabetes from normal or impaired glucose tolerance. Diabetes2004;53(1):160‐5. [PUBMED: 14693710] HaffnerSM , GonzalezC , MykkanenL , SternM . Total immunoreactive proinsulin, immunoreactive insulin and specific insulin in relation to conversion to NIDDM: the Mexico City diabetes study. Diabetologia1997;40(7):830‐7. [PUBMED: 9243105] HaffnerSM , KennedyE , GonzalezC , SternMP , MiettinenH . A prospective analysis of the HOMA model. The Mexico City diabetes study. Diabetes Care1996;19(10):1138‐41. [PUBMED: 8886564] NannipieriM , GonzalesC , BaldiS , PosadasR , WilliamsK , HaffnerSM , et al. Liver enzymes, the metabolic syndrome, and incident diabetes: the Mexico City diabetes study. Diabetes Care2005;28(7):1757‐62. [PUBMED: 15983331] ">Ferrannini 2009</a>; <a href="./references#CD012661-bbs2-0024" title="GarciaL , LeeA , Al HazzouriAZ , NeuhausJM , MoyceS , AielloA , et al. Influence of neighbourhood socioeconomic position on the transition to type II diabetes in older Mexican Americans: the Sacramento area longitudinal study on aging. BMJ Open2016;6(8):e010905. [PUBMED: 27515749] ">Garcia 2016</a>; <a href="./references#CD012661-bbs2-0026" title="Gomez‐ArbelaezD , Alvarado‐JuradoL , Ayala‐CastilloM , Forero‐NaranjoL , CamachoPA , Lopez‐JaramilloP . Evaluation of the Finnish diabetes risk score to predict type 2 diabetes mellitus in a Colombian population: a longitudinal observational study. World Journal of Diabetes2015;6(17):1337‐44. [PUBMED: 26675051] ">Gomez‐Arbelaez 2015</a>; <a href="./references#CD012661-bbs2-0027" title="Guerrero‐RomerF , Rodriguez‐MoranM , Gonzalez‐OrtizM , Martinez‐AbundisE . Insulin action and secretion in healthy Hispanic‐Mexican first‐degree relatives of subjects with type 2 diabetes. Journal of Endocrinological Investigation2001;24:580‐6. [PUBMED: 11686540] Guerrero‐RomeroF , Rodriguez‐MoranM . Assessing progression to impaired glucose tolerance and type 2 diabetes mellitus. European Journal of Clinical Investigation2006;36(11):796‐802. [PUBMED: 17032347] Rodriguez‐MoranM , Guerrero‐RomeroF . Hyperinsulinemia and abdominal obesity are more prevalent in non‐diabetic subjects with family history of type 2 diabetes. Archives of Medical Research2000;31:399‐403. [PUBMED: 11068083] ">Guerrero‐Romero 2006</a>; <a href="./references#CD012661-bbs2-0048" title="LeivaE , MujicaV , OrregoR , WehingerS , SotoA , IcazaG , et al. Subjects with impaired fasting glucose: evolution in a period of 6 years. Journal of Diabetes Research2014;2014:710370. [DOI: 10.1155/2014/710370; PUBMED: 25215305] PalomoGI , IcazaNG , MujicaEV , NunezFL , LeivaME , VasquezRM , et al. Prevalence of cardiovascular risk factors in adult from Talca, Chile [Prevalencia de factores de riesgo cardiovascular clásicos en población adulta de Talca, Chile, 2005]. Revista Medica de Chile2007;135(7):904‐12. [PUBMED: 17914548] ">Leiva 2014</a>; <a href="./references#CD012661-bbs2-0057" title="Abdul‐GhaniMA , WilliamsK , DeFronzoR , SternM . Risk of progression to type 2 diabetes based on relationship between postload plasma glucose and fasting plasma glucose. Diabetes Care2006;29(7):1613‐8. HaffnerSM , BowsherRR , MykkänenL , HazudaHP , MitchellBD , ValdezRA , et al. Proinsulin and specific insulin concentration in high‐ and low‐risk populations for NIDDM. Diabetes1994;43(12):1490‐3. HaffnerSM , MiettinenH , GaskillSP , SternMP . Decreased insulin secretion and increased insulin resistance are independently related to the 7‐year risk of NIDDM in Mexican‐Americans. Diabetes1995;44(12):1386‐91. [PUBMED: 7589843] HaffnerSM , MiettinenH , SternM P . The homeostasis model in the San Antonio heart study. Diabetes Care1997;20(7):1087‐92. HaffnerSM , MiettinenH , SternMP . Are risk factors for conversion to NIDDM similar in high and low risk populations?. Diabetologia1997;40(1):62‐6. [PUBMED: 9028719] HaffnerSM , SternMP , MitchellBD , HazudaHP , PattersonJK . Incidence of type II diabetes in Mexican Americans predicted by fasting insulin and glucose levels, obesity, and body‐fat distribution. Diabetes1990;39(3):283‐8. [PUBMED: 2407581] HazudaHP , HaffnerSM , SternMP , EiflerCW . Effects of acculturation and socioeconomic status on obesity and diabetes in Mexican Americans. The San Antonio heart study. American Journal of Epidemiology1988;128(6):1289‐301. LorenzoC , OkoloiseM , WilliamsK , SternMP , HaffnerS M . The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study. Diabetes Care2003;26(11):3153‐9. [PUBMED: 14578254] MitchellBD , SternMP , HaffnerSM , HazudaHP , PattersonJK . Risk factors for cardiovascular mortality in Mexican Americans and non‐Hispanic whites. San Antonio heart study. American Journal of Epidemiology1990;131(3):423‐33. SternMP , MoralesPA , ValdezRA , MonterrosaA , HaffnerSM , MitchellBD , et al. Predicting diabetes. Moving beyond impaired glucose tolerance. Diabetes1993;42(5):706‐14. [PUBMED: 8482427] SternMP , RosenthalM , HaffnerSM , HazudaHP , FrancoLJ . Sex difference in the effects of sociocultural status on diabetes and cardiovascular risk factors in Mexican Americans. The San Antonio heart study. American Journal of Epidemiology1984;120(6):834‐51. [PUBMED: 6507426] ">Lorenzo 2003</a>). Although <a href="./references#CD012661-bbs2-0024" title="GarciaL , LeeA , Al HazzouriAZ , NeuhausJM , MoyceS , AielloA , et al. Influence of neighbourhood socioeconomic position on the transition to type II diabetes in older Mexican Americans: the Sacramento area longitudinal study on aging. BMJ Open2016;6(8):e010905. [PUBMED: 27515749] ">Garcia 2016</a> and <a href="./references#CD012661-bbs2-0057" title="Abdul‐GhaniMA , WilliamsK , DeFronzoR , SternM . Risk of progression to type 2 diabetes based on relationship between postload plasma glucose and fasting plasma glucose. Diabetes Care2006;29(7):1613‐8. HaffnerSM , BowsherRR , MykkänenL , HazudaHP , MitchellBD , ValdezRA , et al. Proinsulin and specific insulin concentration in high‐ and low‐risk populations for NIDDM. Diabetes1994;43(12):1490‐3. HaffnerSM , MiettinenH , GaskillSP , SternMP . Decreased insulin secretion and increased insulin resistance are independently related to the 7‐year risk of NIDDM in Mexican‐Americans. Diabetes1995;44(12):1386‐91. [PUBMED: 7589843] HaffnerSM , MiettinenH , SternM P . The homeostasis model in the San Antonio heart study. Diabetes Care1997;20(7):1087‐92. HaffnerSM , MiettinenH , SternMP . Are risk factors for conversion to NIDDM similar in high and low risk populations?. Diabetologia1997;40(1):62‐6. [PUBMED: 9028719] HaffnerSM , SternMP , MitchellBD , HazudaHP , PattersonJK . Incidence of type II diabetes in Mexican Americans predicted by fasting insulin and glucose levels, obesity, and body‐fat distribution. Diabetes1990;39(3):283‐8. [PUBMED: 2407581] HazudaHP , HaffnerSM , SternMP , EiflerCW . Effects of acculturation and socioeconomic status on obesity and diabetes in Mexican Americans. The San Antonio heart study. American Journal of Epidemiology1988;128(6):1289‐301. LorenzoC , OkoloiseM , WilliamsK , SternMP , HaffnerS M . The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study. Diabetes Care2003;26(11):3153‐9. [PUBMED: 14578254] MitchellBD , SternMP , HaffnerSM , HazudaHP , PattersonJK . Risk factors for cardiovascular mortality in Mexican Americans and non‐Hispanic whites. San Antonio heart study. American Journal of Epidemiology1990;131(3):423‐33. SternMP , MoralesPA , ValdezRA , MonterrosaA , HaffnerSM , MitchellBD , et al. Predicting diabetes. Moving beyond impaired glucose tolerance. Diabetes1993;42(5):706‐14. [PUBMED: 8482427] SternMP , RosenthalM , HaffnerSM , HazudaHP , FrancoLJ . Sex difference in the effects of sociocultural status on diabetes and cardiovascular risk factors in Mexican Americans. The San Antonio heart study. American Journal of Epidemiology1984;120(6):834‐51. [PUBMED: 6507426] ">Lorenzo 2003</a> took place in the USA, they included primarily Mexican Americans, hence the rationale for this categorisation. </p> <p>We categorised 50 studies as 'Asia/Middle East' (<a href="./references#CD012661-bbs2-0002" title="AekplakornW , BunnagP , WoodwardM , SritaraP , CheepudomwitS , YamwongS , et al. A risk score for predicting incident diabetes in the Thai population. Diabetes Care2006;29(8):1872‐7. [PUBMED: 16873795] SritaraP , CheepudomwitS , ChapmanN , WoodwardM , KositchaiwatC , TunlayadechanontS , et al. Twelve‐year changes in vascular risk factors and their associations with mortality in a cohort of 3499 Thais: the electricity generating authority of Thailand study. International Journal of Epidemiology2003;32:461‐8. [PUBMED: 12777437] ">Aekplakorn 2006</a>; <a href="./references#CD012661-bbs2-0003" title="AjlouniK , JaddouH , BatiehaA . Obesity in Jordan. International Journal of Obesity and Related Metabolic Disorders1998;22(7):624‐8. [PUBMED: 9705020] AmmariF , BatiehaA , JaddouPH , OkashiM , AjlouniK . A natural history of impaired glucose tolerance in North Jordan. Practical Diabetes International1998;15(5):139‐40. ">Ammari 1998</a>; <a href="./references#CD012661-bbs2-0004" title="AnjanaRM , Shanthi RaniCS , DeepaM , PradeepaR , SudhaV , Divya NairH , et al. Incidence of diabetes and prediabetes and predictors of progression among Asian Indians: 10‐year follow‐up of the Chennai urban rural epidemiology study (CURES). Diabetes Care2015;38(8):1441‐8. [PUBMED: 25906786] DeepaM , PradeepaR , RemaM , MohanA , DeepaR , ShanthiraniS , et al. The Chennai urban rural epidemiology study (CURES) ‐ study design and methodology (urban component) (CURES‐I). Journal of the Association of Physicians of India2003;51:863‐70. [PUBMED: 14710970] MohanD , RajD , ShanthiraniCS , DattaM , UnwinNC , KapurA , et al. Awareness and knowledge of diabetes in Chennai ‐ the Chennai urban rural epidemiology study [CURES‐9]. Journal of the Association of Physicians of India2005;53:283‐7. MohanV , DeepaM , FarooqS , DattaM , DeepaR . Prevalence, awareness and control of hypertension in Chennai ‐ the Chennai urban rural epidemiology study (CURES‐52). Journal of the Association of Physicians of India2007;55:326‐32. MohanV , DeepaR , PradeepaR , VimaleswaranKS , MohanA , VelmuruganK , et al. Association of low adiponectin levels with the metabolic syndrome ‐ the Chennai urban rural epidemiology study (CURES‐4). Metabolism2005;54(4):476‐81. MohanV , SandeepS , DeepaM , GokulakrishnanK , DattaM , DeepaR . A diabetes risk score helps identify metabolic syndrome and cardiovascular risk in Indians ‐ the Chennai urban rural epidemiology study (CURES‐38). Diabetes, Obesity &amp; Metabolism2007;9(3):337‐43. RadhikaG , SathyaRM , SudhaV , GanesanA , MohanV . Dietary salt intake and hypertension in an urban south Indian population ‐ [CURES ‐ 53]. Journal of the Association of Physicians of India2007;55:405‐11. ">Anjana 2015</a>; <a href="./references#CD012661-bbs2-0005" title="BaeJC , RheeEJ , LeeWY , ParkSE , ParkCY , OhKW , et al. Combined effect of nonalcoholic fatty liver disease and impaired fasting glucose on the development of type 2 diabetes: a 4‐year retrospective longitudinal study. Diabetes Care2011;34(3):727‐9. [PUBMED: 21278140] BaeJC , RheeEJ , LeeWY , ParkSE , ParkCY , OhKW , et al. Optimal range of HbA1c for the prediction of future diabetes: a 4‐year longitudinal study. Diabetes Research and Clinical Practice2011;93(2):255‐9. [PUBMED: 21676480] ">Bae 2011</a>; <a href="./references#CD012661-bbs2-0007" title="BaiPV , KrishnaswamiCV , ChellamariappanM . Prevalence and incidence of type‐2 diabetes and impaired glucose tolerance in a selected Indian urban population. Journal of the Association of Physicians of India1999;47(11):1060‐4. [PUBMED: 10862313] ">Bai 1999</a>; <a href="./references#CD012661-bbs2-0008" title="BergmanM , ChetritA , RothJ , JagannathanR , SevickM , DanknerR . One‐hour post‐load plasma glucose level during the OGTT predicts dysglycemia: observations from the 24year follow‐up of the Israel study of glucose intolerance, obesity and hypertension. Diabetes Research and Clinical Practice2016;120:221‐8. [PUBMED: 27596059] DanknerR , Abdul‐GhaniMA , GerberY , ChetritA , WainsteinJ , RazI . Predicting the 20‐year diabetes incidence rate. Diabetes/metabolism Research and Reviews2007;23(7):551‐8. [PUBMED: 17315136] ModanM , HalkinH , KarasikA , LuskyA . Effectiveness of glycosylated hemoglobin, fasting plasma glucose, and a single post load plasma glucose level in population screening for glucose intolerance. American Journal of Epidemiology1984;119(3):431‐44. [PUBMED: 6702817] ModanM , KarasikA , HalkinH , FuchsZ , LuskyA , ShitritA , et al. Effect of past and concurrent body mass index on prevalence of glucose intolerance and type 2 (non‐insulin‐dependent) diabetes and on insulin response. Diabetologia1986;29(2):82‐9. [PUBMED: 3516770] ">Bergman 2016</a>; <a href="./references#CD012661-bbs2-0013" title="ChenKT , ChenCJ , GreggEW , ImperatoreG , NarayanKMV . Impaired fasting glucose and risk of diabetes in Taiwan: follow‐up over 3 years. Diabetes Research and Clinical Practice2003;60(3):177‐82. [PUBMED: 12757990] ChenKT , ChenCJ , GreggEW , WilliamsonDF , NarayanKM . High prevalence of impaired fasting glucose and type 2 diabetes mellitus in Penghu Islets, Taiwan: evidence of a rapidly emerging epidemic?. Diabetes Research and Clinical Practice1999;44(1):59‐69. [PUBMED: 10414941] ">Chen 2003</a>; <a href="./references#CD012661-bbs2-0014" title="ChenG , LinL , ChenL , LiL , HuangH , WangW , et al. Comparison of insulin resistance and beta‐cell dysfunction between the young and the elderly in normal glucose tolerance and prediabetes population: a prospective study. Hormone and Metabolic Research2017;49(2):135‐41. [DOI: 10.1055/s‐0042‐111325; PUBMED: 27459384] ">Chen 2017</a>; <a href="./references#CD012661-bbs2-0019" title="Aghaei MeybodiHR , AziziF . Changes in body weight and fat distribution; risk factors for abnormal glucose homeostasis? Tehran lipid and glucose study. Iranian Journal of Diabetes and Lipid Disorders2009;8(1):1‐12. BozorgmaneshM , HadaeghF , AziziF . A simple clinical model predicted diabetes progression among prediabetic individuals. Diabetes Research and Clinical Practice2012;97(2):e34‐6. [PUBMED: 22647753] DerakhshanA , Bagherzadeh‐KhiabaniF , ArshiB , RamezankhaniA , AziziF , HadaeghF . Different combinations of glucose tolerance and blood pressure status and incident diabetes, hypertension, and chronic kidney disease. Journal of the American Heart Association2016;5(8):pii: e003917. [DOI: 10.1161/JAHA.116.003917; PUBMED: 27543801] DerakhshanA , SardariniaM , KhaliliD , MomenanAA , AziziF , HadaeghF . Sex specific incidence rates of type 2 diabetes and its risk factors over 9 years of follow‐up: Tehran lipid and glucose study. PLOS ONE2014;9(7):e102563. [PUBMED: 25029368] DerakhshanA , TohidiM , ArshiB , KhaliliD , AziziF , HadaeghF . Relationship of hyperinsulinaemia, insulin resistance and beta‐cell dysfunction with incident diabetes and pre‐diabetes: the Tehran lipid and glucose study. Diabetic Medicine2015;32(1):24‐32. [PUBMED: 25131451] HadaeghF , BozorgmaneshMR , GhasemiA , HaratiH , SaadatN , AziziF . High prevalence of undiagnosed diabetes and abnormal glucose tolerance in the Iranian urban population: Tehran lipid and glucose study. BMC Public Health2008;8:176. HadaeghF , DerakhshanA , ZafariN , KhaliliD , MirboloukM , SaadatN , et al. Pre‐diabetes tsunami: incidence rates and risk factors of pre‐diabetes and its different phenotypes over 9 years of follow‐up. Diabetic Medicine2017;34(1):69‐78. [PUBMED: 26606421] HadaeghF , GhasemiAr , PadyabM , TohidiM , AziziF . The metabolic syndrome and incident diabetes: assessment of alternative definitions of the metabolic syndrome in an Iranian urban population. Diabetes Research and Clinical Practice2008;80(2):328‐34. [PUBMED: 18282630] HaratiH , HadaeghF , SaadatN , AziziF . Population‐based incidence of type 2 diabetes and its associated risk factors: results from a six‐year cohort study in Iran. BMC Public Health2009;9:186. [DOI: 10.1186/1471‐2458‐9‐186; PUBMED: 19531260] HaratiH , HadaeghF , TohidiM , AziziF . Impaired fasting glucose cutoff value of 5.6 mmol/l combined with other cardiovascular risk markers is a better predictor for incident type 2 diabetes than the 6.1 mmol/l value: Tehran lipid and glucose study. Diabetes Research and Clinical Practice2009;85(1):90‐5. [PUBMED: 19414206] ">Derakhshan 2016</a>; <a href="./references#CD012661-bbs2-0028" title="ChoiSH , KimTH , LimS , ParkKS , JangHC , ChoNH . Hemoglobin A1c as a diagnostic tool for diabetes screening and new‐onset diabetes prediction: a 6‐year community‐based prospective study. Diabetes Care2011;34(4):944‐9. [PUBMED: 21335372] HanSJ , KimHJ , KimDJ , LeeKW , ChoNH . Incidence and predictors of type 2 diabetes among Koreans: a 12‐year follow up of the Korean genome and epidemiology study. Diabetes Research and Clinical Practice2017;123:173‐80. [PUBMED: 28043048] JungDH , ByunYS , KwonYJ , KimGS . Microalbuminuria as a simple predictor of incident diabetes over 8 years in the Korean genome and epidemiology study (KoGES). Scientific Reports2017;7(1):15445. [PUBMED: 29133894] JungJY , OhCM , RyooJH , ChoiJM , ChoiYJ , HamW T , et al. The influence of prehypertension, hypertension, and glycated hemoglobin on the development of type 2 diabetes mellitus in prediabetes: the Korean genome and epidemiology study (KoGES). Endocrine2018;59(3):593‐601. [PUBMED: 29380232] Keun ParkS , RyooJH , OhCM , ChoiJM , ChoiYJ , Ok LeeK , et al. The risk of type 2 diabetes mellitus according to 2‐hour plasma glucose level: the Korean genome and epidemiology study (KoGES). Diabetes Research and Clinical Practice 2017 Aug 9 [Epub ahead of print]. [DOI: 10.1016/j.diabres.2017.08.002; PUBMED: 28951335] LimNK , ParkSH , ChoiSJ , LeeKS , ParkHY . A risk score for predicting the incidence of type 2 diabetes in a middle‐aged Korean cohort: the Korean genome and epidemiology study. Circulation Journal2012;76(8):1904‐10. [PUBMED: 22640983] ">Han 2017</a>; <a href="./references#CD012661-bbs2-0030" title="HeianzaY , AraseY , FujiharaK , HsiehSD , SaitoK , TsujiH , et al. Longitudinal trajectories of HbA1c and fasting plasma glucose levels during the development of type 2 diabetes: the Toranomon hospital health management center study 7 (TOPICS 7). Diabetes Care2012;35(5):1050‐2. [PUBMED: 22456865] HeianzaY , AraseY , FujiharaK , TsujiH , SaitoK , HsiehSD , et al. High normal HbA(1c) levels were associated with impaired insulin secretion without escalating insulin resistance in Japanese individuals: the Toranomon hospital health management center study 8 (TOPICS 8). Diabetic Medicine2012;29(10):1285‐90. HeianzaY , AraseY , FujiharaK , TsujiH , SaitoK , HsiehSD , et al. Screening for pre‐diabetes to predict future diabetes using various cut‐off points for HbA(1c) and impaired fasting glucose: the Toranomon hospital health management center study 4 (TOPICS 4). Diabetic Medicine2012;29(9):e279‐85. [PUBMED: 22510023] HeianzaY , AraseY , HsiehSD , SaitoK , TsujiH , KodamaS , et al. Development of a new scoring system for predicting the 5 year incidence of type 2 diabetes in Japan: the Toranomon hospital health management center study 6 (TOPICS 6). Diabetologia2012;55(12):3213‐23. [PUBMED: 22955996] HeianzaY , HaraS , AraseY , SaitoK , FujiwaraK , TsujiH , et al. HbA1c 5.7‐6.4% and impaired fasting plasma glucose for diagnosis of prediabetes and risk of progression to diabetes in Japan (TOPICS 3): a longitudinal cohort study. Lancet2011;378(9786):147‐55. [MEDLINE: 21705064] HeianzaY , HaraS , AraseY , SaitoK , TotsukaK , TsujiH , et al. Low serum potassium levels and risk of type 2 diabetes: the Toranomon hospital health management center study 1 (TOPICS 1). Diabetologia2011;54(4):762‐6. [PUBMED: 21212932] ">Heianza 2012</a>; <a href="./references#CD012661-bbs2-0031" title="InoueI , TakahashiK , KatayamaS , HaradaY , NegishiK , IshiiJ , et al. A higher proinsulin response to glucose loading predicts deteriorating fasting plasma glucose and worsening to diabetes in subjects with impaired glucose tolerance. Diabetoc Medicine1996;13(4):330‐6. [PUBMED: 9162608] ">Inoue 1996</a>; <a href="./references#CD012661-bbs2-0032" title="AminiM , JanghorbaniM . Comparison of metabolic syndrome with glucose measurement for prediction of type 2 diabetes: the Isfahan diabetes prevention study. Diabetes &amp; Metabolic Syndrome: Clinical Research &amp; Reviews2009;3(2):84‐9. HaghighatdoostF , AminiM , FeiziA , IrajB . Are body mass index and waist circumference significant predictors of diabetes and prediabetes risk: results from a population based cohort study. World Journal of Diabetes2017;8(7):365‐73. [PUBMED: 28751960] JanghorbaniM , AminiM . Normal fasting plasma glucose and risk of prediabetes and type 2 diabetes: the Isfahan diabetes prevention study. Review of Diabetic Studies2011;8(4):490‐8. [PUBMED: 22580730] JanghorbaniM , AminiM . Progression from optimal blood glucose and pre‐diabetes to type 2 diabetes in a high risk population with or without hypertension in Isfahan, Iran. Diabetes Research and Clinical Practice2015;108(3):414‐22. [PUBMED: 25814432] ">Janghorbani 2015</a>; <a href="./references#CD012661-bbs2-0033" title="JaruratanasirikulS , ThammaratchuchaiS , PuwanantM , Mo‐SuwanL , SriplungH . Progression from impaired glucose tolerance to type 2 diabetes in obese children and adolescents: a 3‐6‐year cohort study in southern Thailand. Journal of Pediatric Endocrinology &amp; Metabolism2016;29(11):1267‐75. [PUBMED: 27740930] ">Jaruratanasirikul 2016</a>; <a href="./references#CD012661-bbs2-0034" title="JeongJY , KimJG , KimBW , MoonSS , KimHS , ParkKG , et al. Trend analysis of diabetic prevalence and incidence in a rural area of South Korea between 2003‐2008. Journal of Diabetes Investigation2010;1(5):184‐90. [PUBMED: 24843430] ">Jeong 2010</a>; <a href="./references#CD012661-bbs2-0035" title="JiamjarasrangsiW , AekplakornW . Incidence and predictors of type 2 diabetes among professional and office workers in Bangkok, Thailand. Journal of the Medical Association of Thailand2005;88(12):1896‐904. [PUBMED: 16518992] JiamjarasrangsiW , SangwatanarojS , LohsoonthornV , LertmaharitS . Increased alanine aminotransferase level and future risk of type 2 diabetes and impaired fasting glucose among the employees in a university hospital in Thailand. Diabetes &amp; Metabolism2008;34(3):283‐9. [PUBMED: 18486512] ">Jiamjarasrangsi 2008a</a>; <a href="./references#CD012661-bbs2-0036" title="KimDJ , ChoNH , NohJH , KimHJ , ChoiYH , JungJH , et al. Fasting plasma glucose cutoff value for the prediction of future diabetes development: a study of middle‐aged Koreans in a health promotion center. Journal of Korean Medical Science2005;20(4):562‐5. [PUBMED: 16100444] KimDJ , ChoNH , NohJH , LeeMS , LeeMK , KimKW . Lack of excess maternal transmission of type 2 diabetes in a Korean population. Diabetes Research and Clinical Practice2004;65(2):117‐24. [PUBMED: 15223223] ">Kim 2005</a>; <a href="./references#CD012661-bbs2-0037" title="KimSH , ShimWS , KimEA , KimEJ , LeeSH , HongSB , et al. The effect of lowering the threshold for diagnosis of impaired fasting glucose. Yonsei Medical Journal2008;49(2):217‐23. [PUBMED: 18452257] ">Kim 2008</a>; <a href="./references#CD012661-bbs2-0038" title="KimYA , KuEJ , KhangAR , HongES , KimKM , MoonJH , et al. Role of various indices derived from an oral glucose tolerance test in the prediction of conversion from prediabetes to type 2 diabetes. Diabetes Research and Clinical Practice2014;106(2):351‐9. [PUBMED: 25245975] ">Kim 2014</a>; <a href="./references#CD012661-bbs2-0039" title="KimCH , KimHK , KimEH , BaeSJ , ChoeJ , ParkJY . Risk of progression to diabetes from prediabetes defined by HbA1c or fasting plasma glucose criteria in Koreans. Diabetes Research and Clinical Practice2016;118:105‐11. [PUBMED: 27368062] ">Kim 2016a</a>; <a href="./references#CD012661-bbs2-0042" title="KoGT , ChanJC , LauE , WooJ , CockramCS . Fasting plasma glucose as a screening test for diabetes and its relationship with cardiovascular risk factors in Hong Kong Chinese. Diabetes Care1997;20(2):170‐2. KoGT , LiJK , CheungAY , YeungVT , ChowCC , TsangLW , et al. Two‐hour post‐glucose loading plasma glucose is the main determinant for the progression from impaired glucose tolerance to diabetes in Hong Kong Chinese. Diabetes Care1999;22(12):2096‐7. [PUBMED: 10587859] ">Ko 1999</a>; <a href="./references#CD012661-bbs2-0043" title="KoGT , ChanJC , CockramCS . Change of glycaemic status in Chinese subjects with impaired fasting glycaemia. Diabetic Medicine2001;18(9):745‐8. [PUBMED: 11606173] ">Ko 2001</a>; <a href="./references#CD012661-bbs2-0045" title="LatifiSM , KarandishM , ShahbazianH , Hardani PasandL . Incidence of prediabetes and type 2 diabetes among people aged over 20 years in Ahvaz: a 5‐year perspective study (2009‐2014). Journal of Diabetes and Research2016;2016:4908647. [PUBMED: 28004008] ShahbazianH , LatifiSM , JalaliMT , ShahbazianH , AmaniR , NikhooA , et al. Metabolic syndrome and its correlated factors in an urban population in South West of Iran. Journal of Diabetes &amp; Metabolic Disorders2013;12(1):11. [PUBMED: 23497506] ">Latifi 2016</a>; <a href="./references#CD012661-bbs2-0047" title="LeeJH , LimJT , KimHG , OhMK , LeeWJ . Effect of coffee consumption on the progression of type 2 diabetes mellitus among prediabetic individuals. Korean Journal of Family Medicine2016;37(1):7‐13. [PUBMED: 26885316] ">Lee 2016</a>; <a href="./references#CD012661-bbs2-0050" title="ChouPS , LiCL , WuGS , TsaiST . Progression to type 2 diabetes among high‐risk groups in Kin‐Chen, Kinmen ‐ exploring the natural history of type 2 diabetes. Diabetes Care1998;21(7):1183‐7. [PUBMED: 9653617] LiCL , TsaiST , ChouP . Comparison of the results between two diagnostic criteria by ADA and WHO among subjects with FPG 5.6‐7.8 mmol/l in Kin‐Hu and Kin‐Chen, Kinmen, 1991‐94. Diabetes Research and Clinical Practice1999;45(1):51‐9. LiCL , TsaiST , ChouP . Persistent impaired glucose tolerance, insulin resistance, and beta‐cell dysfunction were independent predictors of type 2 diabetes. Journal of Clinical Epidemiology2005;58(7):728‐32. LiCL , TsaiST , ChouP . Relative role of insulin resistance and beta‐cell dysfunction in the progression to type 2 diabetes ‐ the Kinmen study. Diabetes Research and Clinical Practice2003;59(3):225‐32. [PUBMED: 12590020] TsaiST , LiCL , ChenCH , ChouP . Community‐based epidemiological study of glucose tolerance in Kin‐Chen, Kinmen: support for a new intermediate classification. Journal of Clinical Epidemiology2000;53(5):505‐10. [PUBMED: 10812323] ">Li 2003</a>; <a href="./references#CD012661-bbs2-0053" title="LiuSJ , GuoZR , HuXS , WuM , ChenFM , KangGD , et al. Risks for type‐2 diabetes associated with the metabolic syndrome and the interaction between impaired fasting glucose and other components of metabolic syndrome. Diabetes Research and Clinical Practice2008;81(1):117‐23. [PUBMED: 18485514] ">Liu 2008</a>; <a href="./references#CD012661-bbs2-0054" title="LiuJ , WuYY , HuangXM , YangM , ZhaBB , WangF , et al. Ageing and type 2 diabetes in an elderly Chinese population: the role of insulin resistance and beta cell dysfunction. European Review for Medical and Pharmacological Sciences2014;18(12):1790‐7. [PUBMED: 24992623] ">Liu 2014</a>; <a href="./references#CD012661-bbs2-0055" title="LiuX , FineJ P , ChenZ , LiuL , LiX , WangA , et al. Prediction of the 20‐year incidence of diabetes in older Chinese: application of the competing risk method in a longitudinal study. Medicine2016;95(40):e5057. [PUBMED: 27749572] TangZ , WangHX , MengC , WuXG , EricssonK , WinbladB , et al. The prevalence of functional disability in activities of daily living and instrumental activities of daily living among elderly Beijing Chinese. Archives of Gerontology and Geriatrics1999;29(2):115‐25. TangZ , ZhouT , LuoY , XieC , HuoD , TaoL , et al. Risk factors for cerebrovascular disease mortality among the elderly in Beijing: a competing risk analysis. PLOS ONE2014;9(2):e87884. ">Liu 2016</a>; <a href="./references#CD012661-bbs2-0056" title="HeJ , NealB , GuD , SuriyawongpaisalP , XinX , ReynoldsR , et al. International collaborative study of cardiovascular disease in Asia: design, rationale, and preliminary results. Ethnicity &amp; Disease2004;14(2):260‐8. LiuFC , YangXL , LiJX , CaoJ , ChenJC , LiY , et al. Association of fasting glucose levels with incident atherosclerotic cardiovascular disease: an 8‐year follow‐up study in a Chinese population. Journal of Diabetes2017;9(1):14‐23. [PUBMED: 26840038] ">Liu 2017</a>; <a href="./references#CD012661-bbs2-0060" title="FoongAW , SawSM , LooJL , ShenS , LoonSC , RosmanM , et al. Rationale and methodology for a population‐based study of eye diseases in Malay people: the Singapore Malay eye study (SiMES). Ophthalmic Epidemiology2007;14(1):25‐35. ManRE , CharumathiS , GanAT , FenwickEK , TeyCS , ChuaJ , et al. Cumulative incidence and risk factors of prediabetes and type 2 diabetes in a Singaporean Malay cohort. Diabetes Research and Clinical Practice2017;127:163‐71. [PUBMED: 28371687] ">Man 2017</a>; <a href="./references#CD012661-bbs2-0064" title="DeepaR , Shanthi RaniS , PremalathaG , MohanV . Comparison of ADA 1997 and WHO 1985 criteria for diabetes in south Indiansb ‐ the Chennai urban population study. Diabetic Medicine2000;17(12):872‐4. MohanV , DeepaM , AnjanaRM , LanthornH , DeepaR . Incidence of diabetes and pre‐diabetes in a selected urban south Indian population (CUPS‐19). Journal of the Association of Physicians of India2008;56:152‐7. [PUBMED: 18697630] MohanV , GokulakrishnanK , DeepaR , ShanthiraniCS , DattaM . Association of physical inactivity with components of metabolic syndrome and coronary artery disease ‐ the Chennai urban population study (CUPS no. 15). Diabetic Medicine2005;22(9):1206‐11. MohanV , ShanthiraniCS , DeepaM , DeepaR , UnnikrishnanRI , DattaM . Mortality rates due to diabetes in a selected urban south Indian population ‐ the Chennai urban population study [CUPS‐16]. Journal of the Association of Physicians of India2006;54:113‐7. MohanV , ShanthiraniCS , DeepaR . Glucose intolerance (diabetes and IGT) in a selected South Indian population with special reference to family history, obesity and lifestyle factors ‐ the Chennai urban population study (CUPS 14). Journal of the Association of Physicians of India2003;51:771‐7. MohanV , ShanthiraniS , DeepaR , PremalathaG , SastryNG , SarojaR , et al. Intra‐urban differences in the prevalence of the metabolic syndrome in southern India ‐ the Chennai urban population study (CUPS No. 4). Diabetic Medicine2001;18:280‐7. [PUBMED: 11437858] MohanV , VijayachandrikaV , GokulakrishnanK , AnjanaRM , GanesanA , WeberMB , et al. A1C cut points to define various glucose intolerance groups in Asian Indians. Diabetes Care2010;33(3):515‐9. PradeepaR , DeepaR , RaniSS , PremalathaG , SarojaR , MohanV . Socioeconomic status and dyslipidaemia in a South Indian population: the Chennai urban population study (CUPS 11). National Medical Journal of India2003;16(2):73‐8. PremalathaG , ShanthiraniS , DeepaR , MarkovitzJ , MohanV . Prevalence and risk factors of peripheral vascular disease in a selected South Indian population: the Chennai urban population study. Diabetes Care2000;23(9):1295‐300. ShanthiraniCS , PradeepaR , DeepaR , PremalathaG , SarojaR , MohanV . Prevalence and risk factors of hypertension in a selected South Indian population ‐ the Chennai urban population study. Journal of the Association of Physicians of India2003;51:20‐7. ">Mohan 2008</a>; <a href="./references#CD012661-bbs2-0065" title="MotalaAA , OmarMA . Evaluation of WHO and NDDG criteria for impaired glucose tolerance. Diabetes Research and Clinical Practice1994;23(2):103‐9. [PUBMED: 8070301] MotalaAA , OmarMA . Evidence for impaired pancreatic beta cell function in South African Indians with impaired glucose tolerance. Diabetic Medicine1994;11(5):437‐44. MotalaAA , OmarMA , GouwsE . High risk of progression to NIDDM in South‐African Indians with impaired glucose tolerance. Diabetes1993;42(4):556‐63. [PUBMED: 8454106] MotalaAA , OmarMA , GouwsE . Transient impaired glucose tolerance in South African Indians does not carry a risk for progression to NIDDM. Diabetes Care1997;20(7):1101‐7. [PUBMED: 9203444] MotalaAA , PirieFJ , GouwsE , AmodA , OmarMA . High incidence of type 2 diabetes mellitus in South African Indians: a 10‐year follow‐up study. Diabetic Medicine2003;20(1):23‐30. [PUBMED: 12519316] OmarMA , SeedatMA , DyerRB , MotalaAA , KnightLT , BeckerPJ . South African Indians show a high prevalence of NIDDM and bimodality in plasma glucose distribution patterns. Diabetes Care1994;17(1):70‐3. ">Motala 2003</a>; <a href="./references#CD012661-bbs2-0068" title="NakagamiT , TanakaY , OyaJ , KuritaM , IsagoC , HasegawaY , et al. Associations of HbA1c and fasting plasma glucose with incident diabetes: implications for pre‐diabetes thresholds in a Japanese population. Primary Care Diabetes2016;10(6):407‐14. [PUBMED: 27515716] ">Nakagami 2016</a>; <a href="./references#CD012661-bbs2-0069" title="NakanishiN , TakatorigeT , FukudaH , ShiraiK , LiW , OkamotoM , et al. Components of the metabolic syndrome as predictors of cardiovascular disease and type 2 diabetes in middle‐aged Japanese men. Diabetes Research and Clinical Practice2004;64(1):59‐70. [PUBMED: 15036828] ">Nakanishi 2004</a>; <a href="./references#CD012661-bbs2-0070" title="InoueM , IwasakiM , OtaniT , SasazukiS , NodaM , TsuganeS . Diabetes mellitus and the risk of cancer: results from a large‐scale population‐based cohort study in Japan. Archives of Internal Medicine2006;166(17):1871‐7. [PUBMED: 17000944] KatoM , TakahashiY , MatsushitaY , MizoueT , InoueM , KadowakiT , et al. Diabetes mellitus defined by hemoglobin A1c value: risk characterization for incidence among Japanese subjects in the JPHC diabetes study. Journal of Diabetes Investigation2011;2(5):359‐65. [PUBMED: 24843514] NodaM , KatoM , TakahashiY , MatsushitaY , MizoueT , InoueM , et al. Fasting plasma glucose and 5‐year incidence of diabetes in the JPHC diabetes study ‐ suggestion for the threshold for impaired fasting glucose among Japanese. Endocrine Journal2010;57(7):629‐37. [PUBMED: 20508383] ">Noda 2010</a>; <a href="./references#CD012661-bbs2-0071" title="ParkYW , ChangY , SungKC , RyuS , SungE , KimWS . The sequential changes in the fasting plasma glucose levels within normoglycemic range predict type 2 diabetes in healthy, young men. Diabetes Research and Clinical Practice2006;73(3):329‐35. [PUBMED: 16600415] RyuS , ShinH , ChangY , SungKC , SongJ , LeeS J . Should the lower limit of impaired fasting glucose be reduced from 110 mg/dL in Korea?. Metabolism2006;55(4):489‐93. ">Park 2006</a>; <a href="./references#CD012661-bbs2-0073" title="FengB , LiX , HuangYW . A survey of diabetes mellitus and its risk factors among permanent inhabitants in Shanghai Pudong new economic area. Chinese Journal of Diabetes2004;12:187‐90. QianQ , LiX , HuangX , FuM , MengZ , ChenM , et al. Glucose metabolism among residents in Shanghai: natural outcome of a 5‐year follow‐up study. Journal of Endocrinological Investigation2012;35(5):453‐8. [PUBMED: 21738002] ">Qian 2012</a>; <a href="./references#CD012661-bbs2-0075" title="RamachandranA , SnehalathaC , NaikRA , MohanV , ShobanaR , ViswanathanM . Significance of impaired glucose tolerance in an Asian Indian population: a follow‐up study. Diabetes Research and Clinical Practice1986;2(3):173‐8. [PUBMED: 3527626] ">Ramachandran 1986</a>; <a href="./references#CD012661-bbs2-0079" title="HosseiniN , TalaeiM , DianatkhahM , SadeghiM , OveisgharanS , SarrafzadeganN . Determinants of incident metabolic syndrome in a Middle Eastern population: Isfahan cohort study. Metabolic Syndrome and Related Disorders2017;15(7):354‐62. [PUBMED: 28677982] SadeghiM , TalaeiM , ParvareshRE , DianatkhahM , OveisgharanS , SarrafzadeganN . Determinants of incident prediabetes and type 2 diabetes in a 7‐year cohort in a developing country: the Isfahan cohort study. Journal of Diabetes2015;7(5):633‐41. [PUBMED: 25350916] SarrafzadeganN , TalaeiM , SadeghiM , KelishadiR , OveisgharanS , MohammadifardN , et al. The Isfahan cohort study: rationale, methods and main findings. Journal of Human Hypertension2011;25(9):545‐53. [PUBMED: 21107436] ">Sadeghi 2015</a>; <a href="./references#CD012661-bbs2-0080" title="SasakiA , SuzukiT , HoriuchiN . Development of diabetes in Japanese subjects with impaired glucose tolerance: a seven year follow‐up study. Diabetologia1982;22(3):154‐7. [PUBMED: 7075915] SasakiA , SuzukiT , HoriuchiN . Survival rate and causes of death in Japan. A 10‐year follow‐up study. Journal of Chronic Diseases1980;33:341‐6. ">Sasaki 1982</a>; <a href="./references#CD012661-bbs2-0081" title="SatoKK , HayashiT , HaritaN , YonedaT , NakamuraY , EndoG , et al. Combined measurement of fasting plasma glucose and A1C is effective for the prediction of type 2 diabetes: the Kansai healthcare study. Diabetes Care2009;32(4):644‐6. [PUBMED: 19131461] SatoKK , HayashiT , KambeH , NakamuraY , HaritaN , EndoG , et al. Walking to work is an independent predictor of incidence of type 2 diabetes in Japanese men: the Kansai healthcare study. Diabetes Care2007;30(9):2296‐8. [PUBMED: 17536075] SatoKK , HayashiT , NakamuraY , HaritaN , YonedaT , EndoG , et al. Liver enzymes compared with alcohol consumption in predicting the risk of type 2 diabetes: the Kansai healthcare study. Diabetes Care2008;31:1230‐6. [PUBMED: 18316395] ">Sato 2009</a>; <a href="./references#CD012661-bbs2-0083" title="SharifiF , JaberiY , MirzamohammadiF , MirzamohammadiH , MousavinasabN . Determinants of developing diabetes mellitus and vascular complications in patients with impaired fasting glucose. Indian Journal of Endocrinology and Metabolism2013;17(5):899‐905. [PUBMED: 24083174] ">Sharifi 2013</a>; <a href="./references#CD012661-bbs2-0084" title="ParkY , LeeH , KohCS , MinH , YooK , KimY , et al. Prevalence of diabetes and IGT in Yonchon county, South Korea. Diabetes Care1995;18:545‐8. [PUBMED: 7497867] ShinCS , LeeHK , KohCS , KimYI , ShinYS , YooKY , et al. Risk factors for the development of NIDDM in Yonchon county, Korea. Diabetes Care1997;20(12):1842‐6. [PUBMED: 9405904] ">Shin 1997</a>; <a href="./references#CD012661-bbs2-0086" title="KimY , HanBG . Cohort profile: the Korean genome and epidemiology study (KoGES) consortium. International Journal of Epidemiology2017;46(2):e20. [PUBMED: 27085081] KimY , HanBG . Cohort profile: the Korean genome and epidemiology study (KoGES) consortium [Erratum]. International Journal of Epidemiology2017;46(4):1350. [PUBMED: 28938752] SongBM , KimHC , LeeJY , LeeJM , KimDJ , LeeYH , et al. Performance of HbA1c for the prediction of diabetes in a rural community in Korea. Diabetic Medicine2015;32(12):1602‐10. [PUBMED: 25962707] ">Song 2015</a>; <a href="./references#CD012661-bbs2-0087" title="QiuM , ShenW , SongX , JuL , TongW , WangH , et al. Effects of prediabetes mellitus alone or plus hypertension on subsequent occurrence of cardiovascular disease and diabetes mellitus: longitudinal study. Hypertension2015;65(3):525‐30. [PUBMED: 25624343] SongX , QiuM , ZhangX , WangH , TongW , JuL , et al. Gender‐related affecting factors of prediabetes on its 10‐year outcome. BMJ Open Diabetes Research &amp; Care2016;4(1):e000169. [PUBMED: 27239315] TianJY , ChengQ , SongXM , LiG , JiangGX , GuYY , et al. Birth weight and risk of type 2 diabetes, abdominal obesity and hypertension among Chinese adults. European Journal of Endocrinology/European Federation of Endocrine Societies2006;155(4):601‐7. [PUBMED: 16990660] ">Song 2016a</a>; <a href="./references#CD012661-bbs2-0090" title="ToshihiroM , SaitoK , TakikawaS , TakebeN , OnodaT , SatohJ . Psychosocial factors are independent risk factors for the development of type 2 diabetes in Japanese workers with impaired fasting glucose and/or impaired glucose tolerance. Diabetic Medicine2008;25(10):1211‐7. [PUBMED: 19046200] ">Toshihiro 2008</a>; <a href="./references#CD012661-bbs2-0094" title="ViswanathanV , ClementinaM , NairBM , SatyavaniK . Risk of future diabetes is as high with abnormal intermediate post‐glucose response as with impaired glucose tolerance. Journal of the Association of Physicians of India2007;55:833‐7. [PUBMED: 18405128] ">Viswanathan 2007</a>; <a href="./references#CD012661-bbs2-0095" title="WangJJ , LiHB , KinnunenL , HuG , JarvinenTM , MiettinenME , et al. How well does the metabolic syndrome defined by five definitions predict incident diabetes and incident coronary heart disease in a Chinese population?. Atherosclerosis2007;192(1):161‐8. [PUBMED: 16720024] WangJJ , QiaoQ , MiettinenME , LappalainenJ , HuG , TuomilehtoJ . The metabolic syndrome defined by factor analysis and incident type 2 diabetes in a Chinese population with high postprandial glucose. Diabetes Care2004;27(10):2429‐37. [PUBMED: 15451912] WangJJ , YuanSY , ZhuLX , FuHJ , LiHB , HuG , et al. Effects of impaired fasting glucose and impaired glucose tolerance on predicting incident type 2 diabetes in a Chinese population with high post‐prandial glucose. Diabetes Research and Clinical Practice2004;66(2):183‐91. [PUBMED: 15533586] ">Wang 2007</a>; <a href="./references#CD012661-bbs2-0098" title="JanusED . Epidemiology of cardiovascular risk factors in Hong Kong. Clinical and Experimental Pharmacology &amp; Physiology1997;24(12):987‐8. [PUBMED: 9406673] JanusED , WattNM , LamKS , CockramCS , SiuST , LiuLJ , et al. The prevalence of diabetes, association with cardiovascular risk factors and implications of diagnostic criteria (ADA 1997 and WHO 1998) in a 1996 community‐based population study in Hong Kong Chinese. Diabetic Medicine2000;17(10):741‐5. [PUBMED: 11110508] TanKC , WatNM , TamSC , JanusED , LamTH , LamKS . C‐reactive protein predicts the deterioration of glycemia in Chinese subjects with impaired glucose tolerance. Diabetes Care2003;26(8):2323‐8. WatNM , LamTH , JanusED , LamKS . Central obesity predicts the worsening of glycemia in southern Chinese. International Journal of Obesity and Related Metabolic Disorders2001;25(12):1789‐93. [PUBMED: 11781759] ">Wat 2001</a>; <a href="./references#CD012661-bbs2-0101" title="TanCE , EmmanuelSC , TanBY , JacobE . Prevalence of diabetes and ethnic differences in cardiovascular risk factors. The 1992 Singapore national health survey. Diabetes Care1999;22(2):241‐7. [PUBMED: 10333940] WongMS , GuK , HengD , ChewSK , ChewLS , TaiES . The Singapore impaired glucose tolerance follow‐up study: does the ticking clock go backward as well as forward?. Diabetes Care2003;26(11):3024‐30. [PUBMED: 14578234] ">Wong 2003</a>). Of these, 37 studies recruited participants from China, Japan, South Korea, Singapore, Taiwan and Thailand (<a href="./references#CD012661-bbs2-0002" title="AekplakornW , BunnagP , WoodwardM , SritaraP , CheepudomwitS , YamwongS , et al. A risk score for predicting incident diabetes in the Thai population. Diabetes Care2006;29(8):1872‐7. [PUBMED: 16873795] SritaraP , CheepudomwitS , ChapmanN , WoodwardM , KositchaiwatC , TunlayadechanontS , et al. Twelve‐year changes in vascular risk factors and their associations with mortality in a cohort of 3499 Thais: the electricity generating authority of Thailand study. International Journal of Epidemiology2003;32:461‐8. [PUBMED: 12777437] ">Aekplakorn 2006</a>; <a href="./references#CD012661-bbs2-0005" title="BaeJC , RheeEJ , LeeWY , ParkSE , ParkCY , OhKW , et al. Combined effect of nonalcoholic fatty liver disease and impaired fasting glucose on the development of type 2 diabetes: a 4‐year retrospective longitudinal study. Diabetes Care2011;34(3):727‐9. [PUBMED: 21278140] BaeJC , RheeEJ , LeeWY , ParkSE , ParkCY , OhKW , et al. Optimal range of HbA1c for the prediction of future diabetes: a 4‐year longitudinal study. Diabetes Research and Clinical Practice2011;93(2):255‐9. [PUBMED: 21676480] ">Bae 2011</a>; <a href="./references#CD012661-bbs2-0013" title="ChenKT , ChenCJ , GreggEW , ImperatoreG , NarayanKMV . Impaired fasting glucose and risk of diabetes in Taiwan: follow‐up over 3 years. Diabetes Research and Clinical Practice2003;60(3):177‐82. [PUBMED: 12757990] ChenKT , ChenCJ , GreggEW , WilliamsonDF , NarayanKM . High prevalence of impaired fasting glucose and type 2 diabetes mellitus in Penghu Islets, Taiwan: evidence of a rapidly emerging epidemic?. Diabetes Research and Clinical Practice1999;44(1):59‐69. [PUBMED: 10414941] ">Chen 2003</a>; <a href="./references#CD012661-bbs2-0014" title="ChenG , LinL , ChenL , LiL , HuangH , WangW , et al. Comparison of insulin resistance and beta‐cell dysfunction between the young and the elderly in normal glucose tolerance and prediabetes population: a prospective study. Hormone and Metabolic Research2017;49(2):135‐41. [DOI: 10.1055/s‐0042‐111325; PUBMED: 27459384] ">Chen 2017</a>; <a href="./references#CD012661-bbs2-0028" title="ChoiSH , KimTH , LimS , ParkKS , JangHC , ChoNH . Hemoglobin A1c as a diagnostic tool for diabetes screening and new‐onset diabetes prediction: a 6‐year community‐based prospective study. Diabetes Care2011;34(4):944‐9. [PUBMED: 21335372] HanSJ , KimHJ , KimDJ , LeeKW , ChoNH . Incidence and predictors of type 2 diabetes among Koreans: a 12‐year follow up of the Korean genome and epidemiology study. Diabetes Research and Clinical Practice2017;123:173‐80. [PUBMED: 28043048] JungDH , ByunYS , KwonYJ , KimGS . Microalbuminuria as a simple predictor of incident diabetes over 8 years in the Korean genome and epidemiology study (KoGES). Scientific Reports2017;7(1):15445. [PUBMED: 29133894] JungJY , OhCM , RyooJH , ChoiJM , ChoiYJ , HamW T , et al. The influence of prehypertension, hypertension, and glycated hemoglobin on the development of type 2 diabetes mellitus in prediabetes: the Korean genome and epidemiology study (KoGES). Endocrine2018;59(3):593‐601. [PUBMED: 29380232] Keun ParkS , RyooJH , OhCM , ChoiJM , ChoiYJ , Ok LeeK , et al. The risk of type 2 diabetes mellitus according to 2‐hour plasma glucose level: the Korean genome and epidemiology study (KoGES). Diabetes Research and Clinical Practice 2017 Aug 9 [Epub ahead of print]. [DOI: 10.1016/j.diabres.2017.08.002; PUBMED: 28951335] LimNK , ParkSH , ChoiSJ , LeeKS , ParkHY . A risk score for predicting the incidence of type 2 diabetes in a middle‐aged Korean cohort: the Korean genome and epidemiology study. Circulation Journal2012;76(8):1904‐10. [PUBMED: 22640983] ">Han 2017</a>; <a href="./references#CD012661-bbs2-0030" title="HeianzaY , AraseY , FujiharaK , HsiehSD , SaitoK , TsujiH , et al. Longitudinal trajectories of HbA1c and fasting plasma glucose levels during the development of type 2 diabetes: the Toranomon hospital health management center study 7 (TOPICS 7). Diabetes Care2012;35(5):1050‐2. [PUBMED: 22456865] HeianzaY , AraseY , FujiharaK , TsujiH , SaitoK , HsiehSD , et al. High normal HbA(1c) levels were associated with impaired insulin secretion without escalating insulin resistance in Japanese individuals: the Toranomon hospital health management center study 8 (TOPICS 8). Diabetic Medicine2012;29(10):1285‐90. HeianzaY , AraseY , FujiharaK , TsujiH , SaitoK , HsiehSD , et al. Screening for pre‐diabetes to predict future diabetes using various cut‐off points for HbA(1c) and impaired fasting glucose: the Toranomon hospital health management center study 4 (TOPICS 4). Diabetic Medicine2012;29(9):e279‐85. [PUBMED: 22510023] HeianzaY , AraseY , HsiehSD , SaitoK , TsujiH , KodamaS , et al. Development of a new scoring system for predicting the 5 year incidence of type 2 diabetes in Japan: the Toranomon hospital health management center study 6 (TOPICS 6). Diabetologia2012;55(12):3213‐23. [PUBMED: 22955996] HeianzaY , HaraS , AraseY , SaitoK , FujiwaraK , TsujiH , et al. HbA1c 5.7‐6.4% and impaired fasting plasma glucose for diagnosis of prediabetes and risk of progression to diabetes in Japan (TOPICS 3): a longitudinal cohort study. Lancet2011;378(9786):147‐55. [MEDLINE: 21705064] HeianzaY , HaraS , AraseY , SaitoK , TotsukaK , TsujiH , et al. Low serum potassium levels and risk of type 2 diabetes: the Toranomon hospital health management center study 1 (TOPICS 1). Diabetologia2011;54(4):762‐6. [PUBMED: 21212932] ">Heianza 2012</a>; <a href="./references#CD012661-bbs2-0031" title="InoueI , TakahashiK , KatayamaS , HaradaY , NegishiK , IshiiJ , et al. A higher proinsulin response to glucose loading predicts deteriorating fasting plasma glucose and worsening to diabetes in subjects with impaired glucose tolerance. Diabetoc Medicine1996;13(4):330‐6. [PUBMED: 9162608] ">Inoue 1996</a>; <a href="./references#CD012661-bbs2-0033" title="JaruratanasirikulS , ThammaratchuchaiS , PuwanantM , Mo‐SuwanL , SriplungH . Progression from impaired glucose tolerance to type 2 diabetes in obese children and adolescents: a 3‐6‐year cohort study in southern Thailand. Journal of Pediatric Endocrinology &amp; Metabolism2016;29(11):1267‐75. [PUBMED: 27740930] ">Jaruratanasirikul 2016</a>; <a href="./references#CD012661-bbs2-0034" title="JeongJY , KimJG , KimBW , MoonSS , KimHS , ParkKG , et al. Trend analysis of diabetic prevalence and incidence in a rural area of South Korea between 2003‐2008. Journal of Diabetes Investigation2010;1(5):184‐90. [PUBMED: 24843430] ">Jeong 2010</a>; <a href="./references#CD012661-bbs2-0035" title="JiamjarasrangsiW , AekplakornW . Incidence and predictors of type 2 diabetes among professional and office workers in Bangkok, Thailand. Journal of the Medical Association of Thailand2005;88(12):1896‐904. [PUBMED: 16518992] JiamjarasrangsiW , SangwatanarojS , LohsoonthornV , LertmaharitS . Increased alanine aminotransferase level and future risk of type 2 diabetes and impaired fasting glucose among the employees in a university hospital in Thailand. Diabetes &amp; Metabolism2008;34(3):283‐9. [PUBMED: 18486512] ">Jiamjarasrangsi 2008a</a>; <a href="./references#CD012661-bbs2-0036" title="KimDJ , ChoNH , NohJH , KimHJ , ChoiYH , JungJH , et al. Fasting plasma glucose cutoff value for the prediction of future diabetes development: a study of middle‐aged Koreans in a health promotion center. Journal of Korean Medical Science2005;20(4):562‐5. [PUBMED: 16100444] KimDJ , ChoNH , NohJH , LeeMS , LeeMK , KimKW . Lack of excess maternal transmission of type 2 diabetes in a Korean population. Diabetes Research and Clinical Practice2004;65(2):117‐24. [PUBMED: 15223223] ">Kim 2005</a>; <a href="./references#CD012661-bbs2-0037" title="KimSH , ShimWS , KimEA , KimEJ , LeeSH , HongSB , et al. The effect of lowering the threshold for diagnosis of impaired fasting glucose. Yonsei Medical Journal2008;49(2):217‐23. [PUBMED: 18452257] ">Kim 2008</a>; <a href="./references#CD012661-bbs2-0038" title="KimYA , KuEJ , KhangAR , HongES , KimKM , MoonJH , et al. Role of various indices derived from an oral glucose tolerance test in the prediction of conversion from prediabetes to type 2 diabetes. Diabetes Research and Clinical Practice2014;106(2):351‐9. [PUBMED: 25245975] ">Kim 2014</a>; <a href="./references#CD012661-bbs2-0039" title="KimCH , KimHK , KimEH , BaeSJ , ChoeJ , ParkJY . Risk of progression to diabetes from prediabetes defined by HbA1c or fasting plasma glucose criteria in Koreans. Diabetes Research and Clinical Practice2016;118:105‐11. [PUBMED: 27368062] ">Kim 2016a</a>; <a href="./references#CD012661-bbs2-0042" title="KoGT , ChanJC , LauE , WooJ , CockramCS . Fasting plasma glucose as a screening test for diabetes and its relationship with cardiovascular risk factors in Hong Kong Chinese. Diabetes Care1997;20(2):170‐2. KoGT , LiJK , CheungAY , YeungVT , ChowCC , TsangLW , et al. Two‐hour post‐glucose loading plasma glucose is the main determinant for the progression from impaired glucose tolerance to diabetes in Hong Kong Chinese. Diabetes Care1999;22(12):2096‐7. [PUBMED: 10587859] ">Ko 1999</a>; <a href="./references#CD012661-bbs2-0043" title="KoGT , ChanJC , CockramCS . Change of glycaemic status in Chinese subjects with impaired fasting glycaemia. Diabetic Medicine2001;18(9):745‐8. [PUBMED: 11606173] ">Ko 2001</a>; <a href="./references#CD012661-bbs2-0047" title="LeeJH , LimJT , KimHG , OhMK , LeeWJ . Effect of coffee consumption on the progression of type 2 diabetes mellitus among prediabetic individuals. Korean Journal of Family Medicine2016;37(1):7‐13. [PUBMED: 26885316] ">Lee 2016</a>; <a href="./references#CD012661-bbs2-0050" title="ChouPS , LiCL , WuGS , TsaiST . Progression to type 2 diabetes among high‐risk groups in Kin‐Chen, Kinmen ‐ exploring the natural history of type 2 diabetes. Diabetes Care1998;21(7):1183‐7. [PUBMED: 9653617] LiCL , TsaiST , ChouP . Comparison of the results between two diagnostic criteria by ADA and WHO among subjects with FPG 5.6‐7.8 mmol/l in Kin‐Hu and Kin‐Chen, Kinmen, 1991‐94. Diabetes Research and Clinical Practice1999;45(1):51‐9. LiCL , TsaiST , ChouP . Persistent impaired glucose tolerance, insulin resistance, and beta‐cell dysfunction were independent predictors of type 2 diabetes. Journal of Clinical Epidemiology2005;58(7):728‐32. LiCL , TsaiST , ChouP . Relative role of insulin resistance and beta‐cell dysfunction in the progression to type 2 diabetes ‐ the Kinmen study. Diabetes Research and Clinical Practice2003;59(3):225‐32. [PUBMED: 12590020] TsaiST , LiCL , ChenCH , ChouP . Community‐based epidemiological study of glucose tolerance in Kin‐Chen, Kinmen: support for a new intermediate classification. Journal of Clinical Epidemiology2000;53(5):505‐10. [PUBMED: 10812323] ">Li 2003</a>; <a href="./references#CD012661-bbs2-0053" title="LiuSJ , GuoZR , HuXS , WuM , ChenFM , KangGD , et al. Risks for type‐2 diabetes associated with the metabolic syndrome and the interaction between impaired fasting glucose and other components of metabolic syndrome. Diabetes Research and Clinical Practice2008;81(1):117‐23. [PUBMED: 18485514] ">Liu 2008</a>; <a href="./references#CD012661-bbs2-0054" title="LiuJ , WuYY , HuangXM , YangM , ZhaBB , WangF , et al. Ageing and type 2 diabetes in an elderly Chinese population: the role of insulin resistance and beta cell dysfunction. European Review for Medical and Pharmacological Sciences2014;18(12):1790‐7. [PUBMED: 24992623] ">Liu 2014</a>; <a href="./references#CD012661-bbs2-0055" title="LiuX , FineJ P , ChenZ , LiuL , LiX , WangA , et al. Prediction of the 20‐year incidence of diabetes in older Chinese: application of the competing risk method in a longitudinal study. Medicine2016;95(40):e5057. [PUBMED: 27749572] TangZ , WangHX , MengC , WuXG , EricssonK , WinbladB , et al. The prevalence of functional disability in activities of daily living and instrumental activities of daily living among elderly Beijing Chinese. Archives of Gerontology and Geriatrics1999;29(2):115‐25. TangZ , ZhouT , LuoY , XieC , HuoD , TaoL , et al. Risk factors for cerebrovascular disease mortality among the elderly in Beijing: a competing risk analysis. PLOS ONE2014;9(2):e87884. ">Liu 2016</a>; <a href="./references#CD012661-bbs2-0056" title="HeJ , NealB , GuD , SuriyawongpaisalP , XinX , ReynoldsR , et al. International collaborative study of cardiovascular disease in Asia: design, rationale, and preliminary results. Ethnicity &amp; Disease2004;14(2):260‐8. LiuFC , YangXL , LiJX , CaoJ , ChenJC , LiY , et al. Association of fasting glucose levels with incident atherosclerotic cardiovascular disease: an 8‐year follow‐up study in a Chinese population. Journal of Diabetes2017;9(1):14‐23. [PUBMED: 26840038] ">Liu 2017</a>; <a href="./references#CD012661-bbs2-0060" title="FoongAW , SawSM , LooJL , ShenS , LoonSC , RosmanM , et al. Rationale and methodology for a population‐based study of eye diseases in Malay people: the Singapore Malay eye study (SiMES). Ophthalmic Epidemiology2007;14(1):25‐35. ManRE , CharumathiS , GanAT , FenwickEK , TeyCS , ChuaJ , et al. Cumulative incidence and risk factors of prediabetes and type 2 diabetes in a Singaporean Malay cohort. Diabetes Research and Clinical Practice2017;127:163‐71. [PUBMED: 28371687] ">Man 2017</a>; <a href="./references#CD012661-bbs2-0068" title="NakagamiT , TanakaY , OyaJ , KuritaM , IsagoC , HasegawaY , et al. Associations of HbA1c and fasting plasma glucose with incident diabetes: implications for pre‐diabetes thresholds in a Japanese population. Primary Care Diabetes2016;10(6):407‐14. [PUBMED: 27515716] ">Nakagami 2016</a>; <a href="./references#CD012661-bbs2-0069" title="NakanishiN , TakatorigeT , FukudaH , ShiraiK , LiW , OkamotoM , et al. Components of the metabolic syndrome as predictors of cardiovascular disease and type 2 diabetes in middle‐aged Japanese men. Diabetes Research and Clinical Practice2004;64(1):59‐70. [PUBMED: 15036828] ">Nakanishi 2004</a>; <a href="./references#CD012661-bbs2-0070" title="InoueM , IwasakiM , OtaniT , SasazukiS , NodaM , TsuganeS . Diabetes mellitus and the risk of cancer: results from a large‐scale population‐based cohort study in Japan. Archives of Internal Medicine2006;166(17):1871‐7. [PUBMED: 17000944] KatoM , TakahashiY , MatsushitaY , MizoueT , InoueM , KadowakiT , et al. Diabetes mellitus defined by hemoglobin A1c value: risk characterization for incidence among Japanese subjects in the JPHC diabetes study. Journal of Diabetes Investigation2011;2(5):359‐65. [PUBMED: 24843514] NodaM , KatoM , TakahashiY , MatsushitaY , MizoueT , InoueM , et al. Fasting plasma glucose and 5‐year incidence of diabetes in the JPHC diabetes study ‐ suggestion for the threshold for impaired fasting glucose among Japanese. Endocrine Journal2010;57(7):629‐37. [PUBMED: 20508383] ">Noda 2010</a>; <a href="./references#CD012661-bbs2-0071" title="ParkYW , ChangY , SungKC , RyuS , SungE , KimWS . The sequential changes in the fasting plasma glucose levels within normoglycemic range predict type 2 diabetes in healthy, young men. Diabetes Research and Clinical Practice2006;73(3):329‐35. [PUBMED: 16600415] RyuS , ShinH , ChangY , SungKC , SongJ , LeeS J . Should the lower limit of impaired fasting glucose be reduced from 110 mg/dL in Korea?. Metabolism2006;55(4):489‐93. ">Park 2006</a>; <a href="./references#CD012661-bbs2-0073" title="FengB , LiX , HuangYW . A survey of diabetes mellitus and its risk factors among permanent inhabitants in Shanghai Pudong new economic area. Chinese Journal of Diabetes2004;12:187‐90. QianQ , LiX , HuangX , FuM , MengZ , ChenM , et al. Glucose metabolism among residents in Shanghai: natural outcome of a 5‐year follow‐up study. Journal of Endocrinological Investigation2012;35(5):453‐8. [PUBMED: 21738002] ">Qian 2012</a>; <a href="./references#CD012661-bbs2-0080" title="SasakiA , SuzukiT , HoriuchiN . Development of diabetes in Japanese subjects with impaired glucose tolerance: a seven year follow‐up study. Diabetologia1982;22(3):154‐7. [PUBMED: 7075915] SasakiA , SuzukiT , HoriuchiN . Survival rate and causes of death in Japan. A 10‐year follow‐up study. Journal of Chronic Diseases1980;33:341‐6. ">Sasaki 1982</a>; <a href="./references#CD012661-bbs2-0081" title="SatoKK , HayashiT , HaritaN , YonedaT , NakamuraY , EndoG , et al. Combined measurement of fasting plasma glucose and A1C is effective for the prediction of type 2 diabetes: the Kansai healthcare study. Diabetes Care2009;32(4):644‐6. [PUBMED: 19131461] SatoKK , HayashiT , KambeH , NakamuraY , HaritaN , EndoG , et al. Walking to work is an independent predictor of incidence of type 2 diabetes in Japanese men: the Kansai healthcare study. Diabetes Care2007;30(9):2296‐8. [PUBMED: 17536075] SatoKK , HayashiT , NakamuraY , HaritaN , YonedaT , EndoG , et al. Liver enzymes compared with alcohol consumption in predicting the risk of type 2 diabetes: the Kansai healthcare study. Diabetes Care2008;31:1230‐6. [PUBMED: 18316395] ">Sato 2009</a>; <a href="./references#CD012661-bbs2-0084" title="ParkY , LeeH , KohCS , MinH , YooK , KimY , et al. Prevalence of diabetes and IGT in Yonchon county, South Korea. Diabetes Care1995;18:545‐8. [PUBMED: 7497867] ShinCS , LeeHK , KohCS , KimYI , ShinYS , YooKY , et al. Risk factors for the development of NIDDM in Yonchon county, Korea. Diabetes Care1997;20(12):1842‐6. [PUBMED: 9405904] ">Shin 1997</a>; <a href="./references#CD012661-bbs2-0086" title="KimY , HanBG . Cohort profile: the Korean genome and epidemiology study (KoGES) consortium. International Journal of Epidemiology2017;46(2):e20. [PUBMED: 27085081] KimY , HanBG . Cohort profile: the Korean genome and epidemiology study (KoGES) consortium [Erratum]. International Journal of Epidemiology2017;46(4):1350. [PUBMED: 28938752] SongBM , KimHC , LeeJY , LeeJM , KimDJ , LeeYH , et al. Performance of HbA1c for the prediction of diabetes in a rural community in Korea. Diabetic Medicine2015;32(12):1602‐10. [PUBMED: 25962707] ">Song 2015</a>; <a href="./references#CD012661-bbs2-0087" title="QiuM , ShenW , SongX , JuL , TongW , WangH , et al. Effects of prediabetes mellitus alone or plus hypertension on subsequent occurrence of cardiovascular disease and diabetes mellitus: longitudinal study. Hypertension2015;65(3):525‐30. [PUBMED: 25624343] SongX , QiuM , ZhangX , WangH , TongW , JuL , et al. Gender‐related affecting factors of prediabetes on its 10‐year outcome. BMJ Open Diabetes Research &amp; Care2016;4(1):e000169. [PUBMED: 27239315] TianJY , ChengQ , SongXM , LiG , JiangGX , GuYY , et al. Birth weight and risk of type 2 diabetes, abdominal obesity and hypertension among Chinese adults. European Journal of Endocrinology/European Federation of Endocrine Societies2006;155(4):601‐7. [PUBMED: 16990660] ">Song 2016a</a>; <a href="./references#CD012661-bbs2-0090" title="ToshihiroM , SaitoK , TakikawaS , TakebeN , OnodaT , SatohJ . Psychosocial factors are independent risk factors for the development of type 2 diabetes in Japanese workers with impaired fasting glucose and/or impaired glucose tolerance. Diabetic Medicine2008;25(10):1211‐7. [PUBMED: 19046200] ">Toshihiro 2008</a>; <a href="./references#CD012661-bbs2-0095" title="WangJJ , LiHB , KinnunenL , HuG , JarvinenTM , MiettinenME , et al. How well does the metabolic syndrome defined by five definitions predict incident diabetes and incident coronary heart disease in a Chinese population?. Atherosclerosis2007;192(1):161‐8. [PUBMED: 16720024] WangJJ , QiaoQ , MiettinenME , LappalainenJ , HuG , TuomilehtoJ . The metabolic syndrome defined by factor analysis and incident type 2 diabetes in a Chinese population with high postprandial glucose. Diabetes Care2004;27(10):2429‐37. [PUBMED: 15451912] WangJJ , YuanSY , ZhuLX , FuHJ , LiHB , HuG , et al. Effects of impaired fasting glucose and impaired glucose tolerance on predicting incident type 2 diabetes in a Chinese population with high post‐prandial glucose. Diabetes Research and Clinical Practice2004;66(2):183‐91. [PUBMED: 15533586] ">Wang 2007</a>; <a href="./references#CD012661-bbs2-0098" title="JanusED . Epidemiology of cardiovascular risk factors in Hong Kong. Clinical and Experimental Pharmacology &amp; Physiology1997;24(12):987‐8. [PUBMED: 9406673] JanusED , WattNM , LamKS , CockramCS , SiuST , LiuLJ , et al. The prevalence of diabetes, association with cardiovascular risk factors and implications of diagnostic criteria (ADA 1997 and WHO 1998) in a 1996 community‐based population study in Hong Kong Chinese. Diabetic Medicine2000;17(10):741‐5. [PUBMED: 11110508] TanKC , WatNM , TamSC , JanusED , LamTH , LamKS . C‐reactive protein predicts the deterioration of glycemia in Chinese subjects with impaired glucose tolerance. Diabetes Care2003;26(8):2323‐8. WatNM , LamTH , JanusED , LamKS . Central obesity predicts the worsening of glycemia in southern Chinese. International Journal of Obesity and Related Metabolic Disorders2001;25(12):1789‐93. [PUBMED: 11781759] ">Wat 2001</a>; <a href="./references#CD012661-bbs2-0101" title="TanCE , EmmanuelSC , TanBY , JacobE . Prevalence of diabetes and ethnic differences in cardiovascular risk factors. The 1992 Singapore national health survey. Diabetes Care1999;22(2):241‐7. [PUBMED: 10333940] WongMS , GuK , HengD , ChewSK , ChewLS , TaiES . The Singapore impaired glucose tolerance follow‐up study: does the ticking clock go backward as well as forward?. Diabetes Care2003;26(11):3024‐30. [PUBMED: 14578234] ">Wong 2003</a>), 5 studies recruited participants from India (<a href="./references#CD012661-bbs2-0004" title="AnjanaRM , Shanthi RaniCS , DeepaM , PradeepaR , SudhaV , Divya NairH , et al. Incidence of diabetes and prediabetes and predictors of progression among Asian Indians: 10‐year follow‐up of the Chennai urban rural epidemiology study (CURES). Diabetes Care2015;38(8):1441‐8. [PUBMED: 25906786] DeepaM , PradeepaR , RemaM , MohanA , DeepaR , ShanthiraniS , et al. The Chennai urban rural epidemiology study (CURES) ‐ study design and methodology (urban component) (CURES‐I). Journal of the Association of Physicians of India2003;51:863‐70. [PUBMED: 14710970] MohanD , RajD , ShanthiraniCS , DattaM , UnwinNC , KapurA , et al. Awareness and knowledge of diabetes in Chennai ‐ the Chennai urban rural epidemiology study [CURES‐9]. Journal of the Association of Physicians of India2005;53:283‐7. MohanV , DeepaM , FarooqS , DattaM , DeepaR . Prevalence, awareness and control of hypertension in Chennai ‐ the Chennai urban rural epidemiology study (CURES‐52). Journal of the Association of Physicians of India2007;55:326‐32. MohanV , DeepaR , PradeepaR , VimaleswaranKS , MohanA , VelmuruganK , et al. Association of low adiponectin levels with the metabolic syndrome ‐ the Chennai urban rural epidemiology study (CURES‐4). Metabolism2005;54(4):476‐81. MohanV , SandeepS , DeepaM , GokulakrishnanK , DattaM , DeepaR . A diabetes risk score helps identify metabolic syndrome and cardiovascular risk in Indians ‐ the Chennai urban rural epidemiology study (CURES‐38). Diabetes, Obesity &amp; Metabolism2007;9(3):337‐43. RadhikaG , SathyaRM , SudhaV , GanesanA , MohanV . Dietary salt intake and hypertension in an urban south Indian population ‐ [CURES ‐ 53]. Journal of the Association of Physicians of India2007;55:405‐11. ">Anjana 2015</a>; <a href="./references#CD012661-bbs2-0007" title="BaiPV , KrishnaswamiCV , ChellamariappanM . Prevalence and incidence of type‐2 diabetes and impaired glucose tolerance in a selected Indian urban population. Journal of the Association of Physicians of India1999;47(11):1060‐4. [PUBMED: 10862313] ">Bai 1999</a>; <a href="./references#CD012661-bbs2-0064" title="DeepaR , Shanthi RaniS , PremalathaG , MohanV . Comparison of ADA 1997 and WHO 1985 criteria for diabetes in south Indiansb ‐ the Chennai urban population study. Diabetic Medicine2000;17(12):872‐4. MohanV , DeepaM , AnjanaRM , LanthornH , DeepaR . Incidence of diabetes and pre‐diabetes in a selected urban south Indian population (CUPS‐19). Journal of the Association of Physicians of India2008;56:152‐7. [PUBMED: 18697630] MohanV , GokulakrishnanK , DeepaR , ShanthiraniCS , DattaM . Association of physical inactivity with components of metabolic syndrome and coronary artery disease ‐ the Chennai urban population study (CUPS no. 15). Diabetic Medicine2005;22(9):1206‐11. MohanV , ShanthiraniCS , DeepaM , DeepaR , UnnikrishnanRI , DattaM . Mortality rates due to diabetes in a selected urban south Indian population ‐ the Chennai urban population study [CUPS‐16]. Journal of the Association of Physicians of India2006;54:113‐7. MohanV , ShanthiraniCS , DeepaR . Glucose intolerance (diabetes and IGT) in a selected South Indian population with special reference to family history, obesity and lifestyle factors ‐ the Chennai urban population study (CUPS 14). Journal of the Association of Physicians of India2003;51:771‐7. MohanV , ShanthiraniS , DeepaR , PremalathaG , SastryNG , SarojaR , et al. Intra‐urban differences in the prevalence of the metabolic syndrome in southern India ‐ the Chennai urban population study (CUPS No. 4). Diabetic Medicine2001;18:280‐7. [PUBMED: 11437858] MohanV , VijayachandrikaV , GokulakrishnanK , AnjanaRM , GanesanA , WeberMB , et al. A1C cut points to define various glucose intolerance groups in Asian Indians. Diabetes Care2010;33(3):515‐9. PradeepaR , DeepaR , RaniSS , PremalathaG , SarojaR , MohanV . Socioeconomic status and dyslipidaemia in a South Indian population: the Chennai urban population study (CUPS 11). National Medical Journal of India2003;16(2):73‐8. PremalathaG , ShanthiraniS , DeepaR , MarkovitzJ , MohanV . Prevalence and risk factors of peripheral vascular disease in a selected South Indian population: the Chennai urban population study. Diabetes Care2000;23(9):1295‐300. ShanthiraniCS , PradeepaR , DeepaR , PremalathaG , SarojaR , MohanV . Prevalence and risk factors of hypertension in a selected South Indian population ‐ the Chennai urban population study. Journal of the Association of Physicians of India2003;51:20‐7. ">Mohan 2008</a>; <a href="./references#CD012661-bbs2-0075" title="RamachandranA , SnehalathaC , NaikRA , MohanV , ShobanaR , ViswanathanM . Significance of impaired glucose tolerance in an Asian Indian population: a follow‐up study. Diabetes Research and Clinical Practice1986;2(3):173‐8. [PUBMED: 3527626] ">Ramachandran 1986</a>; <a href="./references#CD012661-bbs2-0094" title="ViswanathanV , ClementinaM , NairBM , SatyavaniK . Risk of future diabetes is as high with abnormal intermediate post‐glucose response as with impaired glucose tolerance. Journal of the Association of Physicians of India2007;55:833‐7. [PUBMED: 18405128] ">Viswanathan 2007</a>), 1 study involved Indian‐South African participants (<a href="./references#CD012661-bbs2-0065" title="MotalaAA , OmarMA . Evaluation of WHO and NDDG criteria for impaired glucose tolerance. Diabetes Research and Clinical Practice1994;23(2):103‐9. [PUBMED: 8070301] MotalaAA , OmarMA . Evidence for impaired pancreatic beta cell function in South African Indians with impaired glucose tolerance. Diabetic Medicine1994;11(5):437‐44. MotalaAA , OmarMA , GouwsE . High risk of progression to NIDDM in South‐African Indians with impaired glucose tolerance. Diabetes1993;42(4):556‐63. [PUBMED: 8454106] MotalaAA , OmarMA , GouwsE . Transient impaired glucose tolerance in South African Indians does not carry a risk for progression to NIDDM. Diabetes Care1997;20(7):1101‐7. [PUBMED: 9203444] MotalaAA , PirieFJ , GouwsE , AmodA , OmarMA . High incidence of type 2 diabetes mellitus in South African Indians: a 10‐year follow‐up study. Diabetic Medicine2003;20(1):23‐30. [PUBMED: 12519316] OmarMA , SeedatMA , DyerRB , MotalaAA , KnightLT , BeckerPJ . South African Indians show a high prevalence of NIDDM and bimodality in plasma glucose distribution patterns. Diabetes Care1994;17(1):70‐3. ">Motala 2003</a>), and 7 studies recruited participants from Iran, Israel and Jordan (<a href="./references#CD012661-bbs2-0003" title="AjlouniK , JaddouH , BatiehaA . Obesity in Jordan. International Journal of Obesity and Related Metabolic Disorders1998;22(7):624‐8. [PUBMED: 9705020] AmmariF , BatiehaA , JaddouPH , OkashiM , AjlouniK . A natural history of impaired glucose tolerance in North Jordan. Practical Diabetes International1998;15(5):139‐40. ">Ammari 1998</a>; <a href="./references#CD012661-bbs2-0008" title="BergmanM , ChetritA , RothJ , JagannathanR , SevickM , DanknerR . One‐hour post‐load plasma glucose level during the OGTT predicts dysglycemia: observations from the 24year follow‐up of the Israel study of glucose intolerance, obesity and hypertension. Diabetes Research and Clinical Practice2016;120:221‐8. [PUBMED: 27596059] DanknerR , Abdul‐GhaniMA , GerberY , ChetritA , WainsteinJ , RazI . Predicting the 20‐year diabetes incidence rate. Diabetes/metabolism Research and Reviews2007;23(7):551‐8. [PUBMED: 17315136] ModanM , HalkinH , KarasikA , LuskyA . Effectiveness of glycosylated hemoglobin, fasting plasma glucose, and a single post load plasma glucose level in population screening for glucose intolerance. American Journal of Epidemiology1984;119(3):431‐44. [PUBMED: 6702817] ModanM , KarasikA , HalkinH , FuchsZ , LuskyA , ShitritA , et al. Effect of past and concurrent body mass index on prevalence of glucose intolerance and type 2 (non‐insulin‐dependent) diabetes and on insulin response. Diabetologia1986;29(2):82‐9. [PUBMED: 3516770] ">Bergman 2016</a>; <a href="./references#CD012661-bbs2-0019" title="Aghaei MeybodiHR , AziziF . Changes in body weight and fat distribution; risk factors for abnormal glucose homeostasis? Tehran lipid and glucose study. Iranian Journal of Diabetes and Lipid Disorders2009;8(1):1‐12. BozorgmaneshM , HadaeghF , AziziF . A simple clinical model predicted diabetes progression among prediabetic individuals. Diabetes Research and Clinical Practice2012;97(2):e34‐6. [PUBMED: 22647753] DerakhshanA , Bagherzadeh‐KhiabaniF , ArshiB , RamezankhaniA , AziziF , HadaeghF . Different combinations of glucose tolerance and blood pressure status and incident diabetes, hypertension, and chronic kidney disease. Journal of the American Heart Association2016;5(8):pii: e003917. [DOI: 10.1161/JAHA.116.003917; PUBMED: 27543801] DerakhshanA , SardariniaM , KhaliliD , MomenanAA , AziziF , HadaeghF . Sex specific incidence rates of type 2 diabetes and its risk factors over 9 years of follow‐up: Tehran lipid and glucose study. PLOS ONE2014;9(7):e102563. [PUBMED: 25029368] DerakhshanA , TohidiM , ArshiB , KhaliliD , AziziF , HadaeghF . Relationship of hyperinsulinaemia, insulin resistance and beta‐cell dysfunction with incident diabetes and pre‐diabetes: the Tehran lipid and glucose study. Diabetic Medicine2015;32(1):24‐32. [PUBMED: 25131451] HadaeghF , BozorgmaneshMR , GhasemiA , HaratiH , SaadatN , AziziF . High prevalence of undiagnosed diabetes and abnormal glucose tolerance in the Iranian urban population: Tehran lipid and glucose study. BMC Public Health2008;8:176. HadaeghF , DerakhshanA , ZafariN , KhaliliD , MirboloukM , SaadatN , et al. Pre‐diabetes tsunami: incidence rates and risk factors of pre‐diabetes and its different phenotypes over 9 years of follow‐up. Diabetic Medicine2017;34(1):69‐78. [PUBMED: 26606421] HadaeghF , GhasemiAr , PadyabM , TohidiM , AziziF . The metabolic syndrome and incident diabetes: assessment of alternative definitions of the metabolic syndrome in an Iranian urban population. Diabetes Research and Clinical Practice2008;80(2):328‐34. [PUBMED: 18282630] HaratiH , HadaeghF , SaadatN , AziziF . Population‐based incidence of type 2 diabetes and its associated risk factors: results from a six‐year cohort study in Iran. BMC Public Health2009;9:186. [DOI: 10.1186/1471‐2458‐9‐186; PUBMED: 19531260] HaratiH , HadaeghF , TohidiM , AziziF . Impaired fasting glucose cutoff value of 5.6 mmol/l combined with other cardiovascular risk markers is a better predictor for incident type 2 diabetes than the 6.1 mmol/l value: Tehran lipid and glucose study. Diabetes Research and Clinical Practice2009;85(1):90‐5. [PUBMED: 19414206] ">Derakhshan 2016</a>; <a href="./references#CD012661-bbs2-0032" title="AminiM , JanghorbaniM . Comparison of metabolic syndrome with glucose measurement for prediction of type 2 diabetes: the Isfahan diabetes prevention study. Diabetes &amp; Metabolic Syndrome: Clinical Research &amp; Reviews2009;3(2):84‐9. HaghighatdoostF , AminiM , FeiziA , IrajB . Are body mass index and waist circumference significant predictors of diabetes and prediabetes risk: results from a population based cohort study. World Journal of Diabetes2017;8(7):365‐73. [PUBMED: 28751960] JanghorbaniM , AminiM . Normal fasting plasma glucose and risk of prediabetes and type 2 diabetes: the Isfahan diabetes prevention study. Review of Diabetic Studies2011;8(4):490‐8. [PUBMED: 22580730] JanghorbaniM , AminiM . Progression from optimal blood glucose and pre‐diabetes to type 2 diabetes in a high risk population with or without hypertension in Isfahan, Iran. Diabetes Research and Clinical Practice2015;108(3):414‐22. [PUBMED: 25814432] ">Janghorbani 2015</a>; <a href="./references#CD012661-bbs2-0045" title="LatifiSM , KarandishM , ShahbazianH , Hardani PasandL . Incidence of prediabetes and type 2 diabetes among people aged over 20 years in Ahvaz: a 5‐year perspective study (2009‐2014). Journal of Diabetes and Research2016;2016:4908647. [PUBMED: 28004008] ShahbazianH , LatifiSM , JalaliMT , ShahbazianH , AmaniR , NikhooA , et al. Metabolic syndrome and its correlated factors in an urban population in South West of Iran. Journal of Diabetes &amp; Metabolic Disorders2013;12(1):11. [PUBMED: 23497506] ">Latifi 2016</a>; <a href="./references#CD012661-bbs2-0079" title="HosseiniN , TalaeiM , DianatkhahM , SadeghiM , OveisgharanS , SarrafzadeganN . Determinants of incident metabolic syndrome in a Middle Eastern population: Isfahan cohort study. Metabolic Syndrome and Related Disorders2017;15(7):354‐62. [PUBMED: 28677982] SadeghiM , TalaeiM , ParvareshRE , DianatkhahM , OveisgharanS , SarrafzadeganN . Determinants of incident prediabetes and type 2 diabetes in a 7‐year cohort in a developing country: the Isfahan cohort study. Journal of Diabetes2015;7(5):633‐41. [PUBMED: 25350916] SarrafzadeganN , TalaeiM , SadeghiM , KelishadiR , OveisgharanS , MohammadifardN , et al. The Isfahan cohort study: rationale, methods and main findings. Journal of Human Hypertension2011;25(9):545‐53. [PUBMED: 21107436] ">Sadeghi 2015</a>; <a href="./references#CD012661-bbs2-0083" title="SharifiF , JaberiY , MirzamohammadiF , MirzamohammadiH , MousavinasabN . Determinants of developing diabetes mellitus and vascular complications in patients with impaired fasting glucose. Indian Journal of Endocrinology and Metabolism2013;17(5):899‐905. [PUBMED: 24083174] ">Sharifi 2013</a>). </p> <p>We categorised the origin of participants as 'American Indians/Islands' in five studies. Three of the five studies had American Indians as participants (<a href="./references#CD012661-bbs2-0093" title="VijayakumarP , NelsonR G , HansonR L , KnowlerW C , SinhaM . HbA1c and the prediction of type 2 diabetes in children and adults. Diabetes Care2017;40(1):16‐21. [PUBMED: 27810987] ">Vijayakumar 2017</a>; <a href="./references#CD012661-bbs2-0096" title="HowardBV , LeeET , CowanLD , DevereuxRB , GallowayJM , GoOT , et al. Rising tide of cardiovascular disease in American Indians. The strong heart study. Circulation1999;99(18):2389‐95. LeeET , HowardBV , GoO , SavagePJ , FabsitzRR , RobbinsDC , et al. Prevalence of undiagnosed diabetes in three American Indian populations. A comparison of the 1997 American Diabetes Association diagnostic criteria and the 1985 World Health Organization diagnostic criteria: the strong heart study. Diabetes Care2000;23(2):181‐6. LeeET , HowardBV , SavagePJ , CowanLD , FabsitzRR , OopikAJ , et al. Diabetes and impaired glucose tolerance in three American Indian populations aged 45‐74 years. The strong heart study. Diabetes Care1995;18(5):599‐610. LeeET , WeltyTK , CowanLD , WangW , RhoadesDA , DevereuxR , et al. Incidence of diabetes in American Indians of three geographic areas: the strong heart study. Diabetes Care2002;25(1):49‐54. [PUBMED: 11772900] LeeET , WeltyTK , FabsitzR , CowanLD , LeNA , OopikAJ , et al. The strong heart study. A study of cardiovascular disease in American Indians: design and methods. American Journal of Epidemiology1990;132(6):1141‐55. [PUBMED: 2260546] LuW , ResnickHE , JainAK , Adams‐CampbellLL , JablonskiKA , GottliebAM , et al. Effects of isolated post‐challenge hyperglycemia on mortality in American Indians: the strong heart study. Annals of Epidemiology2003;13(3):182‐8. WangH , SharaN M , CalhounD , UmansJG , LeeET , HowardBV . Incidence rates and predictors of diabetes in those with prediabetes: the strong heart study. Diabetes/metabolism Research and Reviews2010;26(5):378‐85. [PUBMED: 20578203] WangW , LeeET , FabsitzR , WeltyTK , HowardBV . Using HbA(1c) to improve efficacy of the American Diabetes Association fasting plasma glucose criterion in screening for new type 2 diabetes in American Indians: the strong heart study. Diabetes Care2002;25(8):1365‐70. WangW , LeeET , HowardBV , FabsitzRR , DevereuxRB , WeltyTK . Fasting plasma glucose and hemoglobin A1c in identifying and predicting diabetes: the strong heart study. Diabetes Care2011;34(2):363‐8. [PUBMED: 21270194] deSimoneG , DevereuxRB , ChinaliM , BestLG , LeeET , GallowayJM , et al. Prognostic impact of metabolic syndrome by different definitions in a population with high prevalence of obesity and diabetes: the strong heart study. Diabetes Care2007;30(7):1851‐6. ">Wang 2011</a>; <a href="./references#CD012661-bbs2-0100" title="WheelockKM , SinhaM , KnowlerWC , NelsonRG , FufaaGD , HansonRL . Metabolic risk factors and type 2 diabetes incidence in American Indian children. Journal of Clinical Endocrinology &amp; Metabolism2016;101(4):1437‐44. [PUBMED: 26913636] ">Wheelock 2016</a>), one included Mauritians (<a href="./references#CD012661-bbs2-0085" title="BoykoEJ , ShawJE , ZimmetPZ , ChitsonP , TuomilehtoJ , AlbertiKG . A prospective study of glycemia, body size, insulin resistance and the risk of hypertension in Mauritius. Journal of Hypertension2008;26(9):1742‐9. DowseGK , ZimmetPZ , GareebooH , GeorgeK , AlbertiMM , TuomilehtoJ , et al. Abdominal obesity and physical inactivity as risk factors for NIDDM and impaired glucose tolerance in Indian, Creole, and Chinese Mauritians. Diabetes Care1991;14(4):271‐82. ShawJA , ZimmetPZ , deCourtenM , DowseGK , ChitsonP , GareebooH , et al. Impaired fasting glucose or impaired glucose tolerance ‐ what best predicts future diabetes in Mauritius?. Diabetes Care1999;22(3):399‐402. [PUBMED: 10097917] SöderbergS , ZimmetP , TuomilehtoJ , CourtenM , DowseGK , ChitsonP , et al. High incidence of type 2 diabetes and increasing conversion rates from impaired fasting glucose and impaired glucose tolerance to diabetes in Mauritius. Journal of Internal Medicine2004;256(1):37‐47. [PUBMED: 15189364] SöderbergS , ZimmetP , TuomilehtoJ , deCourtenM , DowseGK , ChitsonP , et al. Increasing prevalence of type 2 diabetes mellitus in all ethnic groups in Mauritius. Diabetic Medicine2005;22(1):61‐8. WilliamsJW , ZimmetPZ , ShawJE , deCourtenMP , CameronAJ , ChitsonP , et al. Gender differences in the prevalence of impaired fasting glycaemia and impaired glucose tolerance in Mauritius. Does sex matter?. Diabetic Medicine2003;20(11):915‐20. ">Söderberg 2004</a>), and the remaining study included Nauruans (<a href="./references#CD012661-bbs2-0020" title='DowseGK , ZimmetPZ , CollinsVR . Insulin levels and the natural history of glucose intolerance in Nauruans. Diabetes1996;45(10):1367‐72. DowseGK , ZimmetPZ , CollinsVR . Insulin levels and the natural history of glucose intolerance in Nauruans. Diabetes1996;45(10):1367‐72. [PUBMED: 8826973] DowseGK , ZimmetPZ , FinchCF , CollinsVR . Decline in incidence of epidemic glucose intolerance in Nauruans: implications for the "thrifty genotype". American Journal of Epidemiology1991;133(11):1093‐104. [PUBMED: 2035513] KingH , ZimmetP , RaperLR , BalkauB . The natural history of impaired glucose tolerance in the Micronesian population of Nauru: a six‐year follow‐up study. Diabetologia1984;26(1):39‐43. [PUBMED: 6706044] SicreeRA , ZimmetPZ , KingHOM , CoventryJS . Plasma‐insulin response among Nauruans ‐ prediction of deterioration in glucose‐tolerance over 6‐yr. Diabetes1987;36(2):179‐86. [PUBMED: 3542644] '>Dowse 1991</a>). </p> <p>Six studies included black participants (<a href="./references#CD012661-bbs2-0001" title="AdmiraalWM , HollemanF , SnijderMB , PetersRJ , BrewsterLM , HoekstraJB , et al. Ethnic disparities in the association of impaired fasting glucose with the 10‐year cumulative incidence of type 2 diabetes. Diabetes Research and Clinical Practice2014;103(1):127‐32. [PUBMED: 24355200] AgyemangC , vanValkengoedI , van denBornB J , StronksK . Prevalence and determinants of prehypertension among African Surinamese, Hindustani Surinamese, and White Dutch in Amsterdam, the Netherlands: the SUNSET study. European Journal of Cardiovascular Prevention and Rehabilitation2007;14(6):775‐81. BindrabanNR , vanValkengoedIG , MairuhuG , HollemanF , HoekstraJB , MichelsBP , et al. Prevalence of diabetes mellitus and the performance of a risk score among Hindustani Surinamese, African Surinamese and ethnic Dutch: a cross‐sectional population‐based study. BMC Public Health2008;8:271. [PUBMED: 18673544] DekkerLH , NicolaouM , van derADl , BusschersWB , BrewsterLM , SnijderMB , et al. Sex differences in the association between serum ferritin and fasting glucose in type 2 diabetes among South Asian Surinamese, African Surinamese, and ethnic Dutch: the population‐based SUNSET study. Diabetes Care2013;36(4):965‐71. ">Admiraal 2014</a>; <a href="./references#CD012661-bbs2-0008" title="BergmanM , ChetritA , RothJ , JagannathanR , SevickM , DanknerR . One‐hour post‐load plasma glucose level during the OGTT predicts dysglycemia: observations from the 24year follow‐up of the Israel study of glucose intolerance, obesity and hypertension. Diabetes Research and Clinical Practice2016;120:221‐8. [PUBMED: 27596059] DanknerR , Abdul‐GhaniMA , GerberY , ChetritA , WainsteinJ , RazI . Predicting the 20‐year diabetes incidence rate. Diabetes/metabolism Research and Reviews2007;23(7):551‐8. [PUBMED: 17315136] ModanM , HalkinH , KarasikA , LuskyA . Effectiveness of glycosylated hemoglobin, fasting plasma glucose, and a single post load plasma glucose level in population screening for glucose intolerance. American Journal of Epidemiology1984;119(3):431‐44. [PUBMED: 6702817] ModanM , KarasikA , HalkinH , FuchsZ , LuskyA , ShitritA , et al. Effect of past and concurrent body mass index on prevalence of glucose intolerance and type 2 (non‐insulin‐dependent) diabetes and on insulin response. Diabetologia1986;29(2):82‐9. [PUBMED: 3516770] ">Bergman 2016</a>; <a href="./references#CD012661-bbs2-0029" title="FestaA , D'AgostinoRJr , HanleyAJ , KarterAJ , SaadMF , HaffnerSM . Differences in insulin resistance in nondiabetic subjects with isolated impaired glucose tolerance or isolated impaired fasting glucose. Diabetes2004;53(6):1549‐55. FestaA , D'AgostinoRJr , RichSS , JennyNS , TracyRP , HaffnerSM . Promoter (4G/5G) plasminogen activator inhibitor‐1 genotype and plasminogen activator inhibitor‐1 levels in blacks, Hispanics, and non‐Hispanic whites: the insulin resistance atherosclerosis study. Circulation2003;107(19):2422‐7. HaffnerSM , D'AgostinoRJr , GoffD , HowardB , FestaA , SaadMF , et al. LDL size in African Americans, Hispanics, and non‐Hispanic whites : the insulin resistance atherosclerosis study. Arteriosclerosis, Thrombosis, and Vascular Biology1999;19(9):2234‐40. HaffnerSM , D'AgostinoR , SaadMF , RewersM , MykkanenL , SelbyJ , et al. Increased insulin resistance and insulin secretion in nondiabetic African‐Americans and Hispanics compared with non‐Hispanic whites. The insulin resistance atherosclerosis study. Diabetes1996;45(6):742‐8. [PUBMED: 8635647] HaffnerSM , HowardG , MayerE , BergmanRN , SavagePJ , RewersM , et al. Insulin sensitivity and acute insulin response in African‐Americans, non‐Hispanic whites, and Hispanics with NIDDM: the insulin resistance atherosclerosis study. Diabetes1997;46(1):63‐9. HanleyAJ , D'AgostinoRBJr , WagenknechtLE , SaadMF , SavagePJ , BergmanR , et al. Increased proinsulin levels and decreased acute insulin response independently predict the incidence of type 2 diabetes in the insulin resistance atherosclerosis study. Diabetes2002;51(4):1263‐70. [PUBMED: 11916954] HanleyAJ , KarterAJ , WilliamsK , FestaA , D'AgostinoRBJr , WagenknechtLE , et al. Prediction of type 2 diabetes mellitus with alternative definitions of the metabolic syndrome: the insulin resistance atherosclerosis study. Circulation2005;112(24):3713‐21. [PUBMED: 16344402] HowardBV , Mayer‐DavisEJ , GoffD , ZaccaroDJ , LawsA , RobbinsDC , et al. Relationships between insulin resistance and lipoproteins in nondiabetic African Americans, Hispanics, and non‐Hispanic whites: the insulin resistance atherosclerosis study. Metabolism1998;47(10):1174‐9. KarterAJ , Mayer‐DavisEJ , SelbyJV , D'AgostinoRBJr , HaffnerSM , SholinskyP , et al. Insulin sensitivity and abdominal obesity in African‐American, Hispanic, and non‐Hispanic white men and women. The insulin resistance and atherosclerosis study. Diabetes1996;45(11):1547‐55. Mayer‐DavisEJ , LevinS , BergmanRN , D'AgostinoRBJr , KarterAJ , SaadMF , et al. Insulin secretion, obesity, and potential behavioral influences: results from the insulin resistance atherosclerosis study (IRAS). Diabetes/metabolism Research and Reviews2001;17(2):137‐45. Sanchez‐LugoL , Mayer‐DavisEJ , HowardG , SelbyJV , AyadMF , RewersM , et al. Insulin sensitivity and intake of vitamins E and C in African American, Hispanic, and non‐Hispanic white men and women: the insulin resistance and atherosclerosis study (IRAS). American Journal of Clinical Nutrition1997;66(5):1224‐31. WagenknechtLE , MayerEJ , RewersM , HaffnerS , SelbyJ , BorokGM , et al. The insulin resistance atherosclerosis study (IRAS) objectives, design, and recruitment results. Annals of Epidemiology1995;5(6):464‐72. [PUBMED: 8680609] ">Hanley 2005</a>; <a href="./references#CD012661-bbs2-0085" title="BoykoEJ , ShawJE , ZimmetPZ , ChitsonP , TuomilehtoJ , AlbertiKG . A prospective study of glycemia, body size, insulin resistance and the risk of hypertension in Mauritius. Journal of Hypertension2008;26(9):1742‐9. DowseGK , ZimmetPZ , GareebooH , GeorgeK , AlbertiMM , TuomilehtoJ , et al. Abdominal obesity and physical inactivity as risk factors for NIDDM and impaired glucose tolerance in Indian, Creole, and Chinese Mauritians. Diabetes Care1991;14(4):271‐82. ShawJA , ZimmetPZ , deCourtenM , DowseGK , ChitsonP , GareebooH , et al. Impaired fasting glucose or impaired glucose tolerance ‐ what best predicts future diabetes in Mauritius?. Diabetes Care1999;22(3):399‐402. [PUBMED: 10097917] SöderbergS , ZimmetP , TuomilehtoJ , CourtenM , DowseGK , ChitsonP , et al. High incidence of type 2 diabetes and increasing conversion rates from impaired fasting glucose and impaired glucose tolerance to diabetes in Mauritius. Journal of Internal Medicine2004;256(1):37‐47. [PUBMED: 15189364] SöderbergS , ZimmetP , TuomilehtoJ , deCourtenM , DowseGK , ChitsonP , et al. Increasing prevalence of type 2 diabetes mellitus in all ethnic groups in Mauritius. Diabetic Medicine2005;22(1):61‐8. WilliamsJW , ZimmetPZ , ShawJE , deCourtenMP , CameronAJ , ChitsonP , et al. Gender differences in the prevalence of impaired fasting glycaemia and impaired glucose tolerance in Mauritius. Does sex matter?. Diabetic Medicine2003;20(11):915‐20. ">Söderberg 2004</a>; <a href="./references#CD012661-bbs2-0097" title="LeongA , DayaN , PornealaB , DevlinJJ , ShiffmanD , McPhaulMJ , et al. Prediction of type 2 diabetes by hemoglobin A1c in two community‐based cohorts. Diabetes Care2018;41(1):60‐8. [PUBMED: 29074816] SchmidtMI , DuncanBB , BangH , PankowJS , BallantyneCM , GoldenSH , et al. Identifying individuals at high risk for diabetes ‐ the atherosclerosis risk in communities study. Diabetes Care2005;28(8):2013‐8. [PUBMED: 16043747] SelvinE , RawlingsAM , GramsM , KleinR , SharrettAR , SteffesM , et al. Fructosamine and glycated albumin for risk stratification and prediction of incident diabetes and microvascular complications: a prospective cohort analysis of the atherosclerosis risk in communities (ARIC) study. Lancet Diabetes &amp; Endocrinology2014;2(4):279‐88. [PUBMED: 24703046] SelvinE , SteffesM W , GreggE , BrancatiF L , CoreshJ . Performance of A1C for the classification and prediction of diabetes. Diabetes Care2011;34(1):84‐9. [PUBMED: 20855549] SelvinE , SteffesMW , ZhuH , MatsushitaK , WagenknechtL , PankowJ , et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. New England Journal of Medicine2010;362(9):800‐11. [PUBMED: 20200384] WarrenB , PankowJ S , MatsushitaK , PunjabiNM , DayaNR , GramsM , et al. Comparative prognostic performance of definitions of prediabetes: a prospective cohort analysis of the atherosclerosis risk in communities (ARIC) study. Lancet Diabetes &amp; Endocrinology2017;5(1):34‐42. [PUBMED: 27863979] WheltonSP , McEvoyJW , LazoM , CoreshJ , BallantyneCM , SelvinE . High‐sensitivity cardiac troponin T (hs‐cTnT) as a predictor of incident diabetes in the atherosclerosis risk in communities study. Diabetes Care2017;40(2):261‐9. [PUBMED: 28108537] ">Warren 2017</a>; <a href="./references#CD012661-bbs2-0102" title="BildDE , BluemkeDA , BurkeGL , DetranoR , Diez RouxAV , FolsomAR , et al. Multi‐ethnic study of atherosclerosis: objectives and design. American Journal of Epidemiology2002;156(9):871‐81. [PUBMED: 12397006] YeboahJ , BertoniA G , HerringtonDM , PostWS , BurkeGL . Impaired fasting glucose and the risk of incident diabetes mellitus and cardiovascular events in an adult population: MESA (multi‐ethnic study of atherosclerosis). Journal of the American College of Cardiology2011;58(2):140‐6. [PUBMED: 21718910] ">Yeboah 2011</a>), representing 25% to 47% of all participants in these studies. </p> <p>Six studies included children, adolescents or both as participants (<a href="./references#CD012661-bbs2-0033" title="JaruratanasirikulS , ThammaratchuchaiS , PuwanantM , Mo‐SuwanL , SriplungH . Progression from impaired glucose tolerance to type 2 diabetes in obese children and adolescents: a 3‐6‐year cohort study in southern Thailand. Journal of Pediatric Endocrinology &amp; Metabolism2016;29(11):1267‐75. [PUBMED: 27740930] ">Jaruratanasirikul 2016</a>; <a href="./references#CD012661-bbs2-0040" title="KleberM , LassN , PapckeS , WabitschM , ReinehrT . One‐year follow‐up of untreated obese white children and adolescents with impaired glucose tolerance: high conversion rate to normal glucose tolerance. Diabetic Medicine2010;27(5):516‐21. [PUBMED: 20536946] ">Kleber 2010</a>; <a href="./references#CD012661-bbs2-0041" title="KleberM , deSousaG , PapckeS , WabitschM , ReinehrT . Impaired glucose tolerance in obese white children and adolescents: three to five year follow‐up in untreated patients. Experimental and Clinical Endocrinology &amp; Diabetes2011;119(3):172‐6. [PUBMED: 20827664] ">Kleber 2011</a>; <a href="./references#CD012661-bbs2-0093" title="VijayakumarP , NelsonR G , HansonR L , KnowlerW C , SinhaM . HbA1c and the prediction of type 2 diabetes in children and adults. Diabetes Care2017;40(1):16‐21. [PUBMED: 27810987] ">Vijayakumar 2017</a>; <a href="./references#CD012661-bbs2-0099" title="WeissR , DziuraJ , BurgertTS , TamborlaneWV , TaksaliSE , YeckelCW , et al. Obesity and the metabolic syndrome in children and adolescents. New England Journal of Medicine2004;350(23):2362‐74. [PUBMED: 15175438] WeissR , TaksaliSE , TamborlaneWV , BurgertTS , SavoyeM , CaprioS . Predictors of changes in glucose tolerance status in obese youth. Diabetes Care2005;28(4):902‐9. [PUBMED: 15793193] ">Weiss 2005</a>; <a href="./references#CD012661-bbs2-0100" title="WheelockKM , SinhaM , KnowlerWC , NelsonRG , FufaaGD , HansonRL . Metabolic risk factors and type 2 diabetes incidence in American Indian children. Journal of Clinical Endocrinology &amp; Metabolism2016;101(4):1437‐44. [PUBMED: 26913636] ">Wheelock 2016</a>). </p> </section> <section id="CD012661-sec-0070"> <h5 class="title">Measurement of the development of T2DM</h5> <p>Almost all studies combined criteria to define incident T2DM, using indicators such as FPG of 7.0 mmol/L or more, two‐hour postload glucose level of 11.1 mmol/L or more, HbA1c of 6.5% or more, receipt of antidiabetic medication, physician diagnosis or self‐report. </p> <p>Of the 103 included studies, 64 included FPG of 7.0 mmol/L or more, and 52, two‐hour postload glucose level of 11.1 mmol/L or more, in their definition of incident T2DM. Eighteen studies used HbA1c as part of the definition of T2DM, typically an HbA1c level of 6.5% or more. One study defined T2DM incidence based only on an HbA1c level of 6.5% or more (<a href="./references#CD012661-bbs2-0047" title="LeeJH , LimJT , KimHG , OhMK , LeeWJ . Effect of coffee consumption on the progression of type 2 diabetes mellitus among prediabetic individuals. Korean Journal of Family Medicine2016;37(1):7‐13. [PUBMED: 26885316] ">Lee 2016</a>). In 34 studies, antidiabetic treatment comprised part of the definition of T2DM, and in 15 studies physician diagnosis or self‐report was part of the T2DM incidence definition. </p> </section> </section> <section id="CD012661-sec-0071"> <h4 class="title">Risk of bias in included studies</h4> <p>For details on the QUIPS tool and the risk of bias of the included studies see <a href="./appendices#CD012661-sec-0138">Appendix 3</a> and <a href="./references#CD012661-sec-0161" title="">Characteristics of included studies</a>. The results are summarised below separately for studies that provided data on overall prognosis for people with IH and on IH versus normoglycaemia as a prognostic factor. </p> <section id="CD012661-sec-0072"> <h5 class="title">a) Overall prognosis of people with IH for the development of T2DM and b) regression from IH to normoglycaemia </h5> <p>There were 93 studies providing data on cumulative incidence. <a href="#CD012661-fig-0002">Figure 2</a> summarises the risk of bias results across all studies, while the results for each study are shown in <a href="#CD012661-fig-0003">Figure 3</a> and <a href="#CD012661-fig-0004">Figure 4</a> (split into two figures because of the large number of studies). We evaluated the first four risk of bias domains (i.e. study participation, study attrition, glycaemic status measurement, outcome measurement) of the QUIPS tool. </p> <div class="figure" id="CD012661-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph for studies of overall prognosis of people with intermediate hyperglycaemia for developing type 2 diabetes: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD012661-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph for studies of overall prognosis of people with intermediate hyperglycaemia for developing type 2 diabetes: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> </div> <div class="figure" id="CD012661-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' summary for studies of overall prognosis in people with intermediate hyperglycaemia for developing type 2 diabetes: review authors' judgements about each risk of bias item for each included study (part 1). The summary was split into part 1 () and part 2 () for better legibility" data-id="CD012661-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary for studies of overall prognosis in people with intermediate hyperglycaemia for developing type 2 diabetes: review authors' judgements about each risk of bias item for each included study (part 1). The summary was split into part 1 (<a href="#CD012661-fig-0003">Figure 3</a>) and part 2 (<a href="#CD012661-fig-0004">Figure 4</a>) for better legibility </p> </div> </div> </div> <div class="figure" id="CD012661-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Risk of bias summary for studies of overall prognosis of people with intermediate hyperglycaemia for developing type 2 diabetes: review authors' judgements about each risk of bias item for each included study (part 2)" data-id="CD012661-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary for studies of overall prognosis of people with intermediate hyperglycaemia for developing type 2 diabetes: review authors' judgements about each risk of bias item for each included study (part 2) </p> </div> </div> </div> <section id="CD012661-sec-0073"> <h6 class="title">Study participation</h6> <p>Study authors described the five items in this domain sufficiently in most (65 studies; 70%) included studies. Eleven studies did not adequately characterise the sampling frame and/or recruitment procedures (<a href="./references#CD012661-bbs2-0005" title="BaeJC , RheeEJ , LeeWY , ParkSE , ParkCY , OhKW , et al. Combined effect of nonalcoholic fatty liver disease and impaired fasting glucose on the development of type 2 diabetes: a 4‐year retrospective longitudinal study. Diabetes Care2011;34(3):727‐9. [PUBMED: 21278140] BaeJC , RheeEJ , LeeWY , ParkSE , ParkCY , OhKW , et al. Optimal range of HbA1c for the prediction of future diabetes: a 4‐year longitudinal study. Diabetes Research and Clinical Practice2011;93(2):255‐9. [PUBMED: 21676480] ">Bae 2011</a>; <a href="./references#CD012661-bbs2-0006" title="Baena‐DiezJM , Bermudez‐ChillidaN , MundetX , delVal‐GarciaJL , MunozMA , SchroderH . Impaired fasting glucose and risk of diabetes mellitus at 10 years. Cohort study. Medicina Clinica2011;136(9):382‐5. [PUBMED: 21300382] ">Baena‐Diez 2011</a>; <a href="./references#CD012661-bbs2-0025" title="BalkauB , LangeC , FezeuL , TichetJ , deLauzon‐GuillainB , CzernichowS , et al. Predicting diabetes: clinical, biological, and genetic approaches: data from the epidemiological study on the insulin resistance syndrome (DESIR). Diabetes Care2008;31(10):2056‐61. [PUBMED: 18689695] DroumaguetC , BalkauB , SimonD , CacesE , TichetJ , CharlesMA , et al. Use of HbA1c in predicting progression to diabetes in French men and women: data from an epidemiological study on the insulin resistance syndrome (DESIR). Diabetes Care2006;29(7):1619‐25. [PUBMED: 16801588] GautierA , RousselR , DucluzeauPH , LangeC , VolS , BalkauB , et al. Increases in waist circumference and weight as predictors of type 2 diabetes in individuals with impaired fasting glucose: influence of baseline BMI. Data from the DESIR study. Diabetes Care2010;33(8):1850‐2. [PUBMED: 20484131] SoulimaneS , SimonD , ShawJ , WitteD , ZimmetP , VolS , et al. HbA1c, fasting plasma glucose and the prediction of diabetes: Inter99, AusDiab and D.E.S.I.R. Diabetes Research and Clinical Practice2012;96(3):392‐9. [PUBMED: 21741107] SoulimaneS , SimonD , ShawJE , ZimmetPZ , VolS , VistisenD , et al. Comparing incident diabetes as defined by fasting plasma glucose or by HbA(1c). The AusDiab, Inter99 and DESIR studies. Diabetic Medicine2011;28(11):1311‐8. [PUBMED: 21824186] ">Gautier 2010</a>; <a href="./references#CD012661-bbs2-0027" title="Guerrero‐RomerF , Rodriguez‐MoranM , Gonzalez‐OrtizM , Martinez‐AbundisE . Insulin action and secretion in healthy Hispanic‐Mexican first‐degree relatives of subjects with type 2 diabetes. Journal of Endocrinological Investigation2001;24:580‐6. [PUBMED: 11686540] Guerrero‐RomeroF , Rodriguez‐MoranM . Assessing progression to impaired glucose tolerance and type 2 diabetes mellitus. European Journal of Clinical Investigation2006;36(11):796‐802. [PUBMED: 17032347] Rodriguez‐MoranM , Guerrero‐RomeroF . Hyperinsulinemia and abdominal obesity are more prevalent in non‐diabetic subjects with family history of type 2 diabetes. Archives of Medical Research2000;31:399‐403. [PUBMED: 11068083] ">Guerrero‐Romero 2006</a>; <a href="./references#CD012661-bbs2-0031" title="InoueI , TakahashiK , KatayamaS , HaradaY , NegishiK , IshiiJ , et al. A higher proinsulin response to glucose loading predicts deteriorating fasting plasma glucose and worsening to diabetes in subjects with impaired glucose tolerance. Diabetoc Medicine1996;13(4):330‐6. [PUBMED: 9162608] ">Inoue 1996</a>; <a href="./references#CD012661-bbs2-0042" title="KoGT , ChanJC , LauE , WooJ , CockramCS . Fasting plasma glucose as a screening test for diabetes and its relationship with cardiovascular risk factors in Hong Kong Chinese. Diabetes Care1997;20(2):170‐2. KoGT , LiJK , CheungAY , YeungVT , ChowCC , TsangLW , et al. Two‐hour post‐glucose loading plasma glucose is the main determinant for the progression from impaired glucose tolerance to diabetes in Hong Kong Chinese. Diabetes Care1999;22(12):2096‐7. [PUBMED: 10587859] ">Ko 1999</a>; <a href="./references#CD012661-bbs2-0062" title="BergstromRW , Newell‐MorrisLL , LeonettiDL , ShumanWP , WahlPW , FujimotoWY . Association of elevated fasting C‐peptide level and increased intra‐abdominal fat distribution with development of NIDDM in Japanese‐American men. Diabetes1990;39(1):104‐11. FujimotoWY , BergstromRW , BoykoEJ , KinyounJL , LeonettiDL , Newell‐MorrisLL , et al. Diabetes and diabetes risk factors in second‐ and third‐generation Japanese Americans in Seattle, Washington. Diabetes Research and Clinical Practice1994;24(Suppl):S43‐52. [PUBMED: 7859632] FujimotoWY , BergstromRW , Newell‐MorrisL , LeonettiD L . Nature and nurture in the etiology of type 2 diabetes mellitus in Japanese Americans. Diabetes/metabolism Reviews1989;5(7):607‐25. [PUBMED: 2689122] KahnSE , LeonettiDL , PrigeonRL , BoykoEJ , BergstomRW , FujimotoWY . Proinsulin levels predict the development of non‐insulin‐dependent diabetes mellitus (NIDDM) in Japanese‐American men. Diabetic Medicine1996;13(9 Suppl 6):S63‐6. [PUBMED: 8894485] KahnSE , LeonettiDL , PrigeonRL , BoykoEJ , BergstromRW , FujimotoWY . Proinsulin as a marker for the development of NIDDM in Japanese‐American men. Diabetes1995;44(2):173‐9. McNeelyMJ , BoykoEJ , LeonettiDL , KahnSE , FujimotoWY . Comparison of a clinical model, the oral glucose tolerance test, and fasting glucose for prediction of type 2 diabetes risk in Japanese Americans. Diabetes Care2003;26(3):758‐63. [PUBMED: 12610034] RodriguezBL , AbbottRD , FujimotoW , WaitzfelderB , ChenR , MasakiK , et al. The American Diabetes Association and World Health Organization classifications for diabetes ‐ their impact on diabetes prevalence and total and cardiovascular disease mortality in elderly Japanese‐American men. Diabetes Care2002;25(6):951‐5. [PUBMED: 12032097] ">McNeely 2003</a>; <a href="./references#CD012661-bbs2-0075" title="RamachandranA , SnehalathaC , NaikRA , MohanV , ShobanaR , ViswanathanM . Significance of impaired glucose tolerance in an Asian Indian population: a follow‐up study. Diabetes Research and Clinical Practice1986;2(3):173‐8. [PUBMED: 3527626] ">Ramachandran 1986</a>; <a href="./references#CD012661-bbs2-0082" title="KatonaG , AganovicI , VuksanV , SkrabaloZ . National Diabetes Programme in Malta: Phase I and II Final Report. Valletta: WHO, 1983. SchranzAG . Abnormal glucose tolerance in the Maltese. A population‐based longitudinal study of the natural history of NIDDM and IGT in Malta. Diabetes Research and Clinical Practice1989;7(1):7‐16. [PUBMED: 2752891] ">Schranz 1989</a>; <a href="./references#CD012661-bbs2-0094" title="ViswanathanV , ClementinaM , NairBM , SatyavaniK . Risk of future diabetes is as high with abnormal intermediate post‐glucose response as with impaired glucose tolerance. Journal of the Association of Physicians of India2007;55:833‐7. [PUBMED: 18405128] ">Viswanathan 2007</a>; <a href="./references#CD012661-bbs2-0099" title="WeissR , DziuraJ , BurgertTS , TamborlaneWV , TaksaliSE , YeckelCW , et al. Obesity and the metabolic syndrome in children and adolescents. New England Journal of Medicine2004;350(23):2362‐74. [PUBMED: 15175438] WeissR , TaksaliSE , TamborlaneWV , BurgertTS , SavoyeM , CaprioS . Predictors of changes in glucose tolerance status in obese youth. Diabetes Care2005;28(4):902‐9. [PUBMED: 15793193] ">Weiss 2005</a>). One study was at high risk of bias for the item 'description of the source population or population of interest' (<a href="./references#CD012661-bbs2-0075" title="RamachandranA , SnehalathaC , NaikRA , MohanV , ShobanaR , ViswanathanM . Significance of impaired glucose tolerance in an Asian Indian population: a follow‐up study. Diabetes Research and Clinical Practice1986;2(3):173‐8. [PUBMED: 3527626] ">Ramachandran 1986</a>). </p> </section> <section id="CD012661-sec-0074"> <h6 class="title">Study attrition</h6> <p>Forty‐eight studies attempted to collect information on participants who were lost to follow‐up, while 40 studies were at unclear risk of bias and five studies were at high risk of bias (<a href="./references#CD012661-bbs2-0003" title="AjlouniK , JaddouH , BatiehaA . Obesity in Jordan. International Journal of Obesity and Related Metabolic Disorders1998;22(7):624‐8. [PUBMED: 9705020] AmmariF , BatiehaA , JaddouPH , OkashiM , AjlouniK . A natural history of impaired glucose tolerance in North Jordan. Practical Diabetes International1998;15(5):139‐40. ">Ammari 1998</a>; <a href="./references#CD012661-bbs2-0007" title="BaiPV , KrishnaswamiCV , ChellamariappanM . Prevalence and incidence of type‐2 diabetes and impaired glucose tolerance in a selected Indian urban population. Journal of the Association of Physicians of India1999;47(11):1060‐4. [PUBMED: 10862313] ">Bai 1999</a>; <a href="./references#CD012661-bbs2-0012" title="BalkauB , ForhanA , EschwegeE . Two hour plasma glucose is not unequivocally predictive for early death in men with impaired fasting glucose: more results from the Paris prospective study. Diabetologia2002;45(9):1224‐30. CharlesMA , EschwegeE , ThibultN , ClaudeJR , WarnetJM , RosselinGE , et al. The role of non‐esterified fatty acids in the deterioration of glucose tolerance in Caucasian subjects: results of the Paris prospective study. Diabetologia1997;40(9):1101‐6. [PUBMED: 9300248] CharlesMA , FontbonneA , ThibultN , WarnetJM , RosselinGE , EschwegeE . Risk factors for NIDDM in white population. Paris prospective study. Diabetes1991;40(7):796‐9. [PUBMED: 2060716] EschwegeE , CharlesMA , SimonD , ThibultN , BalkauB . From policemen to policies: what is the future for 2‐h glucose? The Kelly West lecture, 2000. Diabetes Care2001;24(11):1945‐50. EschwegeE , CharlesMA , SimonD , ThibultN , BalkauB . Reproducibility of the diagnosis of diabetes over a 30‐month follow‐up: the Paris prospective study. Diabetes Care2001;24(11):1941‐4. [PUBMED: 11679461] ">Charles 1997</a>; <a href="./references#CD012661-bbs2-0025" title="BalkauB , LangeC , FezeuL , TichetJ , deLauzon‐GuillainB , CzernichowS , et al. Predicting diabetes: clinical, biological, and genetic approaches: data from the epidemiological study on the insulin resistance syndrome (DESIR). Diabetes Care2008;31(10):2056‐61. [PUBMED: 18689695] DroumaguetC , BalkauB , SimonD , CacesE , TichetJ , CharlesMA , et al. Use of HbA1c in predicting progression to diabetes in French men and women: data from an epidemiological study on the insulin resistance syndrome (DESIR). Diabetes Care2006;29(7):1619‐25. [PUBMED: 16801588] GautierA , RousselR , DucluzeauPH , LangeC , VolS , BalkauB , et al. Increases in waist circumference and weight as predictors of type 2 diabetes in individuals with impaired fasting glucose: influence of baseline BMI. Data from the DESIR study. Diabetes Care2010;33(8):1850‐2. [PUBMED: 20484131] SoulimaneS , SimonD , ShawJ , WitteD , ZimmetP , VolS , et al. HbA1c, fasting plasma glucose and the prediction of diabetes: Inter99, AusDiab and D.E.S.I.R. Diabetes Research and Clinical Practice2012;96(3):392‐9. [PUBMED: 21741107] SoulimaneS , SimonD , ShawJE , ZimmetPZ , VolS , VistisenD , et al. Comparing incident diabetes as defined by fasting plasma glucose or by HbA(1c). The AusDiab, Inter99 and DESIR studies. Diabetic Medicine2011;28(11):1311‐8. [PUBMED: 21824186] ">Gautier 2010</a>; <a href="./references#CD012661-bbs2-0063" title="BlakeDR , MeigsJB , MullerDC , NajjarSS , AndresR , NathanDM . Impaired glucose tolerance, but not impaired fasting glucose, is associated with increased levels of coronary heart disease risk factors: results from the Baltimore longitudinal study on aging. Diabetes2004;53(8):2095‐100. MeigsJB , MullerDC , NathanDM , BlakeDR , AndresR . The natural history of progression from normal glucose tolerance to type 2 diabetes in the Baltimore longitudinal study of aging. Diabetes2003;52(6):1475‐84. [PUBMED: 12765960] RodriguezA , MullerDC , EngelhardtM , AndresR . Contribution of impaired glucose tolerance in subjects with the metabolic syndrome: Baltimore longitudinal study of aging. Metabolism2005;54(4):542‐7. ShockNW , GreulichRC , ArembergD , CostaPT , LakattaEG , TobinJD . Normal human aging: the Baltimore longitudinal study of aging. Washington, DC: U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health, National Institute on Aging, Gerontology Research Center, Baltimore City Hospitals; 1984. Report No.: NIH‐84‐2450. SorkinJD , MullerDC , FlegJL , AndresR . The relation of fasting and 2‐h postchallenge plasma glucose concentrations to mortality: data from the Baltimore longitudinal study of aging with a critical review of the literature. Diabetes Care2005;28(11):2626‐32. ">Meigs 2003</a>). </p> <p>In most (61 studies; 66%) of the studies we could not identify the reasons for loss to follow‐up or adequate descriptions of these participants. Five studies were at high risk of bias for one or both of the items (<a href="./references#CD012661-bbs2-0004" title="AnjanaRM , Shanthi RaniCS , DeepaM , PradeepaR , SudhaV , Divya NairH , et al. Incidence of diabetes and prediabetes and predictors of progression among Asian Indians: 10‐year follow‐up of the Chennai urban rural epidemiology study (CURES). Diabetes Care2015;38(8):1441‐8. [PUBMED: 25906786] DeepaM , PradeepaR , RemaM , MohanA , DeepaR , ShanthiraniS , et al. The Chennai urban rural epidemiology study (CURES) ‐ study design and methodology (urban component) (CURES‐I). Journal of the Association of Physicians of India2003;51:863‐70. [PUBMED: 14710970] MohanD , RajD , ShanthiraniCS , DattaM , UnwinNC , KapurA , et al. Awareness and knowledge of diabetes in Chennai ‐ the Chennai urban rural epidemiology study [CURES‐9]. Journal of the Association of Physicians of India2005;53:283‐7. MohanV , DeepaM , FarooqS , DattaM , DeepaR . Prevalence, awareness and control of hypertension in Chennai ‐ the Chennai urban rural epidemiology study (CURES‐52). Journal of the Association of Physicians of India2007;55:326‐32. MohanV , DeepaR , PradeepaR , VimaleswaranKS , MohanA , VelmuruganK , et al. Association of low adiponectin levels with the metabolic syndrome ‐ the Chennai urban rural epidemiology study (CURES‐4). Metabolism2005;54(4):476‐81. MohanV , SandeepS , DeepaM , GokulakrishnanK , DattaM , DeepaR . A diabetes risk score helps identify metabolic syndrome and cardiovascular risk in Indians ‐ the Chennai urban rural epidemiology study (CURES‐38). Diabetes, Obesity &amp; Metabolism2007;9(3):337‐43. RadhikaG , SathyaRM , SudhaV , GanesanA , MohanV . Dietary salt intake and hypertension in an urban south Indian population ‐ [CURES ‐ 53]. Journal of the Association of Physicians of India2007;55:405‐11. ">Anjana 2015</a>; <a href="./references#CD012661-bbs2-0007" title="BaiPV , KrishnaswamiCV , ChellamariappanM . Prevalence and incidence of type‐2 diabetes and impaired glucose tolerance in a selected Indian urban population. Journal of the Association of Physicians of India1999;47(11):1060‐4. [PUBMED: 10862313] ">Bai 1999</a>; <a href="./references#CD012661-bbs2-0009" title="BonoraE , KiechlS , MayrA , ZoppiniG , TargherG , BonadonnaRC , et al. High‐normal HbA1c is a strong predictor of type 2 diabetes in the general population. Diabetes Care2011;34(4):1038‐40. [PUBMED: 21307378] BonoraE , KiechlS , WilleitJ , OberhollenzerF , EggerG , MeigsJB , et al. Insulin resistance as estimated by homeostasis model assessment predicts incident symptomatic cardiovascular disease in Caucasian subjects from the general population: the Bruneck study. Diabetes Care2007;30(2):318‐24. BonoraE , KiechlS , WilleitJ , OberhollenzerF , EggerG , MeigsJB , et al. Population‐based incidence rates and risk factors for type 2 diabetes in white individuals: the Bruneck study. Diabetes2004;53(7):1782‐9. [PUBMED: 15220202] ">Bonora 2011</a>; <a href="./references#CD012661-bbs2-0012" title="BalkauB , ForhanA , EschwegeE . Two hour plasma glucose is not unequivocally predictive for early death in men with impaired fasting glucose: more results from the Paris prospective study. Diabetologia2002;45(9):1224‐30. CharlesMA , EschwegeE , ThibultN , ClaudeJR , WarnetJM , RosselinGE , et al. The role of non‐esterified fatty acids in the deterioration of glucose tolerance in Caucasian subjects: results of the Paris prospective study. Diabetologia1997;40(9):1101‐6. [PUBMED: 9300248] CharlesMA , FontbonneA , ThibultN , WarnetJM , RosselinGE , EschwegeE . Risk factors for NIDDM in white population. Paris prospective study. Diabetes1991;40(7):796‐9. [PUBMED: 2060716] EschwegeE , CharlesMA , SimonD , ThibultN , BalkauB . From policemen to policies: what is the future for 2‐h glucose? The Kelly West lecture, 2000. Diabetes Care2001;24(11):1945‐50. EschwegeE , CharlesMA , SimonD , ThibultN , BalkauB . Reproducibility of the diagnosis of diabetes over a 30‐month follow‐up: the Paris prospective study. Diabetes Care2001;24(11):1941‐4. [PUBMED: 11679461] ">Charles 1997</a>; <a href="./references#CD012661-bbs2-0033" title="JaruratanasirikulS , ThammaratchuchaiS , PuwanantM , Mo‐SuwanL , SriplungH . Progression from impaired glucose tolerance to type 2 diabetes in obese children and adolescents: a 3‐6‐year cohort study in southern Thailand. Journal of Pediatric Endocrinology &amp; Metabolism2016;29(11):1267‐75. [PUBMED: 27740930] ">Jaruratanasirikul 2016</a>). </p> <p>Only 23 studies (25%) provided information on potentially important differences between participants who completed the studies and those who did not. </p> </section> <section id="CD012661-sec-0075"> <h6 class="title">Glycaemic status measurement</h6> <p>Study authors described these items sufficiently in 85 studies (91%). One study did not describe three of the four items ('clear definition of the outcome provided', 'adequately valid and reliable method of measurement', and 'continuous variables reported or appropriate cut points used') in enough detail (<a href="./references#CD012661-bbs2-0084" title="ParkY , LeeH , KohCS , MinH , YooK , KimY , et al. Prevalence of diabetes and IGT in Yonchon county, South Korea. Diabetes Care1995;18:545‐8. [PUBMED: 7497867] ShinCS , LeeHK , KohCS , KimYI , ShinYS , YooKY , et al. Risk factors for the development of NIDDM in Yonchon county, Korea. Diabetes Care1997;20(12):1842‐6. [PUBMED: 9405904] ">Shin 1997</a>). </p> </section> <section id="CD012661-sec-0076"> <h6 class="title">Outcome measurement</h6> <p>Study authors described the three items sufficiently in 89 studies (96%). One study was at high risk of bias for the item 'provision of clear definition of the outcome' (<a href="./references#CD012661-bbs2-0029" title="FestaA , D'AgostinoRJr , HanleyAJ , KarterAJ , SaadMF , HaffnerSM . Differences in insulin resistance in nondiabetic subjects with isolated impaired glucose tolerance or isolated impaired fasting glucose. Diabetes2004;53(6):1549‐55. FestaA , D'AgostinoRJr , RichSS , JennyNS , TracyRP , HaffnerSM . Promoter (4G/5G) plasminogen activator inhibitor‐1 genotype and plasminogen activator inhibitor‐1 levels in blacks, Hispanics, and non‐Hispanic whites: the insulin resistance atherosclerosis study. Circulation2003;107(19):2422‐7. HaffnerSM , D'AgostinoRJr , GoffD , HowardB , FestaA , SaadMF , et al. LDL size in African Americans, Hispanics, and non‐Hispanic whites : the insulin resistance atherosclerosis study. Arteriosclerosis, Thrombosis, and Vascular Biology1999;19(9):2234‐40. HaffnerSM , D'AgostinoR , SaadMF , RewersM , MykkanenL , SelbyJ , et al. Increased insulin resistance and insulin secretion in nondiabetic African‐Americans and Hispanics compared with non‐Hispanic whites. The insulin resistance atherosclerosis study. Diabetes1996;45(6):742‐8. [PUBMED: 8635647] HaffnerSM , HowardG , MayerE , BergmanRN , SavagePJ , RewersM , et al. Insulin sensitivity and acute insulin response in African‐Americans, non‐Hispanic whites, and Hispanics with NIDDM: the insulin resistance atherosclerosis study. Diabetes1997;46(1):63‐9. HanleyAJ , D'AgostinoRBJr , WagenknechtLE , SaadMF , SavagePJ , BergmanR , et al. Increased proinsulin levels and decreased acute insulin response independently predict the incidence of type 2 diabetes in the insulin resistance atherosclerosis study. Diabetes2002;51(4):1263‐70. [PUBMED: 11916954] HanleyAJ , KarterAJ , WilliamsK , FestaA , D'AgostinoRBJr , WagenknechtLE , et al. Prediction of type 2 diabetes mellitus with alternative definitions of the metabolic syndrome: the insulin resistance atherosclerosis study. Circulation2005;112(24):3713‐21. [PUBMED: 16344402] HowardBV , Mayer‐DavisEJ , GoffD , ZaccaroDJ , LawsA , RobbinsDC , et al. Relationships between insulin resistance and lipoproteins in nondiabetic African Americans, Hispanics, and non‐Hispanic whites: the insulin resistance atherosclerosis study. Metabolism1998;47(10):1174‐9. KarterAJ , Mayer‐DavisEJ , SelbyJV , D'AgostinoRBJr , HaffnerSM , SholinskyP , et al. Insulin sensitivity and abdominal obesity in African‐American, Hispanic, and non‐Hispanic white men and women. The insulin resistance and atherosclerosis study. Diabetes1996;45(11):1547‐55. Mayer‐DavisEJ , LevinS , BergmanRN , D'AgostinoRBJr , KarterAJ , SaadMF , et al. Insulin secretion, obesity, and potential behavioral influences: results from the insulin resistance atherosclerosis study (IRAS). Diabetes/metabolism Research and Reviews2001;17(2):137‐45. Sanchez‐LugoL , Mayer‐DavisEJ , HowardG , SelbyJV , AyadMF , RewersM , et al. Insulin sensitivity and intake of vitamins E and C in African American, Hispanic, and non‐Hispanic white men and women: the insulin resistance and atherosclerosis study (IRAS). American Journal of Clinical Nutrition1997;66(5):1224‐31. WagenknechtLE , MayerEJ , RewersM , HaffnerS , SelbyJ , BorokGM , et al. The insulin resistance atherosclerosis study (IRAS) objectives, design, and recruitment results. Annals of Epidemiology1995;5(6):464‐72. [PUBMED: 8680609] ">Hanley 2005</a>). </p> </section> </section> <section id="CD012661-sec-0077"> <h5 class="title">c) Development of T2DM in people with IH as compared to people with normoglycaemia</h5> <p>There were 52 studies comparing IH with normoglycaemia as a prognostic factor for T2DM. <a href="#CD012661-fig-0005">Figure 5</a> shows the results for the six domains summarised across studies, and the result for each study is shown in <a href="#CD012661-fig-0006">Figure 6</a>. </p> <div class="figure" id="CD012661-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Risk of bias graph for studies of intermediate hyperglycaemia versus normoglycaemia as a prognostic factor for developing type 2 diabetes: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD012661-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph for studies of intermediate hyperglycaemia versus normoglycaemia as a prognostic factor for developing type 2 diabetes: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> </div> <div class="figure" id="CD012661-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Risk of bias summary for studies of intermediate hyperglycaemia versus normoglycaemia as a prognostic factor for developing type 2 diabetes: review authors' judgements about each risk of bias item for each included study" data-id="CD012661-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary for studies of intermediate hyperglycaemia versus normoglycaemia as a prognostic factor for developing type 2 diabetes: review authors' judgements about each risk of bias item for each included study </p> </div> </div> </div> <p>Fourteen studies provided data on multivariable HRs of T2DM incidence, adjusted for 2 to 13 covariates (<a href="./references#CD012661-bbs2-0005" title="BaeJC , RheeEJ , LeeWY , ParkSE , ParkCY , OhKW , et al. Combined effect of nonalcoholic fatty liver disease and impaired fasting glucose on the development of type 2 diabetes: a 4‐year retrospective longitudinal study. Diabetes Care2011;34(3):727‐9. [PUBMED: 21278140] BaeJC , RheeEJ , LeeWY , ParkSE , ParkCY , OhKW , et al. Optimal range of HbA1c for the prediction of future diabetes: a 4‐year longitudinal study. Diabetes Research and Clinical Practice2011;93(2):255‐9. [PUBMED: 21676480] ">Bae 2011</a>; <a href="./references#CD012661-bbs2-0009" title="BonoraE , KiechlS , MayrA , ZoppiniG , TargherG , BonadonnaRC , et al. High‐normal HbA1c is a strong predictor of type 2 diabetes in the general population. Diabetes Care2011;34(4):1038‐40. [PUBMED: 21307378] BonoraE , KiechlS , WilleitJ , OberhollenzerF , EggerG , MeigsJB , et al. Insulin resistance as estimated by homeostasis model assessment predicts incident symptomatic cardiovascular disease in Caucasian subjects from the general population: the Bruneck study. Diabetes Care2007;30(2):318‐24. BonoraE , KiechlS , WilleitJ , OberhollenzerF , EggerG , MeigsJB , et al. Population‐based incidence rates and risk factors for type 2 diabetes in white individuals: the Bruneck study. Diabetes2004;53(7):1782‐9. [PUBMED: 15220202] ">Bonora 2011</a>; <a href="./references#CD012661-bbs2-0023" title="ForouhiNG , LuanJ , HenningsS , WarehamNJ . Incidence of type 2 diabetes in England and its association with baseline impaired fasting glucose: the Ely study 1990‐2000. Diabetic Medicine2007;24(2):200‐7. [PUBMED: 17257284] SimmonsRK , RahmanM , JakesRW , YuyunMF , NiggebruggeAR , HenningsSH , et al. Effect of population screening for type 2 diabetes on mortality: long‐term follow‐up of the Ely cohort. Diabetologia2011;54:312‐9. [PUBMED: 20978739] WarehamNJ , ByrneCD , WilliamsR , DayNE , HalesCN . Fasting proinsulin concentrations predict the development of type 2 diabetes. Diabetes Care1999;22(2):262‐70. [PUBMED: 10333943] WilliamsDR , WarehamNJ , BrownDC , ByrneCD , ClarkPM , CoxBD , et al. Undiagnosed glucose intolerance in the community: the Isle of Ely diabetes project. Diabetic Medicine1995;12:30‐5. [PUBMED: 7712700] ">Forouhi 2007</a>; <a href="./references#CD012661-bbs2-0028" title="ChoiSH , KimTH , LimS , ParkKS , JangHC , ChoNH . Hemoglobin A1c as a diagnostic tool for diabetes screening and new‐onset diabetes prediction: a 6‐year community‐based prospective study. Diabetes Care2011;34(4):944‐9. [PUBMED: 21335372] HanSJ , KimHJ , KimDJ , LeeKW , ChoNH . Incidence and predictors of type 2 diabetes among Koreans: a 12‐year follow up of the Korean genome and epidemiology study. Diabetes Research and Clinical Practice2017;123:173‐80. [PUBMED: 28043048] JungDH , ByunYS , KwonYJ , KimGS . Microalbuminuria as a simple predictor of incident diabetes over 8 years in the Korean genome and epidemiology study (KoGES). Scientific Reports2017;7(1):15445. [PUBMED: 29133894] JungJY , OhCM , RyooJH , ChoiJM , ChoiYJ , HamW T , et al. The influence of prehypertension, hypertension, and glycated hemoglobin on the development of type 2 diabetes mellitus in prediabetes: the Korean genome and epidemiology study (KoGES). Endocrine2018;59(3):593‐601. [PUBMED: 29380232] Keun ParkS , RyooJH , OhCM , ChoiJM , ChoiYJ , Ok LeeK , et al. The risk of type 2 diabetes mellitus according to 2‐hour plasma glucose level: the Korean genome and epidemiology study (KoGES). Diabetes Research and Clinical Practice 2017 Aug 9 [Epub ahead of print]. [DOI: 10.1016/j.diabres.2017.08.002; PUBMED: 28951335] LimNK , ParkSH , ChoiSJ , LeeKS , ParkHY . A risk score for predicting the incidence of type 2 diabetes in a middle‐aged Korean cohort: the Korean genome and epidemiology study. Circulation Journal2012;76(8):1904‐10. [PUBMED: 22640983] ">Han 2017</a>; <a href="./references#CD012661-bbs2-0030" title="HeianzaY , AraseY , FujiharaK , HsiehSD , SaitoK , TsujiH , et al. Longitudinal trajectories of HbA1c and fasting plasma glucose levels during the development of type 2 diabetes: the Toranomon hospital health management center study 7 (TOPICS 7). Diabetes Care2012;35(5):1050‐2. [PUBMED: 22456865] HeianzaY , AraseY , FujiharaK , TsujiH , SaitoK , HsiehSD , et al. High normal HbA(1c) levels were associated with impaired insulin secretion without escalating insulin resistance in Japanese individuals: the Toranomon hospital health management center study 8 (TOPICS 8). Diabetic Medicine2012;29(10):1285‐90. HeianzaY , AraseY , FujiharaK , TsujiH , SaitoK , HsiehSD , et al. Screening for pre‐diabetes to predict future diabetes using various cut‐off points for HbA(1c) and impaired fasting glucose: the Toranomon hospital health management center study 4 (TOPICS 4). Diabetic Medicine2012;29(9):e279‐85. [PUBMED: 22510023] HeianzaY , AraseY , HsiehSD , SaitoK , TsujiH , KodamaS , et al. Development of a new scoring system for predicting the 5 year incidence of type 2 diabetes in Japan: the Toranomon hospital health management center study 6 (TOPICS 6). Diabetologia2012;55(12):3213‐23. [PUBMED: 22955996] HeianzaY , HaraS , AraseY , SaitoK , FujiwaraK , TsujiH , et al. HbA1c 5.7‐6.4% and impaired fasting plasma glucose for diagnosis of prediabetes and risk of progression to diabetes in Japan (TOPICS 3): a longitudinal cohort study. Lancet2011;378(9786):147‐55. [MEDLINE: 21705064] HeianzaY , HaraS , AraseY , SaitoK , TotsukaK , TsujiH , et al. Low serum potassium levels and risk of type 2 diabetes: the Toranomon hospital health management center study 1 (TOPICS 1). Diabetologia2011;54(4):762‐6. [PUBMED: 21212932] ">Heianza 2012</a>; <a href="./references#CD012661-bbs2-0032" title="AminiM , JanghorbaniM . Comparison of metabolic syndrome with glucose measurement for prediction of type 2 diabetes: the Isfahan diabetes prevention study. Diabetes &amp; Metabolic Syndrome: Clinical Research &amp; Reviews2009;3(2):84‐9. HaghighatdoostF , AminiM , FeiziA , IrajB . Are body mass index and waist circumference significant predictors of diabetes and prediabetes risk: results from a population based cohort study. World Journal of Diabetes2017;8(7):365‐73. [PUBMED: 28751960] JanghorbaniM , AminiM . Normal fasting plasma glucose and risk of prediabetes and type 2 diabetes: the Isfahan diabetes prevention study. Review of Diabetic Studies2011;8(4):490‐8. [PUBMED: 22580730] JanghorbaniM , AminiM . Progression from optimal blood glucose and pre‐diabetes to type 2 diabetes in a high risk population with or without hypertension in Isfahan, Iran. Diabetes Research and Clinical Practice2015;108(3):414‐22. [PUBMED: 25814432] ">Janghorbani 2015</a>; <a href="./references#CD012661-bbs2-0036" title="KimDJ , ChoNH , NohJH , KimHJ , ChoiYH , JungJH , et al. Fasting plasma glucose cutoff value for the prediction of future diabetes development: a study of middle‐aged Koreans in a health promotion center. Journal of Korean Medical Science2005;20(4):562‐5. [PUBMED: 16100444] KimDJ , ChoNH , NohJH , LeeMS , LeeMK , KimKW . Lack of excess maternal transmission of type 2 diabetes in a Korean population. Diabetes Research and Clinical Practice2004;65(2):117‐24. [PUBMED: 15223223] ">Kim 2005</a>; <a href="./references#CD012661-bbs2-0050" title="ChouPS , LiCL , WuGS , TsaiST . Progression to type 2 diabetes among high‐risk groups in Kin‐Chen, Kinmen ‐ exploring the natural history of type 2 diabetes. Diabetes Care1998;21(7):1183‐7. [PUBMED: 9653617] LiCL , TsaiST , ChouP . Comparison of the results between two diagnostic criteria by ADA and WHO among subjects with FPG 5.6‐7.8 mmol/l in Kin‐Hu and Kin‐Chen, Kinmen, 1991‐94. Diabetes Research and Clinical Practice1999;45(1):51‐9. LiCL , TsaiST , ChouP . Persistent impaired glucose tolerance, insulin resistance, and beta‐cell dysfunction were independent predictors of type 2 diabetes. Journal of Clinical Epidemiology2005;58(7):728‐32. LiCL , TsaiST , ChouP . Relative role of insulin resistance and beta‐cell dysfunction in the progression to type 2 diabetes ‐ the Kinmen study. Diabetes Research and Clinical Practice2003;59(3):225‐32. [PUBMED: 12590020] TsaiST , LiCL , ChenCH , ChouP . Community‐based epidemiological study of glucose tolerance in Kin‐Chen, Kinmen: support for a new intermediate classification. Journal of Clinical Epidemiology2000;53(5):505‐10. [PUBMED: 10812323] ">Li 2003</a>; <a href="./references#CD012661-bbs2-0055" title="LiuX , FineJ P , ChenZ , LiuL , LiX , WangA , et al. Prediction of the 20‐year incidence of diabetes in older Chinese: application of the competing risk method in a longitudinal study. Medicine2016;95(40):e5057. [PUBMED: 27749572] TangZ , WangHX , MengC , WuXG , EricssonK , WinbladB , et al. The prevalence of functional disability in activities of daily living and instrumental activities of daily living among elderly Beijing Chinese. Archives of Gerontology and Geriatrics1999;29(2):115‐25. TangZ , ZhouT , LuoY , XieC , HuoD , TaoL , et al. Risk factors for cerebrovascular disease mortality among the elderly in Beijing: a competing risk analysis. PLOS ONE2014;9(2):e87884. ">Liu 2016</a>; <a href="./references#CD012661-bbs2-0058" title="GroopL , ForsblomC , LehtovirtaM , TuomiT , KarankoS , NissenM , et al. Metabolic consequences of a family history of NIDDM (the Botnia study): evidence for sex‐specific parental effects. Diabetes1996;45(11):1585‐93. [PUBMED: 8866565] LyssenkoV , AlmgrenP , AnevskiD , PerfektR , LahtiK , NissenM , et al. Predictors of and longitudinal changes in insulin sensitivity and secretion preceding onset of type 2 diabetes. Diabetes2005;54(1):166‐74. [PUBMED: 15616025] TripathyD , CarlssonM , AlmgrenP , IsomaaB , TaskinenMR , TuomiT , et al. Insulin secretion and insulin sensitivity in relation to glucose tolerance: lessons from the Botnia Study. Diabetes2000;49(6):975‐80. ">Lyssenko 2005</a>; <a href="./references#CD012661-bbs2-0068" title="NakagamiT , TanakaY , OyaJ , KuritaM , IsagoC , HasegawaY , et al. Associations of HbA1c and fasting plasma glucose with incident diabetes: implications for pre‐diabetes thresholds in a Japanese population. Primary Care Diabetes2016;10(6):407‐14. [PUBMED: 27515716] ">Nakagami 2016</a>; <a href="./references#CD012661-bbs2-0096" title="HowardBV , LeeET , CowanLD , DevereuxRB , GallowayJM , GoOT , et al. Rising tide of cardiovascular disease in American Indians. The strong heart study. Circulation1999;99(18):2389‐95. LeeET , HowardBV , GoO , SavagePJ , FabsitzRR , RobbinsDC , et al. Prevalence of undiagnosed diabetes in three American Indian populations. A comparison of the 1997 American Diabetes Association diagnostic criteria and the 1985 World Health Organization diagnostic criteria: the strong heart study. Diabetes Care2000;23(2):181‐6. LeeET , HowardBV , SavagePJ , CowanLD , FabsitzRR , OopikAJ , et al. Diabetes and impaired glucose tolerance in three American Indian populations aged 45‐74 years. The strong heart study. Diabetes Care1995;18(5):599‐610. LeeET , WeltyTK , CowanLD , WangW , RhoadesDA , DevereuxR , et al. Incidence of diabetes in American Indians of three geographic areas: the strong heart study. Diabetes Care2002;25(1):49‐54. [PUBMED: 11772900] LeeET , WeltyTK , FabsitzR , CowanLD , LeNA , OopikAJ , et al. The strong heart study. A study of cardiovascular disease in American Indians: design and methods. American Journal of Epidemiology1990;132(6):1141‐55. [PUBMED: 2260546] LuW , ResnickHE , JainAK , Adams‐CampbellLL , JablonskiKA , GottliebAM , et al. Effects of isolated post‐challenge hyperglycemia on mortality in American Indians: the strong heart study. Annals of Epidemiology2003;13(3):182‐8. WangH , SharaN M , CalhounD , UmansJG , LeeET , HowardBV . Incidence rates and predictors of diabetes in those with prediabetes: the strong heart study. Diabetes/metabolism Research and Reviews2010;26(5):378‐85. [PUBMED: 20578203] WangW , LeeET , FabsitzR , WeltyTK , HowardBV . Using HbA(1c) to improve efficacy of the American Diabetes Association fasting plasma glucose criterion in screening for new type 2 diabetes in American Indians: the strong heart study. Diabetes Care2002;25(8):1365‐70. WangW , LeeET , HowardBV , FabsitzRR , DevereuxRB , WeltyTK . Fasting plasma glucose and hemoglobin A1c in identifying and predicting diabetes: the strong heart study. Diabetes Care2011;34(2):363‐8. [PUBMED: 21270194] deSimoneG , DevereuxRB , ChinaliM , BestLG , LeeET , GallowayJM , et al. Prognostic impact of metabolic syndrome by different definitions in a population with high prevalence of obesity and diabetes: the strong heart study. Diabetes Care2007;30(7):1851‐6. ">Wang 2011</a>; <a href="./references#CD012661-bbs2-0097" title="LeongA , DayaN , PornealaB , DevlinJJ , ShiffmanD , McPhaulMJ , et al. Prediction of type 2 diabetes by hemoglobin A1c in two community‐based cohorts. Diabetes Care2018;41(1):60‐8. [PUBMED: 29074816] SchmidtMI , DuncanBB , BangH , PankowJS , BallantyneCM , GoldenSH , et al. Identifying individuals at high risk for diabetes ‐ the atherosclerosis risk in communities study. Diabetes Care2005;28(8):2013‐8. [PUBMED: 16043747] SelvinE , RawlingsAM , GramsM , KleinR , SharrettAR , SteffesM , et al. Fructosamine and glycated albumin for risk stratification and prediction of incident diabetes and microvascular complications: a prospective cohort analysis of the atherosclerosis risk in communities (ARIC) study. Lancet Diabetes &amp; Endocrinology2014;2(4):279‐88. [PUBMED: 24703046] SelvinE , SteffesM W , GreggE , BrancatiF L , CoreshJ . Performance of A1C for the classification and prediction of diabetes. Diabetes Care2011;34(1):84‐9. [PUBMED: 20855549] SelvinE , SteffesMW , ZhuH , MatsushitaK , WagenknechtL , PankowJ , et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. New England Journal of Medicine2010;362(9):800‐11. [PUBMED: 20200384] WarrenB , PankowJ S , MatsushitaK , PunjabiNM , DayaNR , GramsM , et al. Comparative prognostic performance of definitions of prediabetes: a prospective cohort analysis of the atherosclerosis risk in communities (ARIC) study. Lancet Diabetes &amp; Endocrinology2017;5(1):34‐42. [PUBMED: 27863979] WheltonSP , McEvoyJW , LazoM , CoreshJ , BallantyneCM , SelvinE . High‐sensitivity cardiac troponin T (hs‐cTnT) as a predictor of incident diabetes in the atherosclerosis risk in communities study. Diabetes Care2017;40(2):261‐9. [PUBMED: 28108537] ">Warren 2017</a>; <a href="./references#CD012661-bbs2-0102" title="BildDE , BluemkeDA , BurkeGL , DetranoR , Diez RouxAV , FolsomAR , et al. Multi‐ethnic study of atherosclerosis: objectives and design. American Journal of Epidemiology2002;156(9):871‐81. [PUBMED: 12397006] YeboahJ , BertoniA G , HerringtonDM , PostWS , BurkeGL . Impaired fasting glucose and the risk of incident diabetes mellitus and cardiovascular events in an adult population: MESA (multi‐ethnic study of atherosclerosis). Journal of the American College of Cardiology2011;58(2):140‐6. [PUBMED: 21718910] ">Yeboah 2011</a>). Whenever possible, we used the reported model with the greatest number of covariates. </p> <section id="CD012661-sec-0078"> <h6 class="title">Study participation</h6> <p>Study authors described the items of this domain sufficiently in most (42 studies; 82%) of the included studies. Two studies did not adequately characterise the sampling frame and/or recruitment procedures (<a href="./references#CD012661-bbs2-0005" title="BaeJC , RheeEJ , LeeWY , ParkSE , ParkCY , OhKW , et al. Combined effect of nonalcoholic fatty liver disease and impaired fasting glucose on the development of type 2 diabetes: a 4‐year retrospective longitudinal study. Diabetes Care2011;34(3):727‐9. [PUBMED: 21278140] BaeJC , RheeEJ , LeeWY , ParkSE , ParkCY , OhKW , et al. Optimal range of HbA1c for the prediction of future diabetes: a 4‐year longitudinal study. Diabetes Research and Clinical Practice2011;93(2):255‐9. [PUBMED: 21676480] ">Bae 2011</a>; <a href="./references#CD012661-bbs2-0094" title="ViswanathanV , ClementinaM , NairBM , SatyavaniK . Risk of future diabetes is as high with abnormal intermediate post‐glucose response as with impaired glucose tolerance. Journal of the Association of Physicians of India2007;55:833‐7. [PUBMED: 18405128] ">Viswanathan 2007</a>). </p> </section> <section id="CD012661-sec-0079"> <h6 class="title">Study attrition</h6> <p>Study authors usually described these items sufficiently and attempted to collect information on participants who were lost to follow‐up. However, in most (32 studies; 63%) of the included studies we could not identify the reasons for losses to follow‐up or adequate descriptions of these participants. Only 10 studies (20%) provided information on potentially important differences between participants who completed the studies and those who did not. Two studies were at high risk of bias on one of the four items (<a href="./references#CD012661-bbs2-0009" title="BonoraE , KiechlS , MayrA , ZoppiniG , TargherG , BonadonnaRC , et al. High‐normal HbA1c is a strong predictor of type 2 diabetes in the general population. Diabetes Care2011;34(4):1038‐40. [PUBMED: 21307378] BonoraE , KiechlS , WilleitJ , OberhollenzerF , EggerG , MeigsJB , et al. Insulin resistance as estimated by homeostasis model assessment predicts incident symptomatic cardiovascular disease in Caucasian subjects from the general population: the Bruneck study. Diabetes Care2007;30(2):318‐24. BonoraE , KiechlS , WilleitJ , OberhollenzerF , EggerG , MeigsJB , et al. Population‐based incidence rates and risk factors for type 2 diabetes in white individuals: the Bruneck study. Diabetes2004;53(7):1782‐9. [PUBMED: 15220202] ">Bonora 2011</a>; <a href="./references#CD012661-bbs2-0034" title="JeongJY , KimJG , KimBW , MoonSS , KimHS , ParkKG , et al. Trend analysis of diabetic prevalence and incidence in a rural area of South Korea between 2003‐2008. Journal of Diabetes Investigation2010;1(5):184‐90. [PUBMED: 24843430] ">Jeong 2010</a>). </p> </section> <section id="CD012661-sec-0080"> <h6 class="title">Glycaemic status measurement</h6> <p>Study authors described the items sufficiently in 40 (78%) studies.</p> </section> <section id="CD012661-sec-0081"> <h6 class="title">Outcome measurement</h6> <p>Study authors described these items sufficiently in 46 studies (90%). One study had a high risk of bias for the item 'clear definition of the outcome provided' (<a href="./references#CD012661-bbs2-0029" title="FestaA , D'AgostinoRJr , HanleyAJ , KarterAJ , SaadMF , HaffnerSM . Differences in insulin resistance in nondiabetic subjects with isolated impaired glucose tolerance or isolated impaired fasting glucose. Diabetes2004;53(6):1549‐55. FestaA , D'AgostinoRJr , RichSS , JennyNS , TracyRP , HaffnerSM . Promoter (4G/5G) plasminogen activator inhibitor‐1 genotype and plasminogen activator inhibitor‐1 levels in blacks, Hispanics, and non‐Hispanic whites: the insulin resistance atherosclerosis study. Circulation2003;107(19):2422‐7. HaffnerSM , D'AgostinoRJr , GoffD , HowardB , FestaA , SaadMF , et al. LDL size in African Americans, Hispanics, and non‐Hispanic whites : the insulin resistance atherosclerosis study. Arteriosclerosis, Thrombosis, and Vascular Biology1999;19(9):2234‐40. HaffnerSM , D'AgostinoR , SaadMF , RewersM , MykkanenL , SelbyJ , et al. Increased insulin resistance and insulin secretion in nondiabetic African‐Americans and Hispanics compared with non‐Hispanic whites. The insulin resistance atherosclerosis study. Diabetes1996;45(6):742‐8. [PUBMED: 8635647] HaffnerSM , HowardG , MayerE , BergmanRN , SavagePJ , RewersM , et al. Insulin sensitivity and acute insulin response in African‐Americans, non‐Hispanic whites, and Hispanics with NIDDM: the insulin resistance atherosclerosis study. Diabetes1997;46(1):63‐9. HanleyAJ , D'AgostinoRBJr , WagenknechtLE , SaadMF , SavagePJ , BergmanR , et al. Increased proinsulin levels and decreased acute insulin response independently predict the incidence of type 2 diabetes in the insulin resistance atherosclerosis study. Diabetes2002;51(4):1263‐70. [PUBMED: 11916954] HanleyAJ , KarterAJ , WilliamsK , FestaA , D'AgostinoRBJr , WagenknechtLE , et al. Prediction of type 2 diabetes mellitus with alternative definitions of the metabolic syndrome: the insulin resistance atherosclerosis study. Circulation2005;112(24):3713‐21. [PUBMED: 16344402] HowardBV , Mayer‐DavisEJ , GoffD , ZaccaroDJ , LawsA , RobbinsDC , et al. Relationships between insulin resistance and lipoproteins in nondiabetic African Americans, Hispanics, and non‐Hispanic whites: the insulin resistance atherosclerosis study. Metabolism1998;47(10):1174‐9. KarterAJ , Mayer‐DavisEJ , SelbyJV , D'AgostinoRBJr , HaffnerSM , SholinskyP , et al. Insulin sensitivity and abdominal obesity in African‐American, Hispanic, and non‐Hispanic white men and women. The insulin resistance and atherosclerosis study. Diabetes1996;45(11):1547‐55. Mayer‐DavisEJ , LevinS , BergmanRN , D'AgostinoRBJr , KarterAJ , SaadMF , et al. Insulin secretion, obesity, and potential behavioral influences: results from the insulin resistance atherosclerosis study (IRAS). Diabetes/metabolism Research and Reviews2001;17(2):137‐45. Sanchez‐LugoL , Mayer‐DavisEJ , HowardG , SelbyJV , AyadMF , RewersM , et al. Insulin sensitivity and intake of vitamins E and C in African American, Hispanic, and non‐Hispanic white men and women: the insulin resistance and atherosclerosis study (IRAS). American Journal of Clinical Nutrition1997;66(5):1224‐31. WagenknechtLE , MayerEJ , RewersM , HaffnerS , SelbyJ , BorokGM , et al. The insulin resistance atherosclerosis study (IRAS) objectives, design, and recruitment results. Annals of Epidemiology1995;5(6):464‐72. [PUBMED: 8680609] ">Hanley 2005</a>). </p> </section> <section id="CD012661-sec-0082"> <h6 class="title">Study confounding</h6> <p>Only one study described all items sufficiently (<a href="./references#CD012661-bbs2-0019" title="Aghaei MeybodiHR , AziziF . Changes in body weight and fat distribution; risk factors for abnormal glucose homeostasis? Tehran lipid and glucose study. Iranian Journal of Diabetes and Lipid Disorders2009;8(1):1‐12. BozorgmaneshM , HadaeghF , AziziF . A simple clinical model predicted diabetes progression among prediabetic individuals. Diabetes Research and Clinical Practice2012;97(2):e34‐6. [PUBMED: 22647753] DerakhshanA , Bagherzadeh‐KhiabaniF , ArshiB , RamezankhaniA , AziziF , HadaeghF . Different combinations of glucose tolerance and blood pressure status and incident diabetes, hypertension, and chronic kidney disease. Journal of the American Heart Association2016;5(8):pii: e003917. [DOI: 10.1161/JAHA.116.003917; PUBMED: 27543801] DerakhshanA , SardariniaM , KhaliliD , MomenanAA , AziziF , HadaeghF . Sex specific incidence rates of type 2 diabetes and its risk factors over 9 years of follow‐up: Tehran lipid and glucose study. PLOS ONE2014;9(7):e102563. [PUBMED: 25029368] DerakhshanA , TohidiM , ArshiB , KhaliliD , AziziF , HadaeghF . Relationship of hyperinsulinaemia, insulin resistance and beta‐cell dysfunction with incident diabetes and pre‐diabetes: the Tehran lipid and glucose study. Diabetic Medicine2015;32(1):24‐32. [PUBMED: 25131451] HadaeghF , BozorgmaneshMR , GhasemiA , HaratiH , SaadatN , AziziF . High prevalence of undiagnosed diabetes and abnormal glucose tolerance in the Iranian urban population: Tehran lipid and glucose study. BMC Public Health2008;8:176. HadaeghF , DerakhshanA , ZafariN , KhaliliD , MirboloukM , SaadatN , et al. Pre‐diabetes tsunami: incidence rates and risk factors of pre‐diabetes and its different phenotypes over 9 years of follow‐up. Diabetic Medicine2017;34(1):69‐78. [PUBMED: 26606421] HadaeghF , GhasemiAr , PadyabM , TohidiM , AziziF . The metabolic syndrome and incident diabetes: assessment of alternative definitions of the metabolic syndrome in an Iranian urban population. Diabetes Research and Clinical Practice2008;80(2):328‐34. [PUBMED: 18282630] HaratiH , HadaeghF , SaadatN , AziziF . Population‐based incidence of type 2 diabetes and its associated risk factors: results from a six‐year cohort study in Iran. BMC Public Health2009;9:186. [DOI: 10.1186/1471‐2458‐9‐186; PUBMED: 19531260] HaratiH , HadaeghF , TohidiM , AziziF . Impaired fasting glucose cutoff value of 5.6 mmol/l combined with other cardiovascular risk markers is a better predictor for incident type 2 diabetes than the 6.1 mmol/l value: Tehran lipid and glucose study. Diabetes Research and Clinical Practice2009;85(1):90‐5. [PUBMED: 19414206] ">Derakhshan 2016</a>). </p> <p>It was difficult to judge study confounding because the number of important covariates measured was limited. If studies analysed data by means of multivariable regression models, they often adjusted these analyses taking into account several covariates: age (43 out of 52 studies), anthropometric measures such as BMI (33 out of 52 studies), sex (31 out of 52 studies), family history of diabetes (24 out of 52 studies), smoking status (24 out of 52 studies), blood pressure/hypertension (19 out of 52 studies), triglycerides (18 out of 52 studies), cholesterol (17 out of 52 studies), physical activity (14 out of 52 studies), drinking status (12 out of 52 studies), socioeconomic status (8 out of 52 studies), 'ethnicity' (5 out 52 studies), medications (3 out of 52 studies) and renal function (1 study); for details see <a href="./appendices#CD012661-sec-0151">Appendix 16</a> and <a href="./appendices#CD012661-sec-0152">Appendix 17</a>. </p> <p>Twenty studies (39%) adjusted their analyses for age, sex and anthropometric measures (e.g. BMI or waist circumference) (<a href="./references#CD012661-bbs2-0001" title="AdmiraalWM , HollemanF , SnijderMB , PetersRJ , BrewsterLM , HoekstraJB , et al. Ethnic disparities in the association of impaired fasting glucose with the 10‐year cumulative incidence of type 2 diabetes. Diabetes Research and Clinical Practice2014;103(1):127‐32. [PUBMED: 24355200] AgyemangC , vanValkengoedI , van denBornB J , StronksK . Prevalence and determinants of prehypertension among African Surinamese, Hindustani Surinamese, and White Dutch in Amsterdam, the Netherlands: the SUNSET study. European Journal of Cardiovascular Prevention and Rehabilitation2007;14(6):775‐81. BindrabanNR , vanValkengoedIG , MairuhuG , HollemanF , HoekstraJB , MichelsBP , et al. Prevalence of diabetes mellitus and the performance of a risk score among Hindustani Surinamese, African Surinamese and ethnic Dutch: a cross‐sectional population‐based study. BMC Public Health2008;8:271. [PUBMED: 18673544] DekkerLH , NicolaouM , van derADl , BusschersWB , BrewsterLM , SnijderMB , et al. Sex differences in the association between serum ferritin and fasting glucose in type 2 diabetes among South Asian Surinamese, African Surinamese, and ethnic Dutch: the population‐based SUNSET study. Diabetes Care2013;36(4):965‐71. ">Admiraal 2014</a>; <a href="./references#CD012661-bbs2-0008" title="BergmanM , ChetritA , RothJ , JagannathanR , SevickM , DanknerR . One‐hour post‐load plasma glucose level during the OGTT predicts dysglycemia: observations from the 24year follow‐up of the Israel study of glucose intolerance, obesity and hypertension. Diabetes Research and Clinical Practice2016;120:221‐8. [PUBMED: 27596059] DanknerR , Abdul‐GhaniMA , GerberY , ChetritA , WainsteinJ , RazI . Predicting the 20‐year diabetes incidence rate. Diabetes/metabolism Research and Reviews2007;23(7):551‐8. [PUBMED: 17315136] ModanM , HalkinH , KarasikA , LuskyA . Effectiveness of glycosylated hemoglobin, fasting plasma glucose, and a single post load plasma glucose level in population screening for glucose intolerance. American Journal of Epidemiology1984;119(3):431‐44. [PUBMED: 6702817] ModanM , KarasikA , HalkinH , FuchsZ , LuskyA , ShitritA , et al. Effect of past and concurrent body mass index on prevalence of glucose intolerance and type 2 (non‐insulin‐dependent) diabetes and on insulin response. Diabetologia1986;29(2):82‐9. [PUBMED: 3516770] ">Bergman 2016</a>; <a href="./references#CD012661-bbs2-0009" title="BonoraE , KiechlS , MayrA , ZoppiniG , TargherG , BonadonnaRC , et al. High‐normal HbA1c is a strong predictor of type 2 diabetes in the general population. Diabetes Care2011;34(4):1038‐40. [PUBMED: 21307378] BonoraE , KiechlS , WilleitJ , OberhollenzerF , EggerG , MeigsJB , et al. Insulin resistance as estimated by homeostasis model assessment predicts incident symptomatic cardiovascular disease in Caucasian subjects from the general population: the Bruneck study. Diabetes Care2007;30(2):318‐24. BonoraE , KiechlS , WilleitJ , OberhollenzerF , EggerG , MeigsJB , et al. Population‐based incidence rates and risk factors for type 2 diabetes in white individuals: the Bruneck study. Diabetes2004;53(7):1782‐9. [PUBMED: 15220202] ">Bonora 2011</a>; <a href="./references#CD012661-bbs2-0011" title="ChamnanP , SimmonsRK , ForouhiNG , LubenRN , KhawKT , WarehamNJ , et al. Incidence of type 2 diabetes using proposed HbA1c diagnostic criteria in the European prospective investigation of Cancer‐Norfolk cohort: implications for preventive strategies. Diabetes Care2011;34(4):950‐6. [PUBMED: 20622160] DayN , OakesS , LubenR , KhawKT , BinghamS , WelchA , et al. EPIC‐Norfolk: study design and characteristics of the cohort. European prospective investigation of cancer. British Journal of Cancer1999;80(Suppl 1):95‐103. [PUBMED: 10466767] KhawKT , WarehamN , LubenR , BinghamS , OakesS , WelchA , et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European prospective investigation of cancer and nutrition (EPIC‐Norfolk). BMJ2001;322(7277):15‐8. [PUBMED: 11141143] ">Chamnan 2011</a>; <a href="./references#CD012661-bbs2-0013" title="ChenKT , ChenCJ , GreggEW , ImperatoreG , NarayanKMV . Impaired fasting glucose and risk of diabetes in Taiwan: follow‐up over 3 years. Diabetes Research and Clinical Practice2003;60(3):177‐82. [PUBMED: 12757990] ChenKT , ChenCJ , GreggEW , WilliamsonDF , NarayanKM . High prevalence of impaired fasting glucose and type 2 diabetes mellitus in Penghu Islets, Taiwan: evidence of a rapidly emerging epidemic?. Diabetes Research and Clinical Practice1999;44(1):59‐69. [PUBMED: 10414941] ">Chen 2003</a>; <a href="./references#CD012661-bbs2-0019" title="Aghaei MeybodiHR , AziziF . Changes in body weight and fat distribution; risk factors for abnormal glucose homeostasis? Tehran lipid and glucose study. Iranian Journal of Diabetes and Lipid Disorders2009;8(1):1‐12. BozorgmaneshM , HadaeghF , AziziF . A simple clinical model predicted diabetes progression among prediabetic individuals. Diabetes Research and Clinical Practice2012;97(2):e34‐6. [PUBMED: 22647753] DerakhshanA , Bagherzadeh‐KhiabaniF , ArshiB , RamezankhaniA , AziziF , HadaeghF . Different combinations of glucose tolerance and blood pressure status and incident diabetes, hypertension, and chronic kidney disease. Journal of the American Heart Association2016;5(8):pii: e003917. [DOI: 10.1161/JAHA.116.003917; PUBMED: 27543801] DerakhshanA , SardariniaM , KhaliliD , MomenanAA , AziziF , HadaeghF . Sex specific incidence rates of type 2 diabetes and its risk factors over 9 years of follow‐up: Tehran lipid and glucose study. PLOS ONE2014;9(7):e102563. [PUBMED: 25029368] DerakhshanA , TohidiM , ArshiB , KhaliliD , AziziF , HadaeghF . Relationship of hyperinsulinaemia, insulin resistance and beta‐cell dysfunction with incident diabetes and pre‐diabetes: the Tehran lipid and glucose study. Diabetic Medicine2015;32(1):24‐32. [PUBMED: 25131451] HadaeghF , BozorgmaneshMR , GhasemiA , HaratiH , SaadatN , AziziF . High prevalence of undiagnosed diabetes and abnormal glucose tolerance in the Iranian urban population: Tehran lipid and glucose study. BMC Public Health2008;8:176. HadaeghF , DerakhshanA , ZafariN , KhaliliD , MirboloukM , SaadatN , et al. Pre‐diabetes tsunami: incidence rates and risk factors of pre‐diabetes and its different phenotypes over 9 years of follow‐up. Diabetic Medicine2017;34(1):69‐78. [PUBMED: 26606421] HadaeghF , GhasemiAr , PadyabM , TohidiM , AziziF . The metabolic syndrome and incident diabetes: assessment of alternative definitions of the metabolic syndrome in an Iranian urban population. Diabetes Research and Clinical Practice2008;80(2):328‐34. [PUBMED: 18282630] HaratiH , HadaeghF , SaadatN , AziziF . Population‐based incidence of type 2 diabetes and its associated risk factors: results from a six‐year cohort study in Iran. BMC Public Health2009;9:186. [DOI: 10.1186/1471‐2458‐9‐186; PUBMED: 19531260] HaratiH , HadaeghF , TohidiM , AziziF . Impaired fasting glucose cutoff value of 5.6 mmol/l combined with other cardiovascular risk markers is a better predictor for incident type 2 diabetes than the 6.1 mmol/l value: Tehran lipid and glucose study. Diabetes Research and Clinical Practice2009;85(1):90‐5. [PUBMED: 19414206] ">Derakhshan 2016</a>; <a href="./references#CD012661-bbs2-0023" title="ForouhiNG , LuanJ , HenningsS , WarehamNJ . Incidence of type 2 diabetes in England and its association with baseline impaired fasting glucose: the Ely study 1990‐2000. Diabetic Medicine2007;24(2):200‐7. [PUBMED: 17257284] SimmonsRK , RahmanM , JakesRW , YuyunMF , NiggebruggeAR , HenningsSH , et al. Effect of population screening for type 2 diabetes on mortality: long‐term follow‐up of the Ely cohort. Diabetologia2011;54:312‐9. [PUBMED: 20978739] WarehamNJ , ByrneCD , WilliamsR , DayNE , HalesCN . Fasting proinsulin concentrations predict the development of type 2 diabetes. Diabetes Care1999;22(2):262‐70. [PUBMED: 10333943] WilliamsDR , WarehamNJ , BrownDC , ByrneCD , ClarkPM , CoxBD , et al. Undiagnosed glucose intolerance in the community: the Isle of Ely diabetes project. Diabetic Medicine1995;12:30‐5. [PUBMED: 7712700] ">Forouhi 2007</a>; <a href="./references#CD012661-bbs2-0028" title="ChoiSH , KimTH , LimS , ParkKS , JangHC , ChoNH . Hemoglobin A1c as a diagnostic tool for diabetes screening and new‐onset diabetes prediction: a 6‐year community‐based prospective study. Diabetes Care2011;34(4):944‐9. [PUBMED: 21335372] HanSJ , KimHJ , KimDJ , LeeKW , ChoNH . Incidence and predictors of type 2 diabetes among Koreans: a 12‐year follow up of the Korean genome and epidemiology study. Diabetes Research and Clinical Practice2017;123:173‐80. [PUBMED: 28043048] JungDH , ByunYS , KwonYJ , KimGS . Microalbuminuria as a simple predictor of incident diabetes over 8 years in the Korean genome and epidemiology study (KoGES). Scientific Reports2017;7(1):15445. [PUBMED: 29133894] JungJY , OhCM , RyooJH , ChoiJM , ChoiYJ , HamW T , et al. The influence of prehypertension, hypertension, and glycated hemoglobin on the development of type 2 diabetes mellitus in prediabetes: the Korean genome and epidemiology study (KoGES). Endocrine2018;59(3):593‐601. [PUBMED: 29380232] Keun ParkS , RyooJH , OhCM , ChoiJM , ChoiYJ , Ok LeeK , et al. The risk of type 2 diabetes mellitus according to 2‐hour plasma glucose level: the Korean genome and epidemiology study (KoGES). Diabetes Research and Clinical Practice 2017 Aug 9 [Epub ahead of print]. [DOI: 10.1016/j.diabres.2017.08.002; PUBMED: 28951335] LimNK , ParkSH , ChoiSJ , LeeKS , ParkHY . A risk score for predicting the incidence of type 2 diabetes in a middle‐aged Korean cohort: the Korean genome and epidemiology study. Circulation Journal2012;76(8):1904‐10. [PUBMED: 22640983] ">Han 2017</a>; <a href="./references#CD012661-bbs2-0030" title="HeianzaY , AraseY , FujiharaK , HsiehSD , SaitoK , TsujiH , et al. Longitudinal trajectories of HbA1c and fasting plasma glucose levels during the development of type 2 diabetes: the Toranomon hospital health management center study 7 (TOPICS 7). Diabetes Care2012;35(5):1050‐2. [PUBMED: 22456865] HeianzaY , AraseY , FujiharaK , TsujiH , SaitoK , HsiehSD , et al. High normal HbA(1c) levels were associated with impaired insulin secretion without escalating insulin resistance in Japanese individuals: the Toranomon hospital health management center study 8 (TOPICS 8). Diabetic Medicine2012;29(10):1285‐90. HeianzaY , AraseY , FujiharaK , TsujiH , SaitoK , HsiehSD , et al. Screening for pre‐diabetes to predict future diabetes using various cut‐off points for HbA(1c) and impaired fasting glucose: the Toranomon hospital health management center study 4 (TOPICS 4). Diabetic Medicine2012;29(9):e279‐85. [PUBMED: 22510023] HeianzaY , AraseY , HsiehSD , SaitoK , TsujiH , KodamaS , et al. Development of a new scoring system for predicting the 5 year incidence of type 2 diabetes in Japan: the Toranomon hospital health management center study 6 (TOPICS 6). Diabetologia2012;55(12):3213‐23. [PUBMED: 22955996] HeianzaY , HaraS , AraseY , SaitoK , FujiwaraK , TsujiH , et al. HbA1c 5.7‐6.4% and impaired fasting plasma glucose for diagnosis of prediabetes and risk of progression to diabetes in Japan (TOPICS 3): a longitudinal cohort study. Lancet2011;378(9786):147‐55. [MEDLINE: 21705064] HeianzaY , HaraS , AraseY , SaitoK , TotsukaK , TsujiH , et al. Low serum potassium levels and risk of type 2 diabetes: the Toranomon hospital health management center study 1 (TOPICS 1). Diabetologia2011;54(4):762‐6. [PUBMED: 21212932] ">Heianza 2012</a>; <a href="./references#CD012661-bbs2-0032" title="AminiM , JanghorbaniM . Comparison of metabolic syndrome with glucose measurement for prediction of type 2 diabetes: the Isfahan diabetes prevention study. Diabetes &amp; Metabolic Syndrome: Clinical Research &amp; Reviews2009;3(2):84‐9. HaghighatdoostF , AminiM , FeiziA , IrajB . Are body mass index and waist circumference significant predictors of diabetes and prediabetes risk: results from a population based cohort study. World Journal of Diabetes2017;8(7):365‐73. [PUBMED: 28751960] JanghorbaniM , AminiM . Normal fasting plasma glucose and risk of prediabetes and type 2 diabetes: the Isfahan diabetes prevention study. Review of Diabetic Studies2011;8(4):490‐8. [PUBMED: 22580730] JanghorbaniM , AminiM . Progression from optimal blood glucose and pre‐diabetes to type 2 diabetes in a high risk population with or without hypertension in Isfahan, Iran. Diabetes Research and Clinical Practice2015;108(3):414‐22. [PUBMED: 25814432] ">Janghorbani 2015</a>; <a href="./references#CD012661-bbs2-0036" title="KimDJ , ChoNH , NohJH , KimHJ , ChoiYH , JungJH , et al. Fasting plasma glucose cutoff value for the prediction of future diabetes development: a study of middle‐aged Koreans in a health promotion center. Journal of Korean Medical Science2005;20(4):562‐5. [PUBMED: 16100444] KimDJ , ChoNH , NohJH , LeeMS , LeeMK , KimKW . Lack of excess maternal transmission of type 2 diabetes in a Korean population. Diabetes Research and Clinical Practice2004;65(2):117‐24. [PUBMED: 15223223] ">Kim 2005</a>; <a href="./references#CD012661-bbs2-0039" title="KimCH , KimHK , KimEH , BaeSJ , ChoeJ , ParkJY . Risk of progression to diabetes from prediabetes defined by HbA1c or fasting plasma glucose criteria in Koreans. Diabetes Research and Clinical Practice2016;118:105‐11. [PUBMED: 27368062] ">Kim 2016a</a>; <a href="./references#CD012661-bbs2-0050" title="ChouPS , LiCL , WuGS , TsaiST . Progression to type 2 diabetes among high‐risk groups in Kin‐Chen, Kinmen ‐ exploring the natural history of type 2 diabetes. Diabetes Care1998;21(7):1183‐7. [PUBMED: 9653617] LiCL , TsaiST , ChouP . Comparison of the results between two diagnostic criteria by ADA and WHO among subjects with FPG 5.6‐7.8 mmol/l in Kin‐Hu and Kin‐Chen, Kinmen, 1991‐94. Diabetes Research and Clinical Practice1999;45(1):51‐9. LiCL , TsaiST , ChouP . Persistent impaired glucose tolerance, insulin resistance, and beta‐cell dysfunction were independent predictors of type 2 diabetes. Journal of Clinical Epidemiology2005;58(7):728‐32. LiCL , TsaiST , ChouP . Relative role of insulin resistance and beta‐cell dysfunction in the progression to type 2 diabetes ‐ the Kinmen study. Diabetes Research and Clinical Practice2003;59(3):225‐32. [PUBMED: 12590020] TsaiST , LiCL , ChenCH , ChouP . Community‐based epidemiological study of glucose tolerance in Kin‐Chen, Kinmen: support for a new intermediate classification. Journal of Clinical Epidemiology2000;53(5):505‐10. [PUBMED: 10812323] ">Li 2003</a>; <a href="./references#CD012661-bbs2-0060" title="FoongAW , SawSM , LooJL , ShenS , LoonSC , RosmanM , et al. Rationale and methodology for a population‐based study of eye diseases in Malay people: the Singapore Malay eye study (SiMES). Ophthalmic Epidemiology2007;14(1):25‐35. ManRE , CharumathiS , GanAT , FenwickEK , TeyCS , ChuaJ , et al. Cumulative incidence and risk factors of prediabetes and type 2 diabetes in a Singaporean Malay cohort. Diabetes Research and Clinical Practice2017;127:163‐71. [PUBMED: 28371687] ">Man 2017</a>; <a href="./references#CD012661-bbs2-0079" title="HosseiniN , TalaeiM , DianatkhahM , SadeghiM , OveisgharanS , SarrafzadeganN . Determinants of incident metabolic syndrome in a Middle Eastern population: Isfahan cohort study. Metabolic Syndrome and Related Disorders2017;15(7):354‐62. [PUBMED: 28677982] SadeghiM , TalaeiM , ParvareshRE , DianatkhahM , OveisgharanS , SarrafzadeganN . Determinants of incident prediabetes and type 2 diabetes in a 7‐year cohort in a developing country: the Isfahan cohort study. Journal of Diabetes2015;7(5):633‐41. [PUBMED: 25350916] SarrafzadeganN , TalaeiM , SadeghiM , KelishadiR , OveisgharanS , MohammadifardN , et al. The Isfahan cohort study: rationale, methods and main findings. Journal of Human Hypertension2011;25(9):545‐53. [PUBMED: 21107436] ">Sadeghi 2015</a>; <a href="./references#CD012661-bbs2-0088" title="SoriguerF , Rojo‐MartínezG , AlmarazMC , EstevaI , Ruiz de AdanaMS , MorcilloS , et al. Incidence of type 2 diabetes in southern Spain (Pizarra study). European Journal of Clinical Investigation2008;38(2):126‐33. [PUBMED: 18226046] Soriguer‐EscofetF , EstevaI , Rojo‐MartinezG , Ruiz de AdanaS , CatalaM , MereloMJ , et al. Prevalence of latent autoimmune diabetes of adults (LADA) in Southern Spain. Diabetes Research and Clinical Practice2002;56(3):213‐20. ">Soriguer 2008</a>; <a href="./references#CD012661-bbs2-0092" title="ValdesS , BotasP , DelgadoE , AlvarezF , CadornigaFD . Population‐based incidence of type 2 diabetes in northern Spain: the Asturias study. Diabetes Care2007;30(9):2258‐63. [PUBMED: 17536076] ValdesS , BotasP , DelgadoE , AlvarezF , Diaz‐CadornigaF . HbA(1c) in the prediction of type 2 diabetes compared with fasting and 2‐h post‐challenge plasma glucose: the Asturias study (1998‐2005). Diabetes &amp; Metabolism2011;37(1):27‐32. [PUBMED: 20934897] ValdésS , BotasP , DelgadoE , ÁlvarezF , CadórnigaFD . Does the new American Diabetes Association definition for impaired fasting glucose improve its ability to predict type 2 diabetes mellitus in Spanish persons? The Asturias study. Metabolism2008;57(3):399‐403. [PUBMED: 18249214] ">Valdes 2008</a>; <a href="./references#CD012661-bbs2-0096" title="HowardBV , LeeET , CowanLD , DevereuxRB , GallowayJM , GoOT , et al. Rising tide of cardiovascular disease in American Indians. The strong heart study. Circulation1999;99(18):2389‐95. LeeET , HowardBV , GoO , SavagePJ , FabsitzRR , RobbinsDC , et al. Prevalence of undiagnosed diabetes in three American Indian populations. A comparison of the 1997 American Diabetes Association diagnostic criteria and the 1985 World Health Organization diagnostic criteria: the strong heart study. Diabetes Care2000;23(2):181‐6. LeeET , HowardBV , SavagePJ , CowanLD , FabsitzRR , OopikAJ , et al. Diabetes and impaired glucose tolerance in three American Indian populations aged 45‐74 years. The strong heart study. Diabetes Care1995;18(5):599‐610. LeeET , WeltyTK , CowanLD , WangW , RhoadesDA , DevereuxR , et al. Incidence of diabetes in American Indians of three geographic areas: the strong heart study. Diabetes Care2002;25(1):49‐54. [PUBMED: 11772900] LeeET , WeltyTK , FabsitzR , CowanLD , LeNA , OopikAJ , et al. The strong heart study. A study of cardiovascular disease in American Indians: design and methods. American Journal of Epidemiology1990;132(6):1141‐55. [PUBMED: 2260546] LuW , ResnickHE , JainAK , Adams‐CampbellLL , JablonskiKA , GottliebAM , et al. Effects of isolated post‐challenge hyperglycemia on mortality in American Indians: the strong heart study. Annals of Epidemiology2003;13(3):182‐8. WangH , SharaN M , CalhounD , UmansJG , LeeET , HowardBV . Incidence rates and predictors of diabetes in those with prediabetes: the strong heart study. Diabetes/metabolism Research and Reviews2010;26(5):378‐85. [PUBMED: 20578203] WangW , LeeET , FabsitzR , WeltyTK , HowardBV . Using HbA(1c) to improve efficacy of the American Diabetes Association fasting plasma glucose criterion in screening for new type 2 diabetes in American Indians: the strong heart study. Diabetes Care2002;25(8):1365‐70. WangW , LeeET , HowardBV , FabsitzRR , DevereuxRB , WeltyTK . Fasting plasma glucose and hemoglobin A1c in identifying and predicting diabetes: the strong heart study. Diabetes Care2011;34(2):363‐8. [PUBMED: 21270194] deSimoneG , DevereuxRB , ChinaliM , BestLG , LeeET , GallowayJM , et al. Prognostic impact of metabolic syndrome by different definitions in a population with high prevalence of obesity and diabetes: the strong heart study. Diabetes Care2007;30(7):1851‐6. ">Wang 2011</a>; <a href="./references#CD012661-bbs2-0097" title="LeongA , DayaN , PornealaB , DevlinJJ , ShiffmanD , McPhaulMJ , et al. Prediction of type 2 diabetes by hemoglobin A1c in two community‐based cohorts. Diabetes Care2018;41(1):60‐8. [PUBMED: 29074816] SchmidtMI , DuncanBB , BangH , PankowJS , BallantyneCM , GoldenSH , et al. Identifying individuals at high risk for diabetes ‐ the atherosclerosis risk in communities study. Diabetes Care2005;28(8):2013‐8. [PUBMED: 16043747] SelvinE , RawlingsAM , GramsM , KleinR , SharrettAR , SteffesM , et al. Fructosamine and glycated albumin for risk stratification and prediction of incident diabetes and microvascular complications: a prospective cohort analysis of the atherosclerosis risk in communities (ARIC) study. Lancet Diabetes &amp; Endocrinology2014;2(4):279‐88. [PUBMED: 24703046] SelvinE , SteffesM W , GreggE , BrancatiF L , CoreshJ . Performance of A1C for the classification and prediction of diabetes. Diabetes Care2011;34(1):84‐9. [PUBMED: 20855549] SelvinE , SteffesMW , ZhuH , MatsushitaK , WagenknechtL , PankowJ , et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. New England Journal of Medicine2010;362(9):800‐11. [PUBMED: 20200384] WarrenB , PankowJ S , MatsushitaK , PunjabiNM , DayaNR , GramsM , et al. Comparative prognostic performance of definitions of prediabetes: a prospective cohort analysis of the atherosclerosis risk in communities (ARIC) study. Lancet Diabetes &amp; Endocrinology2017;5(1):34‐42. [PUBMED: 27863979] WheltonSP , McEvoyJW , LazoM , CoreshJ , BallantyneCM , SelvinE . High‐sensitivity cardiac troponin T (hs‐cTnT) as a predictor of incident diabetes in the atherosclerosis risk in communities study. Diabetes Care2017;40(2):261‐9. [PUBMED: 28108537] ">Warren 2017</a>; <a href="./references#CD012661-bbs2-0102" title="BildDE , BluemkeDA , BurkeGL , DetranoR , Diez RouxAV , FolsomAR , et al. Multi‐ethnic study of atherosclerosis: objectives and design. American Journal of Epidemiology2002;156(9):871‐81. [PUBMED: 12397006] YeboahJ , BertoniA G , HerringtonDM , PostWS , BurkeGL . Impaired fasting glucose and the risk of incident diabetes mellitus and cardiovascular events in an adult population: MESA (multi‐ethnic study of atherosclerosis). Journal of the American College of Cardiology2011;58(2):140‐6. [PUBMED: 21718910] ">Yeboah 2011</a>). Six studies (12%) adjusted for age, sex, anthropometric measures and physical activity (<a href="./references#CD012661-bbs2-0009" title="BonoraE , KiechlS , MayrA , ZoppiniG , TargherG , BonadonnaRC , et al. High‐normal HbA1c is a strong predictor of type 2 diabetes in the general population. Diabetes Care2011;34(4):1038‐40. [PUBMED: 21307378] BonoraE , KiechlS , WilleitJ , OberhollenzerF , EggerG , MeigsJB , et al. Insulin resistance as estimated by homeostasis model assessment predicts incident symptomatic cardiovascular disease in Caucasian subjects from the general population: the Bruneck study. Diabetes Care2007;30(2):318‐24. BonoraE , KiechlS , WilleitJ , OberhollenzerF , EggerG , MeigsJB , et al. Population‐based incidence rates and risk factors for type 2 diabetes in white individuals: the Bruneck study. Diabetes2004;53(7):1782‐9. [PUBMED: 15220202] ">Bonora 2011</a>; <a href="./references#CD012661-bbs2-0019" title="Aghaei MeybodiHR , AziziF . Changes in body weight and fat distribution; risk factors for abnormal glucose homeostasis? Tehran lipid and glucose study. Iranian Journal of Diabetes and Lipid Disorders2009;8(1):1‐12. BozorgmaneshM , HadaeghF , AziziF . A simple clinical model predicted diabetes progression among prediabetic individuals. Diabetes Research and Clinical Practice2012;97(2):e34‐6. [PUBMED: 22647753] DerakhshanA , Bagherzadeh‐KhiabaniF , ArshiB , RamezankhaniA , AziziF , HadaeghF . Different combinations of glucose tolerance and blood pressure status and incident diabetes, hypertension, and chronic kidney disease. Journal of the American Heart Association2016;5(8):pii: e003917. [DOI: 10.1161/JAHA.116.003917; PUBMED: 27543801] DerakhshanA , SardariniaM , KhaliliD , MomenanAA , AziziF , HadaeghF . Sex specific incidence rates of type 2 diabetes and its risk factors over 9 years of follow‐up: Tehran lipid and glucose study. PLOS ONE2014;9(7):e102563. [PUBMED: 25029368] DerakhshanA , TohidiM , ArshiB , KhaliliD , AziziF , HadaeghF . Relationship of hyperinsulinaemia, insulin resistance and beta‐cell dysfunction with incident diabetes and pre‐diabetes: the Tehran lipid and glucose study. Diabetic Medicine2015;32(1):24‐32. [PUBMED: 25131451] HadaeghF , BozorgmaneshMR , GhasemiA , HaratiH , SaadatN , AziziF . High prevalence of undiagnosed diabetes and abnormal glucose tolerance in the Iranian urban population: Tehran lipid and glucose study. BMC Public Health2008;8:176. HadaeghF , DerakhshanA , ZafariN , KhaliliD , MirboloukM , SaadatN , et al. Pre‐diabetes tsunami: incidence rates and risk factors of pre‐diabetes and its different phenotypes over 9 years of follow‐up. Diabetic Medicine2017;34(1):69‐78. [PUBMED: 26606421] HadaeghF , GhasemiAr , PadyabM , TohidiM , AziziF . The metabolic syndrome and incident diabetes: assessment of alternative definitions of the metabolic syndrome in an Iranian urban population. Diabetes Research and Clinical Practice2008;80(2):328‐34. [PUBMED: 18282630] HaratiH , HadaeghF , SaadatN , AziziF . Population‐based incidence of type 2 diabetes and its associated risk factors: results from a six‐year cohort study in Iran. BMC Public Health2009;9:186. [DOI: 10.1186/1471‐2458‐9‐186; PUBMED: 19531260] HaratiH , HadaeghF , TohidiM , AziziF . Impaired fasting glucose cutoff value of 5.6 mmol/l combined with other cardiovascular risk markers is a better predictor for incident type 2 diabetes than the 6.1 mmol/l value: Tehran lipid and glucose study. Diabetes Research and Clinical Practice2009;85(1):90‐5. [PUBMED: 19414206] ">Derakhshan 2016</a>; <a href="./references#CD012661-bbs2-0023" title="ForouhiNG , LuanJ , HenningsS , WarehamNJ . Incidence of type 2 diabetes in England and its association with baseline impaired fasting glucose: the Ely study 1990‐2000. Diabetic Medicine2007;24(2):200‐7. [PUBMED: 17257284] SimmonsRK , RahmanM , JakesRW , YuyunMF , NiggebruggeAR , HenningsSH , et al. Effect of population screening for type 2 diabetes on mortality: long‐term follow‐up of the Ely cohort. Diabetologia2011;54:312‐9. [PUBMED: 20978739] WarehamNJ , ByrneCD , WilliamsR , DayNE , HalesCN . Fasting proinsulin concentrations predict the development of type 2 diabetes. Diabetes Care1999;22(2):262‐70. [PUBMED: 10333943] WilliamsDR , WarehamNJ , BrownDC , ByrneCD , ClarkPM , CoxBD , et al. Undiagnosed glucose intolerance in the community: the Isle of Ely diabetes project. Diabetic Medicine1995;12:30‐5. [PUBMED: 7712700] ">Forouhi 2007</a>; <a href="./references#CD012661-bbs2-0028" title="ChoiSH , KimTH , LimS , ParkKS , JangHC , ChoNH . Hemoglobin A1c as a diagnostic tool for diabetes screening and new‐onset diabetes prediction: a 6‐year community‐based prospective study. Diabetes Care2011;34(4):944‐9. [PUBMED: 21335372] HanSJ , KimHJ , KimDJ , LeeKW , ChoNH . Incidence and predictors of type 2 diabetes among Koreans: a 12‐year follow up of the Korean genome and epidemiology study. Diabetes Research and Clinical Practice2017;123:173‐80. [PUBMED: 28043048] JungDH , ByunYS , KwonYJ , KimGS . Microalbuminuria as a simple predictor of incident diabetes over 8 years in the Korean genome and epidemiology study (KoGES). Scientific Reports2017;7(1):15445. [PUBMED: 29133894] JungJY , OhCM , RyooJH , ChoiJM , ChoiYJ , HamW T , et al. The influence of prehypertension, hypertension, and glycated hemoglobin on the development of type 2 diabetes mellitus in prediabetes: the Korean genome and epidemiology study (KoGES). Endocrine2018;59(3):593‐601. [PUBMED: 29380232] Keun ParkS , RyooJH , OhCM , ChoiJM , ChoiYJ , Ok LeeK , et al. The risk of type 2 diabetes mellitus according to 2‐hour plasma glucose level: the Korean genome and epidemiology study (KoGES). Diabetes Research and Clinical Practice 2017 Aug 9 [Epub ahead of print]. [DOI: 10.1016/j.diabres.2017.08.002; PUBMED: 28951335] LimNK , ParkSH , ChoiSJ , LeeKS , ParkHY . A risk score for predicting the incidence of type 2 diabetes in a middle‐aged Korean cohort: the Korean genome and epidemiology study. Circulation Journal2012;76(8):1904‐10. [PUBMED: 22640983] ">Han 2017</a>; <a href="./references#CD012661-bbs2-0039" title="KimCH , KimHK , KimEH , BaeSJ , ChoeJ , ParkJY . Risk of progression to diabetes from prediabetes defined by HbA1c or fasting plasma glucose criteria in Koreans. Diabetes Research and Clinical Practice2016;118:105‐11. [PUBMED: 27368062] ">Kim 2016a</a>; <a href="./references#CD012661-bbs2-0102" title="BildDE , BluemkeDA , BurkeGL , DetranoR , Diez RouxAV , FolsomAR , et al. Multi‐ethnic study of atherosclerosis: objectives and design. American Journal of Epidemiology2002;156(9):871‐81. [PUBMED: 12397006] YeboahJ , BertoniA G , HerringtonDM , PostWS , BurkeGL . Impaired fasting glucose and the risk of incident diabetes mellitus and cardiovascular events in an adult population: MESA (multi‐ethnic study of atherosclerosis). Journal of the American College of Cardiology2011;58(2):140‐6. [PUBMED: 21718910] ">Yeboah 2011</a>), and five studies (10%) also included smoking status (<a href="./references#CD012661-bbs2-0009" title="BonoraE , KiechlS , MayrA , ZoppiniG , TargherG , BonadonnaRC , et al. High‐normal HbA1c is a strong predictor of type 2 diabetes in the general population. Diabetes Care2011;34(4):1038‐40. [PUBMED: 21307378] BonoraE , KiechlS , WilleitJ , OberhollenzerF , EggerG , MeigsJB , et al. Insulin resistance as estimated by homeostasis model assessment predicts incident symptomatic cardiovascular disease in Caucasian subjects from the general population: the Bruneck study. Diabetes Care2007;30(2):318‐24. BonoraE , KiechlS , WilleitJ , OberhollenzerF , EggerG , MeigsJB , et al. Population‐based incidence rates and risk factors for type 2 diabetes in white individuals: the Bruneck study. Diabetes2004;53(7):1782‐9. [PUBMED: 15220202] ">Bonora 2011</a>; <a href="./references#CD012661-bbs2-0019" title="Aghaei MeybodiHR , AziziF . Changes in body weight and fat distribution; risk factors for abnormal glucose homeostasis? Tehran lipid and glucose study. Iranian Journal of Diabetes and Lipid Disorders2009;8(1):1‐12. BozorgmaneshM , HadaeghF , AziziF . A simple clinical model predicted diabetes progression among prediabetic individuals. Diabetes Research and Clinical Practice2012;97(2):e34‐6. [PUBMED: 22647753] DerakhshanA , Bagherzadeh‐KhiabaniF , ArshiB , RamezankhaniA , AziziF , HadaeghF . Different combinations of glucose tolerance and blood pressure status and incident diabetes, hypertension, and chronic kidney disease. Journal of the American Heart Association2016;5(8):pii: e003917. [DOI: 10.1161/JAHA.116.003917; PUBMED: 27543801] DerakhshanA , SardariniaM , KhaliliD , MomenanAA , AziziF , HadaeghF . Sex specific incidence rates of type 2 diabetes and its risk factors over 9 years of follow‐up: Tehran lipid and glucose study. PLOS ONE2014;9(7):e102563. [PUBMED: 25029368] DerakhshanA , TohidiM , ArshiB , KhaliliD , AziziF , HadaeghF . Relationship of hyperinsulinaemia, insulin resistance and beta‐cell dysfunction with incident diabetes and pre‐diabetes: the Tehran lipid and glucose study. Diabetic Medicine2015;32(1):24‐32. [PUBMED: 25131451] HadaeghF , BozorgmaneshMR , GhasemiA , HaratiH , SaadatN , AziziF . High prevalence of undiagnosed diabetes and abnormal glucose tolerance in the Iranian urban population: Tehran lipid and glucose study. BMC Public Health2008;8:176. HadaeghF , DerakhshanA , ZafariN , KhaliliD , MirboloukM , SaadatN , et al. Pre‐diabetes tsunami: incidence rates and risk factors of pre‐diabetes and its different phenotypes over 9 years of follow‐up. Diabetic Medicine2017;34(1):69‐78. [PUBMED: 26606421] HadaeghF , GhasemiAr , PadyabM , TohidiM , AziziF . The metabolic syndrome and incident diabetes: assessment of alternative definitions of the metabolic syndrome in an Iranian urban population. Diabetes Research and Clinical Practice2008;80(2):328‐34. [PUBMED: 18282630] HaratiH , HadaeghF , SaadatN , AziziF . Population‐based incidence of type 2 diabetes and its associated risk factors: results from a six‐year cohort study in Iran. BMC Public Health2009;9:186. [DOI: 10.1186/1471‐2458‐9‐186; PUBMED: 19531260] HaratiH , HadaeghF , TohidiM , AziziF . Impaired fasting glucose cutoff value of 5.6 mmol/l combined with other cardiovascular risk markers is a better predictor for incident type 2 diabetes than the 6.1 mmol/l value: Tehran lipid and glucose study. Diabetes Research and Clinical Practice2009;85(1):90‐5. [PUBMED: 19414206] ">Derakhshan 2016</a>; <a href="./references#CD012661-bbs2-0023" title="ForouhiNG , LuanJ , HenningsS , WarehamNJ . Incidence of type 2 diabetes in England and its association with baseline impaired fasting glucose: the Ely study 1990‐2000. Diabetic Medicine2007;24(2):200‐7. [PUBMED: 17257284] SimmonsRK , RahmanM , JakesRW , YuyunMF , NiggebruggeAR , HenningsSH , et al. Effect of population screening for type 2 diabetes on mortality: long‐term follow‐up of the Ely cohort. Diabetologia2011;54:312‐9. [PUBMED: 20978739] WarehamNJ , ByrneCD , WilliamsR , DayNE , HalesCN . Fasting proinsulin concentrations predict the development of type 2 diabetes. Diabetes Care1999;22(2):262‐70. [PUBMED: 10333943] WilliamsDR , WarehamNJ , BrownDC , ByrneCD , ClarkPM , CoxBD , et al. Undiagnosed glucose intolerance in the community: the Isle of Ely diabetes project. Diabetic Medicine1995;12:30‐5. [PUBMED: 7712700] ">Forouhi 2007</a>; <a href="./references#CD012661-bbs2-0028" title="ChoiSH , KimTH , LimS , ParkKS , JangHC , ChoNH . Hemoglobin A1c as a diagnostic tool for diabetes screening and new‐onset diabetes prediction: a 6‐year community‐based prospective study. Diabetes Care2011;34(4):944‐9. [PUBMED: 21335372] HanSJ , KimHJ , KimDJ , LeeKW , ChoNH . Incidence and predictors of type 2 diabetes among Koreans: a 12‐year follow up of the Korean genome and epidemiology study. Diabetes Research and Clinical Practice2017;123:173‐80. [PUBMED: 28043048] JungDH , ByunYS , KwonYJ , KimGS . Microalbuminuria as a simple predictor of incident diabetes over 8 years in the Korean genome and epidemiology study (KoGES). Scientific Reports2017;7(1):15445. [PUBMED: 29133894] JungJY , OhCM , RyooJH , ChoiJM , ChoiYJ , HamW T , et al. The influence of prehypertension, hypertension, and glycated hemoglobin on the development of type 2 diabetes mellitus in prediabetes: the Korean genome and epidemiology study (KoGES). Endocrine2018;59(3):593‐601. [PUBMED: 29380232] Keun ParkS , RyooJH , OhCM , ChoiJM , ChoiYJ , Ok LeeK , et al. The risk of type 2 diabetes mellitus according to 2‐hour plasma glucose level: the Korean genome and epidemiology study (KoGES). Diabetes Research and Clinical Practice 2017 Aug 9 [Epub ahead of print]. [DOI: 10.1016/j.diabres.2017.08.002; PUBMED: 28951335] LimNK , ParkSH , ChoiSJ , LeeKS , ParkHY . A risk score for predicting the incidence of type 2 diabetes in a middle‐aged Korean cohort: the Korean genome and epidemiology study. Circulation Journal2012;76(8):1904‐10. [PUBMED: 22640983] ">Han 2017</a>; <a href="./references#CD012661-bbs2-0039" title="KimCH , KimHK , KimEH , BaeSJ , ChoeJ , ParkJY . Risk of progression to diabetes from prediabetes defined by HbA1c or fasting plasma glucose criteria in Koreans. Diabetes Research and Clinical Practice2016;118:105‐11. [PUBMED: 27368062] ">Kim 2016a</a>). When used, covariates were usually clearly defined and measured. However, only two studies reported an imputation method for missing confounders (<a href="./references#CD012661-bbs2-0019" title="Aghaei MeybodiHR , AziziF . Changes in body weight and fat distribution; risk factors for abnormal glucose homeostasis? Tehran lipid and glucose study. Iranian Journal of Diabetes and Lipid Disorders2009;8(1):1‐12. BozorgmaneshM , HadaeghF , AziziF . A simple clinical model predicted diabetes progression among prediabetic individuals. Diabetes Research and Clinical Practice2012;97(2):e34‐6. [PUBMED: 22647753] DerakhshanA , Bagherzadeh‐KhiabaniF , ArshiB , RamezankhaniA , AziziF , HadaeghF . Different combinations of glucose tolerance and blood pressure status and incident diabetes, hypertension, and chronic kidney disease. Journal of the American Heart Association2016;5(8):pii: e003917. [DOI: 10.1161/JAHA.116.003917; PUBMED: 27543801] DerakhshanA , SardariniaM , KhaliliD , MomenanAA , AziziF , HadaeghF . Sex specific incidence rates of type 2 diabetes and its risk factors over 9 years of follow‐up: Tehran lipid and glucose study. PLOS ONE2014;9(7):e102563. [PUBMED: 25029368] DerakhshanA , TohidiM , ArshiB , KhaliliD , AziziF , HadaeghF . Relationship of hyperinsulinaemia, insulin resistance and beta‐cell dysfunction with incident diabetes and pre‐diabetes: the Tehran lipid and glucose study. Diabetic Medicine2015;32(1):24‐32. [PUBMED: 25131451] HadaeghF , BozorgmaneshMR , GhasemiA , HaratiH , SaadatN , AziziF . High prevalence of undiagnosed diabetes and abnormal glucose tolerance in the Iranian urban population: Tehran lipid and glucose study. BMC Public Health2008;8:176. HadaeghF , DerakhshanA , ZafariN , KhaliliD , MirboloukM , SaadatN , et al. Pre‐diabetes tsunami: incidence rates and risk factors of pre‐diabetes and its different phenotypes over 9 years of follow‐up. Diabetic Medicine2017;34(1):69‐78. [PUBMED: 26606421] HadaeghF , GhasemiAr , PadyabM , TohidiM , AziziF . The metabolic syndrome and incident diabetes: assessment of alternative definitions of the metabolic syndrome in an Iranian urban population. Diabetes Research and Clinical Practice2008;80(2):328‐34. [PUBMED: 18282630] HaratiH , HadaeghF , SaadatN , AziziF . Population‐based incidence of type 2 diabetes and its associated risk factors: results from a six‐year cohort study in Iran. BMC Public Health2009;9:186. [DOI: 10.1186/1471‐2458‐9‐186; PUBMED: 19531260] HaratiH , HadaeghF , TohidiM , AziziF . Impaired fasting glucose cutoff value of 5.6 mmol/l combined with other cardiovascular risk markers is a better predictor for incident type 2 diabetes than the 6.1 mmol/l value: Tehran lipid and glucose study. Diabetes Research and Clinical Practice2009;85(1):90‐5. [PUBMED: 19414206] ">Derakhshan 2016</a>; <a href="./references#CD012661-bbs2-0079" title="HosseiniN , TalaeiM , DianatkhahM , SadeghiM , OveisgharanS , SarrafzadeganN . Determinants of incident metabolic syndrome in a Middle Eastern population: Isfahan cohort study. Metabolic Syndrome and Related Disorders2017;15(7):354‐62. [PUBMED: 28677982] SadeghiM , TalaeiM , ParvareshRE , DianatkhahM , OveisgharanS , SarrafzadeganN . Determinants of incident prediabetes and type 2 diabetes in a 7‐year cohort in a developing country: the Isfahan cohort study. Journal of Diabetes2015;7(5):633‐41. [PUBMED: 25350916] SarrafzadeganN , TalaeiM , SadeghiM , KelishadiR , OveisgharanS , MohammadifardN , et al. The Isfahan cohort study: rationale, methods and main findings. Journal of Human Hypertension2011;25(9):545‐53. [PUBMED: 21107436] ">Sadeghi 2015</a>). </p> </section> <section id="CD012661-sec-0083"> <h6 class="title">Statistical analysis and reporting</h6> <p>Study authors addressed this domain sufficiently in 44 studies (86%).</p> </section> </section> </section> <section id="CD012661-sec-0084"> <h4 class="title">Development of T2DM in people with IH</h4> <p>In the following we report the results of the analyses for the overall prognosis of people with IH as well as regression from IH to normoglycaemia, and the effects of glycaemic status (IH versus normoglycaemia) as a prognostic factor for T2DM. </p> <section id="CD012661-sec-0085"> <h5 class="title">Definition of IH at baseline</h5> <p>Studies defined IH as follows.</p> <p> <ul id="CD012661-list-0013"> <li> <p>IFG<sub>5.6</sub> threshold, usually defined as a fasting plasma glucose level of 5.6 mmol/L to 6.9 mmol/L. </p> </li> <li> <p>IFG<sub>6.1</sub> threshold, usually defined as a fasting plasma glucose level of 6.1 mmol/L to 6.9 mmol/L. </p> </li> <li> <p>IGT, usually defined as a plasma glucose level of 7.8 mmol/L to 11.1 mmol/L two hours after a 75 g OGTT. </p> </li> <li> <p>Isolated IFG was defined as IFG<sub>5.6</sub> or IFG<sub>6.1</sub> alone, without IGT, and isolated IGT was defined as IGT alone, without IFG<sub>5.6</sub> or IFG<sub>6.1</sub>. </p> </li> <li> <p>HbA1c<sub>5.7</sub> threshold, usually defined as HbA1c measurement of 5.7% to 6.4%. </p> </li> <li> <p>HbA1c<sub>6.0</sub> threshold, usually defined as HbA1c measurement of 6.0% to 6.4%. </p> </li> </ul> </p> <p>Depending on how investigators measured IH, the following number of study cohorts provided information on T2DM incidence associated with glycaemic status at baseline (one study might have investigated several associations between glycaemic status and T2DM incidence within the same study, for example, one cohort with IFG<sub>5.6</sub>, another cohort with IFG<sub>6.1</sub> and a third cohort with IGT). </p> <p> <ul id="CD012661-list-0014"> <li> <p>IFG<sub>5.6</sub>/isolated IFG<sub>5.6</sub>: 27/10 study cohorts. </p> </li> <li> <p>IFG<sub>6.1</sub>/isolated IFG<sub>6.1</sub>: 22/9 study cohorts. </p> </li> <li> <p>IGT/isolated IGT: 39/18 study cohorts.</p> </li> <li> <p>Combined IFG and IGT: 15 study cohorts.</p> </li> <li> <p>HbA1c<sub>5.7</sub>: 7 study cohorts. </p> </li> <li> <p>HbA1c<sub>6.0</sub>: 10 study cohorts. </p> </li> <li> <p>Combined HbA1c<sub>5.7</sub> and IFG<sub>5.6</sub>: 3 study cohorts. </p> </li> </ul> </p> </section> <section id="CD012661-sec-0086"> <h5 class="title">a) Overall prognosis of people with IH for developing T2DM</h5> <p>Irrespective of the definition of IH at baseline, the cumulative incidence of T2DM seemed to increase with length of follow‐up, though there was no obvious linear trend. There was no clear pattern of differences between geographic regions. </p> <section id="CD012661-sec-0087"> <h6 class="title">IH defined by IFG<sub>5.6</sub> mmol/L threshold </h6> <p>Diabetes incidence associated with IFG<sub>5.6</sub> at baseline and follow‐up periods from 2 to 12 years showed pooled cumulative incidences of 2% to 38% (<a href="#CD012661-fig-0007">Figure 7</a>; <a href="#CD012661-fig-0008">Figure 8</a>). </p> <div class="figure" id="CD012661-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Impaired fasting glucose 5.6 mmol/L (IFG5.6) threshold: association with cumulative type 2 diabetes mellitus (T2DM) incidence over 2–5 years  *Isolated IFG5.6  CI: confidence interval; M: men; n/N: events/number of participants; W: women" data-id="CD012661-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-AFig-FIG07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Impaired fasting glucose 5.6 mmol/L (IFG<sub>5.6</sub>) threshold: association with cumulative type 2 diabetes mellitus (T2DM) incidence over 2–5 years<br/> *Isolated IFG<sub>5.6</sub><br/> <b>CI</b> : confidence interval; <b>M</b> : men; <b>n/N</b> : events/number of participants; <b>W</b>: women </p> </div> </div> </div> <div class="figure" id="CD012661-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="Impaired fasting glucose 5.6 mmol/L (IFG5.6) threshold: association with cumulative type 2 diabetes mellitus (T2DM) incidence over 6–12 years  *Isolated IFG5.6   **'Africa': African Surinamese cohort, 'Asia': Asian Surinamese cohort, 'Australia/Europe/North America': 'ethnic Dutch' cohort.  CI: confidence interval; M: men; n/N: events/number of participants; W: women" data-id="CD012661-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-AFig-FIG08.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Impaired fasting glucose 5.6 mmol/L (IFG<sub>5.6</sub>) threshold: association with cumulative type 2 diabetes mellitus (T2DM) incidence over 6–12 years<br/> *Isolated IFG<sub>5.6</sub> <br/> **'Africa': African Surinamese cohort, 'Asia': Asian Surinamese cohort, 'Australia/Europe/North America': 'ethnic Dutch' cohort.<br/> <b>CI</b> : confidence interval; <b>M</b> : men; <b>n/N</b> : events/number of participants; <b>W</b>: women </p> </div> </div> </div> <p>The number of studies and participants, and the cumulative incidence of T2DM (pooled if more than one study) according to follow‐up period were as follows. </p> <p> <ul id="CD012661-list-0015"> <li> <p>2 years' follow‐up: 1 study, 1335 participants, cumulative incidence 2% (95% confidence interval (CI) 1 to 2). </p> </li> <li> <p>3 years' follow‐up: 3 studies, 1091 participants, cumulative incidence 17% (95% CI 6 to 32). </p> </li> <li> <p>4 years' follow‐up: 3 studies, 800 participants, cumulative incidence 17% (95% CI 13 to 22). </p> </li> <li> <p>5 years' follow‐up: 7 studies, 3530 participants, cumulative incidence 18% (95% CI 10 to 27). </p> </li> <li> <p>6 years' follow‐up: 4 studies, 783 participants, cumulative incidence 22% (95% CI 15 to 31). </p> </li> <li> <p>7 years' follow‐up: 5 studies, 980 participants, cumulative incidence 18% (95% CI 8 to 30). </p> </li> <li> <p>8 years' follow‐up: 2 studies, 1887 participants, cumulative incidence 34% (95% CI 27 to 40). </p> </li> <li> <p>9 years' follow‐up: 3 studies, 1356 participants, cumulative incidence 38% (95% CI 10 to 70). </p> </li> <li> <p>10 years' follow‐up: 6 studies, 1542 participants, cumulative incidence 23% (95% CI 14 to 33). </p> </li> <li> <p>12 years' follow‐up: 3 studies, 433 participants, cumulative incidence 31% (95% CI 19 to 34). </p> </li> </ul> </p> </section> <section id="CD012661-sec-0088"> <h6 class="title">IH defined by IFG<sub>6.1</sub> mmol/L threshold </h6> <p>Diabetes incidence, as associated with IFG<sub>6.1</sub> at baseline and a follow‐up period of 2 to 15 years, showed pooled cumulative incidences of 9% to 48% (<a href="#CD012661-fig-0009">Figure 9</a>; <a href="#CD012661-fig-0010">Figure 10</a>). </p> <div class="figure" id="CD012661-fig-0009"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 9</div> </div> <hr class="top"/><img alt="Impaired fasting glucose 6.1 mmol/L (IFG6.1) threshold: association with cumulative type 2 diabetes mellitus (T2DM) incidence over 2–5 years  *Isolated IFG6.1  CI: confidence interval; M: men; n/N: events/number of participants; W: women" data-id="CD012661-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-AFig-FIG09.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Impaired fasting glucose 6.1 mmol/L (IFG<sub>6.1</sub>) threshold: association with cumulative type 2 diabetes mellitus (T2DM) incidence over 2–5 years<br/> *Isolated IFG<sub>6.1</sub><br/> <b>CI</b> : confidence interval; <b>M</b> : men; <b>n/N</b> : events/number of participants; <b>W</b>: women </p> </div> </div> </div> <div class="figure" id="CD012661-fig-0010"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 10</div> </div> <hr class="top"/><img alt="Impaired fasting glucose 6.1 mmol/L (IFG6.1) threshold: association with cumulative type 2 diabetes mellitus (T2DM) incidence over 6–15 years  *Isolated IFG6.1  CI: confidence interval; n/N: events/number of participants" data-id="CD012661-fig-0010" src="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-AFig-FIG10.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Impaired fasting glucose 6.1 mmol/L (IFG<sub>6.1</sub>) threshold: association with cumulative type 2 diabetes mellitus (T2DM) incidence over 6–15 years<br/> *Isolated IFG<sub>6.1</sub><br/> <b>CI</b> : confidence interval; <b>n/N</b>: events/number of participants </p> </div> </div> </div> <p>The number of studies and participants, and the cumulative incidence of T2DM (pooled if more than one study) according to follow‐up period were as follows. </p> <p> <ul id="CD012661-list-0016"> <li> <p>2 years' follow‐up: 2 studies, 549 participants, cumulative incidence 11% (95% CI 8 to 14). </p> </li> <li> <p>3 years' follow‐up: 3 studies, 927 participants, cumulative incidence 9% (95% CI 2 to 20). </p> </li> <li> <p>4 years' follow‐up: 2 studies, 1567 participants, cumulative incidence 30% (95% CI 17 to 44). </p> </li> <li> <p>5 years' follow‐up: 11 studies, 3837 participants, cumulative incidence 26% (95% CI 19 to 33). </p> </li> <li> <p>6 years' follow‐up: 5 studies, 279 participants, cumulative incidence 37% (95% CI 31 to 43). </p> </li> <li> <p>7 years' follow‐up: 4 studies, 434 participants, cumulative incidence 15% (95% CI 0 to 45). </p> </li> <li> <p>8 years' follow‐up: 1 study, 29 participants, cumulative incidence 48% (95% CI 31 to 66). </p> </li> <li> <p>10 years' follow‐up: 6 studies, 537 participants, cumulative incidence 29% (95% CI 17 to 43). </p> </li> <li> <p>11 years' follow‐up: 1 study, 402 participants, cumulative incidence 38% (95% CI 33 to 43). </p> </li> <li> <p>15 years' follow‐up: 1 study, 1382 participants, cumulative incidence 31% (95% CI 28 to 33). </p> </li> </ul> </p> </section> <section id="CD012661-sec-0089"> <h6 class="title">IH defined by IGT</h6> <p>Diabetes incidence associated with IGT at baseline showed pooled cumulative incidences of 13% to 60% after a follow‐up period of 1 to 20 years (<a href="#CD012661-fig-0011">Figure 11</a>; <a href="#CD012661-fig-0012">Figure 12</a>). </p> <div class="figure" id="CD012661-fig-0011"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 11</div> </div> <hr class="top"/><img alt="Impaired glucose tolerance (IGT): association with cumulative type 2 diabetes mellitus (T2DM) incidence over 1–5 years  *Isolated IGT  CI: confidence interval; n/N: events/number of participants" data-id="CD012661-fig-0011" src="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-AFig-FIG11.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Impaired glucose tolerance (IGT): association with cumulative type 2 diabetes mellitus (T2DM) incidence over 1–5 years<br/> *Isolated IGT<br/> <b>CI</b> : confidence interval; <b>n/N</b>: events/number of participants </p> </div> </div> </div> <div class="figure" id="CD012661-fig-0012"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 12</div> </div> <hr class="top"/><img alt="Impaired glucose tolerance (IGT): association with cumulative type 2 diabetes mellitus (T2DM) incidence over 6–20 years*Isolated IGT  CI: confidence interval; M: men; n/N: events/number of participants; W: women" data-id="CD012661-fig-0012" src="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-AFig-FIG12.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Impaired glucose tolerance (IGT): association with cumulative type 2 diabetes mellitus (T2DM) incidence over 6–20 years </p> <p>*Isolated IGT<br/> <b>CI</b> : confidence interval; <b>M</b> : men; <b>n/N</b> : events/number of participants; <b>W</b>: women </p> </div> </div> </div> <p>The number of studies and participants, and the cumulative incidence of T2DM (pooled if more than one study) according to follow‐up period were as follows. </p> <p> <ul id="CD012661-list-0017"> <li> <p>1 year's follow‐up: 3 studies, 671 participants, cumulative incidence 13% (95% CI 5 to 23). </p> </li> <li> <p>2 years' follow‐up: 9 studies, 1998 participants, cumulative incidence 16% (95% CI 9 to 26). </p> </li> <li> <p>3 years' follow‐up: 3 studies, 417 participants, cumulative incidence 22% (95% CI 18 to 27). </p> </li> <li> <p>4 years' follow‐up: 5 studies, 1042 participants, cumulative incidence 22% (95% CI 12 to 34). </p> </li> <li> <p>5 years' follow‐up: 12 studies, 3444 participants, cumulative incidence 39% (95% CI 25 to 53). </p> </li> <li> <p>6 years' follow‐up: 7 studies, 775 participants, cumulative incidence 29% (95% CI 25 to 34). </p> </li> <li> <p>7 years' follow‐up: 5 studies, 835 participants, cumulative incidence 19% (95% CI 13 to 26). </p> </li> <li> <p>8 years' follow‐up: 4 studies, 1021 participants, cumulative incidence 43% (95% CI 37 to 49). </p> </li> <li> <p>9 years' follow‐up: 1 study, 163 participants, cumulative incidence 53% (95% CI 45 to 60). </p> </li> <li> <p>10 years' follow‐up: 6 studies, 443 participants, cumulative incidence 26% (95% CI 17 to 37). </p> </li> <li> <p>11 years' follow‐up: 1 study, 1253 participants, cumulative incidence 46% (95% CI 43 to 49). </p> </li> <li> <p>12 years' follow‐up: 2 studies, 1552 participants, cumulative incidence 41% (95% CI 38 to 43). </p> </li> <li> <p>20 years' follow‐up: 1 study, 114 participants, cumulative incidence 60% (95% CI 50 to 68). </p> </li> </ul> </p> </section> <section id="CD012661-sec-0090"> <h6 class="title">IH defined by combined IFG and IGT</h6> <p>Diabetes incidence associated with the combination of both IFG and IGT at baseline showed pooled cumulative incidences of 29% to 84% at 1 to 12 years (<a href="#CD012661-fig-0013">Figure 13</a>). </p> <div class="figure" id="CD012661-fig-0013"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 13</div> </div> <hr class="top"/><img alt="Combined impaired glucose tolerance (IGT) and impaired fasting glucose (IFG): association with cumulative type 2 diabetes mellitus (T2DM) incidence over 1–12 years  CI: confidence interval; M: men; n/N: events/number of participants; W: women" data-id="CD012661-fig-0013" src="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-AFig-FIG13.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Combined impaired glucose tolerance (IGT) and impaired fasting glucose (IFG): association with cumulative type 2 diabetes mellitus (T2DM) incidence over 1–12 years<br/> <b>CI</b> : confidence interval; <b>M</b> : men; <b>n/N</b> : events/number of participants; <b>W</b>: women </p> </div> </div> </div> <p>The number of studies and participants, and the cumulative incidence of T2DM (pooled if more than one study) according to follow‐up period were as follows. </p> <p> <ul id="CD012661-list-0018"> <li> <p>1 year's follow‐up: 1 study, 207 participants, cumulative incidence 29% (95% CI 23 to 36). </p> </li> <li> <p>3 years' follow‐up: 1 study, 209 participants, cumulative incidence 34% (95% CI 28 to 41). </p> </li> <li> <p>5 years' follow‐up: 5 studies, 478 participants, cumulative incidence 50% (95% CI 37 to 63). </p> </li> <li> <p>6 years' follow‐up: 4 studies, 106 participants, cumulative incidence 58% (95% CI 48 to 67). </p> </li> <li> <p>7 years' follow‐up: 4 studies, 753 participants, cumulative incidence 32% (95% CI 20 to 45). </p> </li> <li> <p>8 years' follow‐up: 1 study, 356 participants, cumulative incidence 52% (95% CI 47 to 57). </p> </li> <li> <p>9 years' follow‐up: 1 study, 69 participants, cumulative incidence 84% (95% CI 74 to 91). </p> </li> <li> <p>10 years' follow‐up: 2 studies, 49 participants, cumulative incidence 30% (95% CI 17 to 44). </p> </li> <li> <p>12 years' follow‐up: 2 studies, 207 participants, cumulative incidence 70% (95% CI 63 to 76). </p> </li> </ul> </p> </section> <section id="CD012661-sec-0091"> <h6 class="title">IH defined by HbA1c<sub>5.7</sub> threshold </h6> <p>Diabetes incidence associated with HbA1c<sub>5.7</sub> at baseline and a follow‐up period of 4 to 10 years showed pooled cumulative incidences of 14% to 31% (<a href="#CD012661-fig-0014">Figure 14</a>). </p> <div class="figure" id="CD012661-fig-0014"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 14</div> </div> <hr class="top"/><img alt="Elevated glycosylated haemoglobin A1c (HbA1c) 5.7% threshold: association with cumulative type 2 diabetes mellitus (T2DM) incidence over 4–10 years  CI: confidence interval; n/N: events/number of participants" data-id="CD012661-fig-0014" src="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-AFig-FIG14.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Elevated glycosylated haemoglobin A1c (HbA1c) 5.7% threshold: association with cumulative type 2 diabetes mellitus (T2DM) incidence over 4–10 years<br/> <b>CI</b> : confidence interval; <b>n/N</b>: events/number of participants </p> </div> </div> </div> <p>The number of studies and participants, and the cumulative incidence of T2DM (pooled if more than one study) according to follow‐up period were as follows. </p> <p> <ul id="CD012661-list-0019"> <li> <p>4 years' follow‐up: 3 studies, 5352 participants, cumulative incidence 14% (95% CI 7 to 23). </p> </li> <li> <p>5 years' follow‐up: 4 studies, 3524 participants, cumulative incidence 25% (95% CI 18 to 32). </p> </li> <li> <p>6 years' follow‐up: 1 study, 675 participants, cumulative incidence 17% (95% CI 14 to 20). </p> </li> <li> <p>7 years' follow‐up: 1 study, 207 participants, cumulative incidence 21% (95% CI 16 to 27). </p> </li> <li> <p>10 years' follow‐up: 2 studies, 2854 participants, cumulative incidence 31% (95% CI 29 to 33). </p> </li> </ul> </p> </section> <section id="CD012661-sec-0092"> <h6 class="title">IH defined by HbA1c<sub>6.0</sub> threshold </h6> <p>Most studies were undertaken in Asia. Diabetes incidence associated with HbA1c<sub>6.0</sub> at baseline and a follow‐up period of 3 to 15 years showed pooled cumulative incidences of 7% to 44% (<a href="#CD012661-fig-0015">Figure 15</a>). </p> <div class="figure" id="CD012661-fig-0015"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 15</div> </div> <hr class="top"/><img alt="Elevated glycosylated haemoglobin A1c (HbA1c) 6.0% threshold: association with cumulative type 2 diabetes mellitus (T2DM) incidence over 3–15 years  CI: confidence interval; n/N: events/number of participants" data-id="CD012661-fig-0015" src="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-AFig-FIG15.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Elevated glycosylated haemoglobin A1c (HbA1c) 6.0% threshold: association with cumulative type 2 diabetes mellitus (T2DM) incidence over 3–15 years<br/> <b>CI</b> : confidence interval; <b>n/N</b>: events/number of participants </p> </div> </div> </div> <p>The number of studies and participants, and the cumulative incidence of T2DM (pooled if more than one study) according to follow‐up period were as follows. </p> <p> <ul id="CD012661-list-0020"> <li> <p>3 years' follow‐up: 1 study, 370 participants, cumulative incidence 7% (95% CI 5 to 10). </p> </li> <li> <p>4 years' follow‐up: 2 studies, 627 participants, cumulative incidence 44% (95% CI 40 to 48). </p> </li> <li> <p>5 years' follow‐up: 3 studies, 1462 participants, cumulative incidence 38% (95% CI 26 to 51). </p> </li> <li> <p>15 years' follow‐up: 1 study, 70 participants, cumulative incidence 29% (95% CI 19 to 40). </p> </li> </ul> </p> </section> <section id="CD012661-sec-0093"> <h6 class="title">Children and adolescents with IH (mostly IGT)</h6> <p>Diabetes incidence in children and adolescents, usually associated with IGT at baseline and with follow‐up of 1 to 10 years, showed pooled cumulative incidences of 1% to 56% (<a href="#CD012661-fig-0016">Figure 16</a>). We did not observe any distinct pattern between T2DM incidence and geography. </p> <div class="figure" id="CD012661-fig-0016"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 16</div> </div> <hr class="top"/><img alt="Cumulative type 2 diabetes mellitus (T2DM) incidence in children/adolescents over 1–10 years  CI: confidence interval; HbA1c 5.7: glycosylated haemoglobin A1c 5.7% threshold; (i‐)IGT: (isolated) impaired glucose tolerance; n/N: events/number of participants; NO: non‐overweight; OV: overweight" data-id="CD012661-fig-0016" src="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-AFig-FIG16.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Cumulative type 2 diabetes mellitus (T2DM) incidence in children/adolescents over 1–10 years<br/> <b>CI</b> : confidence interval; <b>HbA1c 5.7</b> : glycosylated haemoglobin A1c 5.7% threshold; <b>(i‐)IGT</b> : (isolated) impaired glucose tolerance; <b>n/N</b> : events/number of participants; <b>NO</b> : non‐overweight; <b>OV</b>: overweight </p> </div> </div> </div> <p>The number of studies and participants, and the cumulative incidence of T2DM (pooled if more than one study) according to follow‐up period were as follows. </p> <p> <ul id="CD012661-list-0021"> <li> <p>1 year's follow‐up: 1 study, 79 participants, cumulative incidence 1% (95% CI 0 to 7). </p> </li> <li> <p>2 years' follow‐up: 1 study, 33 participants, cumulative incidence 24% (95% CI 13 to 41). </p> </li> <li> <p>4 years' follow‐up: 1 study, 119 participants, cumulative incidence 3% (95% CI 1 to 7). </p> </li> <li> <p>5 years' follow‐up: 3 studies, 264 participants, pooled cumulative incidence 32% (95% CI 26 to 38). </p> </li> <li> <p>10 years' follow‐up: 1 study (2 subpopulations), 169 participants, cumulative incidence 56% (95% CI 49 to 64). </p> </li> </ul> </p> </section> <section id="CD012661-sec-0094"> <h6 class="title">Special populations with IH</h6> <p>Studies involving black populations were scarce: one study reported a cumulative T2DM incidence of 35% in African Surinamese after 10 years of follow‐up in association with IFG<sub>5.6</sub> at baseline (<a href="./references#CD012661-bbs2-0001" title="AdmiraalWM , HollemanF , SnijderMB , PetersRJ , BrewsterLM , HoekstraJB , et al. Ethnic disparities in the association of impaired fasting glucose with the 10‐year cumulative incidence of type 2 diabetes. Diabetes Research and Clinical Practice2014;103(1):127‐32. [PUBMED: 24355200] AgyemangC , vanValkengoedI , van denBornB J , StronksK . Prevalence and determinants of prehypertension among African Surinamese, Hindustani Surinamese, and White Dutch in Amsterdam, the Netherlands: the SUNSET study. European Journal of Cardiovascular Prevention and Rehabilitation2007;14(6):775‐81. BindrabanNR , vanValkengoedIG , MairuhuG , HollemanF , HoekstraJB , MichelsBP , et al. Prevalence of diabetes mellitus and the performance of a risk score among Hindustani Surinamese, African Surinamese and ethnic Dutch: a cross‐sectional population‐based study. BMC Public Health2008;8:271. [PUBMED: 18673544] DekkerLH , NicolaouM , van derADl , BusschersWB , BrewsterLM , SnijderMB , et al. Sex differences in the association between serum ferritin and fasting glucose in type 2 diabetes among South Asian Surinamese, African Surinamese, and ethnic Dutch: the population‐based SUNSET study. Diabetes Care2013;36(4):965‐71. ">Admiraal 2014</a>). Another study, which used IFG<sub>5.6</sub> at baseline, reported a T2DM cumulative incidence of 33% in African Americans after 7.5 years of follow‐up (<a href="./references#CD012661-bbs2-0102" title="BildDE , BluemkeDA , BurkeGL , DetranoR , Diez RouxAV , FolsomAR , et al. Multi‐ethnic study of atherosclerosis: objectives and design. American Journal of Epidemiology2002;156(9):871‐81. [PUBMED: 12397006] YeboahJ , BertoniA G , HerringtonDM , PostWS , BurkeGL . Impaired fasting glucose and the risk of incident diabetes mellitus and cardiovascular events in an adult population: MESA (multi‐ethnic study of atherosclerosis). Journal of the American College of Cardiology2011;58(2):140‐6. [PUBMED: 21718910] ">Yeboah 2011</a>). </p> </section> </section> <section id="CD012661-sec-0095"> <h5 class="title">b) Regression from IH to normoglycaemia</h5> <section id="CD012661-sec-0096"> <h6 class="title">Adults</h6> <p>In the 47 studies reporting data on regression from IH to normoglycaemia in adults within a follow‐up period of 1 to 11 years, pooled percentages ranged from 17% to 59% (<a href="#CD012661-fig-0017">Figure 17</a>; <a href="#CD012661-fig-0018">Figure 18</a>). Regression to normoglycaemia varied widely and showed neither a clear linear reduction or increase nor a distinct pattern associated with geography. Regression rates were often reported in association with IGT at baseline; however, there were no distinct differences in regression rates when compared with IFG<sub>5.6</sub>, IFG<sub>6.1</sub> or HbA1c<sub>5.7</sub> as IH risk factors. </p> <div class="figure" id="CD012661-fig-0017"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 17</div> </div> <hr class="top"/><img alt="Regression from intermediate hyperglycaemia to normoglycaemia in adults over 1–5 years  CI: confidence interval; HbA1c5.7 : glycosylated haemoglobin A1c 5.7%; i‐IFG5.6/6.1 : (isolated) impaired fasting glucose 5.6/6.1 mmol/L threshold;IGT: impaired glucose tolerance; n/N: events/number of participants" data-id="CD012661-fig-0017" src="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-AFig-FIG17.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Regression from intermediate hyperglycaemia to normoglycaemia in adults over 1–5 years<br/> <b>CI</b> : confidence interval; <b>HbA1c<sub>5.7</sub> </b> : glycosylated haemoglobin A1c 5.7%; <b>i‐IFG<sub>5.6/6.1</sub> </b> : (isolated) impaired fasting glucose 5.6/6.1 mmol/L threshold;<b>IGT</b> : impaired glucose tolerance; <b>n/N</b>: events/number of participants </p> </div> </div> </div> <div class="figure" id="CD012661-fig-0018"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 18</div> </div> <hr class="top"/><img alt="Regression from intermediate hyperglycaemia to normoglycaemia in adults over 6–11 years  CI: confidence interval; i‐IFG5.6/6.1 : (isolated) impaired fasting glucose 5.6/6.1 mmol/L threshold; i‐IGT: (isolated) impaired glucose tolerance; n/N: events/number of participants" data-id="CD012661-fig-0018" src="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-AFig-FIG18.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Regression from intermediate hyperglycaemia to normoglycaemia in adults over 6–11 years<br/> <b>CI</b> : confidence interval; <b>i‐IFG<sub>5.6/6.1</sub> </b> : (isolated) impaired fasting glucose 5.6/6.1 mmol/L threshold; <b>i‐IGT</b> : (isolated) impaired glucose tolerance; <b>n/N</b>: events/number of participants </p> </div> </div> </div> <p>The number of studies and participants, and the proportion regressing from IH to normoglycaemia (pooled if more than one study) according to follow‐up period were as follows. </p> <p> <ul id="CD012661-list-0022"> <li> <p>1 year's follow‐up: 2 studies, 375 participants, regression to normoglycaemia 59% (95% CI 54 to 64). </p> </li> <li> <p>2 years' follow‐up: 9 studies, 2852 participants, regression to normoglycaemia 46% (95% CI 36 to 55). </p> </li> <li> <p>3 years' follow‐up: 7 studies, 1356 participants, regression to normoglycaemia 41% (95% CI 24 to 59). </p> </li> <li> <p>4 years' follow‐up: 3 studies, 807 participants, regression to normoglycaemia 33% (95% CI 26 to 40). </p> </li> <li> <p>5 years' follow‐up: nine studies, 2603 participants, regression to normoglycaemia 34% (95% CI 27 to 42). </p> </li> <li> <p>6 years' follow‐up: 5 studies, 1328 participants, regression to normoglycaemia 23% (95% CI 3 to 53). </p> </li> <li> <p>7 years' follow‐up: 4 studies, 679 participants, regression to normoglycaemia 41% (95% CI 37 to 45). </p> </li> <li> <p>8 years' follow‐up: 2 studies, 328 participants, regression to normoglycaemia 39% (95% CI 33 to 44). </p> </li> <li> <p>9 years' follow‐up: 1 study, 299 participants, regression to normoglycaemia 17% (95% CI 14 to 22) </p> </li> <li> <p>10 years' follow‐up: 7 studies, 894 participants, regression to normoglycaemia 42% (95% CI 22 to 63). </p> </li> <li> <p>11 years' follow‐up: 2 studies, 736 participants, regression to normoglycaemia 28% (95% CI 17 to 39). </p> </li> </ul> </p> </section> <section id="CD012661-sec-0097"> <h6 class="title">Children and adolescents</h6> <p>Regression from IH to normoglycaemia in children and adolescents within a follow‐up period of one to four years showed percentages from 45% to 81% (<a href="#CD012661-fig-0019">Figure 19</a>). There were no distinct patterns with regard to geography. IGT at baseline was often investigated as the IH risk factor. </p> <div class="figure" id="CD012661-fig-0019"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 19</div> </div> <hr class="top"/><img alt="Regression from intermediate hyperglycaemia to normoglycaemia in children/adolescents over 1–4 years  CI: confidence interval; IGT: impaired glucose tolerance; n/N: events/number of participants" data-id="CD012661-fig-0019" src="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-AFig-FIG19.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Regression from intermediate hyperglycaemia to normoglycaemia in children/adolescents over 1–4 years<br/> <b>CI</b> : confidence interval; <b>IGT</b> : impaired glucose tolerance; <b>n/N</b>: events/number of participants </p> </div> </div> </div> <p>The number of studies and participants, and the proportion regressing from IH to normoglycaemia according to follow‐up period were as follows. </p> <p> <ul id="CD012661-list-0023"> <li> <p>1 year's follow‐up: 1 study, 79 participants, regression to normoglycaemia 66% (95% CI 55 to 75). </p> </li> <li> <p>2 years' follow‐up: 1 study, 33 participants, regression to normoglycaemia 45% (95% CI 30 to 62). </p> </li> <li> <p>4 years' follow‐up: 1 study, 119 participants, regression to normoglycaemia 81% (95% CI 73 to 87). </p> </li> </ul> </p> </section> </section> <section id="CD012661-sec-0098"> <h5 class="title">c) IH versus normoglycaemia as a prognostic factor for developing T2DM</h5> <p>Prognostic factor studies used various definitions for IH and different effect measures (IRR, OR and HR) to express the effect of glycaemic status on development of T2DM. The findings are presented below according to IH definition and effect measure. No data were available on the prognostic factor IH versus normoglycaemia for children or adolescents. </p> <section id="CD012661-sec-0099"> <h6 class="title">HR as the effect measure</h6> <section id="CD012661-sec-0100"> <p><b>IFG 5.6 mmol/L threshold</b></p> <p>Eight studies reported HRs and the IFG<sub>5.6</sub> threshold for IH at baseline (<a href="./references#CD012661-fig-0027" title="">Analysis 1.1</a>). The length of follow‐up ranged from 4 to 22 years (studies are ordered with ascending length of follow‐up in <a href="./references#CD012661-fig-0027" title="">Analysis 1.1</a>). The studies included 9017 participants with IH and 25,850 participants with normoglycaemia. The overall HR was 4.32 (95% CI 2.61 to 7.12). The 95% prediction interval ranged from 0.75 to 25.01 </p> <p>The comparison of geographic regions showed the following results (<a href="./references#CD012661-fig-0027" title="">Analysis 1.1</a>). </p> <p> <ul id="CD012661-list-0024"> <li> <p>Asia/Middle East (4 studies, 2385 participants with IH and 12,418 participants with normoglycaemia, 5 to 12 years' follow‐up): the pooled HR was 5.07 (95% CI 3.41 to 7.53). The 95% prediction interval ranged from 1.07 to 24.02. </p> </li> <li> <p>Australia/Europe/North America (3 studies, 5685 participants with IH and 12,837 participants with normoglycaemia, 8 to 22 years' follow‐up): the pooled HR was 4.15 (95% CI 1.24 to 13.87). Calculation of the 95% prediction interval did not provide a meaningful estimate. </p> </li> <li> <p>American Indians/Islands (1 study, 947 participants with IH and 595 participants with normoglycaemia, 4 years' follow‐up): the HR was 2.38 (95% CI 1.85 to 3.06). </p> </li> </ul> </p> </section> <section id="CD012661-sec-0101"> <p><b>IFG 6.1 mmol/L threshold</b></p> <p>Nine studies reported HRs and the IFG<sub>6.1</sub> threshold for IH at baseline (<a href="./references#CD012661-fig-0028" title="">Analysis 1.2</a>). The length of follow‐up ranged from 5 to 22 years (studies are ordered by ascending length of follow‐up in <a href="./references#CD012661-fig-0028" title="">Analysis 1.2</a>). The studies included 2818 participants with IH and 18,591 participants with normoglycaemia. The overall HR was 5.47 (95% CI 3.50 to 8.54). The 95% prediction interval ranged from 1.09 to 27.56 </p> <p>The comparison of geographic regions showed the following results (<a href="./references#CD012661-fig-0028" title="">Analysis 1.2</a>). </p> <p> <ul id="CD012661-list-0025"> <li> <p>Asia/Middle East (5 studies, 1054 participants with IH and 9756 participants with normoglycaemia, 5 to 11 years' follow‐up): the pooled HR was 10.55 (95% CI 3.61 to 30.81). Calculation of the 95% prediction interval did not provide a meaningful estimate. </p> </li> <li> <p>Australia/Europe/North America (4 studies, 1736 participants with IH and 8835 participants with normoglycaemia, 6 to 22 years' follow‐up): the pooled HR was 3.30 (95% CI 2.32 to 4.67). The 95% prediction interval ranged from 0.84 to 12.99. </p> </li> <li> <p>Latin America (1 study, 28 participants with IH and 66 participants with normoglycaemia, 6 years' follow‐up): the HR was 2.06 (95% CI 1.76 to 2.41). </p> </li> </ul> </p> </section> <section id="CD012661-sec-0102"> <p><b>IGT</b></p> <p>Five studies reported HRs and IGT for IH at baseline (<a href="./references#CD012661-fig-0029" title="">Analysis 1.3</a>). The length of follow‐up ranged from 5 to 16 years (studies are ordered by ascending length of follow‐up in <a href="./references#CD012661-fig-0029" title="">Analysis 1.3</a>). These studies included 4010 participants with IH and 12,566 participants with normoglycaemia. The overall HR was 3.61 (95% CI 2.31 to 5.64). The 95% prediction interval ranged from 0.69 to 18.97. </p> <p>The comparison of geographic regions showed the following results (<a href="./references#CD012661-fig-0029" title="">Analysis 1.3</a>). </p> <p> <ul id="CD012661-list-0026"> <li> <p>Asia/Middle East (3 studies, 1780 participants with IH and 6695 participants with normoglycaemia, 5 to 12 years' follow‐up): the pooled HR was 4.48 (95% CI 2.81 to 7.15). Calculation of the 95% prediction interval did not provide a meaningful estimate. </p> </li> <li> <p>Australia/Europe/North America (2 studies, 2230 participants with IH and 5871 participants with normoglycaemia, 6 to 16 years' follow‐up): the pooled HR was 2.53 (95% CI 1.52 to 4.19). </p> </li> </ul> </p> </section> <section id="CD012661-sec-0103"> <p><b>Combined IFG and IGT</b></p> <p>Five studies reported HRs and used both IFG and IGT for defining IH at baseline (<a href="./references#CD012661-fig-0030" title="">Analysis 1.4</a>). The length of follow‐up ranged from 4 to 12 years (studies are ordered by ascending length of follow‐up in <a href="./references#CD012661-fig-0030" title="">Analysis 1.4</a>). These studies included 1038 participants with IH and 8719 participants with normoglycaemia. The overall HR was 6.90 (95% CI 4.15 to 11.45). The 95% prediction interval ranged from 1.06 to 44.95. </p> <p>The comparison of geographic regions showed the following results (<a href="./references#CD012661-fig-0030" title="">Analysis 1.4</a>). </p> <p> <ul id="CD012661-list-0027"> <li> <p>Asia/Middle East (3 studies, 461 participants with IH and 6695 participants with normoglycaemia, 5 to 12 years' follow‐up): the pooled HR was 10.20 (95% CI 5.45 to 19.09). Calculation of the 95% prediction interval did not provide a meaningful estimate. </p> </li> <li> <p>Australia/Europe/North America (1 study, 221 participants with IH and 1429 participants with normoglycaemia, 6 years' follow‐up): the HR was 3.80 (95% CI 2.30 to 6.28). </p> </li> <li> <p>American Indians/Islands (1 study, 356 participants with both IFG and IGT and 595 participants with normoglycaemia, 4 years' follow‐up): the HR was 4.06 (95% CI 3.05 to 5.40). </p> </li> </ul> </p> </section> <section id="CD012661-sec-0104"> <p><b>HbA1c 5.7% threshold</b></p> <p>Four studies reported HRs and the HbA1c<sub>5.7</sub> threshold for IH at baseline (<a href="./references#CD012661-fig-0031" title="">Analysis 1.5</a>). The length of follow‐up ranged from 4 to 22 years (studies are ordered by ascending length of follow‐up in <a href="./references#CD012661-fig-0031" title="">Analysis 1.5</a>). The studies included 5223 participants with IH and 19,824 participants with normoglycaemia. The overall HR was 5.55 (95% CI 2.77 to 11.12). The 95% prediction interval ranged from 0.23 to 141.18. </p> <p>The comparison of geographic regions showed the following results (<a href="./references#CD012661-fig-0031" title="">Analysis 1.5</a>). </p> <p> <ul id="CD012661-list-0028"> <li> <p>Asia/Middle East (3 studies, 3196 participants with IH and 13,609 participants with normoglycaemia, 4 to 5 years' follow‐up): the pooled HR was 7.21 (95% CI 5.14 to 10.11). The 95% prediction interval ranged from 0.81 to 64.52. </p> </li> <li> <p>Australia/Europe/North America (1 study, 2027 participants with IH and 6215 participants with normoglycaemia, 22 years' follow‐up): the HR was 2.71 (95% CI 2.48 to 2.96). </p> </li> </ul> </p> </section> <section id="CD012661-sec-0105"> <p><b>HbA1c 6.0% threshold</b></p> <p>Six studies reported HRs and the HbA1c<sub>6.0</sub> threshold for IH at baseline (<a href="./references#CD012661-fig-0032" title="">Analysis 1.6</a>). The length of follow‐up ranged from 4 to 22 years (studies are ordered by ascending length of follow‐up in <a href="./references#CD012661-fig-0032" title="">Analysis 1.6</a>). The studies included 4532 participants with IH and 26,167 participants with normoglycaemia. The overall HR was 10.10 (95% CI 3.59 to 28.43). Calculation of the 95% prediction interval did not provide a meaningful estimate. </p> <p>The comparison of geographic regions showed the following results (<a href="./references#CD012661-fig-0032" title="">Analysis 1.6</a>). </p> <p> <ul id="CD012661-list-0029"> <li> <p>Asia/Middle East (4 studies, 3492 participants with IH and 19,242 participants with normoglycaemia, 4 to 12 years' follow‐up): the pooled HR was 13.12 (95% CI 4.10 to 41.96). Calculation of the 95% prediction interval did not provide a meaningful estimate. </p> </li> <li> <p>Australia/Europe/North America (2 studies, 1040 participants with IH and 6925 participants with normoglycaemia, 15 to 22 years' follow‐up): the pooled HR was 5.09 (95% CI 1.69 to 15.37). </p> </li> </ul> </p> </section> <section id="CD012661-sec-0106"> <p><b>Both elevated HbA1c and IFG</b></p> <p>One study in Japanese participants provided data on elevated HbA1c and IFG for defining IH at baseline and estimated the effect of IH versus normoglycaemia using the HR (<a href="./references#CD012661-fig-0033" title="">Analysis 1.7</a>). The combination of HbA1c<sub>5.7</sub> plus IFG<sub>5.6</sub> (410 participants) when compared with normoglycaemia (4149 participants) showed an HR of 32.50 (95% CI 23.00 to 45.92). The combination of HbA1c<sub>5.7</sub> plus IFG<sub>6.1</sub> (159 participants) when compared with normoglycaemia (5198 participants) showed an HR of 37.90 (95% CI 28.10 to 51.12). The combination of HbA1c<sub>6.0</sub> plus IFG<sub>5.6</sub> (135 participants) when compared with normoglycaemia (4493 participants) showed an HR of 53.70 (95% CI 38.40 to 75.09). The combination of HbA1c<sub>6.0</sub> plus IFG<sub>6.1</sub> (72 participants) when compared with normoglycaemia (5730 participants) showed an HR of 52.30 (95% CI 37.80 to 72.37). </p> </section> <section id="CD012661-sec-0107"> <p><b>IH in special populations</b></p> <p>Data on black populations were scarce: one study in African Surinamese reported an adjusted OR of 5.1 (95% CI 2.0 to 13.3) for the association between IFG<sub>5.6</sub> at baseline and T2DM incidence at 7.5 years' follow‐up (<a href="./references#CD012661-bbs2-0001" title="AdmiraalWM , HollemanF , SnijderMB , PetersRJ , BrewsterLM , HoekstraJB , et al. Ethnic disparities in the association of impaired fasting glucose with the 10‐year cumulative incidence of type 2 diabetes. Diabetes Research and Clinical Practice2014;103(1):127‐32. [PUBMED: 24355200] AgyemangC , vanValkengoedI , van denBornB J , StronksK . Prevalence and determinants of prehypertension among African Surinamese, Hindustani Surinamese, and White Dutch in Amsterdam, the Netherlands: the SUNSET study. European Journal of Cardiovascular Prevention and Rehabilitation2007;14(6):775‐81. BindrabanNR , vanValkengoedIG , MairuhuG , HollemanF , HoekstraJB , MichelsBP , et al. Prevalence of diabetes mellitus and the performance of a risk score among Hindustani Surinamese, African Surinamese and ethnic Dutch: a cross‐sectional population‐based study. BMC Public Health2008;8:271. [PUBMED: 18673544] DekkerLH , NicolaouM , van derADl , BusschersWB , BrewsterLM , SnijderMB , et al. Sex differences in the association between serum ferritin and fasting glucose in type 2 diabetes among South Asian Surinamese, African Surinamese, and ethnic Dutch: the population‐based SUNSET study. Diabetes Care2013;36(4):965‐71. ">Admiraal 2014</a>). Another study including a subgroup of African Americans reported the association of various measures of IH at baseline with the development of T2DM using HRs (<a href="./references#CD012661-bbs2-0097" title="LeongA , DayaN , PornealaB , DevlinJJ , ShiffmanD , McPhaulMJ , et al. Prediction of type 2 diabetes by hemoglobin A1c in two community‐based cohorts. Diabetes Care2018;41(1):60‐8. [PUBMED: 29074816] SchmidtMI , DuncanBB , BangH , PankowJS , BallantyneCM , GoldenSH , et al. Identifying individuals at high risk for diabetes ‐ the atherosclerosis risk in communities study. Diabetes Care2005;28(8):2013‐8. [PUBMED: 16043747] SelvinE , RawlingsAM , GramsM , KleinR , SharrettAR , SteffesM , et al. Fructosamine and glycated albumin for risk stratification and prediction of incident diabetes and microvascular complications: a prospective cohort analysis of the atherosclerosis risk in communities (ARIC) study. Lancet Diabetes &amp; Endocrinology2014;2(4):279‐88. [PUBMED: 24703046] SelvinE , SteffesM W , GreggE , BrancatiF L , CoreshJ . Performance of A1C for the classification and prediction of diabetes. Diabetes Care2011;34(1):84‐9. [PUBMED: 20855549] SelvinE , SteffesMW , ZhuH , MatsushitaK , WagenknechtL , PankowJ , et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. New England Journal of Medicine2010;362(9):800‐11. [PUBMED: 20200384] WarrenB , PankowJ S , MatsushitaK , PunjabiNM , DayaNR , GramsM , et al. Comparative prognostic performance of definitions of prediabetes: a prospective cohort analysis of the atherosclerosis risk in communities (ARIC) study. Lancet Diabetes &amp; Endocrinology2017;5(1):34‐42. [PUBMED: 27863979] WheltonSP , McEvoyJW , LazoM , CoreshJ , BallantyneCM , SelvinE . High‐sensitivity cardiac troponin T (hs‐cTnT) as a predictor of incident diabetes in the atherosclerosis risk in communities study. Diabetes Care2017;40(2):261‐9. [PUBMED: 28108537] ">Warren 2017</a>): after 16 years of follow‐up the HR for IFG<sub>5.6</sub> was 2.65 (95% CI 2.11 to 3.32); for IFG<sub>6.1</sub>, the HR was 3.16 (95% CI 2.47 to 4.06); and for IGT, the HR was 2.55 (95% CI 2.01 to 3.22). After 22 years' follow‐up, the HR for IFG<sub>5.6</sub> was 2.05 (95% CI 1.75 to 2.40); for IFG<sub>6.1</sub>, the HR was 2.66 (95% CI 2.26 to 3.13); for HbA1c<sub>5.7</sub>, the HR was 2.24 (95% CI 1.92 to 2.61); and for HbA1c<sub>6.0</sub>, the HR was 2.60 (95% CI 2.21 to 3.05). </p> </section> </section> <section id="CD012661-sec-0108"> <h6 class="title">Incidence rate ratio as the effect measure</h6> <section id="CD012661-sec-0109"> <p><b>IFG 5.6 mmol/L threshold</b></p> <p>Ten studies reported incidence rate ratios (IRRs) and used the IFG<sub>5.6</sub> threshold for IH. The studies included 24,357 participants with IH and 155,272 participants with normoglycaemia (<a href="#CD012661-fig-0020">Figure 20</a>). Of those with IH, 661 (2.7%) developed T2DM compared with 1270 (0.8%) in participants with normoglycaemia. The overall IRR was 4.81 (95% CI 3.67 to 6.30) with a 95% prediction interval ranging from 1.95 to 11.83. </p> <div class="figure" id="CD012661-fig-0020"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 20</div> </div> <hr class="top"/><img alt="IFG: impaired fasting glucose; IRR: incidence rate ratio; n: number of cases; T: person‐time in years" data-id="CD012661-fig-0020" src="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-AFig-FIG20.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p><b>IFG</b> : impaired fasting glucose; <b>IRR</b> : incidence rate ratio; <b>n</b> : number of cases; <b>T</b>: person‐time in years </p> </div> </div> </div> <p>The results for the geographic regions were as follows.</p> <p> <ul id="CD012661-list-0030"> <li> <p>Asia/Middle East (6 studies): T2DM developed in 434/15,661 (2.8%) participants with IH and in 1204/145,597 (0.8%) participants with normoglycaemia. The pooled IRR was 5.23 (95% CI 3.77 to 7.25) with a 95% prediction interval ranging from 1.72 to 15.89. </p> </li> <li> <p>Australia/Europe/North America (3 studies): T2DM developed in 90/6322 (1.4%) participants with IH and in 32/8062 (0.4%) participants with normoglycaemia. The pooled IRR was 4.96 (95% CI 3.25 to 7.57) with a 95% prediction interval ranging from 0.32 to 77.24. </p> </li> <li> <p>American Indians/Islands (1 study): T2DM developed in 137/2374 (5.8%) participants with IH and in 34/1613 (2.1%) participants with normoglycaemia. The IRR was 2.74 (95% CI 1.88 to 3.99). </p> </li> </ul> </p> </section> <section id="CD012661-sec-0110"> <p><b>IFG 6.1 mmol/L threshold</b></p> <p>Six studies reported IRRs and used an IFG<sub>6.1</sub> threshold for IH. Thee studies included 5115 participants with IH, of whom 127 (2.5%) developed T2DM, plus 56,580 participants with normoglycaemia, of whom 188 (0.3%) developed T2DM (<a href="#CD012661-fig-0021">Figure 21</a>). The overall IRR was 6.82 (95% CI 4.53 to 10.25) with a 95% prediction interval ranging from 2.03 to 22.87. </p> <div class="figure" id="CD012661-fig-0021"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 21</div> </div> <hr class="top"/><img alt="IFG: impaired fasting glucose; IRR: incidence rate ratio; n: number of cases; T: person‐time in years" data-id="CD012661-fig-0021" src="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-AFig-FIG21.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p><b>IFG</b> : impaired fasting glucose; <b>IRR</b> : incidence rate ratio; <b>n</b> : number of cases; <b>T</b>: person‐time in years </p> </div> </div> </div> <p>The comparison of geographic regions showed a lower IRR for Asia/Middle East as follows.</p> <p> <ul id="CD012661-list-0031"> <li> <p>Asia/Middle East (2 studies): T2DM developed in 21/1677 (1.3%) participants with IH and in 89/36,334 (0.2%) participants with normoglycaemia. The pooled IRR was 3.62 (95% CI 1.67 to 7.83). </p> </li> <li> <p>Australia/Europe/North America (4 studies): T2DM developed in 106/3438 (3.1%) participants with IH and in 99/20,246 (0.5%) participants with normoglycaemia. The pooled IRR was 8.55 (95% CI 6.37 to 11.48) with a 95% prediction interval ranging from 4.37 to 16.73. </p> </li> </ul> </p> </section> <section id="CD012661-sec-0111"> <p><b>IGT threshold</b></p> <p>Twelve studies reported IRRs and defined IH using IGT. The studies included 18,468 participants with IH and 98,409 participants with normoglycaemia (<a href="#CD012661-fig-0022">Figure 22</a>). T2DM developed in 947 (5.1%) participants with IH compared to 1147 (1.2%) in participants with normoglycaemia. The overall IRR was 4.48 (95% CI 3.69 to 5.44) with a 95% prediction interval ranging from 2.60 to 7.70. </p> <div class="figure" id="CD012661-fig-0022"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 22</div> </div> <hr class="top"/><img alt="IGT: impaired glucose tolerance; IRR: incidence rate ratio; n: number of cases; T: person‐time in years" data-id="CD012661-fig-0022" src="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-AFig-FIG22.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p><b>IGT</b> : impaired glucose tolerance; <b>IRR</b> : incidence rate ratio; <b>n</b> : number of cases; <b>T</b>: person‐time in years </p> </div> </div> </div> <p>The findings according to geographic regions were as follows.</p> <p> <ul id="CD012661-list-0032"> <li> <p>Asia/Middle East (5 studies): T2DM developed in 766/14,809 (5.2%) participants with IH and in 390/73,128 (0.5%) participants with normoglycaemia. The pooled IRR was 3.93 (95% CI 3.03 to 5.10) with a 95% prediction interval ranging from 1.71 to 9.02. </p> </li> <li> <p>Australia/Europe/North America (5 studies): T2DM developed in 75/2572 participants with IH and in 117/22,329 (0.5%) participants with normoglycaemia. The pooled IRR was 5.93 (95% CI 4.11 to 8.57) with a 95% prediction interval ranging from 2.38 to 14.81. </p> </li> <li> <p>American Indians/Islands (2 studies): T2DM developed in 88/1087 (8.1%) participants with IH and in 48/2952 (1.6%) participants with normoglycaemia. The pooled IRR was 4.46 (95% CI 3.12 to 6.38). </p> </li> </ul> </p> </section> <section id="CD012661-sec-0112"> <p><b>Combined IFG and IGT</b></p> <p>Nine studies used both IFG and IGT to define IH and reported IRRs. Of the 4470 participants with IH included in the studies, 551 (12.3%) developed T2DM compared with 1091 of the 90,072 (1.2%) participants with normoglycaemia (<a href="#CD012661-fig-0023">Figure 23</a>). The overall IRR was 10.94 (95% CI 7.22 to 16.58) with 95% prediction interval ranging from 2.58 to 46.46. </p> <div class="figure" id="CD012661-fig-0023"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 23</div> </div> <hr class="top"/><img alt="IFG: impaired fasting glucose; IGT: impaired glucose tolerance; IRR: incidence rate ratio; n: number of cases; T: person‐time in years" data-id="CD012661-fig-0023" src="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-AFig-FIG23.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p><b>IFG</b> : impaired fasting glucose; <b>IGT</b> : impaired glucose tolerance; <b>IRR</b> : incidence rate ratio; <b>n</b> : number of cases; <b>T</b>: person‐time in years </p> </div> </div> </div> <p>A lower pooled IRR was observed for the American Indians/Islands cohort compared to other cohorts as shown below. </p> <p> <ul id="CD012661-list-0033"> <li> <p>Asia/Middle East (4 studies): T2DM developed in 430/3166 (13.6%) participants with IH and in 918/69,463 (1.3%) participants with normoglycaemia. The pooled IRR was 11.20 (95% CI 5.59 to 22.43). Calculation of the 95% prediction interval did not provide a meaningful estimate. </p> </li> <li> <p>Australia/Europe/North America (4 studies): T2DM developed in 55/699 (7.9%) participants with IH and in 109/18,966 (0.6%) participants with normoglycaemia. The pooled IRR was 13.92 (95% CI 9.99 to 19.40) with a 95% prediction interval ranging from 6.71 to 28.85. </p> </li> <li> <p>American Indians/Islands (1 study): T2DM developed in 66/605 (10.9%) participants with IH and in 34/1613 (2.1%) participants with normoglycaemia. The pooled IRR was 5.18 (95% CI 3.42 to 7.83). </p> </li> </ul> </p> </section> <section id="CD012661-sec-0113"> <p><b>HbA1c 5.7% threshold only and the combination of HbA1c 5.7% threshold with IFG 5.6 mmol/L threshold</b></p> <p>One study, <a href="./references#CD012661-bbs2-0030" title="HeianzaY , AraseY , FujiharaK , HsiehSD , SaitoK , TsujiH , et al. Longitudinal trajectories of HbA1c and fasting plasma glucose levels during the development of type 2 diabetes: the Toranomon hospital health management center study 7 (TOPICS 7). Diabetes Care2012;35(5):1050‐2. [PUBMED: 22456865] HeianzaY , AraseY , FujiharaK , TsujiH , SaitoK , HsiehSD , et al. High normal HbA(1c) levels were associated with impaired insulin secretion without escalating insulin resistance in Japanese individuals: the Toranomon hospital health management center study 8 (TOPICS 8). Diabetic Medicine2012;29(10):1285‐90. HeianzaY , AraseY , FujiharaK , TsujiH , SaitoK , HsiehSD , et al. Screening for pre‐diabetes to predict future diabetes using various cut‐off points for HbA(1c) and impaired fasting glucose: the Toranomon hospital health management center study 4 (TOPICS 4). Diabetic Medicine2012;29(9):e279‐85. [PUBMED: 22510023] HeianzaY , AraseY , HsiehSD , SaitoK , TsujiH , KodamaS , et al. Development of a new scoring system for predicting the 5 year incidence of type 2 diabetes in Japan: the Toranomon hospital health management center study 6 (TOPICS 6). Diabetologia2012;55(12):3213‐23. [PUBMED: 22955996] HeianzaY , HaraS , AraseY , SaitoK , FujiwaraK , TsujiH , et al. HbA1c 5.7‐6.4% and impaired fasting plasma glucose for diagnosis of prediabetes and risk of progression to diabetes in Japan (TOPICS 3): a longitudinal cohort study. Lancet2011;378(9786):147‐55. [MEDLINE: 21705064] HeianzaY , HaraS , AraseY , SaitoK , TotsukaK , TsujiH , et al. Low serum potassium levels and risk of type 2 diabetes: the Toranomon hospital health management center study 1 (TOPICS 1). Diabetologia2011;54(4):762‐6. [PUBMED: 21212932] ">Heianza 2012</a>, reported using HbA1c<sub>5.7</sub> only or the combination of IFG<sub>5.6</sub> plus HbA1c<sub>5.7</sub> to define IH at baseline (<a href="#CD012661-fig-0024">Figure 24</a>). </p> <div class="figure" id="CD012661-fig-0024"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 24</div> </div> <hr class="top"/><img alt="IFG: impaired fasting glucose; HbA1c: glycosylated haemoglobin A1c; IRR: incidence rate ratio; n: number of cases; T: person‐time in years" data-id="CD012661-fig-0024" src="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-AFig-FIG24.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p><b>IFG</b> : impaired fasting glucose; <b>HbA1c</b> : glycosylated haemoglobin A1c; <b>IRR</b> : incidence rate ratio; <b>n</b> : number of cases; <b>T</b>: person‐time in years </p> </div> </div> </div> <p>T2DM developed in 30/1965 (1.5%) participants with IH defined using HbA1c<sub>5.7</sub> only compared with 46/19,961 (0.2%) in participants with normoglycaemia. The IRR was 6.62 (4.18 to 10.49). </p> <p>In the cohort with both HbA1c<sub>5.7</sub> and IFG<sub>5.6</sub>, T2DM developed in 154/1641 (9.4%) participants compared with 46/19961 (0.2%) in participants with normoglycaemia. The IRR was 40.72 (95% CI 29.30 to 56.61). </p> </section> </section> <section id="CD012661-sec-0114"> <h6 class="title">Odds ratio as the effect measure</h6> <section id="CD012661-sec-0115"> <p><b>IFG 5.6 mmol/L threshold</b></p> <p>Twenty‐one studies reported ORs and the IFG<sub>5.6</sub> threshold for IH (<a href="./references#CD012661-fig-0034" title="">Analysis 2.1</a>). The length of follow‐up ranged from 4 to 24 years (studies are ordered by ascending length of follow‐up in <a href="./references#CD012661-fig-0034" title="">Analysis 2.1</a>). The studies included 9320 participants with IH and 38,327 participants with normoglycaemia. The overall OR was 4.15 (95% CI 2.75 to 6.28). The 95% prediction interval ranged from 0.54 to 32.00. </p> <p>The comparison of geographic regions showed the following results (<a href="./references#CD012661-fig-0034" title="">Analysis 2.1</a>). </p> <p> <ul id="CD012661-list-0034"> <li> <p>Asia/Middle East (10 studies, 6359 participants with IH and 28,218 participants with normoglycaemia, 4 to 24 years' follow‐up): the pooled OR was 2.94 (95% CI 1.77 to 4.86). The 95% prediction interval ranged from 0.43 to 19.93. </p> </li> <li> <p>Australia/Europe/North America (9 studies, 1949 participants with IH and 7920 participants with normoglycaemia, 4 to 12 years' follow‐up): the pooled OR was 6.47 (95% CI 3.81 to 11.00). The 95% prediction interval ranged from 0.99 to 42.32. </p> </li> <li> <p>Latin America (1 study, 65 participants with IH and 1594 participants with normoglycaemia, 7 years' follow‐up): the OR was 4.28 (95% CI 3.21 to 5.71). </p> </li> <li> <p>American Indians/Islands (1 study, 947 participants with IH and 595 participants with normoglycaemia, 4 years' follow‐up): the OR was 3.12 (95% CI 2.31 to 4.21). </p> </li> </ul> </p> <p>The test for subgroup differences did not indicate a significant subgroup effect (P = 0.07). However, two of the four subgroups had only one study each, so the validity of the analysis is uncertain. Furthermore, there is substantial heterogeneity between studies (Tau<sup>2</sup> = 0.65 and 0.59) within each of the other two subgroups, and the subgroup analysis does not appear to have explained heterogeneity. </p> </section> <section id="CD012661-sec-0116"> <p><b>IFG 6.1 mmol/L threshold</b></p> <p>Fifteen studies reported ORs and the IFG<sub>6.1</sub> threshold for IH at baseline (<a href="./references#CD012661-fig-0035" title="">Analysis 2.2</a>). The length of follow‐up ranged from 3 to 24 years (studies are ordered by ascending length of follow‐up in <a href="./references#CD012661-fig-0035" title="">Analysis 2.2</a>). The studies included 4574 participants with threshold for IH and 32,292 participants with normoglycaemia. The overall OR was 6.60 (95% CI 4.18 to 10.43). The 95% prediction interval ranged from 0.93 to 46.82. </p> <p>The comparison between geographic regions showed the following results (<a href="./references#CD012661-fig-0035" title="">Analysis 2.2</a>). </p> <p> <ul id="CD012661-list-0035"> <li> <p>Asia/Middle East (7 studies, 3317 participants with IH and 25,604 participants with normoglycaemia, 3 to 24 years' follow‐up): the pooled OR was 5.18 (95% CI 2.32 to 11.53). The 95% prediction interval ranged from 0.29 to 91.37. </p> </li> <li> <p>Australia/Europe/North America (7 studies, 1240 participants with IH and 5094 participants with normoglycaemia, 4 to 15 years' follow‐up): the pooled OR was 8.69 (95% CI 4.95 to 15.24). The 95% prediction interval ranged from 1.20 to 62.69. </p> </li> <li> <p>Latin America (1 study, 17 participants with IH and 1594 participants with normoglycaemia, 7 years' follow‐up): the OR was 3.73 (95% CI 2.18 to 6.38). </p> </li> </ul> </p> <p>The test for subgroup differences did not indicate a significant subgroup effect (P = 0.10). However, one of the three subgroups had only one study, and there is substantial heterogeneity between studies (Tau<sup>2</sup> = 1.08 and 0.57) within each of the other two subgroups. </p> </section> <section id="CD012661-sec-0117"> <p><b>IGT</b></p> <p>Twenty studies reported adjusted ORs and IGT for IH at baseline (<a href="./references#CD012661-fig-0036" title="">Analysis 2.3</a>). The length of follow‐up ranged from 5 to 24 years (studies are ordered by ascending length of follow‐up in <a href="./references#CD012661-fig-0036" title="">Analysis 2.3</a>). The studies included 3139 participants with IH and 18,413 participants with normoglycaemia. The overall OR was 4.61 (95% CI 3.76 to 5.64). The 95% prediction interval ranged from 2.10 to 10.13. </p> <p>The comparison of geographic regions showed the following results (<a href="./references#CD012661-fig-0036" title="">Analysis 2.3</a>). </p> <p> <ul id="CD012661-list-0036"> <li> <p>Asia/Middle East (6 studies, 1226 participants with IH and 7417 participants with normoglycaemia, 5 to 24 years' follow‐up): the pooled OR was 3.74 (95% CI 2.83 to 4.94). The 95% prediction interval ranged from 1.70 to 8.21. </p> </li> <li> <p>Australia/Europe/North America (11 studies, 1481 participants with IH and 7684 participants with normoglycaemia, 4 to 12 years' follow‐up): the pooled OR was 5.20 (95% CI 3.62 to 7.45). The 95% prediction interval ranged from 1.50 to 18.09. </p> </li> <li> <p>Latin America (2 studies, 381 participants with IH and 3097 participants with normoglycaemia, 7 to 8 years' follow‐up): the pooled OR was 4.94 (95% CI 3.15 to 7.76). </p> </li> <li> <p>American Indians/Islands (1 study, 51 participants with IH and 215 participants with normoglycaemia, 5 to 8 years' follow‐up): the OR was 3.60 (95% CI 1.40 to 9.26). </p> </li> </ul> </p> <p>The test for subgroup differences did not indicate a significant subgroup effect (P = 0.47). However, two of the four subgroups had only one or two studies, so the validity of the analysis is uncertain. </p> </section> <section id="CD012661-sec-0118"> <p><b>Combined IFG and IGT</b></p> <p>Nine studies reported ORs and used both IFG and IGT for defining IH at baseline (<a href="./references#CD012661-fig-0037" title="">Analysis 2.4</a>). The length of follow‐up ranged from 5 to 24 years (studies are ordered by ascending length of follow‐up in <a href="./references#CD012661-fig-0037" title="">Analysis 2.4</a>). The studies included 652 participants with IH and 9004 participants with normoglycaemia. The overall OR was 13.14 (95% CI 7.41 to 23.30). The 95% prediction interval ranged from 1.84 to 93.66. </p> <p>The comparison of geographic regions showed the following results (<a href="./references#CD012661-fig-0037" title="">Analysis 2.4</a>). </p> <p> <ul id="CD012661-list-0037"> <li> <p>Asia/Middle East (3 studies, 498 participants with IHT and 3704 participants with normoglycaemia, 5 to 24 years' follow‐up): the pooled OR was 6.99 (95% CI 3.09 to 15.83). Calculation of the 95% prediction interval did not provide a meaningful estimate. </p> </li> <li> <p>Australia/Europe/North America (6 studies, 154 participants with IH and 5300 participants with normoglycaemia, 6 to 12 years' follow‐up): the pooled OR was 20.95 (95% CI 12.40 to 35.40). The 95% prediction interval ranged from 4.93 to 89.05. </p> </li> </ul> </p> <p>The OR for the Australia/Europe/North America cohort of studies appeared to be higher compared with the Asia/Middle East cohort. </p> </section> <section id="CD012661-sec-0119"> <p><b>HbA1c 5.7% threshold</b></p> <p>Three studies reported ORs and HbA1c<sub>5.7</sub> threshold for IH at baseline (<a href="./references#CD012661-fig-0038" title="">Analysis 2.5</a>). The length of follow‐up ranged from 6 to 10 years (studies are ordered with ascending length of follow‐up in <a href="./references#CD012661-fig-0038" title="">Analysis 2.5</a>). The studies included 906 participants with IH and 2562 participants with normoglycaemia. The overall OR was 4.43 (95% CI 2.20 to 8.88). Calculation of the 95% prediction interval did not provide a meaningful estimate. </p> <p>The results by geographic region are as follows (<a href="./references#CD012661-fig-0038" title="">Analysis 2.5</a>). </p> <p> <ul id="CD012661-list-0038"> <li> <p>Asia/Middle East (1 study, 675 participants with IH and 462 participants with normoglycaemia, 6 years' follow‐up): the OR was 4.54 (95% CI 2.65 to 7.78). </p> </li> <li> <p>Australia/Europe/North America (2 studies, 231 participants with IH and 2100 participants with normoglycaemia, 7 to 10 years' follow‐up): the pooled OR was 4.38 (95% CI 1.36 to 14.15). </p> </li> </ul> </p> </section> <section id="CD012661-sec-0120"> <p><b>HbA1c 6.0% threshold</b></p> <p>Three studies reported ORs and the HbA1c<sub>6.0</sub> threshold for IH at baseline (<a href="./references#CD012661-fig-0039" title="">Analysis 2.6</a>). The length of follow‐up ranged from three to five years. The studies included 1594 participants with IH and 16,723 participants with normoglycaemia. The overall OR was 12.79 (95% CI 4.56 to 35.85). Calculation of the 95% prediction interval did not provide a meaningful estimate. </p> <p>The comparison of geographic regions showed the following results (<a href="./references#CD012661-fig-0039" title="">Analysis 2.6</a>). </p> <p> <ul id="CD012661-list-0039"> <li> <p>Asia/Middle East (1 study, 1103 participants with IH and 10,763 participants with normoglycaemia, 5 years' follow‐up): the OR was 23.20 (95% CI 18.70 to 28.78). </p> </li> <li> <p>Australia/Europe/North America (1 study, 370 participants with IH and 5365 participants with normoglycaemia, 3 years' follow‐up): the OR was 15.60 (95% CI 6.90 to 35.27). </p> </li> <li> <p>American Indians/Islands (1 study, 121 participants with IH and 595 participants with normoglycaemia, 4 years' follow‐up): the OR was 5.89 (95% CI 4.23 to 8.20). </p> </li> </ul> </p> <p>The OR for the Asia/Middle East and Australia/Europe/North America studies appeared higher compared with the American Indians/Islands study. </p> </section> <section id="CD012661-sec-0121"> <p><b>Combination of HbA1c 5.7% threshold with IFG 5.6 mmol/L threshold</b></p> <p>Two studies defined IH using a combination of HbA1c<sub>5.7</sub> and IFG<sub>5.6</sub> at baseline and reported ORs (<a href="./references#CD012661-fig-0040" title="">Analysis 2.7</a>). The length of follow‐up ranged from five to seven years (studies are ordered by ascending length of follow‐up in <a href="./references#CD012661-fig-0040" title="">Analysis 2.7</a>).The studies included 2120 participants with IH and 11,886 participants with normoglycaemia. The pooled OR was 35.91 (95% CI 20.43 to 63.12). </p> <p>The findings for each geographic region are as follows (<a href="./references#CD012661-fig-0040" title="">Analysis 2.7</a>). </p> <p> <ul id="CD012661-list-0040"> <li> <p>Asia/Middle East (1 study, 1951 participants with IH and 10,761 participants with normoglycaemia, 5 years' follow‐up): the OR was 46.70 (95% CI 33.60 to 64.91). </p> </li> <li> <p>Australia/Europe/North America (1 study, 169 participants with IH and 1125 participants with normoglycaemia, 7 years' follow‐up): the OR was 26.20 (95% CI 16.30 to 42.11). </p> </li> </ul> </p> </section> </section> </section> </section> <section id="CD012661-sec-0122"> <h4 class="title">Subgroup and sensitivity analyses</h4> <p>There were not enough data to perform subgroup analyses by age or sex. The special group of children and adolescents is reported under the headings corresponding to the association between IH and T2DM incidence and regression to normoglycaemia. </p> <p>Sensitivity analyses for risk of bias were not meaningful because of the diversity in measurement of T2DM incidence, definitions of IH, and follow‐up periods. The analysis of adequate adjustment for confounding factors in studies reporting HRs may have provided interesting information, but there were not enough data to analyse the impact of at least four or five well‐known covariates influencing the relationship between prognostic factor and T2DM incidence. There were no very large studies including participants with IH at baseline. </p> </section> </section> <section id="CD012661-sec-0123"> <h3 class="title" id="CD012661-sec-0123">Overview of complete data set and certainty of the evidence</h3> <p><a href="#CD012661-tbl-0008">Table 1</a> provides a succinct overview of the overall prognosis of people with IH as well as regression from IH to normoglycaemia over 1 to 20 years of follow‐up. </p> <p><a href="#CD012661-tbl-0009">Table 2</a> provides a succinct overview of IH compared with normoglycaemia as a prognostic factor for developing T2DM according to geographic regions/special populations and type of outcome measurement. </p> <p><a href="#CD012661-fig-0025">Figure 25</a> shows the overall prognosis of IH as measured by cumulative incidence over different follow‐up periods and across all populations, as well as regression from IH to normoglycaemia. </p> <div class="figure" id="CD012661-fig-0025"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 25</div> </div> <hr class="top"/><img alt="Overall prognosis of people with intermediate hyperglycaemia (cumulative type 2 diabetes incidence and regression to normoglycaemia) associated with measures of intermediate hyperglycaemia  HbA1c5.7/HbA1c6.0: glycosylated haemoglobin A1c 5.7%/6.0% threshold; IFG5.6/6.1: impaired fasting glucose 5.6/6.1 mmol/L threshold; IGT: impaired glucose tolerance" data-id="CD012661-fig-0025" src="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-AFig-FIG25.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p><b>Overall prognosis</b> of people with intermediate hyperglycaemia (cumulative type 2 diabetes incidence and regression to normoglycaemia) associated with measures of intermediate hyperglycaemia<br/> <b>HbA1c5.7/HbA1c6.0</b> : glycosylated haemoglobin A1c 5.7%/6.0% threshold; <b>IFG5.6/6.1</b> : impaired fasting glucose 5.6/6.1 mmol/L threshold; <b>IGT</b>: impaired glucose tolerance </p> </div> </div> </div> <p><a href="#CD012661-fig-0026">Figure 26</a> shows IH versus normoglycaemia as a prognostic factor for developing T2DM measured by IRR, OR or HR across all populations. </p> <div class="figure" id="CD012661-fig-0026"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 26</div> </div> <hr class="top"/><img alt="Intermediate hyperglycaemia versus normoglycaemia as a prognostic factor for developing type 2 diabetes (associated with different measures and relative risks of intermediate hyperglycaemia)  HbA1c5.7/HbA1c6.0: glycosylated haemoglobin A1c 5.7%/6.0% threshold; IFG5.6/6.1: impaired fasting glucose 5.6/6.1 mmol/L threshold; IGT: impaired glucose tolerance; IRR: incidence rate ratio; OR: odds ratio; HR: hazard ratio" data-id="CD012661-fig-0026" src="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-AFig-FIG26.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Intermediate hyperglycaemia versus normoglycaemia as a <b>prognostic factor</b> for developing type 2 diabetes (associated with different measures and relative risks of intermediate hyperglycaemia)<br/> <b>HbA1c5.7/HbA1c6.0</b> : glycosylated haemoglobin A1c 5.7%/6.0% threshold; <b>IFG5.6/6.1</b> : impaired fasting glucose 5.6/6.1 mmol/L threshold; <b>IGT</b> : impaired glucose tolerance; <b>IRR</b> : incidence rate ratio; <b>OR</b> : odds ratio; <b>HR</b>: hazard ratio </p> </div> </div> </div> <p>Taking into account all follow‐up times and all populations, the percentages of people with IH <i>not</i> developing T2DM over time (i.e. either regressing to normoglycaemia or remaining 'prediabetic') were as follows (see <a href="./appendices#CD012661-sec-0146">Appendix 11</a>): IFG<sub>5.6</sub> cohorts, 79.2%; IFG<sub>6.1</sub> cohorts, 75.4%; IGT cohorts, 66.7%; combined IFG and IGT cohorts, 57.2%; HbA1c<sub>5.7</sub> cohorts, 79.7%; and HbA1c<sub>6.0</sub> cohorts, 69.0%. </p> <p>For overall prognosis, we started with high‐certainty evidence because prospective cohort studies represent an adequate study design to investigate overall prognosis. However, we downgraded the certainty of the evidence to moderate because of imprecise results for most definitions of IH (<a href="./full#CD012661-tbl-0001">summary of findings Table for the main comparison</a>). </p> <p>We considered the overall certainty of the evidence for the prognostic factor IH versus normoglycaemia as low (<a href="./full#CD012661-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD012661-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD012661-tbl-0004">summary of findings Table 4</a>; <a href="./full#CD012661-tbl-0005">summary of findings Table 5</a>; <a href="./full#CD012661-tbl-0006">summary of findings Table 6</a>; <a href="./full#CD012661-tbl-0007">summary of findings Table 7</a>). We started with a high level of evidence because most included studies were phase 2 explanatory studies, defined as studies that aimed to confirm independent associations between the prognostic factor and the outcome (<a href="./references#CD012661-bbs2-0339" title="HuguetA , HaydenJA , StinsonJ , McGrathPJ , ChambersCT , TougasME , et al. Judging the quality of evidence in reviews of prognostic factor research: adapting the GRADE framework. Systematic Reviews2013;2:71. ">Huguet 2013</a>). We downgraded the evidence for all IH measurements to low, first one level due to study limitations because many studies did not adequately adjust for confounders (only six studies used the covariate core set of age, sex, anthropometric measures and physical activity for adjustments in multivariable regression analyses ‐ <a href="./references#CD012661-bbs2-0009" title="BonoraE , KiechlS , MayrA , ZoppiniG , TargherG , BonadonnaRC , et al. High‐normal HbA1c is a strong predictor of type 2 diabetes in the general population. Diabetes Care2011;34(4):1038‐40. [PUBMED: 21307378] BonoraE , KiechlS , WilleitJ , OberhollenzerF , EggerG , MeigsJB , et al. Insulin resistance as estimated by homeostasis model assessment predicts incident symptomatic cardiovascular disease in Caucasian subjects from the general population: the Bruneck study. Diabetes Care2007;30(2):318‐24. BonoraE , KiechlS , WilleitJ , OberhollenzerF , EggerG , MeigsJB , et al. Population‐based incidence rates and risk factors for type 2 diabetes in white individuals: the Bruneck study. Diabetes2004;53(7):1782‐9. [PUBMED: 15220202] ">Bonora 2011</a>; <a href="./references#CD012661-bbs2-0019" title="Aghaei MeybodiHR , AziziF . Changes in body weight and fat distribution; risk factors for abnormal glucose homeostasis? Tehran lipid and glucose study. Iranian Journal of Diabetes and Lipid Disorders2009;8(1):1‐12. BozorgmaneshM , HadaeghF , AziziF . A simple clinical model predicted diabetes progression among prediabetic individuals. Diabetes Research and Clinical Practice2012;97(2):e34‐6. [PUBMED: 22647753] DerakhshanA , Bagherzadeh‐KhiabaniF , ArshiB , RamezankhaniA , AziziF , HadaeghF . Different combinations of glucose tolerance and blood pressure status and incident diabetes, hypertension, and chronic kidney disease. Journal of the American Heart Association2016;5(8):pii: e003917. [DOI: 10.1161/JAHA.116.003917; PUBMED: 27543801] DerakhshanA , SardariniaM , KhaliliD , MomenanAA , AziziF , HadaeghF . Sex specific incidence rates of type 2 diabetes and its risk factors over 9 years of follow‐up: Tehran lipid and glucose study. PLOS ONE2014;9(7):e102563. [PUBMED: 25029368] DerakhshanA , TohidiM , ArshiB , KhaliliD , AziziF , HadaeghF . Relationship of hyperinsulinaemia, insulin resistance and beta‐cell dysfunction with incident diabetes and pre‐diabetes: the Tehran lipid and glucose study. Diabetic Medicine2015;32(1):24‐32. [PUBMED: 25131451] HadaeghF , BozorgmaneshMR , GhasemiA , HaratiH , SaadatN , AziziF . High prevalence of undiagnosed diabetes and abnormal glucose tolerance in the Iranian urban population: Tehran lipid and glucose study. BMC Public Health2008;8:176. HadaeghF , DerakhshanA , ZafariN , KhaliliD , MirboloukM , SaadatN , et al. Pre‐diabetes tsunami: incidence rates and risk factors of pre‐diabetes and its different phenotypes over 9 years of follow‐up. Diabetic Medicine2017;34(1):69‐78. [PUBMED: 26606421] HadaeghF , GhasemiAr , PadyabM , TohidiM , AziziF . The metabolic syndrome and incident diabetes: assessment of alternative definitions of the metabolic syndrome in an Iranian urban population. Diabetes Research and Clinical Practice2008;80(2):328‐34. [PUBMED: 18282630] HaratiH , HadaeghF , SaadatN , AziziF . Population‐based incidence of type 2 diabetes and its associated risk factors: results from a six‐year cohort study in Iran. BMC Public Health2009;9:186. [DOI: 10.1186/1471‐2458‐9‐186; PUBMED: 19531260] HaratiH , HadaeghF , TohidiM , AziziF . Impaired fasting glucose cutoff value of 5.6 mmol/l combined with other cardiovascular risk markers is a better predictor for incident type 2 diabetes than the 6.1 mmol/l value: Tehran lipid and glucose study. Diabetes Research and Clinical Practice2009;85(1):90‐5. [PUBMED: 19414206] ">Derakhshan 2016</a>; <a href="./references#CD012661-bbs2-0023" title="ForouhiNG , LuanJ , HenningsS , WarehamNJ . Incidence of type 2 diabetes in England and its association with baseline impaired fasting glucose: the Ely study 1990‐2000. Diabetic Medicine2007;24(2):200‐7. [PUBMED: 17257284] SimmonsRK , RahmanM , JakesRW , YuyunMF , NiggebruggeAR , HenningsSH , et al. Effect of population screening for type 2 diabetes on mortality: long‐term follow‐up of the Ely cohort. Diabetologia2011;54:312‐9. [PUBMED: 20978739] WarehamNJ , ByrneCD , WilliamsR , DayNE , HalesCN . Fasting proinsulin concentrations predict the development of type 2 diabetes. Diabetes Care1999;22(2):262‐70. [PUBMED: 10333943] WilliamsDR , WarehamNJ , BrownDC , ByrneCD , ClarkPM , CoxBD , et al. Undiagnosed glucose intolerance in the community: the Isle of Ely diabetes project. Diabetic Medicine1995;12:30‐5. [PUBMED: 7712700] ">Forouhi 2007</a>; <a href="./references#CD012661-bbs2-0028" title="ChoiSH , KimTH , LimS , ParkKS , JangHC , ChoNH . Hemoglobin A1c as a diagnostic tool for diabetes screening and new‐onset diabetes prediction: a 6‐year community‐based prospective study. Diabetes Care2011;34(4):944‐9. [PUBMED: 21335372] HanSJ , KimHJ , KimDJ , LeeKW , ChoNH . Incidence and predictors of type 2 diabetes among Koreans: a 12‐year follow up of the Korean genome and epidemiology study. Diabetes Research and Clinical Practice2017;123:173‐80. [PUBMED: 28043048] JungDH , ByunYS , KwonYJ , KimGS . Microalbuminuria as a simple predictor of incident diabetes over 8 years in the Korean genome and epidemiology study (KoGES). Scientific Reports2017;7(1):15445. [PUBMED: 29133894] JungJY , OhCM , RyooJH , ChoiJM , ChoiYJ , HamW T , et al. The influence of prehypertension, hypertension, and glycated hemoglobin on the development of type 2 diabetes mellitus in prediabetes: the Korean genome and epidemiology study (KoGES). Endocrine2018;59(3):593‐601. [PUBMED: 29380232] Keun ParkS , RyooJH , OhCM , ChoiJM , ChoiYJ , Ok LeeK , et al. The risk of type 2 diabetes mellitus according to 2‐hour plasma glucose level: the Korean genome and epidemiology study (KoGES). Diabetes Research and Clinical Practice 2017 Aug 9 [Epub ahead of print]. [DOI: 10.1016/j.diabres.2017.08.002; PUBMED: 28951335] LimNK , ParkSH , ChoiSJ , LeeKS , ParkHY . A risk score for predicting the incidence of type 2 diabetes in a middle‐aged Korean cohort: the Korean genome and epidemiology study. Circulation Journal2012;76(8):1904‐10. [PUBMED: 22640983] ">Han 2017</a>; <a href="./references#CD012661-bbs2-0039" title="KimCH , KimHK , KimEH , BaeSJ , ChoeJ , ParkJY . Risk of progression to diabetes from prediabetes defined by HbA1c or fasting plasma glucose criteria in Koreans. Diabetes Research and Clinical Practice2016;118:105‐11. [PUBMED: 27368062] ">Kim 2016a</a>; <a href="./references#CD012661-bbs2-0102" title="BildDE , BluemkeDA , BurkeGL , DetranoR , Diez RouxAV , FolsomAR , et al. Multi‐ethnic study of atherosclerosis: objectives and design. American Journal of Epidemiology2002;156(9):871‐81. [PUBMED: 12397006] YeboahJ , BertoniA G , HerringtonDM , PostWS , BurkeGL . Impaired fasting glucose and the risk of incident diabetes mellitus and cardiovascular events in an adult population: MESA (multi‐ethnic study of atherosclerosis). Journal of the American College of Cardiology2011;58(2):140‐6. [PUBMED: 21718910] ">Yeboah 2011</a>). Furthermore, we downgraded one level for imprecision/inconsistency (wide 95% CIs/wide 95% prediction intervals, sometimes ranging from negative to positive prognostic factor to outcome associations). </p> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012661-sec-0124" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012661-sec-0124"></div> <section id="CD012661-sec-0125"> <h3 class="title" id="CD012661-sec-0125">Summary of main results</h3> <p>We included 103 prospective cohort studies from many parts of the world evaluating people with IH, usually defined using the IFG<sub>5.6</sub> or IFG<sub>6.1</sub> threshold, IGT, combined IFG/IGT or elevated HbA1c. However, we did not identify studies involving black Africans or Eastern Europeans. Participants were of Australian, European or North American origin in 41 studies; primarily of Latin American origin in 7 studies; Asian or Middle Eastern origin in 50 studies; American Indians in 3 studies; Mauritians in 1 study; and Nauruans in 1 study. Six studies included children, adolescents or both. </p> <p>Ninety‐three studies contributed data to estimate the overall prognosis of people with IH, and 52 studies evaluated baseline glycaemic status as a prognostic factor by comparing an IH cohort with a normoglycaemic cohort. </p> <p>Cumulative incidence of T2DM for the IFG<sub>5.6</sub> threshold, the IFG<sub>6.1</sub> threshold, IGT, combined IFG/IGT and elevated HbA1c, showed increasing percentages over follow‐up time; however, there was no clear linear increase over time. Regression rates to normoglycaemia, though decreasing over follow‐up, showed fluctuations and no clear linear decrease over time. The estimates of the prognostic effect of IH versus normoglycaemia were comparable when using HR, IRR or OR across the different definitions of IH. There was no clear pattern of risk differences between geographic regions. </p> </section> <section id="CD012661-sec-0126"> <h3 class="title" id="CD012661-sec-0126">Overall completeness and applicability of evidence</h3> <p>A limiting factor of our review was that most studies took place in Asia, the Middle East, Australia, Western Europe and North America, affecting the generalisability of findings to other populations residing in Africa and Eastern Europe. We are also aware that categorising the included studies based on region or 'ethnicity' has deficiencies with regard to clearly delineating study participants. The complicated interplay of factors like genetics, diets, and changing environmental and social conditions, among others, makes it virtually impossible to achieve a generally accepted categorisation. We chose an approach based primarily on geographic location because we thought that most readers would be interested in having a broad overview of any potential differences in T2DM incidence based on this characteristic. At the same time, we tried not to overload the reader with too much information by fragmenting our dataset into all the different countries or into more precisely defined 'ethnicities', since some investigators even reported several 'ethnic' subgroups within a single study cohort. However, we do provide detailed information, when available, in our appendices to enable the interested reader to identify studies according to whatever combination of factors seems of value to generate hypotheses of potential differences between the diverse study groups. </p> <p>Only six studies addressed the overall prognosis of IH in 495 children or adolescents, with approximately 50% originating from high‐risk American Indian cohorts, also affecting the applicability of findings to other populations. No data were available on the prognostic factor of IH versus normoglycaemia for children or adolescents. Most studies determined the glycaemic status of participants at baseline and follow‐up on the basis of a single FPG, glucose tolerance test or HbA1c. Therefore, participants may have been misclassified at baseline, follow‐up or both in either direction. Interestingly, 93 studies provided data on overall prognosis of IH, but only 49 studies published information on regression from IH to normoglycaemia. </p> </section> <section id="CD012661-sec-0127"> <h3 class="title" id="CD012661-sec-0127">Certainty of the evidence</h3> <p>To our knowledge there is no validated risk of bias tool for studies addressing overall prognosis. Moreover, information on some applicable risk of bias domains of the QUIPS tools were limited. However, as illustrated in <a href="#CD012661-fig-0025">Figure 25</a>, there was a wide fluctuation between the various definitions of IH as well as no linear increase in T2DM incidence over time of follow‐up. Of note, regression rates to normoglycaemia were also high, even after more than five years of follow‐up, emphasising that transition from IH to T2DM might be an intermediate state (<a href="./references#CD012661-bbs2-0372" title="TaylorR , LeslieWS , BarnesAC , BrosnahanN , ThomG , McCombieL , et al. Clinical and metabolic features of the randomised controlled Diabetes Remission Clinical Trial (DiRECT) cohort. Diabetologia2017;30:30. ">Taylor 2017</a>). </p> <p>The certainty of the evidence for the overall prognosis of IH was moderate due to imprecise results for most IH definitions. The certainty of the evidence for the prognostic factor of IH versus normoglycaemia was low, mainly because most studies did not adjust for confounders known to be independently associated with T2DM incidence and due to substantial imprecision (wide 95% CIs) and inconsistency (wide 95% prediction intervals). However, the results of the six studies that adjusted for sex, anthropometric measures and physical activity were similar to the rest of the prospective cohort studies. </p> </section> <section id="CD012661-sec-0128"> <h3 class="title" id="CD012661-sec-0128">Limitations in the review process</h3> <p>As described in the <a href="#CD012661-sec-0039">Methods</a> section, it was difficult to define a reliable search strategy, which probably holds true for many systematic reviews of prognostic studies. We noted that when checking other systematic reviews on the topic and the references of the included studies, around one third of our included studies were identified through reference checking. However, using PubMed's 'similar articles' algorithm did not yield new studies but did help us identify 13 secondary publications of studies we had already included. The 103 prospective cohort studies included in this review represent by far the largest amount of data synthesised on the overall prognosis of IH and the impact of IH versus normoglycaemia as a prognostic factor for T2DM development. We did not contact study authors for additional information, mainly for logistical reasons but also because we anticipated poor response, since many studies were published long ago. Moreover, retrieval of additional information, often demanding recalculations, would have imposed a considerable burden on study authors. </p> <p>During the review process, the need to establish a database of cohort studies specifying details on prognostic factors and outcomes, amongst other things, became clear. Many large cohort studies investigate the association of a great number of prognostic factors with yet another large number of outcomes. These data may only be detected through a detailed analysis of the full text (especially tables and figures). It is evident that screening titles and abstracts will miss this information. </p> <p>We did not include participants of randomised controlled trials. Though potentially some trials with longer time of follow‐up could provide additional data, we decided not to include information from intervention trials at this stage on theoretical grounds, as any intervention will interfere with peoples' lives, as opposed to demonstrating the natural progression of a disorder. In addition, we are conducting a series of Cochrane Reviews on interventions for people with IH and may integrate these data in a later update of this review (<a href="./references#CD012661-bbs2-0328" title="HemmingsenB , KroghJ , MetzendorfMI , RichterB . Sodium‐glucose cotransporter (SGLT) 2 inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD012106.pub2] ">Hemmingsen 2016a</a>; <a href="./references#CD012661-bbs2-0329" title="HemmingsenB , KroghJ , MetzendorfMI , RichterB . Dipeptidyl‐peptidase (DPP)‐4 inhibitors or glucagon‐like peptide (GLP)‐1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews2016, Issue 5. [DOI: 10.1002/14651858.CD012204] ">Hemmingsen 2016b</a>; <a href="./references#CD012661-bbs2-0330" title="HemmingsenB , SonneDP , MetzendorfMI , RichterB . Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews2016, Issue 10. [DOI: 10.1002/14651858.CD012151.pub2] ">Hemmingsen 2016c</a>). </p> </section> <section id="CD012661-sec-0129"> <h3 class="title" id="CD012661-sec-0129">Agreements and disagreements with other reviews</h3> <p><a href="./references#CD012661-bbs2-0323" title="GersteinHC , SantaguidaP , RainaP , MorrisonKM , BalionC , HuntD , et al. Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: a systematic overview and meta‐analysis of prospective studies. Diabetes Research and Clinical Practice2007;78(3):305‐12. ">Gerstein 2007</a> is a widely cited review including 21 cohort studies and nine randomised controlled trials published between 1979 and 2004. The review authors annualised T2DM incidence rates, which varied from 5% to 10%. Their relative risks for T2DM incidence of 6.35 in people with IGT, 4.66 in people with IFG and 12.1 with both IFG and IGT were higher but comparable to our HR data. We did not annualise incidence rates because with pronounced fluctuations between regression and development of T2DM, assumptions to establish a model for annualising incidence data over prolonged period of times appeared too strong. <a href="./references#CD012661-bbs2-0385" title="ZhangX , GreggEW , WilliamsonDF , BarkerL E , ThomasW , BullardKM , et al. A1C level and future risk of diabetes: a systematic review. Diabetes Care2010;33(7):1665‐73. ">Zhang 2010</a> examined ranges of HbA1c and also associated these with annualised diabetes incidences. The results of seven included studies reporting HbA1c categories showed an increase in T2DM incidence across an HbA1c range from 5.0% to 6.5%. No meta‐analysis was performed. Our results also showed increased T2DM incidence when the threshold of the HbA1c value at baseline was raised from 5.7% to 6.0%. Morris et al. performed a meta‐analysis of prospective observational studies in which participants had IH at baseline (<a href="./references#CD012661-bbs2-0354" title="MorrisDH , KhuntiK , AchanaF , SrinivasanB , GrayLJ , DaviesMJ , et al. Progression rates from HbA1c 6.0‐6.4% and other prediabetes definitions to type 2 diabetes: a meta‐analysis. Diabetologia2013;56(7):1489‐93. [PUBMED: 23584433] ">Morris 2013</a>). The review included 70 studies and estimated pooled incidence rates using IFG (35.5 incident cases per 1000 person‐years as defined by ADA and 47.4 incident cases per 1000 person‐years as defined by WHO, 11 and 34 studies, respectively), IGT (45.5 incident cases per 1000 person‐years, 46 studies) and IFG/IGT (70.4 incident cases per 1000 person‐years, 15 studies) definitions for IH. Elevated HbA1c was associated with a pooled incidence rate of 35.6 per 1000 person‐years. Similar to our results, the review found that progression rates to T2DM differed by definition of IH. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012661-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/urn:x-wiley:14651858:media:CD012661:CD012661-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_t/tCD012661-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD012661-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/full#CD012661-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012661-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/urn:x-wiley:14651858:media:CD012661:CD012661-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_t/tCD012661-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph for studies of overall prognosis of people with intermediate hyperglycaemia for developing type 2 diabetes: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD012661-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph for studies of overall prognosis of people with intermediate hyperglycaemia for developing type 2 diabetes: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/full#CD012661-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012661-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/urn:x-wiley:14651858:media:CD012661:CD012661-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_t/tCD012661-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary for studies of overall prognosis in people with intermediate hyperglycaemia for developing type 2 diabetes: review authors' judgements about each risk of bias item for each included study (part 1). The summary was split into part 1 () and part 2 () for better legibility" data-id="CD012661-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' summary for studies of overall prognosis in people with intermediate hyperglycaemia for developing type 2 diabetes: review authors' judgements about each risk of bias item for each included study (part 1). The summary was split into part 1 (<a href="#CD012661-fig-0003">Figure 3</a>) and part 2 (<a href="#CD012661-fig-0004">Figure 4</a>) for better legibility </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/full#CD012661-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012661-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/urn:x-wiley:14651858:media:CD012661:CD012661-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_t/tCD012661-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary for studies of overall prognosis of people with intermediate hyperglycaemia for developing type 2 diabetes: review authors' judgements about each risk of bias item for each included study (part 2)" data-id="CD012661-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Risk of bias summary for studies of overall prognosis of people with intermediate hyperglycaemia for developing type 2 diabetes: review authors' judgements about each risk of bias item for each included study (part 2) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/full#CD012661-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012661-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/urn:x-wiley:14651858:media:CD012661:CD012661-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_t/tCD012661-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph for studies of intermediate hyperglycaemia versus normoglycaemia as a prognostic factor for developing type 2 diabetes: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD012661-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Risk of bias graph for studies of intermediate hyperglycaemia versus normoglycaemia as a prognostic factor for developing type 2 diabetes: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/full#CD012661-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012661-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/urn:x-wiley:14651858:media:CD012661:CD012661-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_t/tCD012661-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary for studies of intermediate hyperglycaemia versus normoglycaemia as a prognostic factor for developing type 2 diabetes: review authors' judgements about each risk of bias item for each included study" data-id="CD012661-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Risk of bias summary for studies of intermediate hyperglycaemia versus normoglycaemia as a prognostic factor for developing type 2 diabetes: review authors' judgements about each risk of bias item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/full#CD012661-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012661-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/urn:x-wiley:14651858:media:CD012661:CD012661-AFig-FIG07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_t/tCD012661-AFig-FIG07.png" target="_blank"><b></b></a></p> </div><img alt="Impaired fasting glucose 5.6 mmol/L (IFG5.6) threshold: association with cumulative type 2 diabetes mellitus (T2DM) incidence over 2–5 years  *Isolated IFG5.6  CI: confidence interval; M: men; n/N: events/number of participants; W: women" data-id="CD012661-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-AFig-FIG07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Impaired fasting glucose 5.6 mmol/L (IFG<sub>5.6</sub>) threshold: association with cumulative type 2 diabetes mellitus (T2DM) incidence over 2–5 years<br/> *Isolated IFG<sub>5.6</sub><br/> <b>CI</b> : confidence interval; <b>M</b> : men; <b>n/N</b> : events/number of participants; <b>W</b>: women </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/full#CD012661-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-AFig-FIG07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012661-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/urn:x-wiley:14651858:media:CD012661:CD012661-AFig-FIG08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_t/tCD012661-AFig-FIG08.png" target="_blank"><b></b></a></p> </div><img alt="Impaired fasting glucose 5.6 mmol/L (IFG5.6) threshold: association with cumulative type 2 diabetes mellitus (T2DM) incidence over 6–12 years  *Isolated IFG5.6   **'Africa': African Surinamese cohort, 'Asia': Asian Surinamese cohort, 'Australia/Europe/North America': 'ethnic Dutch' cohort.  CI: confidence interval; M: men; n/N: events/number of participants; W: women" data-id="CD012661-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-AFig-FIG08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p>Impaired fasting glucose 5.6 mmol/L (IFG<sub>5.6</sub>) threshold: association with cumulative type 2 diabetes mellitus (T2DM) incidence over 6–12 years<br/> *Isolated IFG<sub>5.6</sub> <br/> **'Africa': African Surinamese cohort, 'Asia': Asian Surinamese cohort, 'Australia/Europe/North America': 'ethnic Dutch' cohort.<br/> <b>CI</b> : confidence interval; <b>M</b> : men; <b>n/N</b> : events/number of participants; <b>W</b>: women </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/full#CD012661-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-AFig-FIG08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012661-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/urn:x-wiley:14651858:media:CD012661:CD012661-AFig-FIG09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_t/tCD012661-AFig-FIG09.png" target="_blank"><b></b></a></p> </div><img alt="Impaired fasting glucose 6.1 mmol/L (IFG6.1) threshold: association with cumulative type 2 diabetes mellitus (T2DM) incidence over 2–5 years  *Isolated IFG6.1  CI: confidence interval; M: men; n/N: events/number of participants; W: women" data-id="CD012661-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-AFig-FIG09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 9</div> <div class="figure-caption"> <p>Impaired fasting glucose 6.1 mmol/L (IFG<sub>6.1</sub>) threshold: association with cumulative type 2 diabetes mellitus (T2DM) incidence over 2–5 years<br/> *Isolated IFG<sub>6.1</sub><br/> <b>CI</b> : confidence interval; <b>M</b> : men; <b>n/N</b> : events/number of participants; <b>W</b>: women </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/full#CD012661-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-AFig-FIG09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012661-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/urn:x-wiley:14651858:media:CD012661:CD012661-AFig-FIG10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_t/tCD012661-AFig-FIG10.png" target="_blank"><b></b></a></p> </div><img alt="Impaired fasting glucose 6.1 mmol/L (IFG6.1) threshold: association with cumulative type 2 diabetes mellitus (T2DM) incidence over 6–15 years  *Isolated IFG6.1  CI: confidence interval; n/N: events/number of participants" data-id="CD012661-fig-0010" src="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-AFig-FIG10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 10</div> <div class="figure-caption"> <p>Impaired fasting glucose 6.1 mmol/L (IFG<sub>6.1</sub>) threshold: association with cumulative type 2 diabetes mellitus (T2DM) incidence over 6–15 years<br/> *Isolated IFG<sub>6.1</sub><br/> <b>CI</b> : confidence interval; <b>n/N</b>: events/number of participants </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/full#CD012661-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-AFig-FIG10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012661-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/urn:x-wiley:14651858:media:CD012661:CD012661-AFig-FIG11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_t/tCD012661-AFig-FIG11.png" target="_blank"><b></b></a></p> </div><img alt="Impaired glucose tolerance (IGT): association with cumulative type 2 diabetes mellitus (T2DM) incidence over 1–5 years  *Isolated IGT  CI: confidence interval; n/N: events/number of participants" data-id="CD012661-fig-0011" src="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-AFig-FIG11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 11</div> <div class="figure-caption"> <p>Impaired glucose tolerance (IGT): association with cumulative type 2 diabetes mellitus (T2DM) incidence over 1–5 years<br/> *Isolated IGT<br/> <b>CI</b> : confidence interval; <b>n/N</b>: events/number of participants </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/full#CD012661-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-AFig-FIG11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012661-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/urn:x-wiley:14651858:media:CD012661:CD012661-AFig-FIG12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_t/tCD012661-AFig-FIG12.png" target="_blank"><b></b></a></p> </div><img alt="Impaired glucose tolerance (IGT): association with cumulative type 2 diabetes mellitus (T2DM) incidence over 6–20 years*Isolated IGT  CI: confidence interval; M: men; n/N: events/number of participants; W: women" data-id="CD012661-fig-0012" src="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-AFig-FIG12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 12</div> <div class="figure-caption"> <p>Impaired glucose tolerance (IGT): association with cumulative type 2 diabetes mellitus (T2DM) incidence over 6–20 years </p> <p>*Isolated IGT<br/> <b>CI</b> : confidence interval; <b>M</b> : men; <b>n/N</b> : events/number of participants; <b>W</b>: women </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/full#CD012661-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-AFig-FIG12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012661-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/urn:x-wiley:14651858:media:CD012661:CD012661-AFig-FIG13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_t/tCD012661-AFig-FIG13.png" target="_blank"><b></b></a></p> </div><img alt="Combined impaired glucose tolerance (IGT) and impaired fasting glucose (IFG): association with cumulative type 2 diabetes mellitus (T2DM) incidence over 1–12 years  CI: confidence interval; M: men; n/N: events/number of participants; W: women" data-id="CD012661-fig-0013" src="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-AFig-FIG13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 13</div> <div class="figure-caption"> <p>Combined impaired glucose tolerance (IGT) and impaired fasting glucose (IFG): association with cumulative type 2 diabetes mellitus (T2DM) incidence over 1–12 years<br/> <b>CI</b> : confidence interval; <b>M</b> : men; <b>n/N</b> : events/number of participants; <b>W</b>: women </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/full#CD012661-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-AFig-FIG13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012661-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/urn:x-wiley:14651858:media:CD012661:CD012661-AFig-FIG14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_t/tCD012661-AFig-FIG14.png" target="_blank"><b></b></a></p> </div><img alt="Elevated glycosylated haemoglobin A1c (HbA1c) 5.7% threshold: association with cumulative type 2 diabetes mellitus (T2DM) incidence over 4–10 years  CI: confidence interval; n/N: events/number of participants" data-id="CD012661-fig-0014" src="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-AFig-FIG14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 14</div> <div class="figure-caption"> <p>Elevated glycosylated haemoglobin A1c (HbA1c) 5.7% threshold: association with cumulative type 2 diabetes mellitus (T2DM) incidence over 4–10 years<br/> <b>CI</b> : confidence interval; <b>n/N</b>: events/number of participants </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/full#CD012661-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-AFig-FIG14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012661-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/urn:x-wiley:14651858:media:CD012661:CD012661-AFig-FIG15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_t/tCD012661-AFig-FIG15.png" target="_blank"><b></b></a></p> </div><img alt="Elevated glycosylated haemoglobin A1c (HbA1c) 6.0% threshold: association with cumulative type 2 diabetes mellitus (T2DM) incidence over 3–15 years  CI: confidence interval; n/N: events/number of participants" data-id="CD012661-fig-0015" src="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-AFig-FIG15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 15</div> <div class="figure-caption"> <p>Elevated glycosylated haemoglobin A1c (HbA1c) 6.0% threshold: association with cumulative type 2 diabetes mellitus (T2DM) incidence over 3–15 years<br/> <b>CI</b> : confidence interval; <b>n/N</b>: events/number of participants </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/full#CD012661-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-AFig-FIG15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012661-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/urn:x-wiley:14651858:media:CD012661:CD012661-AFig-FIG16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_t/tCD012661-AFig-FIG16.png" target="_blank"><b></b></a></p> </div><img alt="Cumulative type 2 diabetes mellitus (T2DM) incidence in children/adolescents over 1–10 years  CI: confidence interval; HbA1c 5.7: glycosylated haemoglobin A1c 5.7% threshold; (i‐)IGT: (isolated) impaired glucose tolerance; n/N: events/number of participants; NO: non‐overweight; OV: overweight" data-id="CD012661-fig-0016" src="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-AFig-FIG16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 16</div> <div class="figure-caption"> <p>Cumulative type 2 diabetes mellitus (T2DM) incidence in children/adolescents over 1–10 years<br/> <b>CI</b> : confidence interval; <b>HbA1c 5.7</b> : glycosylated haemoglobin A1c 5.7% threshold; <b>(i‐)IGT</b> : (isolated) impaired glucose tolerance; <b>n/N</b> : events/number of participants; <b>NO</b> : non‐overweight; <b>OV</b>: overweight </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/full#CD012661-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-AFig-FIG16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012661-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/urn:x-wiley:14651858:media:CD012661:CD012661-AFig-FIG17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_t/tCD012661-AFig-FIG17.png" target="_blank"><b></b></a></p> </div><img alt="Regression from intermediate hyperglycaemia to normoglycaemia in adults over 1–5 years  CI: confidence interval; HbA1c5.7 : glycosylated haemoglobin A1c 5.7%; i‐IFG5.6/6.1 : (isolated) impaired fasting glucose 5.6/6.1 mmol/L threshold;IGT: impaired glucose tolerance; n/N: events/number of participants" data-id="CD012661-fig-0017" src="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-AFig-FIG17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 17</div> <div class="figure-caption"> <p>Regression from intermediate hyperglycaemia to normoglycaemia in adults over 1–5 years<br/> <b>CI</b> : confidence interval; <b>HbA1c<sub>5.7</sub> </b> : glycosylated haemoglobin A1c 5.7%; <b>i‐IFG<sub>5.6/6.1</sub> </b> : (isolated) impaired fasting glucose 5.6/6.1 mmol/L threshold;<b>IGT</b> : impaired glucose tolerance; <b>n/N</b>: events/number of participants </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/full#CD012661-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-AFig-FIG17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012661-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/urn:x-wiley:14651858:media:CD012661:CD012661-AFig-FIG18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_t/tCD012661-AFig-FIG18.png" target="_blank"><b></b></a></p> </div><img alt="Regression from intermediate hyperglycaemia to normoglycaemia in adults over 6–11 years  CI: confidence interval; i‐IFG5.6/6.1 : (isolated) impaired fasting glucose 5.6/6.1 mmol/L threshold; i‐IGT: (isolated) impaired glucose tolerance; n/N: events/number of participants" data-id="CD012661-fig-0018" src="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-AFig-FIG18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 18</div> <div class="figure-caption"> <p>Regression from intermediate hyperglycaemia to normoglycaemia in adults over 6–11 years<br/> <b>CI</b> : confidence interval; <b>i‐IFG<sub>5.6/6.1</sub> </b> : (isolated) impaired fasting glucose 5.6/6.1 mmol/L threshold; <b>i‐IGT</b> : (isolated) impaired glucose tolerance; <b>n/N</b>: events/number of participants </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/full#CD012661-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-AFig-FIG18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012661-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/urn:x-wiley:14651858:media:CD012661:CD012661-AFig-FIG19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_t/tCD012661-AFig-FIG19.png" target="_blank"><b></b></a></p> </div><img alt="Regression from intermediate hyperglycaemia to normoglycaemia in children/adolescents over 1–4 years  CI: confidence interval; IGT: impaired glucose tolerance; n/N: events/number of participants" data-id="CD012661-fig-0019" src="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-AFig-FIG19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 19</div> <div class="figure-caption"> <p>Regression from intermediate hyperglycaemia to normoglycaemia in children/adolescents over 1–4 years<br/> <b>CI</b> : confidence interval; <b>IGT</b> : impaired glucose tolerance; <b>n/N</b>: events/number of participants </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/full#CD012661-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-AFig-FIG19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012661-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/urn:x-wiley:14651858:media:CD012661:CD012661-AFig-FIG20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_t/tCD012661-AFig-FIG20.png" target="_blank"><b></b></a></p> </div><img alt="IFG: impaired fasting glucose; IRR: incidence rate ratio; n: number of cases; T: person‐time in years" data-id="CD012661-fig-0020" src="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-AFig-FIG20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 20</div> <div class="figure-caption"> <p><b>IFG</b> : impaired fasting glucose; <b>IRR</b> : incidence rate ratio; <b>n</b> : number of cases; <b>T</b>: person‐time in years </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/full#CD012661-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-AFig-FIG20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012661-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/urn:x-wiley:14651858:media:CD012661:CD012661-AFig-FIG21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_t/tCD012661-AFig-FIG21.png" target="_blank"><b></b></a></p> </div><img alt="IFG: impaired fasting glucose; IRR: incidence rate ratio; n: number of cases; T: person‐time in years" data-id="CD012661-fig-0021" src="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-AFig-FIG21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 21</div> <div class="figure-caption"> <p><b>IFG</b> : impaired fasting glucose; <b>IRR</b> : incidence rate ratio; <b>n</b> : number of cases; <b>T</b>: person‐time in years </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/full#CD012661-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-AFig-FIG21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012661-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/urn:x-wiley:14651858:media:CD012661:CD012661-AFig-FIG22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_t/tCD012661-AFig-FIG22.png" target="_blank"><b></b></a></p> </div><img alt="IGT: impaired glucose tolerance; IRR: incidence rate ratio; n: number of cases; T: person‐time in years" data-id="CD012661-fig-0022" src="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-AFig-FIG22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 22</div> <div class="figure-caption"> <p><b>IGT</b> : impaired glucose tolerance; <b>IRR</b> : incidence rate ratio; <b>n</b> : number of cases; <b>T</b>: person‐time in years </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/full#CD012661-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-AFig-FIG22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012661-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/urn:x-wiley:14651858:media:CD012661:CD012661-AFig-FIG23" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_t/tCD012661-AFig-FIG23.png" target="_blank"><b></b></a></p> </div><img alt="IFG: impaired fasting glucose; IGT: impaired glucose tolerance; IRR: incidence rate ratio; n: number of cases; T: person‐time in years" data-id="CD012661-fig-0023" src="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-AFig-FIG23.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 23</div> <div class="figure-caption"> <p><b>IFG</b> : impaired fasting glucose; <b>IGT</b> : impaired glucose tolerance; <b>IRR</b> : incidence rate ratio; <b>n</b> : number of cases; <b>T</b>: person‐time in years </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/full#CD012661-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-AFig-FIG23.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012661-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/urn:x-wiley:14651858:media:CD012661:CD012661-AFig-FIG24" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_t/tCD012661-AFig-FIG24.png" target="_blank"><b></b></a></p> </div><img alt="IFG: impaired fasting glucose; HbA1c: glycosylated haemoglobin A1c; IRR: incidence rate ratio; n: number of cases; T: person‐time in years" data-id="CD012661-fig-0024" src="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-AFig-FIG24.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 24</div> <div class="figure-caption"> <p><b>IFG</b> : impaired fasting glucose; <b>HbA1c</b> : glycosylated haemoglobin A1c; <b>IRR</b> : incidence rate ratio; <b>n</b> : number of cases; <b>T</b>: person‐time in years </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/full#CD012661-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-AFig-FIG24.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012661-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/urn:x-wiley:14651858:media:CD012661:CD012661-AFig-FIG25" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_t/tCD012661-AFig-FIG25.png" target="_blank"><b></b></a></p> </div><img alt="Overall prognosis of people with intermediate hyperglycaemia (cumulative type 2 diabetes incidence and regression to normoglycaemia) associated with measures of intermediate hyperglycaemia  HbA1c5.7/HbA1c6.0: glycosylated haemoglobin A1c 5.7%/6.0% threshold; IFG5.6/6.1: impaired fasting glucose 5.6/6.1 mmol/L threshold; IGT: impaired glucose tolerance" data-id="CD012661-fig-0025" src="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-AFig-FIG25.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 25</div> <div class="figure-caption"> <p><b>Overall prognosis</b> of people with intermediate hyperglycaemia (cumulative type 2 diabetes incidence and regression to normoglycaemia) associated with measures of intermediate hyperglycaemia<br/> <b>HbA1c5.7/HbA1c6.0</b> : glycosylated haemoglobin A1c 5.7%/6.0% threshold; <b>IFG5.6/6.1</b> : impaired fasting glucose 5.6/6.1 mmol/L threshold; <b>IGT</b>: impaired glucose tolerance </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/full#CD012661-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-AFig-FIG25.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012661-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/urn:x-wiley:14651858:media:CD012661:CD012661-AFig-FIG26" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_t/tCD012661-AFig-FIG26.png" target="_blank"><b></b></a></p> </div><img alt="Intermediate hyperglycaemia versus normoglycaemia as a prognostic factor for developing type 2 diabetes (associated with different measures and relative risks of intermediate hyperglycaemia)  HbA1c5.7/HbA1c6.0: glycosylated haemoglobin A1c 5.7%/6.0% threshold; IFG5.6/6.1: impaired fasting glucose 5.6/6.1 mmol/L threshold; IGT: impaired glucose tolerance; IRR: incidence rate ratio; OR: odds ratio; HR: hazard ratio" data-id="CD012661-fig-0026" src="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-AFig-FIG26.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 26</div> <div class="figure-caption"> <p>Intermediate hyperglycaemia versus normoglycaemia as a <b>prognostic factor</b> for developing type 2 diabetes (associated with different measures and relative risks of intermediate hyperglycaemia)<br/> <b>HbA1c5.7/HbA1c6.0</b> : glycosylated haemoglobin A1c 5.7%/6.0% threshold; <b>IFG5.6/6.1</b> : impaired fasting glucose 5.6/6.1 mmol/L threshold; <b>IGT</b> : impaired glucose tolerance; <b>IRR</b> : incidence rate ratio; <b>OR</b> : odds ratio; <b>HR</b>: hazard ratio </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/full#CD012661-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-AFig-FIG26.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012661-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/urn:x-wiley:14651858:media:CD012661:CD012661-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_t/tCD012661-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Hazard ratio as the effect measure for the development of T2DM, Outcome 1 T2DM incidence (IFG5.6)." data-id="CD012661-fig-0027" src="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Hazard ratio as the effect measure for the development of T2DM, Outcome 1 T2DM incidence (IFG<sub>5.6</sub>). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/references#CD012661-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012661-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/urn:x-wiley:14651858:media:CD012661:CD012661-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_t/tCD012661-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Hazard ratio as the effect measure for the development of T2DM, Outcome 2 T2DM incidence (IFG6.1)." data-id="CD012661-fig-0028" src="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Hazard ratio as the effect measure for the development of T2DM, Outcome 2 T2DM incidence (IFG<sub>6.1</sub>). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/references#CD012661-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012661-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/urn:x-wiley:14651858:media:CD012661:CD012661-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_t/tCD012661-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Hazard ratio as the effect measure for the development of T2DM, Outcome 3 T2DM incidence (IGT)." data-id="CD012661-fig-0029" src="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Hazard ratio as the effect measure for the development of T2DM, Outcome 3 T2DM incidence (IGT). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/references#CD012661-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012661-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/urn:x-wiley:14651858:media:CD012661:CD012661-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_t/tCD012661-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Hazard ratio as the effect measure for the development of T2DM, Outcome 4 T2DM incidence (IFG + IGT)." data-id="CD012661-fig-0030" src="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Hazard ratio as the effect measure for the development of T2DM, Outcome 4 T2DM incidence (IFG + IGT). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/references#CD012661-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012661-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/urn:x-wiley:14651858:media:CD012661:CD012661-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_t/tCD012661-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Hazard ratio as the effect measure for the development of T2DM, Outcome 5 T2DM incidence (HbA1c5.7)." data-id="CD012661-fig-0031" src="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Hazard ratio as the effect measure for the development of T2DM, Outcome 5 T2DM incidence (HbA1c<sub>5.7</sub>). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/references#CD012661-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012661-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/urn:x-wiley:14651858:media:CD012661:CD012661-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_t/tCD012661-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Hazard ratio as the effect measure for the development of T2DM, Outcome 6 T2DM incidence (HbA1c6.0)." data-id="CD012661-fig-0032" src="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Hazard ratio as the effect measure for the development of T2DM, Outcome 6 T2DM incidence (HbA1c<sub>6.0</sub>). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/references#CD012661-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012661-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/urn:x-wiley:14651858:media:CD012661:CD012661-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_t/tCD012661-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Hazard ratio as the effect measure for the development of T2DM, Outcome 7 T2DM incidence (HbA1c + IFG)." data-id="CD012661-fig-0033" src="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Hazard ratio as the effect measure for the development of T2DM, Outcome 7 T2DM incidence (HbA1c + IFG). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/references#CD012661-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012661-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/urn:x-wiley:14651858:media:CD012661:CD012661-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_t/tCD012661-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Odds ratio as the effect measure for the development of T2DM, Outcome 1 T2DM incidence (IFG5.6)." data-id="CD012661-fig-0034" src="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Odds ratio as the effect measure for the development of T2DM, Outcome 1 T2DM incidence (IFG<sub>5.6</sub>). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/references#CD012661-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012661-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/urn:x-wiley:14651858:media:CD012661:CD012661-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_t/tCD012661-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Odds ratio as the effect measure for the development of T2DM, Outcome 2 T2DM incidence (IFG6.1)." data-id="CD012661-fig-0035" src="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Odds ratio as the effect measure for the development of T2DM, Outcome 2 T2DM incidence (IFG<sub>6.1</sub>). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/references#CD012661-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012661-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/urn:x-wiley:14651858:media:CD012661:CD012661-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_t/tCD012661-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Odds ratio as the effect measure for the development of T2DM, Outcome 3 T2DM incidence (IGT)." data-id="CD012661-fig-0036" src="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Odds ratio as the effect measure for the development of T2DM, Outcome 3 T2DM incidence (IGT). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/references#CD012661-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012661-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/urn:x-wiley:14651858:media:CD012661:CD012661-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_t/tCD012661-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Odds ratio as the effect measure for the development of T2DM, Outcome 4 T2DM incidence (IFG + IGT)." data-id="CD012661-fig-0037" src="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Odds ratio as the effect measure for the development of T2DM, Outcome 4 T2DM incidence (IFG + IGT). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/references#CD012661-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012661-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/urn:x-wiley:14651858:media:CD012661:CD012661-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_t/tCD012661-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Odds ratio as the effect measure for the development of T2DM, Outcome 5 T2DM incidence (HbA1c5.7)." data-id="CD012661-fig-0038" src="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Odds ratio as the effect measure for the development of T2DM, Outcome 5 T2DM incidence (HbA1c<sub>5.7</sub>). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/references#CD012661-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012661-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/urn:x-wiley:14651858:media:CD012661:CD012661-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_t/tCD012661-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Odds ratio as the effect measure for the development of T2DM, Outcome 6 T2DM incidence (HbA1c6.0)." data-id="CD012661-fig-0039" src="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Odds ratio as the effect measure for the development of T2DM, Outcome 6 T2DM incidence (HbA1c<sub>6.0</sub>). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/references#CD012661-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012661-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/urn:x-wiley:14651858:media:CD012661:CD012661-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_t/tCD012661-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Odds ratio as the effect measure for the development of T2DM, Outcome 7 T2DM incidence (HbA1c5.7 + IFG5.6)." data-id="CD012661-fig-0040" src="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Odds ratio as the effect measure for the development of T2DM, Outcome 7 T2DM incidence (HbA1c<sub>5.7</sub> + IFG<sub>5.6</sub>). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/references#CD012661-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/media/CDSR/CD012661/image_n/nCD012661-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012661-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Summary of findings: overall prognosis of people with intermediate hyperglycaemia for developing T2DM</span></div> <tbody> <tr class="table-header separated"> <td align="" class="table-header" colspan="9" rowspan="1" valign="top"> <p><b>Outcome: development of T2DM<br/> Prognosis of people with intermediate hyperglycaemia</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Follow‐up<br/> (years)</b> </p> </td> <td align="center" class="table-header" colspan="6" rowspan="1" valign="top"> <p><b>Cumulative T2DM incidence % (95% CI) <br/> [no of studies; no of participants with intermediate hyperglycaemia]</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Regression from intermediate hyperglycaemia to normoglycaemia % (95% CI) <br/> [no of studies; no of participants with intermediate hyperglycaemia]</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Overall certainty of the evidence (GRADE)<sup>a</sup> </b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>IFG<sub>5.6</sub> </b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>IFG<sub>6.1</sub> </b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>IGT</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>IFG + IGT</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>HbA1c<sub>5.7</sub> </b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>HbA1c<sub>6.0</sub> </b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>1</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>13 (5–23)</b> </p> <p>[3; 671]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>29 (23–36)</b> </p> <p>[1; 207]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>59 (54–64)</b> </p> <p>[2; 375]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="14" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>b</sup> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>2</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2 (1–2)</b> </p> <p>[1; 1335]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>11 (8–14)</b> </p> <p>[2; 549]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>16 (9–26)</b> </p> <p>[9; 1998]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>46 (36–55)</b> </p> <p>[9; 2852]</p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>3</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>17 (6–32)</b> </p> <p>[3; 1091]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>9 (2–20)</b> </p> <p>[3; 927]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>22 (18–27)</b> </p> <p>[3; 417]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>34 (28–41)</b> </p> <p>[1; 209]—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>7 (5–10)</b> </p> <p>[1; 370]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>41 (24–69)</b> </p> <p>[7; 1356]</p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>4</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>17 (13–22)</b> </p> <p>[3; 800]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>30 (17–44)</b> </p> <p>[2; 1567]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>22 (12–34)</b> </p> <p>[5; 1042]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>14 (7–23)</b> </p> <p>[3; 5352]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>44 (40–48)</b> </p> <p>[2; 627]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>33 (26–40)</b> </p> <p>[3; 807]</p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>5</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>18 (10–27)</b> </p> <p>[7; 3530]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>26 (19–33)</b> </p> <p>[11; 3837]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>39 (25–53)</b> </p> <p>[12; 3444]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>50 (37–63)</b> </p> <p>[5; 478]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>25 (18–32)</b> </p> <p>[4; 3524]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>38 (26–51)</b> </p> <p>[3; 1462]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>34 (27–42)</b> </p> <p>[9; 2603]</p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>6</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>22 (15–31)</b> </p> <p>[4; 738]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>37 (31–43)</b> </p> <p>[5; 279]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>29 (25–34)</b> </p> <p>[7; 775]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>58 (48–67)</b> </p> <p>[4; 106]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>17 (14–20)</b> </p> <p>[1; 675]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>23 (3–53)</b> </p> <p>[5; 1328]</p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>7</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>18 (8–30)</b> </p> <p>[5; 980]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>15 (0–45)</b> </p> <p>[4; 434]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>19 (13–26)</b> </p> <p>[5; 835]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>32 (20–45)</b> </p> <p>[4; 753]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>21 (16–27)</b> </p> <p>[1; 207]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>41 (37–45)</b> </p> <p>[4; 679]</p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>8</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>34 (27–40)</b> </p> <p>[2; 1887]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>48 (31–66)</b> </p> <p>[1;29]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>43 (37–49)</b> </p> <p>[4; 1021]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>52 (47–57)</b> </p> <p>[1; 356]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>39 (33–44)</b> </p> <p>[2; 328]</p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>9</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>38 (10–70)</b> </p> <p>[3; 1356]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>53 (45–60)</b> </p> <p>[1; 163]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>84 (74–91)</b> </p> <p>[1; 69]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>17 (14–22)</b> </p> <p>[1; 299]</p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>10</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>23 (14–33)</b> </p> <p>[6; 1542]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>29 (17–43)</b> </p> <p>[6; 537]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>26 (17–37)</b> </p> <p>[6; 443]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>30 (17–44)</b> </p> <p>[2; 49]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>31 (29–33)</b> </p> <p>[2; 2854]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>42 (22–63)</b> </p> <p>[7; 894]</p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>11</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>38 (33–43)</b> </p> <p>[1; 402]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>46 (43–49)</b> </p> <p>[1; 1253]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>28 (17–39)</b> </p> <p>[2; 736]</p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>12</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>31 (19–34)</b> </p> <p>[3; 433]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>31 (28–33)</b> </p> <p>[1; 1382]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>41 (38–43)</b> </p> <p>[2; 1552]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>70 (63–76)</b> </p> <p>[2; 207]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>15</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>29 (19–40)</b> </p> <p>[1; 70]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>20</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>60 (5–68)</b> </p> <p>[1; 114]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign="top"> <p><b>CI</b> : confidence interval; <b>HbA1c<sub>5.7</sub> </b> : glycosylated haemoglobin A1c, 5.7% threshold; <b>HbA1c<sub>6.0</sub> </b> : glycosylated haemoglobin A1c, 6.0% threshold; <b>IFG<sub>5.6</sub> </b> : impaired fasting glucose, 5.6 mmol/L threshold; <b>IFG<sub>6.1</sub> </b> : impaired fasting glucose, 6.1 mmol/L threshold; <b>IGT</b> : impaired glucose tolerance; <b>T2DM</b>: type 2 diabetes mellitus. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/> <b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p><sup>a</sup>With phase 2 explanatory studies aiming to confirm independent associations between the prognostic factor and the outcome, GRADE starts with 'high quality' (<a href="./references#CD012661-bbs2-0339" title="HuguetA , HaydenJA , StinsonJ , McGrathPJ , ChambersCT , TougasME , et al. Judging the quality of evidence in reviews of prognostic factor research: adapting the GRADE framework. Systematic Reviews2013;2:71. ">Huguet 2013</a>). We assumed the GRADE factor publication bias was inherent with this type of research (phase 2 design), so we did not use it as a potential downgrading factor<br/> <sup>b</sup>Downgraded by one level because of imprecision (wide CIs for most intermediate hyperglycaemia definitions and the association with T2DM incidence and regression from intermediate hyperglycaemia) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Summary of findings: overall prognosis of people with intermediate hyperglycaemia for developing T2DM</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/full#CD012661-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012661-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings: risk of intermediate hyperglycaemia (IFG5.6 mmol/L definition) versus normoglycaemia for developing T2DM</span></div> <tbody> <tr class="table-header separated"> <td align="" class="table-header" colspan="5" rowspan="1" valign="top"> <p><b>Outcome: development of T2DM<br/> Prognostic factor: intermediate hyperglycaemia versus normoglycaemia as measured by IFG<sub>5.6</sub> </b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>No of studies</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>No of participants with intermediate hyperglycaemia</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Geographic region/special population</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Estimated effect (95% CI)<br/> [95% prediction interval]</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Overall certainty of the evidence (GRADE)<sup>a</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 4</p> <p>IRR: 6</p> <p>OR: 10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 2385</p> <p>IRR: 15,661</p> <p>OR: 6359</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asia/Middle East</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR: 5.07 (3.41–4.86)</b> [1.07–24.02] </p> <p><b>IRR: 5.23 (3.77–7.25)</b> [1.72–15.89] </p> <p><b>OR: 2.94 (1.77–4.86)</b> [0.43–19.93] </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 3</p> <p>IRR: 3</p> <p>OR: 9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 5685</p> <p>IRR: 6322</p> <p>OR: 1949</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Australia/Europe/North America</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR: 4.15 (1.24–13.9)</b> [N/M] </p> <p><b>IRR: 4.96 (3.25–7.57)</b> [0.32–77.24] </p> <p><b>OR: 6.47 (3.81–11.00)</b> [0.99–42.32] </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 0</p> <p>IRR: 0</p> <p>OR: 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 0</p> <p>IRR: 0</p> <p>OR: 65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Latin America</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR: NA</b> </p> <p><b>IRR</b> : <b>NA</b> </p> <p><b>OR: 4.28 (3.21–5.71)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 1</p> <p>IRR: 1</p> <p>OR: 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 947</p> <p>IRR: 2374</p> <p>OR: 947</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>American Indians/Islands</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR: 2.38 (1.85–3.06)</b> </p> <p><b>IRR: 2.74 (1.88–3.99)</b> </p> <p><b>OR: 3.12 (2.31–4.21)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 8</p> <p>IRR: 10</p> <p>OR: 21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 9017</p> <p>IRR: 24,357</p> <p>OR: 9320</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR: 4.32 (2.61–7.12)</b> [0.75–25.0] </p> <p><b>IRR: 4.81 (3.67–6.30)</b> [1.95–11.83] </p> <p><b>OR: 4.15 (2.75–6.28)</b> [0.53–32.4] </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>CI</b> : confidence interval; <b>HR</b> : hazard ratio;<b>IFG<sub>5.6</sub> </b> : impaired fasting glucose 5.6 mmol/L threshold; <b>IRR</b> : incidence rate ratio; <b>NA</b> : not applicable; <b>N/M</b> : fewer than 3 studies or calculation of the 95% prediction interval did not provide a meaningful estimate; <b>OR</b> : odds ratio; <b>T2DM</b>: type 2 diabetes mellitus. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/> <b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>a</sup>With phase 2 explanatory studies aiming to confirm independent associations between the prognostic factor and the outcome, GRADE starts with 'high quality' (<a href="./references#CD012661-bbs2-0339" title="HuguetA , HaydenJA , StinsonJ , McGrathPJ , ChambersCT , TougasME , et al. Judging the quality of evidence in reviews of prognostic factor research: adapting the GRADE framework. Systematic Reviews2013;2:71. ">Huguet 2013</a>). We assumed the GRADE factor publication bias was inherent with this type of research (phase 2 design), so we did not use it as a potential downgrading factor<br/> <sup>b</sup>Downgraded by one level because of study limitations (many studies did not adequately adjust for confounders, if at all) and by one level because of imprecision (CIs were wide) and inconsistency (wide 95% prediction intervals sometimes ranging from negative to positive prognostic factor to outcome associations) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings: risk of intermediate hyperglycaemia (IFG5.6 mmol/L definition) versus normoglycaemia for developing T2DM</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/full#CD012661-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012661-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Summary of findings: risk of intermediate hyperglycaemia (IFG6.1 mmol/L definition) versus normoglycaemia for developing T2DM</span></div> <tbody> <tr class="table-header separated"> <td align="" class="table-header" colspan="5" rowspan="1" valign="top"> <p><b>Outcome: development of T2DM<br/> Prognostic factor: intermediate hyperglycaemia as measured by IFG<sub>6.1</sub> </b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>No of studies</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>No of participants with intermediate hyperglycaemia</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Geographic region/special population</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Estimated effect (95% CI)<br/> [95% prediction interval]</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Overall certainty of<br/> the evidence (GRADE)<sup>a</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 5</p> <p>IRR: 2</p> <p>OR: 7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 1054</p> <p>IRR: 1677</p> <p>OR: 3317</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asia/Middle East</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR: 10.55 (3.61–30.81)</b> [N/M] </p> <p><b>IRR: 3.62 (1.67–7.83)</b> [N/M] </p> <p><b>OR: 5.18 (2.32–11.53)</b> [0.29–91.37] </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 4</p> <p>IRR: 4</p> <p>OR: 7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 1736</p> <p>IRR: 3438</p> <p>OR: 1240</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Australia/Europe/North America</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR: 3.30 (2.32–4.67)</b> [0.84–12.99] </p> <p><b>IRR: 8.55 (6.37–11.48)</b> [4.37–16.73] </p> <p><b>OR: 8.69 (4.95–15.24)</b> [1.20–62.69] </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 0</p> <p>IRR: 0</p> <p>OR: 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 0</p> <p>IRR: 0</p> <p>OR: 17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Latin America</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR: NA</b> </p> <p><b>IRR: NA</b> </p> <p><b>OR: 3.73 (2.18–6.38)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 0</p> <p>IRR: 0</p> <p>OR: 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 0</p> <p>IRR: 0</p> <p>OR: 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>American Indians/Islands</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR: NA</b> </p> <p><b>IRR: NA</b> </p> <p><b>OR: NA</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 9</p> <p>IRR: 6</p> <p>OR: 15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 2818</p> <p>IRR: 5115</p> <p>OR: 4574</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR: 5.47 (3.50–8.54)</b> [1.09–27.56] </p> <p><b>IRR: 6.82 (4.53–10.25)</b> [2.03–22.87] </p> <p><b>OR: 6.60 (4.18–10.43)</b> [0.93–46.82] </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>CI</b> : confidence interval; <b>HR</b> : hazard ratio;<b>IFG<sub>6.1</sub> </b> : impaired fasting glucose 6.1 mmol/L threshold; <b>IRR</b> : incidence rate ratio; <b>NA</b> : not applicable; <b>N/M</b> : fewer than 3 studies or calculation of the 95% prediction interval did not provide a meaningful estimate; <b>OR</b> : odds ratio; <b>T2DM</b>: type 2 diabetes mellitus. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/> <b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>a</sup>With phase 2 explanatory studies aiming to confirm independent associations between the prognostic factor and the outcome, GRADE starts with 'high quality' (<a href="./references#CD012661-bbs2-0339" title="HuguetA , HaydenJA , StinsonJ , McGrathPJ , ChambersCT , TougasME , et al. Judging the quality of evidence in reviews of prognostic factor research: adapting the GRADE framework. Systematic Reviews2013;2:71. ">Huguet 2013</a>). We assumed the GRADE factor publication bias was inherent with this type of research (phase 2 design), so we did not use it as a potential downgrading factor<br/> <sup>b</sup>Downgraded by one level because of study limitations (many studies did not adequately adjust for confounders, if at all) and by one level because of imprecision (CIs were wide) and inconsistency (wide 95% prediction intervals sometimes ranging from negative to positive prognostic factor to outcome associations) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Summary of findings: risk of intermediate hyperglycaemia (IFG6.1 mmol/L definition) versus normoglycaemia for developing T2DM</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/full#CD012661-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012661-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Summary of findings: risk of intermediate hyperglycaemia (IGT definition) versus normoglycaemia for developing T2DM</span></div> <tbody> <tr class="table-header separated"> <td align="" class="table-header" colspan="5" rowspan="1" valign="top"> <p><b>Outcome: development of T2DM<br/> Prognostic factor: intermediate hyperglycaemia as measured by IGT</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>No of studies</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>No of participants with intermediate hyperglycaemia</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Geographic region/special population</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Estimated effect (95% CI)<br/> [95% prediction interval]</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Overall certainty of the evidence (GRADE)<sup>a</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 3</p> <p>IRR: 5</p> <p>OR: 6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 1780</p> <p>IRR: 14,809</p> <p>OR: 1226</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asia/Middle East</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR: 4.48 (2.81–7.15)</b> [N/M] </p> <p><b>IRR: 3.93 (3.03–5.10)</b> [1.71–9.02] </p> <p><b>OR: 3.74 (2.83–4.94)</b> [1.70–8.21] </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 2</p> <p>IRR: 5</p> <p>OR: 11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 2230</p> <p>IRR: 2572</p> <p>OR: 1481</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Australia/Europe/North America</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR: 2.53 (1.52–4.19)</b> [N/M] </p> <p><b>IRR: 5.93 (4.11–8.57)</b> [2.38–14.81] </p> <p><b>OR: 5.20 (3.62–7.45)</b> [1.50–18.09] </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 0</p> <p>IRR: 0</p> <p>OR: 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 0</p> <p>IRR: 0</p> <p>OR: 381</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Latin America</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR: NA</b> </p> <p><b>IRR: NA</b> </p> <p><b>OR: 4.94 (3.15–7.76)</b> [N/M] </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IRR: 2<br/> OR: 1<br/> HR: 0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IRR: 1087<br/> OR: 51<br/> HR: 0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>American Indians/Islands</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IRR: 4.46 (3.12–6.38)</b> [N/M] </p> <p><b>OR: 3.60 (1.40–9.26)</b> </p> <p><b>HR: NA</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 5</p> <p>IRR: 12</p> <p>OR: 20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 4010</p> <p>IRR: 18,468</p> <p>OR: 3139</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR: 3.61 (2.31–5.64)</b> [0.69–18.97] </p> <p><b>IRR: 4.48 (3.59–5.44)</b> [2.60–7.70] </p> <p><b>OR: 4.61 (3.76–5.64)</b> [2.10–10.13] </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>CI</b> : confidence interval; <b>HR</b> : hazard ratio;<b>IGT</b> : impaired glucose tolerance; <b>IRR</b> : incidence rate ratio; <b>NA</b> : not applicable; <b>N/M</b> : fewer than 3 studies or calculation of the 95% prediction interval did not provide a meaningful estimate; <b>T2DM</b>: type 2 diabetes mellitus. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/> <b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>a</sup>With phase 2 explanatory studies aiming to confirm independent associations between the prognostic factor and the outcome, GRADE starts with 'high quality' (<a href="./references#CD012661-bbs2-0339" title="HuguetA , HaydenJA , StinsonJ , McGrathPJ , ChambersCT , TougasME , et al. Judging the quality of evidence in reviews of prognostic factor research: adapting the GRADE framework. Systematic Reviews2013;2:71. ">Huguet 2013</a>). We assumed the GRADE factor publication bias was inherent with this type of research (phase 2 design), so we did not use it as a potential downgrading factor<br/> <sup>b</sup>Downgraded by one level because of study limitations (many studies did not adequately adjust for confounders, if at all) and by one level because of imprecision (CIs were wide) and inconsistency (wide 95% prediction intervals sometimes ranging from negative to positive prognostic factor to outcome associations) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Summary of findings: risk of intermediate hyperglycaemia (IGT definition) versus normoglycaemia for developing T2DM</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/full#CD012661-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012661-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Summary of findings: risk of intermediate hyperglycaemia (combined IFG and IGT definition) versus normoglycaemia for developing T2DM</span></div> <tbody> <tr class="table-header separated"> <td align="" class="table-header" colspan="5" rowspan="1" valign="top"> <p><b>Outcome: development of T2DM<br/> Prognostic factor: intermediate hyperglycaemia as measured by combined IFG and IGT</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>No of studies</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>No of participants with intermediate hyperglycaemia</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Geographic region/special population</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Estimated effect (95% CI)<br/> [95% prediction interval]</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Overall certainty of the evidence (GRADE)<sup>a</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 3</p> <p>IRR: 4</p> <p>OR: 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 461</p> <p>IRR: 3166</p> <p>OR: 498</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asia/Middle East</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR: 10.20 (5.45–19.09)</b> [N/M] </p> <p><b>IRR: 11.20 (5.59–22.43)</b> [N/M] </p> <p><b>OR: 6.99 (3.09–15.83)</b> [N/M] </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 1</p> <p>IRR: 4</p> <p>OR: 6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 221</p> <p>IRR: 699</p> <p>OR: 154</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Australia/Europe/North America</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR: 3.80 (2.30–6.28)</b> [N/M] </p> <p><b>IRR: 13.92 (9.99–19.40)</b> [6.71–28.85] </p> <p><b>OR: 20.95 (12.40–35.40)</b> [4.93–89.05] </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 0</p> <p>IRR: 0</p> <p>OR: 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 0</p> <p>IRR: 0</p> <p>OR: 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Latin America</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR: NA</b> </p> <p><b>IRR: NA</b> </p> <p><b>OR: NA</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 1</p> <p>IRR: 1<br/> OR: 0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 356</p> <p>IRR: 605<br/> OR: 0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>American Indians/Islands</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR: 4.06 (3.05–5.40)</b> </p> <p><b>IRR: 5.18 (3.42–7.83)</b> <br/> <b>OR: NA</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 5</p> <p>IRR: 9</p> <p>OR: 9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 1038</p> <p>IRR: 4470</p> <p>OR: 652</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR: 6.90 (4.15–11.45)</b> [1.06–44.95] </p> <p><b>IRR: 10.94 (7.22–16.58)</b> [2.58–46.46] </p> <p><b>OR: 13.14 (7.41–23.30)</b> [1.84–93.66] </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>CI</b> : confidence interval; HR: hazard ratio;<b>IFG</b> : impaired fasting glucose; <b>IGT</b> : impaired glucose tolerance; <b>IRR</b> : incidence rate ratio; <b>NA</b> : not applicable; <b>N/M</b> : fewer than 3 studies or calculation of the 95% prediction interval did not provide a meaningful estimate; <b>OR</b> : odds ratio; <b>T2DM</b>: type 2 diabetes mellitus. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/> <b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>a</sup>With phase 2 explanatory studies aiming to confirm independent associations between the prognostic factor and the outcome, GRADE starts with 'high quality' (<a href="./references#CD012661-bbs2-0339" title="HuguetA , HaydenJA , StinsonJ , McGrathPJ , ChambersCT , TougasME , et al. Judging the quality of evidence in reviews of prognostic factor research: adapting the GRADE framework. Systematic Reviews2013;2:71. ">Huguet 2013</a>). We assumed the GRADE factor publication bias was inherent with this type of research (phase 2 design), so we did not use it as a potential downgrading factor<br/> <sup>b</sup>Downgraded by one level because of study limitations (many studies did not adequately adjust for confounders, if at all) and by one level because of imprecision (CIs were wide) and inconsistency (wide 95% prediction intervals) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Summary of findings: risk of intermediate hyperglycaemia (combined IFG and IGT definition) versus normoglycaemia for developing T2DM</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/full#CD012661-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012661-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Summary of findings: risk of intermediate hyperglycaemia (HbA1c5.7 definition) versus normoglycaemia for developing T2DM</span></div> <tbody> <tr class="table-header separated"> <td align="" class="table-header" colspan="5" rowspan="1" valign="top"> <p><b>Outcome: development of T2DM<br/> Prognostic factor: intermediate hyperglycaemia as measured by HbA1c<sub>5.7</sub> </b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>No of studies</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>No of participants with intermediate hyperglycaemia</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Geographic region/special population</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Estimated effect (95% CI)<br/> [95% prediction interval]</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Overall certainty of the evidence (GRADE)<sup>a</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 3</p> <p>IRR: 1</p> <p>OR: 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 3196</p> <p>IRR: 1965</p> <p>OR: 675</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asia/Middle East</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR: 7.21 (5.14–10.11)</b> [0.81–64.52] </p> <p><b>IRR: 6.62 (4.18–10.49)</b> [N/M] </p> <p><b>OR: 4.54 (2.65–7.78)</b> [N/M] </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 1</p> <p>IRR: 0</p> <p>OR: 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 2027</p> <p>IRR: 0</p> <p>OR: 231</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Australia/Europe/North America</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR: 2.71 (2.48–2.96)</b> [N/M] </p> <p><b>IRR: NA</b> </p> <p><b>OR: 4.38 (1.36–14.15)</b> [N/M] </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 0</p> <p>IRR: 0</p> <p>OR: 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 0</p> <p>IRR: 0</p> <p>OR: 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Latin America</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR: NA</b> </p> <p><b>IRR: NA</b> </p> <p><b>OR: NA</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 0</p> <p>IRR: 0</p> <p>OR: 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 0</p> <p>IRR: 0</p> <p>OR: 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>American Indians/Islands</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR: NA</b> </p> <p><b>IRR: NA</b> </p> <p><b>OR: NA</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 4</p> <p>IRR: 1</p> <p>OR: 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 5223</p> <p>IRR: 1965</p> <p>OR: 906</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR: 5.55 (2.77–11.12)</b> [0.23–141.18] </p> <p><b>IRR: 6.62 (4.18–10.49)</b> [N/M] </p> <p><b>OR: 4.43 (2.20–8.88)</b> [N/M] </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>CI</b> : confidence interval; <b>HbA1c<sub>5.7</sub> </b> : glycosylated haemoglobin A1c 5.7% threshold; <b>HR</b> : hazard ratio;<b>IRR</b> : incidence rate ratio; <b>NA</b> : not applicable; <b>N/M</b> : fewer than 3 studies or calculation of the 95% prediction interval did not provide a meaningful estimate; <b>OR</b> : odds ratio; <b>T2DM</b>: type 2 diabetes mellitus. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/> <b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>a</sup>With phase 2 explanatory studies aiming to confirm independent associations between the prognostic factor and the outcome, GRADE starts with 'high quality' (<a href="./references#CD012661-bbs2-0339" title="HuguetA , HaydenJA , StinsonJ , McGrathPJ , ChambersCT , TougasME , et al. Judging the quality of evidence in reviews of prognostic factor research: adapting the GRADE framework. Systematic Reviews2013;2:71. ">Huguet 2013</a>). We assumed the GRADE factor publication bias was inherent with this type of research (phase 2 design), so we did not use it as a potential downgrading factor<br/> <sup>b</sup>Downgraded by one level because of study limitations (many studies did not adequately adjust for confounders, if at all) and by one level because of imprecision (CIs were wide) and inconsistency (95% prediction intervals sometimes ranging from negative to positive prognostic factor to outcome associations) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Summary of findings: risk of intermediate hyperglycaemia (HbA1c5.7 definition) versus normoglycaemia for developing T2DM</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/full#CD012661-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012661-tbl-0007"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Summary of findings: risk of intermediate hyperglycaemia (HbA1c6.0 definition) versus normoglycaemia for developing T2DM</span></div> <tbody> <tr class="table-header separated"> <td align="" class="table-header" colspan="5" rowspan="1" valign="top"> <p><b>Outcome: development of T2DM<br/> Prognostic factor: intermediate hyperglycaemia as measured by HbA1c<sub>6.0</sub> </b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>No of studies</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>No of participants with intermediate hyperglycaemia</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Geographic region/special population</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Estimated effect (95% CI)<br/> [95% prediction interval]</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Overall certainty of the evidence (GRADE)<sup>a</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 2</p> <p>IRR: 0</p> <p>OR: 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 1040</p> <p>IRR: 0</p> <p>OR: 370</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Australia/Europe/North America</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR: 5.09 (1.69–15.37)</b> [N/M] </p> <p><b>IRR: NA</b> </p> <p><b>OR: 15.60 (6.90–35.27)</b> [N/M] </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 4</p> <p>IRR: 0</p> <p>OR: 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 3492</p> <p>IRR: 0</p> <p>OR: 1103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asia/Middle East</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR: 13.12 (4.10–41.96)</b> [N/M] </p> <p><b>IRR:</b> NA </p> <p><b>OR: 23.20 (18.70–28.78)</b> [N/M] </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 0</p> <p>IRR: 0</p> <p>OR: 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 0</p> <p>IRR: 0</p> <p>OR: 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Latin America</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR: NA</b> </p> <p><b>IRR: NA</b> </p> <p><b>OR: NA</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IRR: 0<br/> OR: 1<br/> HR: 0 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IRR: 0<br/> OR: 121 </p> <p>HR: 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>American Indians/Islands</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IRR: NA</b> </p> <p><b>OR: 5.89 (4.23–8.20)</b> [N/M] </p> <p><b>HR: NA</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 6</p> <p>IRR: 0</p> <p>OR: 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR: 4532</p> <p>IRR: 0</p> <p>OR: 1594</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR: 10.10 (3.59–28.43)</b> [N/M] </p> <p><b>IRR: NA</b> </p> <p><b>OR: 12.79 [4.56–35.85]</b> [N/M] </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>CI</b> : confidence interval; <b>HbA1c<sub>6.0</sub> </b> : glycosylated haemoglobin A1c 6.0% threshold; <b>HR</b> : hazard ratio;<b>IRR</b> : incidence rate ratio; <b>NA</b> : not applicable; <b>N/M</b> : fewer than 3 studies or calculation of the 95% prediction interval did not provide a meaningful estimate; <b>OR</b> : odds ratio; <b>T2DM</b>: type 2 diabetes mellitus. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/> <b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>a</sup>With phase 2 explanatory studies aiming to confirm independent associations between the prognostic factor and the outcome, GRADE starts with 'high quality' (<a href="./references#CD012661-bbs2-0339" title="HuguetA , HaydenJA , StinsonJ , McGrathPJ , ChambersCT , TougasME , et al. Judging the quality of evidence in reviews of prognostic factor research: adapting the GRADE framework. Systematic Reviews2013;2:71. ">Huguet 2013</a>). We assumed the GRADE factor publication bias was inherent with this type of research (phase 2 design), so we did not use it as a potential downgrading factor<br/> <sup>b</sup>Downgraded by one level because of study limitations (many studies did not adequately adjust for confounders, if at all) and by one level because of imprecision (most CIs were wide) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Summary of findings: risk of intermediate hyperglycaemia (HbA1c6.0 definition) versus normoglycaemia for developing T2DM</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/full#CD012661-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012661-tbl-0008"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Overview: overall prognosis of people with intermediate hyperglycaemia and regression from intermediate hyperglycaemia to normoglycaemia</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Follow‐up time (years)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>% (95% CI) cumulative T2DM incidence <br/> [no of studies; no of participants with IH]</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="16" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>% (95% CI) regression from IH to normoglycaemia<br/> [no of studies; no of participants with IH]</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IFG<sub>5.6</sub> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IFG<sub>6.1</sub> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IGT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IFG + IGT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HbA1c<sub>5.7</sub> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HbA1c<sub>6.0</sub> </b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>13 (5–23)</b> </p> <p>[3; 671]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>29 (23–36)</b> </p> <p>[1; 207]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>59 (54–64)</b> </p> <p>[2; 375]</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2 (1–2)</b> </p> <p>[1; 1335]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>11 (8–14)</b> </p> <p>[2; 549]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>16 (9–26)</b> </p> <p>[9; 1998]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>46 (36–55)</b> </p> <p>[9; 2852]</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>17 (6–32)</b> </p> <p>[3; 1091]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>9 (2–20)</b> </p> <p>[3; 927]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>22 (18–27)</b> </p> <p>[3; 417]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>34 (28–41)</b> </p> <p>[1; 209]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>7 (5–10)</b> </p> <p>[1; 370]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>41 (24–59)</b> </p> <p>[7; 1356]</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>17 (13–22)</b> </p> <p>[3; 800]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>30 (17–44)</b> </p> <p>[2; 1567]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>22 (12–34)</b> </p> <p>[5; 1042]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>14 (7–23)</b> </p> <p>[3; 5352]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>44 (40–48)</b> </p> <p>[2; 627]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>33 (26–40)</b> </p> <p>[3; 807]</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>5</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>18 (10–27)</b> </p> <p>[7; 3530]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>26 (19–33)</b> </p> <p>[11; 3837]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>39 (25–53)</b> </p> <p>[12; 3444]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>50 (37–63)</b> </p> <p>[5; 478]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>25 (18–32)</b> </p> <p>[4; 3524]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>38 (26–51)</b> </p> <p>[3; 1462]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>34 (27–42)</b> </p> <p>[9; 2603]</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>6</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>22 (15–31)</b> </p> <p>[4; 738]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>37 (31–43)</b> </p> <p>[5; 279]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>29 (25–34)</b> </p> <p>[7; 775]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>58 (48–67)</b> </p> <p>[4; 106]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>17 (14–20)</b> </p> <p>[1; 675]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>23 (3–53)</b> </p> <p>[5; 1328]</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>7</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>18 (8–30)</b> </p> <p>[5; 980]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>15 (0–45)</b> </p> <p>[4; 434]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>19 (13–26)</b> </p> <p>[5; 835]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>32 (20–45)</b> </p> <p>[4; 753]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>21 (16–27)</b> </p> <p>[1; 207]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>41 (37–45)</b> </p> <p>[4; 679]</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>8</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>34 (27–40)</b> </p> <p>[2; 1887]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>48 (31–66)</b> </p> <p>[1;29]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>43 (37–49)</b> </p> <p>[4; 1021]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>52 (47–57)</b> </p> <p>[1; 356]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>39 (33–44)</b> </p> <p>[2; 328]</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>9</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>38 (10–70)</b> </p> <p>[3; 1356]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>53 (45–60)</b> </p> <p>[1; 163]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>84 (74–91)</b> </p> <p>[1; 69]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>17 (14–22)</b> </p> <p>[1; 299]</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>10</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>23 (14–33)</b> </p> <p>[6; 1542]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>29 (17–43)</b> </p> <p>[6; 537]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>26 (17–37)</b> </p> <p>[6; 443]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>30 (17–44)</b> </p> <p>[2; 49]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>31 (29–33)</b> </p> <p>[2; 2854]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>42 (22–63)</b> </p> <p>[7; 894]</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>11</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>38 (33–43)</b> </p> <p>[1; 402]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>46 (43–49)</b> </p> <p>[1; 1253]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>28 (17–39)</b> </p> <p>[2; 736]</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>12</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>31 (19–34)</b> </p> <p>[3; 433]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>31 (28–33)</b> </p> <p>[1; 1382]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>41 (38–43)</b> </p> <p>[2; 1552]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>70 (63–76)</b> </p> <p>[2; 207]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>15</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>29 (19–40)</b> </p> <p>[1; 70]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>20</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>60 (5–68)</b> </p> <p>[1; 114]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p><b>CI</b> : confidence interval; <b>HbA1c</b>: glycosylated haemoglobin A1c; HbA1c<sub>5.7/6.0</sub> (threshold 5.7% or 6.0%); <b>IFG<sub>5.6/6.1</sub> </b> : impaired fasting glucose (threshold 5.6 mmol/L or 6.1 mmol/L); <b>IGT</b> : impaired glucose tolerance; <b>IFG + IGT</b> : both IFG and IGT; <b>IH</b> : intermediate hyperglycaemia; <b>T2DM</b>: type 2 diabetes mellitus </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Overview: overall prognosis of people with intermediate hyperglycaemia and regression from intermediate hyperglycaemia to normoglycaemia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/full#CD012661-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012661-tbl-0009"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Overview: intermediate hyperglycaemia versus normoglycaemia as a prognostic factor for the development of type 2 diabetes</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Ratio (95% CI)<br/> 95% prediction interval<sup>a,b</sup> </b> </p> <p><b>[no of studies; no of participants with IH/no of participants with normoglycaemia]</b> </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Hazard ratio</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Region</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IFG<sub>5.6</sub> cohort</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IFG<sub>6.1</sub> cohort</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IGT cohort</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IFG + IGT cohort</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HbA1c<sub>5.7</sub> cohort</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HbA1c<sub>6.0</sub> cohort</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HbA1c<sub>5.7</sub> + IFG<sub>5.6</sub> cohort</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asia/Middle East</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>5.07 (3.41‐7.53)</b> </p> <p>1.07–24.02</p> <p>[4; 2385/12,837]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>10.55 (3.61–30.81)</b> </p> <p>NA<sup>b</sup> </p> <p>[5; 1054/9756]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4.48 (2.81–7.15)</b> </p> <p>NA<sup>b</sup> </p> <p>[3; 1780/6695]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>10.20 (5.45–19.09)</b> </p> <p>NA<sup>b</sup> </p> <p>[3; 461/6695]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>7.21 (5.14–10.11)</b> </p> <p>0.81–64.52</p> <p>[3; 3196/13,609]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>13.12 (4.10–41.96)</b> </p> <p>NA<sup>b</sup> </p> <p>[4; 3492/19,242]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>32.50 (23.00–45.92)</b><sup>c</sup> </p> <p>NA<sup>a</sup> </p> <p>[1; 410/4149]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Australia/Europe/North America</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4.15 (1.24–13.87)</b> </p> <p>NA<sup>b</sup> </p> <p>[3; 5685/12,837]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3.30 (2.32–4.67)</b> </p> <p>0.84–12.99</p> <p>[4; 1736/8835]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2.53 (1.52–4.19)</b> </p> <p>NA<sup>a</sup> </p> <p>[2; 2230/5871]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3.80 (2.30–6.28)</b> </p> <p>NA<sup>a</sup> </p> <p>[1; 221/1429]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2.71 (2.48–2.96)</b> </p> <p>NA<sup>a</sup> </p> <p>[1: 2027/6215]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>5.09 (1.69–15.37)</b> </p> <p>NA<sup>a</sup> </p> <p>[2; 1040/6925]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Latin America</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2.06 (1.76–2.41)</b> </p> <p>NA<sup>b</sup><br/> [1; 28/66] </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>American Indians/Islands</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2.38 (1.85–3.06)</b> </p> <p>NA<sup>a</sup> </p> <p>[1; 947/595]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4.06 (3.05–5.40)</b> </p> <p>NA<sup>a</sup> </p> <p>[1; 356/595]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i><b>Overall</b> </i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4.32 (2.61–7.12)</b> </p> <p>0.75–25.01</p> <p>[8; 9017/25,850]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>5.47 (3.50–8.54)</b> </p> <p>1.09–27.56</p> <p>[9; 2818/18,591]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3.61 (2.31–5.64)</b> </p> <p>0.69–18.97</p> <p>[5; 4010/12,566]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>6.90 (4.15–11.45)</b> </p> <p>1.06–44.95</p> <p>[5; 1038/8719]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>5.55 (2.77–11.12)</b> </p> <p>0.23–141.18</p> <p>[4; 5223/19,824]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>10.10 (3.59–28.43)</b> </p> <p>NA<sup>b</sup> </p> <p>[6; 4532/26,167]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>32.50 (23.00–45.92)</b> </p> <p>NA<sup>a</sup> </p> <p>[1; 410/4149]</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Incidence rate ratio</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Region</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IFG<sub>5.6</sub> cohort</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IFG<sub>6.1</sub> cohort</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IGT cohort</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IFG + IGT cohort</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HbA1c<sub>5.7</sub> cohort</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HbA1c<sub>6.0</sub> cohort</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HbA1c<sub>5.7</sub> + IFG<sub>5.6</sub> cohort</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asia/Middle East</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>5.23 (3.77–7.25)</b> </p> <p>1.72–15.89</p> <p>[6; 15,661/145,597]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3.62 (1.67–7.83)</b> </p> <p>NA<sup>a</sup> </p> <p>[2; 1677/36,334]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3.93 (3.03–5.10)</b> </p> <p>1.71–9.02</p> <p>[5; 14,809/73,128]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>11.20 (5.59–22.43)</b> </p> <p>NA<sup>b</sup> </p> <p>[4; 3166/69,463]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>6.62 (4.18–10.49)</b> </p> <p>NA<sup>a</sup> </p> <p>[1; 1965/19961]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>40.72 (29.30–56.61)</b> </p> <p>NA<sup>a</sup> </p> <p>[1; 1641/19,961]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Australia/Europe/North America</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4.96 (3.25–7.57)</b> </p> <p>0.32–77.24</p> <p>[3; 6322/8062]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>8.55 (6.37–11.48)</b> </p> <p>4.37–16.73</p> <p>[4; 3438/20,246]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>5.93 (4.11–8.57)</b> </p> <p>2.38–14.81</p> <p>[5; 2572/22,329]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>13.92 (9.99–19.40)</b> </p> <p>6.71–28.85</p> <p>[4; 699/18,966]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Latin America</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>American Indians/Islands</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2.74 (1.88–3.99)</b> </p> <p>NA<sup>a</sup> </p> <p>[1; 2374/1613]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4.46 (3.12–6.38)</b> </p> <p>NA<sup>a</sup> </p> <p>[2; 1087/2952]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>5.18 (3.42–7.83)</b> </p> <p>NA<sup>a</sup> </p> <p>[1; 605/1613]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i><b>Overall</b> </i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4.81 (3.67–6.30)</b> </p> <p>1.95–11.83</p> <p>[10; 24,357/155,272]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>6.82 (4.53–10.25)</b> </p> <p>2.03–22.87</p> <p>[6; 5115/56,580]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4.48 (3.69–5.44)</b> </p> <p>2.60–7.70</p> <p>[12; 18,468/98,409]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>10.94 (7.22–16.58)</b> </p> <p>2.58–46.46</p> <p>[9; 4470/90,072]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>6.62 (4.18–10.5)</b> </p> <p>NA<sup>a</sup> </p> <p>[1; 1965/19961]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>40.72 (29.30–56.61)</b> </p> <p>NA<sup>a</sup> </p> <p>[1; 1641/19,961]</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Odds ratio</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IFG<sub>5.6</sub> cohort</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IFG<sub>6.1</sub> cohort</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IGT cohort</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IFG + IGT cohort</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HbA1c<sub>5.7</sub> cohort</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HbA1c<sub>6.0</sub> cohort</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HbA1c<sub>5.7</sub> + IFG<sub>5.6</sub> cohort</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asia/Middle East</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2.94 (1.77–4.86)</b> </p> <p>0.43–19.93</p> <p>[10; 6359/28,218]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>5.18 (2.32–11.53)</b> </p> <p>0.29–91.37</p> <p>[7; 3317/25,604]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3.74 (2.83–4.94)</b> </p> <p>1.70–8.21</p> <p>[6; 1226/7417]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>6.99 (3.09–15.83)</b> </p> <p>NA<sup>b</sup> </p> <p>[3; 498/3704]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4.54 (2.65–7.78)</b> </p> <p>NA<sup>a</sup> </p> <p>[1; 675/462]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>23.20 (18.70–28.78)</b> </p> <p>NA<sup>a</sup> </p> <p>[1; 1103/10,763]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>46.70 (33.60–64.91)</b> </p> <p>NA<sup>a</sup> </p> <p>[1; 1951/10,761]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Australia/Europe/North America</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>6.47 (3.81–11.00)</b> </p> <p>0.99–42.32</p> <p>[9; 1949/7920]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>8.69 (4.95–15.24)</b> </p> <p>1.20–62.69</p> <p>[7; 1240/5094]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>5.20 (3.62–7.45)</b> </p> <p>1.50–18.09</p> <p>[11; 1481/7684]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>20.95 (12.40–35.40)</b> </p> <p>4.93–89.05</p> <p>[6; 154/5300]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4.38 (1.36–14.15)</b> </p> <p>NA<sup>a</sup> </p> <p>[2; 231/2100]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>15.60 (6.90–35.27)</b> </p> <p>NA<sup>a</sup> </p> <p>[1; 370/5365]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>26.20 (16.30–41.11)</b> </p> <p>NA<sup>a</sup> </p> <p>[1; 169/1125]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Latin America</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4.28 (3.21–5.71)</b> </p> <p>NA<sup>a</sup> </p> <p>[1; 65/1594]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3.73 (2.18–6.38)</b> </p> <p>NA<sup>a</sup> </p> <p>[1; 17/1594]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4.94 (3.15–7.76)</b> </p> <p>NA<sup>a</sup> </p> <p>[2; 381/3097]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>American Indians/Islands</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3.12 (2.31–4.21)</b> </p> <p>NA<sup>a</sup> </p> <p>[1; 947/595]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3.60 (1.40–9.26)</b> </p> <p>NA<sup>a</sup> </p> <p>[1; 51/215]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>5.89 (4.23–8.20)</b> </p> <p>NA<sup>a</sup> </p> <p>[1; 121/595]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i><b>Overall</b> </i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4.15 (2.75–6.28)</b> </p> <p>0.54–32.00</p> <p>[21; 9320/38,327]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>6.60 (4.18–10.43)</b> </p> <p>0.93–46.82</p> <p>[15; 4574/32,292]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4.61 (3.76–5.64)</b> </p> <p>2.10–10.13</p> <p>[20; 3139/18,413]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>13.14 (7.41–23.30)</b> </p> <p>1.84–93.66</p> <p>[9; 652/9004]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4.43 (2.20–8.88)</b> </p> <p>NA<sup>b</sup> </p> <p>[3; 906/2562]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>12.8 [4.56–35.9]</b> </p> <p>NA<sup>b</sup> </p> <p>[3; 1594/16,723]</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>35.91 (20.43–63.12)</b> </p> <p>NA<sup>a</sup> </p> <p>[2; 2120/11,886]</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><b>CI</b> : confidence interval; <b>HbA1c</b> : glycosylated haemoglobin A1c; <b>HbA1c<sub>5.7/6.0</sub> </b> (threshold 5.7% or 6.0%); <b>HbA1c<sub>5.7</sub> + IFG<sub>5.6</sub> </b>: both HbA1c<sub>5.7</sub> and IFG<sub>5.6</sub>; <b>IFG<sub>5.6/6.1</sub> </b> : impaired fasting glucose (threshold 5.6 mmol/L or 6.1 mmol/L); <b>IGT</b> : impaired glucose tolerance; <b>IFG + IGT</b> : both IFG and IGT; <b>IH</b> : intermediate hyperglycaemia; <b>NA</b> : not applicable; <b>T2DM</b> : type 2 diabetes mellitus; <b>NR</b>: not reported<br/> <sup>a</sup>With fewer than 3 studies a prediction interval could not be calculated<br/> <sup>b</sup>Calculation of the 95% prediction interval did not provide a meaningful estimate<br/> <sup>c</sup>Combination of HbA1c<sub>6.0</sub> plus IFG<sub>5.6</sub> at baseline showed a hazard ratio for T2DM development of 53.7 (95% CI 38.4–75.1) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Overview: intermediate hyperglycaemia versus normoglycaemia as a prognostic factor for the development of type 2 diabetes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/full#CD012661-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012661-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Hazard ratio as the effect measure for the development of T2DM</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 T2DM incidence (IFG<sub>5.6</sub>) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34867</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.32 [2.61, 7.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Asia/Middle East</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14803</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.07 [3.41, 7.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Australia/Europe/North America</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18522</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.15 [1.24, 13.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 American Indians/Islands</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1542</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.38 [1.85, 3.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 T2DM incidence (IFG<sub>6.1</sub>) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21475</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.47 [3.50, 8.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Asia/Middle East</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10810</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.55 [3.61, 30.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Australia/Europe/North America</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10571</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.30 [2.32, 4.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Latin America</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.06 [1.76, 2.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 T2DM incidence (IGT) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16576</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.61 [2.31, 5.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Asia/Middle East</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8475</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.48 [2.81, 7.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Australia/Europe/North America</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.53 [1.52, 4.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 T2DM incidence (IFG + IGT) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9757</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.90 [4.15, 11.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Asia/Middle East</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.20 [5.45, 19.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Australia/Europe/North America</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1650</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.80 [2.30, 6.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 American Indians/Islands</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>951</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.06 [3.05, 5.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 T2DM incidence (HbA1c<sub>5.7</sub>) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25047</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.55 [2.77, 11.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Asia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16805</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.21 [5.14, 10.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Australia/Europe/North America</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8242</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.71 [2.48, 2.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 T2DM incidence (HbA1c<sub>6.0</sub>) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30699</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.10 [3.59, 28.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Asia/Middle East</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22734</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>13.12 [4.10, 41.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Australia/Europe/North America</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7965</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.09 [1.69, 15.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 T2DM incidence (HbA1c + IFG) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 HbA1c5.7 + IFG5.6 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4559</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>32.50 [23.00, 45.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 HbA1c5.7 + IFG6.1 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5357</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>37.90 [28.10, 51.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 HbA1c6.0 + IFG5.6 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4628</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>53.70 [38.40, 75.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4 HbA1c6.0 + IFG6.1 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5802</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>52.30 [37.80, 72.37]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Hazard ratio as the effect measure for the development of T2DM</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/references#CD012661-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012661-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Odds ratio as the effect measure for the development of T2DM</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 T2DM incidence (IFG<sub>5.6</sub>) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47647</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.15 [2.75, 6.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Asia/Middle East</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34577</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.94 [1.77, 4.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Australia/Europe/North America</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9869</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.47 [3.81, 11.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Latin America</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1659</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.28 [3.21, 5.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 American Indians/Islands</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1542</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.12 [2.31, 4.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 T2DM incidence (IFG<sub>6.1</sub>) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36866</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.60 [4.18, 10.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Asia/Middle East</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28921</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.18 [2.32, 11.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Australia/Europe/North America</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6334</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.69 [4.95, 15.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Latin America</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1611</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.73 [2.18, 6.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 T2DM incidence (IGT) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21552</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.61 [3.76, 5.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Asia/Middle East</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8643</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.74 [2.83, 4.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Australia/Europe/North America</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.20 [3.62, 7.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Latin America</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3478</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.94 [3.15, 7.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 American Indians/Islands</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>266</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.60 [1.40, 9.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 T2DM incidence (IFG + IGT) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9656</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>13.14 [7.41, 23.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Asia/Middle East</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4202</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.99 [3.09, 15.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Australia/Europe/North America</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5454</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>20.95 [12.40, 35.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 T2DM incidence (HbA1c<sub>5.7</sub>) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3468</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.43 [2.20, 8.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Asia/Middle East</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1137</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.54 [2.65, 7.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Europe/North America</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2331</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.38 [1.36, 14.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 T2DM incidence (HbA1c<sub>6.0</sub>) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18317</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>12.79 [4.56, 35.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Asia/Middle East</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11866</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>23.20 [18.70, 28.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Australia/Europe/North America</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5735</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>15.60 [6.90, 35.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 American Indians/Islands</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>716</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.89 [4.23, 8.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 T2DM incidence (HbA1c<sub>5.7</sub> + IFG<sub>5.6</sub>) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>35.91 [20.43, 63.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Australia/Europe/North America</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1294</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>26.20 [16.30, 42.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Asia/Middle East</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12712</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>46.70 [33.60, 64.91]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Odds ratio as the effect measure for the development of T2DM</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012661.pub2/references#CD012661-tbl-0011">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012661.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD012661-note-0004">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD012661-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012661-note-0005">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD012661-note-0002">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD012661-note-0001">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pt#CD012661-note-0017">Português</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012661\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012661\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012661\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012661\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012661\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012661\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012661\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012661\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012661\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012661\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012661\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012661\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012661\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012661\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012661\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012661\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012661\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012661\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Xsb6SJyC&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012661.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012661.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012661.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012661.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012661.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740727539395"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012661.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740727539402"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012661.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918eae7cdcd5f573',t:'MTc0MDcyNzUzOS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 